<!DOCTYPE html><html  lang="en" data-capo=""><head><meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Frontiers | Identification of Eleven Novel BRCA Mutations in Tunisia: Impact on the Clinical Management of BRCA Related Cancers</title>
<link rel="stylesheet" href="/ap-2024/_nuxt/entry.CWBB-NGm.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/vue-core.B-WA3Vg5.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/explainer.CMppEa5M.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleDetails.B93eTAmx.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleLayoutHeader.CKWUz2Al.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/AnnouncementCard.Db7nmstV.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/FloatingButtons.xuP8gC33.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleEvent.D0PaxIW7.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/SimilarArticles.BMee4Fk4.css">
<link rel="stylesheet" href="/ap-2024/_nuxt/ArticleTemplateBanner.CXmOJ7NH.css">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/v1IBIWh4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/B674Mi_H.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BXedFy5e.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/eQMj-Fph.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Y8NTh2i4.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUyL5Z_3.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/m8mdd2tc.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DHv8pTSw.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BHPWSuhB.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/x5HZk7Le.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CNJXQ6ZR.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dss5ciUI.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Do5q9QoL.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BhVAcJSK.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/y69VltF1.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Bw-bWKkJ.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/sQBxgu5L.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/D5YKKJGW.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CSLdjdGS.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/BUN89Jk2.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CCeQzihV.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/DVDwh0-U.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/Dw4ta0fP.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/CYv-CzHi.js">
<link rel="modulepreload" as="script" crossorigin href="/ap-2024/_nuxt/U-mJlaMn.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/NhyIC1F3.js">
<link rel="prefetch" as="style" crossorigin href="/ap-2024/_nuxt/ArticleHubLayout.q6CU8_bN.css">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/CKQJuUlk.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/D3plh7Cs.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/GWtHKqLR.js">
<link rel="prefetch" as="script" crossorigin href="/ap-2024/_nuxt/DS3EY-DL.js">
<meta name="theme-color" content="#0C4DED">
<meta name="mobile-web-app-capable" content="yes">
<meta name="apple-mobile-web-app-capable" content="yes">
<script type="text/javascript" data-hid="4cd079c">window.NREUM||(NREUM={});NREUM.info = {"agent":"","beacon":"bam.nr-data.net","errorBeacon":"bam.nr-data.net","licenseKey":"598a124f17","applicationID":"586843029","agentToken":null,"applicationTime":5.48026,"transactionName":"MQcDMkECCkNSW0YMWghNLwlBDgVcWkJXAWAUC04MXBYWXlJUQUpaCAEOClwEHR9SSkYMVgoHEkkZTAJfXVscVwVUU09QBFddBgYXVBBZCg==","queueTime":0,"ttGuid":"d1465ac0b40361ad"}; (window.NREUM||(NREUM={})).init={privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]},feature_flags:["soft_nav"],distributed_tracing:{enabled:true}};(window.NREUM||(NREUM={})).loader_config={agentID:"594460232",accountID:"230385",trustKey:"230385",xpid:"VgUHUl5WGwYIUllWBAEFXw==",licenseKey:"598a124f17",applicationID:"586843029",browserID:"594460232"};;/*! For license information please see nr-loader-spa-1.303.0.min.js.LICENSE.txt */
(()=>{var e,t,r={384:(e,t,r)=>{"use strict";r.d(t,{NT:()=>s,US:()=>d,Zm:()=>a,bQ:()=>u,dV:()=>c,pV:()=>l});var n=r(6154),i=r(1863),o=r(1910);const s={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return n.gm.NREUM||(n.gm.NREUM={}),void 0===n.gm.newrelic&&(n.gm.newrelic=n.gm.NREUM),n.gm.NREUM}function c(){let e=a();return e.o||(e.o={ST:n.gm.setTimeout,SI:n.gm.setImmediate||n.gm.setInterval,CT:n.gm.clearTimeout,XHR:n.gm.XMLHttpRequest,REQ:n.gm.Request,EV:n.gm.Event,PR:n.gm.Promise,MO:n.gm.MutationObserver,FETCH:n.gm.fetch,WS:n.gm.WebSocket},(0,o.i)(...Object.values(e.o))),e}function u(e,t){let r=a();r.initializedAgents??={},t.initializedAt={ms:(0,i.t)(),date:new Date},r.initializedAgents[e]=t}function d(e,t){a()[e]=t}function l(){return function(){let e=a();const t=e.info||{};e.info={beacon:s.beacon,errorBeacon:s.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),c(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},782:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewTiming},860:(e,t,r)=>{"use strict";r.d(t,{$J:()=>d,K7:()=>c,P3:()=>u,XX:()=>i,Yy:()=>a,df:()=>o,qY:()=>n,v4:()=>s});const n="events",i="jserrors",o="browser/blobs",s="rum",a="browser/logs",c={ajax:"ajax",genericEvents:"generic_events",jserrors:i,logging:"logging",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",softNav:"soft_navigations",spa:"spa"},u={[c.pageViewEvent]:1,[c.pageViewTiming]:2,[c.metrics]:3,[c.jserrors]:4,[c.spa]:5,[c.ajax]:6,[c.sessionTrace]:7,[c.softNav]:8,[c.sessionReplay]:9,[c.logging]:10,[c.genericEvents]:11},d={[c.pageViewEvent]:s,[c.pageViewTiming]:n,[c.ajax]:n,[c.spa]:n,[c.softNav]:n,[c.metrics]:i,[c.jserrors]:i,[c.sessionTrace]:o,[c.sessionReplay]:o,[c.logging]:a,[c.genericEvents]:"ins"}},944:(e,t,r)=>{"use strict";r.d(t,{R:()=>i});var n=r(3241);function i(e,t){"function"==typeof console.debug&&(console.debug("New Relic Warning: https://github.com/newrelic/newrelic-browser-agent/blob/main/docs/warning-codes.md#".concat(e),t),(0,n.W)({agentIdentifier:null,drained:null,type:"data",name:"warn",feature:"warn",data:{code:e,secondary:t}}))}},993:(e,t,r)=>{"use strict";r.d(t,{A$:()=>o,ET:()=>s,TZ:()=>a,p_:()=>i});var n=r(860);const i={ERROR:"ERROR",WARN:"WARN",INFO:"INFO",DEBUG:"DEBUG",TRACE:"TRACE"},o={OFF:0,ERROR:1,WARN:2,INFO:3,DEBUG:4,TRACE:5},s="log",a=n.K7.logging},1687:(e,t,r)=>{"use strict";r.d(t,{Ak:()=>u,Ze:()=>f,x3:()=>d});var n=r(3241),i=r(7836),o=r(3606),s=r(860),a=r(2646);const c={};function u(e,t){const r={staged:!1,priority:s.P3[t]||0};l(e),c[e].get(t)||c[e].set(t,r)}function d(e,t){e&&c[e]&&(c[e].get(t)&&c[e].delete(t),p(e,t,!1),c[e].size&&h(e))}function l(e){if(!e)throw new Error("agentIdentifier required");c[e]||(c[e]=new Map)}function f(e="",t="feature",r=!1){if(l(e),!e||!c[e].get(t)||r)return p(e,t);c[e].get(t).staged=!0,h(e)}function h(e){const t=Array.from(c[e]);t.every(([e,t])=>t.staged)&&(t.sort((e,t)=>e[1].priority-t[1].priority),t.forEach(([t])=>{c[e].delete(t),p(e,t)}))}function p(e,t,r=!0){const s=e?i.ee.get(e):i.ee,c=o.i.handlers;if(!s.aborted&&s.backlog&&c){if((0,n.W)({agentIdentifier:e,type:"lifecycle",name:"drain",feature:t}),r){const e=s.backlog[t],r=c[t];if(r){for(let t=0;e&&t<e.length;++t)g(e[t],r);Object.entries(r).forEach(([e,t])=>{Object.values(t||{}).forEach(t=>{t[0]?.on&&t[0]?.context()instanceof a.y&&t[0].on(e,t[1])})})}}s.isolatedBacklog||delete c[t],s.backlog[t]=null,s.emit("drain-"+t,[])}}function g(e,t){var r=e[1];Object.values(t[r]||{}).forEach(t=>{var r=e[0];if(t[0]===r){var n=t[1],i=e[3],o=e[2];n.apply(i,o)}})}},1741:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(944),i=r(4261);class o{#e(e,...t){if(this[e]!==o.prototype[e])return this[e](...t);(0,n.R)(35,e)}addPageAction(e,t){return this.#e(i.hG,e,t)}register(e){return this.#e(i.eY,e)}recordCustomEvent(e,t){return this.#e(i.fF,e,t)}setPageViewName(e,t){return this.#e(i.Fw,e,t)}setCustomAttribute(e,t,r){return this.#e(i.cD,e,t,r)}noticeError(e,t){return this.#e(i.o5,e,t)}setUserId(e){return this.#e(i.Dl,e)}setApplicationVersion(e){return this.#e(i.nb,e)}setErrorHandler(e){return this.#e(i.bt,e)}addRelease(e,t){return this.#e(i.k6,e,t)}log(e,t){return this.#e(i.$9,e,t)}start(){return this.#e(i.d3)}finished(e){return this.#e(i.BL,e)}recordReplay(){return this.#e(i.CH)}pauseReplay(){return this.#e(i.Tb)}addToTrace(e){return this.#e(i.U2,e)}setCurrentRouteName(e){return this.#e(i.PA,e)}interaction(e){return this.#e(i.dT,e)}wrapLogger(e,t,r){return this.#e(i.Wb,e,t,r)}measure(e,t){return this.#e(i.V1,e,t)}consent(e){return this.#e(i.Pv,e)}}},1863:(e,t,r)=>{"use strict";function n(){return Math.floor(performance.now())}r.d(t,{t:()=>n})},1910:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(944);const i=new Map;function o(...e){return e.every(e=>{if(i.has(e))return i.get(e);const t="function"==typeof e&&e.toString().includes("[native code]");return t||(0,n.R)(64,e?.name||e?.toString()),i.set(e,t),t})}},2555:(e,t,r)=>{"use strict";r.d(t,{D:()=>a,f:()=>s});var n=r(384),i=r(8122);const o={beacon:n.NT.beacon,errorBeacon:n.NT.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0};function s(e){try{return!!e.licenseKey&&!!e.errorBeacon&&!!e.applicationID}catch(e){return!1}}const a=e=>(0,i.a)(e,o)},2614:(e,t,r)=>{"use strict";r.d(t,{BB:()=>s,H3:()=>n,g:()=>u,iL:()=>c,tS:()=>a,uh:()=>i,wk:()=>o});const n="NRBA",i="SESSION",o=144e5,s=18e5,a={STARTED:"session-started",PAUSE:"session-pause",RESET:"session-reset",RESUME:"session-resume",UPDATE:"session-update"},c={SAME_TAB:"same-tab",CROSS_TAB:"cross-tab"},u={OFF:0,FULL:1,ERROR:2}},2646:(e,t,r)=>{"use strict";r.d(t,{y:()=>n});class n{constructor(e){this.contextId=e}}},2843:(e,t,r)=>{"use strict";r.d(t,{u:()=>i});var n=r(3878);function i(e,t=!1,r,i){(0,n.DD)("visibilitychange",function(){if(t)return void("hidden"===document.visibilityState&&e());e(document.visibilityState)},r,i)}},3241:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(6154);const i="newrelic";function o(e={}){try{n.gm.dispatchEvent(new CustomEvent(i,{detail:e}))}catch(e){}}},3304:(e,t,r)=>{"use strict";r.d(t,{A:()=>o});var n=r(7836);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())??""}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}return""}}},3333:(e,t,r)=>{"use strict";r.d(t,{$v:()=>d,TZ:()=>n,Xh:()=>c,Zp:()=>i,kd:()=>u,mq:()=>a,nf:()=>s,qN:()=>o});const n=r(860).K7.genericEvents,i=["auxclick","click","copy","keydown","paste","scrollend"],o=["focus","blur"],s=4,a=1e3,c=2e3,u=["PageAction","UserAction","BrowserPerformance"],d={RESOURCES:"experimental.resources",REGISTER:"register"}},3434:(e,t,r)=>{"use strict";r.d(t,{Jt:()=>o,YM:()=>u});var n=r(7836),i=r(5607);const o="nr@original:".concat(i.W),s=50;var a=Object.prototype.hasOwnProperty,c=!1;function u(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");const s="-"===n.charAt(0);for(let a=0;a<t.length;a++){const c=t[a],u=e[c];l(u)||(e[c]=r(u,s?c+n:n,i,c,o))}},r.flag=o,r;function r(t,r,n,c,u){return l(t)?t:(r||(r=""),nrWrapper[o]=t,function(e,t,r){if(Object.defineProperty&&Object.keys)try{return Object.keys(e).forEach(function(r){Object.defineProperty(t,r,{get:function(){return e[r]},set:function(t){return e[r]=t,t}})}),t}catch(e){d([e],r)}for(var n in e)a.call(e,n)&&(t[n]=e[n])}(t,nrWrapper,e),nrWrapper);function nrWrapper(){var o,a,l,f;let h;try{a=this,o=[...arguments],l="function"==typeof n?n(o,a):n||{}}catch(t){d([t,"",[o,a,c],l],e)}i(r+"start",[o,a,c],l,u);const p=performance.now();let g;try{return f=t.apply(a,o),g=performance.now(),f}catch(e){throw g=performance.now(),i(r+"err",[o,a,e],l,u),h=e,h}finally{const e=g-p,t={start:p,end:g,duration:e,isLongTask:e>=s,methodName:c,thrownError:h};t.isLongTask&&i("long-task",[t,a],l,u),i(r+"end",[o,a,f],l,u)}}}function i(r,n,i,o){if(!c||t){var s=c;c=!0;try{e.emit(r,n,i,t,o)}catch(t){d([t,r,n,i],e)}c=s}}}function d(e,t){t||(t=n.ee);try{t.emit("internal-error",e)}catch(e){}}function l(e){return!(e&&"function"==typeof e&&e.apply&&!e[o])}},3606:(e,t,r)=>{"use strict";r.d(t,{i:()=>o});var n=r(9908);o.on=s;var i=o.handlers={};function o(e,t,r,o){s(o||n.d,i,e,t,r)}function s(e,t,r,i,o){o||(o="feature"),e||(e=n.d);var s=t[o]=t[o]||{};(s[r]=s[r]||[]).push([e,i])}},3738:(e,t,r)=>{"use strict";r.d(t,{He:()=>i,Kp:()=>a,Lc:()=>u,Rz:()=>d,TZ:()=>n,bD:()=>o,d3:()=>s,jx:()=>l,sl:()=>f,uP:()=>c});const n=r(860).K7.sessionTrace,i="bstResource",o="resource",s="-start",a="-end",c="fn"+s,u="fn"+a,d="pushState",l=1e3,f=3e4},3785:(e,t,r)=>{"use strict";r.d(t,{R:()=>c,b:()=>u});var n=r(9908),i=r(1863),o=r(860),s=r(8154),a=r(993);function c(e,t,r={},c=a.p_.INFO,u,d=(0,i.t)()){(0,n.p)(s.xV,["API/logging/".concat(c.toLowerCase(),"/called")],void 0,o.K7.metrics,e),(0,n.p)(a.ET,[d,t,r,c,u],void 0,o.K7.logging,e)}function u(e){return"string"==typeof e&&Object.values(a.p_).some(t=>t===e.toUpperCase().trim())}},3878:(e,t,r)=>{"use strict";function n(e,t){return{capture:e,passive:!1,signal:t}}function i(e,t,r=!1,i){window.addEventListener(e,t,n(r,i))}function o(e,t,r=!1,i){document.addEventListener(e,t,n(r,i))}r.d(t,{DD:()=>o,jT:()=>n,sp:()=>i})},3962:(e,t,r)=>{"use strict";r.d(t,{AM:()=>s,O2:()=>l,OV:()=>o,Qu:()=>f,TZ:()=>c,ih:()=>h,pP:()=>a,t1:()=>d,tC:()=>i,wD:()=>u});var n=r(860);const i=["click","keydown","submit"],o="popstate",s="api",a="initialPageLoad",c=n.K7.softNav,u=5e3,d=500,l={INITIAL_PAGE_LOAD:"",ROUTE_CHANGE:1,UNSPECIFIED:2},f={INTERACTION:1,AJAX:2,CUSTOM_END:3,CUSTOM_TRACER:4},h={IP:"in progress",PF:"pending finish",FIN:"finished",CAN:"cancelled"}},4234:(e,t,r)=>{"use strict";r.d(t,{W:()=>o});var n=r(7836),i=r(1687);class o{constructor(e,t){this.agentIdentifier=e,this.ee=n.ee.get(e),this.featureName=t,this.blocked=!1}deregisterDrain(){(0,i.x3)(this.agentIdentifier,this.featureName)}}},4261:(e,t,r)=>{"use strict";r.d(t,{$9:()=>d,BL:()=>c,CH:()=>p,Dl:()=>R,Fw:()=>w,PA:()=>v,Pl:()=>n,Pv:()=>A,Tb:()=>f,U2:()=>s,V1:()=>E,Wb:()=>T,bt:()=>y,cD:()=>b,d3:()=>x,dT:()=>u,eY:()=>g,fF:()=>h,hG:()=>o,hw:()=>i,k6:()=>a,nb:()=>m,o5:()=>l});const n="api-",i=n+"ixn-",o="addPageAction",s="addToTrace",a="addRelease",c="finished",u="interaction",d="log",l="noticeError",f="pauseReplay",h="recordCustomEvent",p="recordReplay",g="register",m="setApplicationVersion",v="setCurrentRouteName",b="setCustomAttribute",y="setErrorHandler",w="setPageViewName",R="setUserId",x="start",T="wrapLogger",E="measure",A="consent"},4387:(e,t,r)=>{"use strict";function n(e={}){return!(!e.id||!e.name)}function i(e){return"string"==typeof e&&e.trim().length<501||"number"==typeof e}function o(e,t){if(2!==t?.harvestEndpointVersion)return{};const r=t.agentRef.runtime.appMetadata.agents[0].entityGuid;return n(e)?{"mfe.id":e.id,"mfe.name":e.name,eventSource:e.eventSource,"parent.id":e.parent?.id||r}:{"entity.guid":r,appId:t.agentRef.info.applicationID}}r.d(t,{Ux:()=>o,c7:()=>n,yo:()=>i})},5205:(e,t,r)=>{"use strict";r.d(t,{j:()=>_});var n=r(384),i=r(1741);var o=r(2555),s=r(3333);const a=e=>{if(!e||"string"!=typeof e)return!1;try{document.createDocumentFragment().querySelector(e)}catch{return!1}return!0};var c=r(2614),u=r(944),d=r(8122);const l="[data-nr-mask]",f=e=>(0,d.a)(e,(()=>{const e={feature_flags:[],experimental:{allow_registered_children:!1,resources:!1},mask_selector:"*",block_selector:"[data-nr-block]",mask_input_options:{color:!1,date:!1,"datetime-local":!1,email:!1,month:!1,number:!1,range:!1,search:!1,tel:!1,text:!1,time:!1,url:!1,week:!1,textarea:!1,select:!1,password:!0}};return{ajax:{deny_list:void 0,block_internal:!0,enabled:!0,autoStart:!0},api:{get allow_registered_children(){return e.feature_flags.includes(s.$v.REGISTER)||e.experimental.allow_registered_children},set allow_registered_children(t){e.experimental.allow_registered_children=t},duplicate_registered_data:!1},browser_consent_mode:{enabled:!1},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},get feature_flags(){return e.feature_flags},set feature_flags(t){e.feature_flags=t},generic_events:{enabled:!0,autoStart:!0},harvest:{interval:30},jserrors:{enabled:!0,autoStart:!0},logging:{enabled:!0,autoStart:!0},metrics:{enabled:!0,autoStart:!0},obfuscate:void 0,page_action:{enabled:!0},page_view_event:{enabled:!0,autoStart:!0},page_view_timing:{enabled:!0,autoStart:!0},performance:{capture_marks:!1,capture_measures:!1,capture_detail:!0,resources:{get enabled(){return e.feature_flags.includes(s.$v.RESOURCES)||e.experimental.resources},set enabled(t){e.experimental.resources=t},asset_types:[],first_party_domains:[],ignore_newrelic:!0}},privacy:{cookies_enabled:!0},proxy:{assets:void 0,beacon:void 0},session:{expiresMs:c.wk,inactiveMs:c.BB},session_replay:{autoStart:!0,enabled:!1,preload:!1,sampling_rate:10,error_sampling_rate:100,collect_fonts:!1,inline_images:!1,fix_stylesheets:!0,mask_all_inputs:!0,get mask_text_selector(){return e.mask_selector},set mask_text_selector(t){a(t)?e.mask_selector="".concat(t,",").concat(l):""===t||null===t?e.mask_selector=l:(0,u.R)(5,t)},get block_class(){return"nr-block"},get ignore_class(){return"nr-ignore"},get mask_text_class(){return"nr-mask"},get block_selector(){return e.block_selector},set block_selector(t){a(t)?e.block_selector+=",".concat(t):""!==t&&(0,u.R)(6,t)},get mask_input_options(){return e.mask_input_options},set mask_input_options(t){t&&"object"==typeof t?e.mask_input_options={...t,password:!0}:(0,u.R)(7,t)}},session_trace:{enabled:!0,autoStart:!0},soft_navigations:{enabled:!0,autoStart:!0},spa:{enabled:!0,autoStart:!0},ssl:void 0,user_actions:{enabled:!0,elementAttributes:["id","className","tagName","type"]}}})());var h=r(6154),p=r(9324);let g=0;const m={buildEnv:p.F3,distMethod:p.Xs,version:p.xv,originTime:h.WN},v={consented:!1},b={appMetadata:{},get consented(){return this.session?.state?.consent||v.consented},set consented(e){v.consented=e},customTransaction:void 0,denyList:void 0,disabled:!1,harvester:void 0,isolatedBacklog:!1,isRecording:!1,loaderType:void 0,maxBytes:3e4,obfuscator:void 0,onerror:void 0,ptid:void 0,releaseIds:{},session:void 0,timeKeeper:void 0,registeredEntities:[],jsAttributesMetadata:{bytes:0},get harvestCount(){return++g}},y=e=>{const t=(0,d.a)(e,b),r=Object.keys(m).reduce((e,t)=>(e[t]={value:m[t],writable:!1,configurable:!0,enumerable:!0},e),{});return Object.defineProperties(t,r)};var w=r(5701);const R=e=>{const t=e.startsWith("http");e+="/",r.p=t?e:"https://"+e};var x=r(7836),T=r(3241);const E={accountID:void 0,trustKey:void 0,agentID:void 0,licenseKey:void 0,applicationID:void 0,xpid:void 0},A=e=>(0,d.a)(e,E),S=new Set;function _(e,t={},r,s){let{init:a,info:c,loader_config:u,runtime:d={},exposed:l=!0}=t;if(!c){const e=(0,n.pV)();a=e.init,c=e.info,u=e.loader_config}e.init=f(a||{}),e.loader_config=A(u||{}),c.jsAttributes??={},h.bv&&(c.jsAttributes.isWorker=!0),e.info=(0,o.D)(c);const p=e.init,g=[c.beacon,c.errorBeacon];S.has(e.agentIdentifier)||(p.proxy.assets&&(R(p.proxy.assets),g.push(p.proxy.assets)),p.proxy.beacon&&g.push(p.proxy.beacon),e.beacons=[...g],function(e){const t=(0,n.pV)();Object.getOwnPropertyNames(i.W.prototype).forEach(r=>{const n=i.W.prototype[r];if("function"!=typeof n||"constructor"===n)return;let o=t[r];e[r]&&!1!==e.exposed&&"micro-agent"!==e.runtime?.loaderType&&(t[r]=(...t)=>{const n=e[r](...t);return o?o(...t):n})})}(e),(0,n.US)("activatedFeatures",w.B),e.runSoftNavOverSpa&&=!0===p.soft_navigations.enabled&&p.feature_flags.includes("soft_nav")),d.denyList=[...p.ajax.deny_list||[],...p.ajax.block_internal?g:[]],d.ptid=e.agentIdentifier,d.loaderType=r,e.runtime=y(d),S.has(e.agentIdentifier)||(e.ee=x.ee.get(e.agentIdentifier),e.exposed=l,(0,T.W)({agentIdentifier:e.agentIdentifier,drained:!!w.B?.[e.agentIdentifier],type:"lifecycle",name:"initialize",feature:void 0,data:e.config})),S.add(e.agentIdentifier)}},5270:(e,t,r)=>{"use strict";r.d(t,{Aw:()=>s,SR:()=>o,rF:()=>a});var n=r(384),i=r(7767);function o(e){return!!(0,n.dV)().o.MO&&(0,i.V)(e)&&!0===e?.session_trace.enabled}function s(e){return!0===e?.session_replay.preload&&o(e)}function a(e,t){try{if("string"==typeof t?.type){if("password"===t.type.toLowerCase())return"*".repeat(e?.length||0);if(void 0!==t?.dataset?.nrUnmask||t?.classList?.contains("nr-unmask"))return e}}catch(e){}return"string"==typeof e?e.replace(/[\S]/g,"*"):"*".repeat(e?.length||0)}},5289:(e,t,r)=>{"use strict";r.d(t,{GG:()=>o,Qr:()=>a,sB:()=>s});var n=r(3878);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.sp)("load",e,t)}function s(e){if(i())return e();(0,n.DD)("DOMContentLoaded",e)}function a(e){if(i())return e();(0,n.sp)("popstate",e)}},5607:(e,t,r)=>{"use strict";r.d(t,{W:()=>n});const n=(0,r(9566).bz)()},5701:(e,t,r)=>{"use strict";r.d(t,{B:()=>o,t:()=>s});var n=r(3241);const i=new Set,o={};function s(e,t){const r=t.agentIdentifier;o[r]??={},e&&"object"==typeof e&&(i.has(r)||(t.ee.emit("rumresp",[e]),o[r]=e,i.add(r),(0,n.W)({agentIdentifier:r,loaded:!0,drained:!0,type:"lifecycle",name:"load",feature:void 0,data:e})))}},6154:(e,t,r)=>{"use strict";r.d(t,{A4:()=>a,OF:()=>d,RI:()=>i,WN:()=>h,bv:()=>o,gm:()=>s,lR:()=>f,m:()=>u,mw:()=>c,sb:()=>l});var n=r(1863);const i="undefined"!=typeof window&&!!window.document,o="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),s=i?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a="complete"===s?.document?.readyState,c=Boolean("hidden"===s?.document?.visibilityState),u=""+s?.location,d=/iPad|iPhone|iPod/.test(s.navigator?.userAgent),l=d&&"undefined"==typeof SharedWorker,f=(()=>{const e=s.navigator?.userAgent?.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),h=Date.now()-(0,n.t)()},6344:(e,t,r)=>{"use strict";r.d(t,{BB:()=>d,Qb:()=>l,TZ:()=>i,Ug:()=>s,Vh:()=>o,_s:()=>a,bc:()=>u,yP:()=>c});var n=r(2614);const i=r(860).K7.sessionReplay,o="errorDuringReplay",s=.12,a={DomContentLoaded:0,Load:1,FullSnapshot:2,IncrementalSnapshot:3,Meta:4,Custom:5},c={[n.g.ERROR]:15e3,[n.g.FULL]:3e5,[n.g.OFF]:0},u={RESET:{message:"Session was reset",sm:"Reset"},IMPORT:{message:"Recorder failed to import",sm:"Import"},TOO_MANY:{message:"429: Too Many Requests",sm:"Too-Many"},TOO_BIG:{message:"Payload was too large",sm:"Too-Big"},CROSS_TAB:{message:"Session Entity was set to OFF on another tab",sm:"Cross-Tab"},ENTITLEMENTS:{message:"Session Replay is not allowed and will not be started",sm:"Entitlement"}},d=5e3,l={API:"api",RESUME:"resume",SWITCH_TO_FULL:"switchToFull",INITIALIZE:"initialize",PRELOAD:"preload"}},6389:(e,t,r)=>{"use strict";function n(e,t=500,r={}){const n=r?.leading||!1;let i;return(...r)=>{n&&void 0===i&&(e.apply(this,r),i=setTimeout(()=>{i=clearTimeout(i)},t)),n||(clearTimeout(i),i=setTimeout(()=>{e.apply(this,r)},t))}}function i(e){let t=!1;return(...r)=>{t||(t=!0,e.apply(this,r))}}r.d(t,{J:()=>i,s:()=>n})},6630:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.pageViewEvent},6774:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.jserrors},7295:(e,t,r)=>{"use strict";r.d(t,{Xv:()=>s,gX:()=>i,iW:()=>o});var n=[];function i(e){if(!e||o(e))return!1;if(0===n.length)return!0;for(var t=0;t<n.length;t++){var r=n[t];if("*"===r.hostname)return!1;if(a(r.hostname,e.hostname)&&c(r.pathname,e.pathname))return!1}return!0}function o(e){return void 0===e.hostname}function s(e){if(n=[],e&&e.length)for(var t=0;t<e.length;t++){let r=e[t];if(!r)continue;0===r.indexOf("http://")?r=r.substring(7):0===r.indexOf("https://")&&(r=r.substring(8));const i=r.indexOf("/");let o,s;i>0?(o=r.substring(0,i),s=r.substring(i)):(o=r,s="");let[a]=o.split(":");n.push({hostname:a,pathname:s})}}function a(e,t){return!(e.length>t.length)&&t.indexOf(e)===t.length-e.length}function c(e,t){return 0===e.indexOf("/")&&(e=e.substring(1)),0===t.indexOf("/")&&(t=t.substring(1)),""===e||e===t}},7378:(e,t,r)=>{"use strict";r.d(t,{$p:()=>x,BR:()=>b,Kp:()=>R,L3:()=>y,Lc:()=>c,NC:()=>o,SG:()=>d,TZ:()=>i,U6:()=>p,UT:()=>m,d3:()=>w,dT:()=>f,e5:()=>E,gx:()=>v,l9:()=>l,oW:()=>h,op:()=>g,rw:()=>u,tH:()=>A,uP:()=>a,wW:()=>T,xq:()=>s});var n=r(384);const i=r(860).K7.spa,o=["click","submit","keypress","keydown","keyup","change"],s=999,a="fn-start",c="fn-end",u="cb-start",d="api-ixn-",l="remaining",f="interaction",h="spaNode",p="jsonpNode",g="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=(0,n.dV)().o.ST,w="-start",R="-end",x="-body",T="cb"+R,E="jsTime",A="fetch"},7485:(e,t,r)=>{"use strict";r.d(t,{D:()=>i});var n=r(6154);function i(e){if(0===(e||"").indexOf("data:"))return{protocol:"data"};try{const t=new URL(e,location.href),r={port:t.port,hostname:t.hostname,pathname:t.pathname,search:t.search,protocol:t.protocol.slice(0,t.protocol.indexOf(":")),sameOrigin:t.protocol===n.gm?.location?.protocol&&t.host===n.gm?.location?.host};return r.port&&""!==r.port||("http:"===t.protocol&&(r.port="80"),"https:"===t.protocol&&(r.port="443")),r.pathname&&""!==r.pathname?r.pathname.startsWith("/")||(r.pathname="/".concat(r.pathname)):r.pathname="/",r}catch(e){return{}}}},7699:(e,t,r)=>{"use strict";r.d(t,{It:()=>o,KC:()=>a,No:()=>i,qh:()=>s});var n=r(860);const i=16e3,o=1e6,s="SESSION_ERROR",a={[n.K7.logging]:!0,[n.K7.genericEvents]:!1,[n.K7.jserrors]:!1,[n.K7.ajax]:!1}},7767:(e,t,r)=>{"use strict";r.d(t,{V:()=>i});var n=r(6154);const i=e=>n.RI&&!0===e?.privacy.cookies_enabled},7836:(e,t,r)=>{"use strict";r.d(t,{P:()=>a,ee:()=>c});var n=r(384),i=r(8990),o=r(2646),s=r(5607);const a="nr@context:".concat(s.W),c=function e(t,r){var n={},s={},d={},l=!1;try{l=16===r.length&&u.initializedAgents?.[r]?.runtime.isolatedBacklog}catch(e){}var f={on:p,addEventListener:p,removeEventListener:function(e,t){var r=n[e];if(!r)return;for(var i=0;i<r.length;i++)r[i]===t&&r.splice(i,1)},emit:function(e,r,n,i,o){!1!==o&&(o=!0);if(c.aborted&&!i)return;t&&o&&t.emit(e,r,n);var a=h(n);g(e).forEach(e=>{e.apply(a,r)});var u=v()[s[e]];u&&u.push([f,e,r,a]);return a},get:m,listeners:g,context:h,buffer:function(e,t){const r=v();if(t=t||"feature",f.aborted)return;Object.entries(e||{}).forEach(([e,n])=>{s[n]=t,t in r||(r[t]=[])})},abort:function(){f._aborted=!0,Object.keys(f.backlog).forEach(e=>{delete f.backlog[e]})},isBuffering:function(e){return!!v()[s[e]]},debugId:r,backlog:l?{}:t&&"object"==typeof t.backlog?t.backlog:{},isolatedBacklog:l};return Object.defineProperty(f,"aborted",{get:()=>{let e=f._aborted||!1;return e||(t&&(e=t.aborted),e)}}),f;function h(e){return e&&e instanceof o.y?e:e?(0,i.I)(e,a,()=>new o.y(a)):new o.y(a)}function p(e,t){n[e]=g(e).concat(t)}function g(e){return n[e]||[]}function m(t){return d[t]=d[t]||e(f,t)}function v(){return f.backlog}}(void 0,"globalEE"),u=(0,n.Zm)();u.ee||(u.ee=c)},8122:(e,t,r)=>{"use strict";r.d(t,{a:()=>i});var n=r(944);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.R)(3);if(!t||"object"!=typeof t)return(0,n.R)(4);const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let s in o)if(void 0!==e[s])try{if(null===e[s]){r[s]=null;continue}Array.isArray(e[s])&&Array.isArray(t[s])?r[s]=Array.from(new Set([...e[s],...t[s]])):"object"==typeof e[s]&&"object"==typeof t[s]?r[s]=i(e[s],t[s]):r[s]=e[s]}catch(e){r[s]||(0,n.R)(1,e)}return r}catch(e){(0,n.R)(2,e)}}},8139:(e,t,r)=>{"use strict";r.d(t,{u:()=>f});var n=r(7836),i=r(3434),o=r(8990),s=r(6154);const a={},c=s.gm.XMLHttpRequest,u="addEventListener",d="removeEventListener",l="nr@wrapped:".concat(n.P);function f(e){var t=function(e){return(e||n.ee).get("events")}(e);if(a[t.debugId]++)return t;a[t.debugId]=1;var r=(0,i.YM)(t,!0);function f(e){r.inPlace(e,[u,d],"-",p)}function p(e,t){return e[1]}return"getPrototypeOf"in Object&&(s.RI&&h(document,f),c&&h(c.prototype,f),h(s.gm,f)),t.on(u+"-start",function(e,t){var n=e[1];if(null!==n&&("function"==typeof n||"object"==typeof n)&&"newrelic"!==e[0]){var i=(0,o.I)(n,l,function(){var e={object:function(){if("function"!=typeof n.handleEvent)return;return n.handleEvent.apply(n,arguments)},function:n}[typeof n];return e?r(e,"fn-",null,e.name||"anonymous"):n});this.wrapped=e[1]=i}}),t.on(d+"-start",function(e){e[1]=this.wrapped||e[1]}),t}function h(e,t,...r){let n=e;for(;"object"==typeof n&&!Object.prototype.hasOwnProperty.call(n,u);)n=Object.getPrototypeOf(n);n&&t(n,...r)}},8154:(e,t,r)=>{"use strict";r.d(t,{z_:()=>o,XG:()=>a,TZ:()=>n,rs:()=>i,xV:()=>s});r(6154),r(9566),r(384);const n=r(860).K7.metrics,i="sm",o="cm",s="storeSupportabilityMetrics",a="storeEventMetrics"},8374:(e,t,r)=>{r.nc=(()=>{try{return document?.currentScript?.nonce}catch(e){}return""})()},8990:(e,t,r)=>{"use strict";r.d(t,{I:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},9300:(e,t,r)=>{"use strict";r.d(t,{T:()=>n});const n=r(860).K7.ajax},9324:(e,t,r)=>{"use strict";r.d(t,{AJ:()=>s,F3:()=>i,Xs:()=>o,Yq:()=>a,xv:()=>n});const n="1.303.0",i="PROD",o="CDN",s="@newrelic/rrweb",a="1.0.1"},9566:(e,t,r)=>{"use strict";r.d(t,{LA:()=>a,ZF:()=>c,bz:()=>s,el:()=>u});var n=r(6154);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function s(){const e=n.gm?.crypto||n.gm?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(30))),i.split("").map(e=>"x"===e?o(t,r++).toString(16):"y"===e?(3&o()|8).toString(16):e).join("")}function a(e){const t=n.gm?.crypto||n.gm?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(e)));const s=[];for(var a=0;a<e;a++)s.push(o(r,i++).toString(16));return s.join("")}function c(){return a(16)}function u(){return a(32)}},9908:(e,t,r)=>{"use strict";r.d(t,{d:()=>n,p:()=>i});var n=r(7836).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce((t,r)=>(i.f[r](e,t),t),[])),i.u=e=>({212:"nr-spa-compressor",249:"nr-spa-recorder",478:"nr-spa"}[e]+"-1.303.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA-1.303.0.PROD:",i.l=(r,n,o,s)=>{if(e[r])e[r].push(n);else{var a,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d<u.length;d++){var l=u[d];if(l.getAttribute("src")==r||l.getAttribute("data-webpack")==t+o){a=l;break}}if(!a){c=!0;var f={478:"sha512-Q1pLqcoiNmLHv0rtq3wFkJBA3kofBdRJl0ExDl0mTuAoCBd0qe/1J0XWrDlQKuNlUryL6aZfVkAMPLmoikWIoQ==",249:"sha512-695ZzudsxlMtHKnpDNvkMlJd3tdMtY03IQKVCw9SX12tjUC+f7Nrx5tnWO72Vg9RFf6DSY6wVmM3cEkRM12kkQ==",212:"sha512-18Gx1wIBsppcn0AnKFhwgw4IciNgFxiw3J74W393Ape+wtg4hlg7t6SBKsIE/Dk/tfl2yltgcgBFvYRs283AFg=="};(a=document.createElement("script")).charset="utf-8",i.nc&&a.setAttribute("nonce",i.nc),a.setAttribute("data-webpack",t+o),a.src=r,0!==a.src.indexOf(window.location.origin+"/")&&(a.crossOrigin="anonymous"),f[s]&&(a.integrity=f[s])}e[r]=[n];var h=(t,n)=>{a.onerror=a.onload=null,clearTimeout(p);var i=e[r];if(delete e[r],a.parentNode&&a.parentNode.removeChild(a),i&&i.forEach(e=>e(n)),t)return t(n)},p=setTimeout(h.bind(null,void 0,{type:"timeout",target:a}),12e4);a.onerror=h.bind(null,a.onerror),a.onload=h.bind(null,a.onload),c&&document.head.appendChild(a)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.p="https://js-agent.newrelic.com/",(()=>{var e={38:0,788:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise((r,i)=>n=e[t]=[r,i]);r.push(n[2]=o);var s=i.p+i.u(t),a=new Error;i.l(s,r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),s=r&&r.target&&r.target.src;a.message="Loading chunk "+t+" failed.\n("+o+": "+s+")",a.name="ChunkLoadError",a.type=o,a.request=s,n[1](a)}},"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[s,a,c]=r,u=0;if(s.some(t=>0!==e[t])){for(n in a)i.o(a,n)&&(i.m[n]=a[n]);if(c)c(i)}for(t&&t(r);u<s.length;u++)o=s[u],i.o(e,o)&&e[o]&&e[o][0](),e[o]=0},r=self["webpackChunk:NRBA-1.303.0.PROD"]=self["webpackChunk:NRBA-1.303.0.PROD"]||[];r.forEach(t.bind(null,0)),r.push=t.bind(null,r.push.bind(r))})(),(()=>{"use strict";i(8374);var e=i(9566),t=i(1741);class r extends t.W{agentIdentifier=(0,e.LA)(16)}var n=i(860);const o=Object.values(n.K7);var s=i(5205);var a=i(9908),c=i(1863),u=i(4261),d=i(3241),l=i(944),f=i(5701),h=i(8154);function p(e,t,i,o){const s=o||i;!s||s[e]&&s[e]!==r.prototype[e]||(s[e]=function(){(0,a.p)(h.xV,["API/"+e+"/called"],void 0,n.K7.metrics,i.ee),(0,d.W)({agentIdentifier:i.agentIdentifier,drained:!!f.B?.[i.agentIdentifier],type:"data",name:"api",feature:u.Pl+e,data:{}});try{return t.apply(this,arguments)}catch(e){(0,l.R)(23,e)}})}function g(e,t,r,n,i){const o=e.info;null===r?delete o.jsAttributes[t]:o.jsAttributes[t]=r,(i||null===r)&&(0,a.p)(u.Pl+n,[(0,c.t)(),t,r],void 0,"session",e.ee)}var m=i(1687),v=i(4234),b=i(5289),y=i(6154),w=i(5270),R=i(7767),x=i(6389),T=i(7699);class E extends v.W{constructor(e,t){super(e.agentIdentifier,t),this.agentRef=e,this.abortHandler=void 0,this.featAggregate=void 0,this.loadedSuccessfully=void 0,this.onAggregateImported=new Promise(e=>{this.loadedSuccessfully=e}),this.deferred=Promise.resolve(),!1===e.init[this.featureName].autoStart?this.deferred=new Promise((t,r)=>{this.ee.on("manual-start-all",(0,x.J)(()=>{(0,m.Ak)(e.agentIdentifier,this.featureName),t()}))}):(0,m.Ak)(e.agentIdentifier,t)}importAggregator(e,t,r={}){if(this.featAggregate)return;const n=async()=>{let n;await this.deferred;try{if((0,R.V)(e.init)){const{setupAgentSession:t}=await i.e(478).then(i.bind(i,8766));n=t(e)}}catch(e){(0,l.R)(20,e),this.ee.emit("internal-error",[e]),(0,a.p)(T.qh,[e],void 0,this.featureName,this.ee)}try{if(!this.#t(this.featureName,n,e.init))return(0,m.Ze)(this.agentIdentifier,this.featureName),void this.loadedSuccessfully(!1);const{Aggregate:i}=await t();this.featAggregate=new i(e,r),e.runtime.harvester.initializedAggregates.push(this.featAggregate),this.loadedSuccessfully(!0)}catch(e){(0,l.R)(34,e),this.abortHandler?.(),(0,m.Ze)(this.agentIdentifier,this.featureName,!0),this.loadedSuccessfully(!1),this.ee&&this.ee.abort()}};y.RI?(0,b.GG)(()=>n(),!0):n()}#t(e,t,r){if(this.blocked)return!1;switch(e){case n.K7.sessionReplay:return(0,w.SR)(r)&&!!t;case n.K7.sessionTrace:return!!t;default:return!0}}}var A=i(6630),S=i(2614);class _ extends E{static featureName=A.T;constructor(e){var t;super(e,A.T),this.setupInspectionEvents(e.agentIdentifier),t=e,p(u.Fw,function(e,r){"string"==typeof e&&("/"!==e.charAt(0)&&(e="/"+e),t.runtime.customTransaction=(r||"http://custom.transaction")+e,(0,a.p)(u.Pl+u.Fw,[(0,c.t)()],void 0,void 0,t.ee))},t),this.importAggregator(e,()=>i.e(478).then(i.bind(i,1983)))}setupInspectionEvents(e){const t=(t,r)=>{t&&(0,d.W)({agentIdentifier:e,timeStamp:t.timeStamp,loaded:"complete"===t.target.readyState,type:"window",name:r,data:t.target.location+""})};(0,b.sB)(e=>{t(e,"DOMContentLoaded")}),(0,b.GG)(e=>{t(e,"load")}),(0,b.Qr)(e=>{t(e,"navigate")}),this.ee.on(S.tS.UPDATE,(t,r)=>{(0,d.W)({agentIdentifier:e,type:"lifecycle",name:"session",data:r})})}}var O=i(384);var N=i(2843),I=i(3878),P=i(782);class j extends E{static featureName=P.T;constructor(e){super(e,P.T),y.RI&&((0,N.u)(()=>(0,a.p)("docHidden",[(0,c.t)()],void 0,P.T,this.ee),!0),(0,I.sp)("pagehide",()=>(0,a.p)("winPagehide",[(0,c.t)()],void 0,P.T,this.ee)),this.importAggregator(e,()=>i.e(478).then(i.bind(i,9917))))}}class k extends E{static featureName=h.TZ;constructor(e){super(e,h.TZ),y.RI&&document.addEventListener("securitypolicyviolation",e=>{(0,a.p)(h.xV,["Generic/CSPViolation/Detected"],void 0,this.featureName,this.ee)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,6555)))}}var C=i(6774),L=i(3304);class H{constructor(e,t,r,n,i){this.name="UncaughtError",this.message="string"==typeof e?e:(0,L.A)(e),this.sourceURL=t,this.line=r,this.column=n,this.__newrelic=i}}function M(e){return U(e)?e:new H(void 0!==e?.message?e.message:e,e?.filename||e?.sourceURL,e?.lineno||e?.line,e?.colno||e?.col,e?.__newrelic,e?.cause)}function K(e){const t="Unhandled Promise Rejection: ";if(!e?.reason)return;if(U(e.reason)){try{e.reason.message.startsWith(t)||(e.reason.message=t+e.reason.message)}catch(e){}return M(e.reason)}const r=M(e.reason);return(r.message||"").startsWith(t)||(r.message=t+r.message),r}function D(e){if(e.error instanceof SyntaxError&&!/:\d+$/.test(e.error.stack?.trim())){const t=new H(e.message,e.filename,e.lineno,e.colno,e.error.__newrelic,e.cause);return t.name=SyntaxError.name,t}return U(e.error)?e.error:M(e)}function U(e){return e instanceof Error&&!!e.stack}function F(e,t,r,i,o=(0,c.t)()){"string"==typeof e&&(e=new Error(e)),(0,a.p)("err",[e,o,!1,t,r.runtime.isRecording,void 0,i],void 0,n.K7.jserrors,r.ee),(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,r.ee)}var W=i(4387),B=i(993),V=i(3785);function G(e,{customAttributes:t={},level:r=B.p_.INFO}={},n,i,o=(0,c.t)()){(0,V.R)(n.ee,e,t,r,i,o)}function z(e,t,r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.hG,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function Z(e,t,r,i,o=(0,c.t)()){const{start:s,end:d,customAttributes:f}=t||{},h={customAttributes:f||{}};if("object"!=typeof h.customAttributes||"string"!=typeof e||0===e.length)return void(0,l.R)(57);const p=(e,t)=>null==e?t:"number"==typeof e?e:e instanceof PerformanceMark?e.startTime:Number.NaN;if(h.start=p(s,0),h.end=p(d,o),Number.isNaN(h.start)||Number.isNaN(h.end))(0,l.R)(57);else{if(h.duration=h.end-h.start,!(h.duration<0))return(0,a.p)(u.Pl+u.V1,[h,e,i],void 0,n.K7.genericEvents,r.ee),h;(0,l.R)(58)}}function q(e,t={},r,i,o=(0,c.t)()){(0,a.p)(u.Pl+u.fF,[o,e,t,i],void 0,n.K7.genericEvents,r.ee)}function X(e){p(u.eY,function(t){return Y(e,t)},e)}function Y(e,t,r){const i={};(0,l.R)(54,"newrelic.register"),t||={},t.eventSource="MicroFrontendBrowserAgent",t.licenseKey||=e.info.licenseKey,t.blocked=!1,t.parent=r||{};let o=()=>{};const s=e.runtime.registeredEntities,u=s.find(({metadata:{target:{id:e,name:r}}})=>e===t.id);if(u)return u.metadata.target.name!==t.name&&(u.metadata.target.name=t.name),u;const d=e=>{t.blocked=!0,o=e};e.init.api.allow_registered_children||d((0,x.J)(()=>(0,l.R)(55))),(0,W.c7)(t)||d((0,x.J)(()=>(0,l.R)(48,t))),(0,W.yo)(t.id)&&(0,W.yo)(t.name)||d((0,x.J)(()=>(0,l.R)(48,t)));const f={addPageAction:(r,n={})=>m(z,[r,{...i,...n},e],t),log:(r,n={})=>m(G,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),measure:(r,n={})=>m(Z,[r,{...n,customAttributes:{...i,...n.customAttributes||{}}},e],t),noticeError:(r,n={})=>m(F,[r,{...i,...n},e],t),register:(t={})=>m(Y,[e,t],f.metadata.target),recordCustomEvent:(r,n={})=>m(q,[r,{...i,...n},e],t),setApplicationVersion:e=>g("application.version",e),setCustomAttribute:(e,t)=>g(e,t),setUserId:e=>g("enduser.id",e),metadata:{customAttributes:i,target:t}},p=()=>(t.blocked&&o(),t.blocked);p()||s.push(f);const g=(e,t)=>{p()||(i[e]=t)},m=(t,r,i)=>{if(p())return;const o=(0,c.t)();(0,a.p)(h.xV,["API/register/".concat(t.name,"/called")],void 0,n.K7.metrics,e.ee);try{return e.init.api.duplicate_registered_data&&"register"!==t.name&&t(...r,void 0,o),t(...r,i,o)}catch(e){(0,l.R)(50,e)}};return f}class J extends E{static featureName=C.T;constructor(e){var t;super(e,C.T),t=e,p(u.o5,(e,r)=>F(e,r,t),t),function(e){p(u.bt,function(t){e.runtime.onerror=t},e)}(e),function(e){let t=0;p(u.k6,function(e,r){++t>10||(this.runtime.releaseIds[e.slice(-200)]=(""+r).slice(-200))},e)}(e),X(e);try{this.removeOnAbort=new AbortController}catch(e){}this.ee.on("internal-error",(t,r)=>{this.abortHandler&&(0,a.p)("ierr",[M(t),(0,c.t)(),!0,{},e.runtime.isRecording,r],void 0,this.featureName,this.ee)}),y.gm.addEventListener("unhandledrejection",t=>{this.abortHandler&&(0,a.p)("err",[K(t),(0,c.t)(),!1,{unhandledPromiseRejection:1},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),y.gm.addEventListener("error",t=>{this.abortHandler&&(0,a.p)("err",[D(t),(0,c.t)(),!1,{},e.runtime.isRecording],void 0,this.featureName,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,2176)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var Q=i(8990);let ee=1;function te(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===y.gm?0:(0,Q.I)(e,"nr@id",function(){return ee++})}function re(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,L.A)(e).length}catch(e){return}}}var ne=i(8139),ie=i(7836),oe=i(3434);const se={},ae=["open","send"];function ce(e){var t=e||ie.ee;const r=function(e){return(e||ie.ee).get("xhr")}(t);if(void 0===y.gm.XMLHttpRequest)return r;if(se[r.debugId]++)return r;se[r.debugId]=1,(0,ne.u)(t);var n=(0,oe.YM)(r),i=y.gm.XMLHttpRequest,o=y.gm.MutationObserver,s=y.gm.Promise,a=y.gm.setInterval,c="readystatechange",u=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"],d=[],f=y.gm.XMLHttpRequest=function(e){const t=new i(e),o=r.context(t);try{r.emit("new-xhr",[t],o),t.addEventListener(c,(s=o,function(){var e=this;e.readyState>3&&!s.resolved&&(s.resolved=!0,r.emit("xhr-resolved",[],e)),n.inPlace(e,u,"fn-",b)}),(0,I.jT)(!1))}catch(e){(0,l.R)(15,e);try{r.emit("internal-error",[e])}catch(e){}}var s;return t};function h(e,t){n.inPlace(t,["onreadystatechange"],"fn-",b)}if(function(e,t){for(var r in e)t[r]=e[r]}(i,f),f.prototype=i.prototype,n.inPlace(f.prototype,ae,"-xhr-",b),r.on("send-xhr-start",function(e,t){h(e,t),function(e){d.push(e),o&&(p?p.then(v):a?a(v):(g=-g,m.data=g))}(t)}),r.on("open-xhr-start",h),o){var p=s&&s.resolve();if(!a&&!s){var g=1,m=document.createTextNode(g);new o(v).observe(m,{characterData:!0})}}else t.on("fn-end",function(e){e[0]&&e[0].type===c||v()});function v(){for(var e=0;e<d.length;e++)h(0,d[e]);d.length&&(d=[])}function b(e,t){return t}return r}var ue="fetch-",de=ue+"body-",le=["arrayBuffer","blob","json","text","formData"],fe=y.gm.Request,he=y.gm.Response,pe="prototype";const ge={};function me(e){const t=function(e){return(e||ie.ee).get("fetch")}(e);if(!(fe&&he&&y.gm.fetch))return t;if(ge[t.debugId]++)return t;function r(e,r,n){var i=e[r];"function"==typeof i&&(e[r]=function(){var e,r=[...arguments],o={};t.emit(n+"before-start",[r],o),o[ie.P]&&o[ie.P].dt&&(e=o[ie.P].dt);var s=i.apply(this,r);return t.emit(n+"start",[r,e],s),s.then(function(e){return t.emit(n+"end",[null,e],s),e},function(e){throw t.emit(n+"end",[e],s),e})})}return ge[t.debugId]=1,le.forEach(e=>{r(fe[pe],e,de),r(he[pe],e,de)}),r(y.gm,"fetch",ue),t.on(ue+"end",function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(ue+"done",[null,r],n)}else t.emit(ue+"done",[e],n)}),t}var ve=i(7485);class be{constructor(e){this.agentRef=e}generateTracePayload(t){const r=this.agentRef.loader_config;if(!this.shouldGenerateTrace(t)||!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var s=(0,e.ZF)(),a=(0,e.el)(),c=Date.now(),u={spanId:s,traceId:a,timestamp:c};return(t.sameOrigin||this.isAllowedOrigin(t)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(s,a),u.traceContextStateHeader=this.generateTraceContextStateHeader(s,c,n,i,o)),(t.sameOrigin&&!this.excludeNewrelicHeader()||!t.sameOrigin&&this.isAllowedOrigin(t)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(s,a,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof y.gm?.btoa))return null;var s={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(s.d.tk=o),btoa((0,L.A)(s))}shouldGenerateTrace(e){return this.agentRef.init?.distributed_tracing?.enabled&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var t=!1;const r=this.agentRef.init?.distributed_tracing;if(e.sameOrigin)t=!0;else if(r?.allowed_origins instanceof Array)for(var n=0;n<r.allowed_origins.length;n++){var i=(0,ve.D)(r.allowed_origins[n]);if(e.hostname===i.hostname&&e.protocol===i.protocol&&e.port===i.port){t=!0;break}}return t}excludeNewrelicHeader(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.exclude_newrelic_header}useNewrelicHeaderForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!1!==e.cors_use_newrelic_header}useTraceContextHeadersForCors(){var e=this.agentRef.init?.distributed_tracing;return!!e&&!!e.cors_use_tracecontext_headers}}var ye=i(9300),we=i(7295);function Re(e){return"string"==typeof e?e:e instanceof(0,O.dV)().o.REQ?e.url:y.gm?.URL&&e instanceof URL?e.href:void 0}var xe=["load","error","abort","timeout"],Te=xe.length,Ee=(0,O.dV)().o.REQ,Ae=(0,O.dV)().o.XHR;const Se="X-NewRelic-App-Data";class _e extends E{static featureName=ye.T;constructor(e){super(e,ye.T),this.dt=new be(e),this.handler=(e,t,r,n)=>(0,a.p)(e,t,r,n,this.ee);try{const e={xmlhttprequest:"xhr",fetch:"fetch",beacon:"beacon"};y.gm?.performance?.getEntriesByType("resource").forEach(t=>{if(t.initiatorType in e&&0!==t.responseStatus){const r={status:t.responseStatus},i={rxSize:t.transferSize,duration:Math.floor(t.duration),cbTime:0};Oe(r,t.name),this.handler("xhr",[r,i,t.startTime,t.responseEnd,e[t.initiatorType]],void 0,n.K7.ajax)}})}catch(e){}me(this.ee),ce(this.ee),function(e,t,r,i){function o(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},t.latestLongtaskEnd=0,e.addEventListener("load",function(r){A(t,e)},(0,I.jT)(!1)),y.lR||e.addEventListener("progress",function(e){t.lastSize=e.loaded},(0,I.jT)(!1))}function s(e){this.params={method:e[0]},Oe(this,e[1]),this.metrics={}}function u(t,r){e.loader_config.xpid&&this.sameOrigin&&r.setRequestHeader("X-NewRelic-ID",e.loader_config.xpid);var n=i.generateTracePayload(this.parsedOrigin);if(n){var o=!1;n.newrelicHeader&&(r.setRequestHeader("newrelic",n.newrelicHeader),o=!0),n.traceContextParentHeader&&(r.setRequestHeader("traceparent",n.traceContextParentHeader),n.traceContextStateHeader&&r.setRequestHeader("tracestate",n.traceContextStateHeader),o=!0),o&&(this.dt=n)}}function d(e,r){var n=this.metrics,i=e[0],o=this;if(n&&i){var s=re(i);s&&(n.txSize=s)}this.startTime=(0,c.t)(),this.body=i,this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof r.onload)&&"function"==typeof o.end)&&o.end(r)}catch(e){try{t.emit("internal-error",[e])}catch(e){}}};for(var a=0;a<Te;a++)r.addEventListener(xe[a],this.listener,(0,I.jT)(!1))}function l(e,t,r){this.cbTime+=e,t?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof r.onload||"function"!=typeof this.end||this.end(r)}function f(e,t){var r=""+te(e)+!!t;this.xhrGuids&&!this.xhrGuids[r]&&(this.xhrGuids[r]=!0,this.totalCbs+=1)}function p(e,t){var r=""+te(e)+!!t;this.xhrGuids&&this.xhrGuids[r]&&(delete this.xhrGuids[r],this.totalCbs-=1)}function g(){this.endTime=(0,c.t)()}function m(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-added",[e[1],e[2]],r)}function v(e,r){r instanceof Ae&&"load"===e[0]&&t.emit("xhr-load-removed",[e[1],e[2]],r)}function b(e,t,r){t instanceof Ae&&("onload"===r&&(this.onload=!0),("load"===(e[0]&&e[0].type)||this.onload)&&(this.xhrCbStart=(0,c.t)()))}function w(e,r){this.xhrCbStart&&t.emit("xhr-cb-time",[(0,c.t)()-this.xhrCbStart,this.onload,r],r)}function R(e){var t,r=e[1]||{};if("string"==typeof e[0]?0===(t=e[0]).length&&y.RI&&(t=""+y.gm.location.href):e[0]&&e[0].url?t=e[0].url:y.gm?.URL&&e[0]&&e[0]instanceof URL?t=e[0].href:"function"==typeof e[0].toString&&(t=e[0].toString()),"string"==typeof t&&0!==t.length){t&&(this.parsedOrigin=(0,ve.D)(t),this.sameOrigin=this.parsedOrigin.sameOrigin);var n=i.generateTracePayload(this.parsedOrigin);if(n&&(n.newrelicHeader||n.traceContextParentHeader))if(e[0]&&e[0].headers)a(e[0].headers,n)&&(this.dt=n);else{var o={};for(var s in r)o[s]=r[s];o.headers=new Headers(r.headers||{}),a(o.headers,n)&&(this.dt=n),e.length>1?e[1]=o:e.push(o)}}function a(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,c.t)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r=this.opts||{},n=this.target;Oe(this,Re(n));var i=(""+(n&&n instanceof Ee&&n.method||r.method||"GET")).toUpperCase();this.params.method=i,this.body=r.body,this.txSize=re(r.body)||0}function T(e,t){if(this.endTime=(0,c.t)(),this.params||(this.params={}),(0,we.iW)(this.params))return;let i;this.params.status=t?t.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(i=+this.rxSize);const o={txSize:this.txSize,rxSize:i,duration:(0,c.t)()-this.startTime};r("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,n.K7.ajax)}function E(e){const t=this.params,i=this.metrics;if(!this.ended){this.ended=!0;for(let t=0;t<Te;t++)e.removeEventListener(xe[t],this.listener,!1);t.aborted||(0,we.iW)(t)||(i.duration=(0,c.t)()-this.startTime,this.loadCaptureCalled||4!==e.readyState?null==t.status&&(t.status=0):A(this,e),i.cbTime=this.cbTime,r("xhr",[t,i,this.startTime,this.endTime,"xhr"],this,n.K7.ajax))}}function A(e,r){e.params.status=r.status;var i=function(e,t){var r=e.responseType;return"json"===r&&null!==t?t:"arraybuffer"===r||"blob"===r||"json"===r?re(e.response):"text"===r||""===r||void 0===r?re(e.responseText):void 0}(r,e.lastSize);if(i&&(e.metrics.rxSize=i),e.sameOrigin&&r.getAllResponseHeaders().indexOf(Se)>=0){var o=r.getResponseHeader(Se);o&&((0,a.p)(h.rs,["Ajax/CrossApplicationTracing/Header/Seen"],void 0,n.K7.metrics,t),e.params.cat=o.split(", ").pop())}e.loadCaptureCalled=!0}t.on("new-xhr",o),t.on("open-xhr-start",s),t.on("open-xhr-end",u),t.on("send-xhr-start",d),t.on("xhr-cb-time",l),t.on("xhr-load-added",f),t.on("xhr-load-removed",p),t.on("xhr-resolved",g),t.on("addEventListener-end",m),t.on("removeEventListener-end",v),t.on("fn-end",w),t.on("fetch-before-start",R),t.on("fetch-start",x),t.on("fn-start",b),t.on("fetch-done",T)}(e,this.ee,this.handler,this.dt),this.importAggregator(e,()=>i.e(478).then(i.bind(i,3845)))}}function Oe(e,t){var r=(0,ve.D)(t),n=e.params||e;n.hostname=r.hostname,n.port=r.port,n.protocol=r.protocol,n.host=r.hostname+":"+r.port,n.pathname=r.pathname,e.parsedOrigin=r,e.sameOrigin=r.sameOrigin}const Ne={},Ie=["pushState","replaceState"];function Pe(e){const t=function(e){return(e||ie.ee).get("history")}(e);return!y.RI||Ne[t.debugId]++||(Ne[t.debugId]=1,(0,oe.YM)(t).inPlace(window.history,Ie,"-")),t}var je=i(3738);function ke(e){p(u.BL,function(t=Date.now()){const r=t-y.WN;r<0&&(0,l.R)(62,t),(0,a.p)(h.XG,[u.BL,{time:r}],void 0,n.K7.metrics,e.ee),e.addToTrace({name:u.BL,start:t,origin:"nr"}),(0,a.p)(u.Pl+u.hG,[r,u.BL],void 0,n.K7.genericEvents,e.ee)},e)}const{He:Ce,bD:Le,d3:He,Kp:Me,TZ:Ke,Lc:De,uP:Ue,Rz:Fe}=je;class We extends E{static featureName=Ke;constructor(e){var t;super(e,Ke),t=e,p(u.U2,function(e){if(!(e&&"object"==typeof e&&e.name&&e.start))return;const r={n:e.name,s:e.start-y.WN,e:(e.end||e.start)-y.WN,o:e.origin||"",t:"api"};r.s<0||r.e<0||r.e<r.s?(0,l.R)(61,{start:r.s,end:r.e}):(0,a.p)("bstApi",[r],void 0,n.K7.sessionTrace,t.ee)},t),ke(e);if(!(0,R.V)(e.init))return void this.deregisterDrain();const r=this.ee;let o;Pe(r),this.eventsEE=(0,ne.u)(r),this.eventsEE.on(Ue,function(e,t){this.bstStart=(0,c.t)()}),this.eventsEE.on(De,function(e,t){(0,a.p)("bst",[e[0],t,this.bstStart,(0,c.t)()],void 0,n.K7.sessionTrace,r)}),r.on(Fe+He,function(e){this.time=(0,c.t)(),this.startPath=location.pathname+location.hash}),r.on(Fe+Me,function(e){(0,a.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,n.K7.sessionTrace,r)});try{o=new PerformanceObserver(e=>{const t=e.getEntries();(0,a.p)(Ce,[t],void 0,n.K7.sessionTrace,r)}),o.observe({type:Le,buffered:!0})}catch(e){}this.importAggregator(e,()=>i.e(478).then(i.bind(i,6974)),{resourceObserver:o})}}var Be=i(6344);class Ve extends E{static featureName=Be.TZ;#n;recorder;constructor(e){var t;let r;super(e,Be.TZ),t=e,p(u.CH,function(){(0,a.p)(u.CH,[],void 0,n.K7.sessionReplay,t.ee)},t),function(e){p(u.Tb,function(){(0,a.p)(u.Tb,[],void 0,n.K7.sessionReplay,e.ee)},e)}(e);try{r=JSON.parse(localStorage.getItem("".concat(S.H3,"_").concat(S.uh)))}catch(e){}(0,w.SR)(e.init)&&this.ee.on(u.CH,()=>this.#i()),this.#o(r)&&this.importRecorder().then(e=>{e.startRecording(Be.Qb.PRELOAD,r?.sessionReplayMode)}),this.importAggregator(this.agentRef,()=>i.e(478).then(i.bind(i,6167)),this),this.ee.on("err",e=>{this.blocked||this.agentRef.runtime.isRecording&&(this.errorNoticed=!0,(0,a.p)(Be.Vh,[e],void 0,this.featureName,this.ee))})}#o(e){return e&&(e.sessionReplayMode===S.g.FULL||e.sessionReplayMode===S.g.ERROR)||(0,w.Aw)(this.agentRef.init)}importRecorder(){return this.recorder?Promise.resolve(this.recorder):(this.#n??=Promise.all([i.e(478),i.e(249)]).then(i.bind(i,4866)).then(({Recorder:e})=>(this.recorder=new e(this),this.recorder)).catch(e=>{throw this.ee.emit("internal-error",[e]),this.blocked=!0,e}),this.#n)}#i(){this.blocked||(this.featAggregate?this.featAggregate.mode!==S.g.FULL&&this.featAggregate.initializeRecording(S.g.FULL,!0,Be.Qb.API):this.importRecorder().then(()=>{this.recorder.startRecording(Be.Qb.API,S.g.FULL)}))}}var Ge=i(3962);function ze(e){const t=e.ee.get("tracer");function r(){}p(u.dT,function(e){return(new r).get("object"==typeof e?e:{})},e);const i=r.prototype={createTracer:function(r,i){var o={},s=this,d="function"==typeof i;return(0,a.p)(h.xV,["API/createTracer/called"],void 0,n.K7.metrics,e.ee),e.runSoftNavOverSpa||(0,a.p)(u.hw+"tracer",[(0,c.t)(),r,o],s,n.K7.spa,e.ee),function(){if(t.emit((d?"":"no-")+"fn-start",[(0,c.t)(),s,d],o),d)try{return i.apply(this,arguments)}catch(e){const r="string"==typeof e?new Error(e):e;throw t.emit("fn-err",[arguments,this,r],o),r}finally{t.emit("fn-end",[(0,c.t)()],o)}}}};["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach(t=>{p.apply(this,[t,function(){return(0,a.p)(u.hw+t,[(0,c.t)(),...arguments],this,e.runSoftNavOverSpa?n.K7.softNav:n.K7.spa,e.ee),this},e,i])}),p(u.PA,function(){e.runSoftNavOverSpa?(0,a.p)(u.hw+"routeName",[performance.now(),...arguments],void 0,n.K7.softNav,e.ee):(0,a.p)(u.Pl+"routeName",[(0,c.t)(),...arguments],this,n.K7.spa,e.ee)},e)}class Ze extends E{static featureName=Ge.TZ;constructor(e){if(super(e,Ge.TZ),ze(e),!y.RI||!(0,O.dV)().o.MO)return;const t=Pe(this.ee);try{this.removeOnAbort=new AbortController}catch(e){}Ge.tC.forEach(e=>{(0,I.sp)(e,e=>{s(e)},!0,this.removeOnAbort?.signal)});const r=()=>(0,a.p)("newURL",[(0,c.t)(),""+window.location],void 0,this.featureName,this.ee);t.on("pushState-end",r),t.on("replaceState-end",r),(0,I.sp)(Ge.OV,e=>{s(e),(0,a.p)("newURL",[e.timeStamp,""+window.location],void 0,this.featureName,this.ee)},!0,this.removeOnAbort?.signal);let n=!1;const o=new((0,O.dV)().o.MO)((e,t)=>{n||(n=!0,requestAnimationFrame(()=>{(0,a.p)("newDom",[(0,c.t)()],void 0,this.featureName,this.ee),n=!1}))}),s=(0,x.s)(e=>{(0,a.p)("newUIEvent",[e],void 0,this.featureName,this.ee),o.observe(document.body,{attributes:!0,childList:!0,subtree:!0,characterData:!0})},100,{leading:!0});this.abortHandler=function(){this.removeOnAbort?.abort(),o.disconnect(),this.abortHandler=void 0},this.importAggregator(e,()=>i.e(478).then(i.bind(i,4393)),{domObserver:o})}}var qe=i(7378);const Xe={},Ye=["appendChild","insertBefore","replaceChild"];function Je(e){const t=function(e){return(e||ie.ee).get("jsonp")}(e);if(!y.RI||Xe[t.debugId])return t;Xe[t.debugId]=!0;var r=(0,oe.YM)(t),n=/[?&](?:callback|cb)=([^&#]+)/,i=/(.*)\.([^.]+)/,o=/^(\w+)(\.|$)(.*)$/;function s(e,t){if(!e)return t;const r=e.match(o),n=r[1];return s(r[3],t[n])}return r.inPlace(Node.prototype,Ye,"dom-"),t.on("dom-start",function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var o=(a=e.src,c=a.match(n),c?c[1]:null);var a,c;if(!o)return;var u=function(e){var t=e.match(i);if(t&&t.length>=3)return{key:t[2],parent:s(t[1],window)};return{key:e,parent:window}}(o);if("function"!=typeof u.parent[u.key])return;var d={};function l(){t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}function f(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",l,(0,I.jT)(!1)),e.removeEventListener("error",f,(0,I.jT)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",l,(0,I.jT)(!1)),e.addEventListener("error",f,(0,I.jT)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])}),t}const $e={};function Qe(e){const t=function(e){return(e||ie.ee).get("promise")}(e);if($e[t.debugId])return t;$e[t.debugId]=!0;var r=t.context,n=(0,oe.YM)(t),i=y.gm.Promise;return i&&function(){function e(r){var o=t.context(),s=n(r,"executor-",o,null,!1);const a=Reflect.construct(i,[s],e);return t.context(a).getCtx=function(){return o},a}y.gm.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return i.toString()},Object.setPrototypeOf(e,i),["all","race"].forEach(function(r){const n=i[r];e[r]=function(e){let i=!1;[...e||[]].forEach(e=>{this.resolve(e).then(s("all"===r),s(!1))});const o=n.apply(this,arguments);return o;function s(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}}),["resolve","reject"].forEach(function(r){const n=i[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}}),e.prototype=i.prototype;const o=i.prototype.then;i.prototype.then=function(...e){var i=this,s=r(i);s.promise=i,e[0]=n(e[0],"cb-",s,null,!1),e[1]=n(e[1],"cb-",s,null,!1);const a=o.apply(this,e);return s.nextPromise=a,t.emit("propagate",[i,!0],a,!1,!1),a},i.prototype.then[oe.Jt]=o,t.on("executor-start",function(e){e[0]=n(e[0],"resolve-",this,null,!1),e[1]=n(e[1],"resolve-",this,null,!1)}),t.on("executor-err",function(e,t,r){e[1](r)}),t.on("cb-end",function(e,r,n){t.emit("propagate",[n,!0],this.nextPromise,!1,!1)}),t.on("propagate",function(e,r,n){if(!this.getCtx||r){const r=this,n=e instanceof Promise?t.context(e):null;let i;this.getCtx=function(){return i||(i=n&&n!==r?"function"==typeof n.getCtx?n.getCtx():n:r,i)}}})}(),t}const et={},tt="setTimeout",rt="setInterval",nt="clearTimeout",it="-start",ot=[tt,"setImmediate",rt,nt,"clearImmediate"];function st(e){const t=function(e){return(e||ie.ee).get("timer")}(e);if(et[t.debugId]++)return t;et[t.debugId]=1;var r=(0,oe.YM)(t);return r.inPlace(y.gm,ot.slice(0,2),tt+"-"),r.inPlace(y.gm,ot.slice(2,3),rt+"-"),r.inPlace(y.gm,ot.slice(3),nt+"-"),t.on(rt+it,function(e,t,n){e[0]=r(e[0],"fn-",null,n)}),t.on(tt+it,function(e,t,n){this.method=n,this.timerDuration=isNaN(e[1])?0:+e[1],e[0]=r(e[0],"fn-",this,n)}),t}const at={};function ct(e){const t=function(e){return(e||ie.ee).get("mutation")}(e);if(!y.RI||at[t.debugId])return t;at[t.debugId]=!0;var r=(0,oe.YM)(t),n=y.gm.MutationObserver;return n&&(window.MutationObserver=function(e){return this instanceof n?new n(r(e,"fn-")):n.apply(this,arguments)},MutationObserver.prototype=n.prototype),t}const{TZ:ut,d3:dt,Kp:lt,$p:ft,wW:ht,e5:pt,tH:gt,uP:mt,rw:vt,Lc:bt}=qe;class yt extends E{static featureName=ut;constructor(e){if(super(e,ut),ze(e),!y.RI)return;try{this.removeOnAbort=new AbortController}catch(e){}let t,r=0;const n=this.ee.get("tracer"),o=Je(this.ee),s=Qe(this.ee),u=st(this.ee),d=ce(this.ee),l=this.ee.get("events"),f=me(this.ee),h=Pe(this.ee),p=ct(this.ee);function g(e,t){h.emit("newURL",[""+window.location,t])}function m(){r++,t=window.location.hash,this[mt]=(0,c.t)()}function v(){r--,window.location.hash!==t&&g(0,!0);var e=(0,c.t)();this[pt]=~~this[pt]+e-this[mt],this[bt]=e}function b(e,t){e.on(t,function(){this[t]=(0,c.t)()})}this.ee.on(mt,m),s.on(vt,m),o.on(vt,m),this.ee.on(bt,v),s.on(ht,v),o.on(ht,v),this.ee.on("fn-err",(...t)=>{t[2]?.__newrelic?.[e.agentIdentifier]||(0,a.p)("function-err",[...t],void 0,this.featureName,this.ee)}),this.ee.buffer([mt,bt,"xhr-resolved"],this.featureName),l.buffer([mt],this.featureName),u.buffer(["setTimeout"+lt,"clearTimeout"+dt,mt],this.featureName),d.buffer([mt,"new-xhr","send-xhr"+dt],this.featureName),f.buffer([gt+dt,gt+"-done",gt+ft+dt,gt+ft+lt],this.featureName),h.buffer(["newURL"],this.featureName),p.buffer([mt],this.featureName),s.buffer(["propagate",vt,ht,"executor-err","resolve"+dt],this.featureName),n.buffer([mt,"no-"+mt],this.featureName),o.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),b(f,gt+dt),b(f,gt+"-done"),b(o,"new-jsonp"),b(o,"jsonp-end"),b(o,"cb-start"),h.on("pushState-end",g),h.on("replaceState-end",g),window.addEventListener("hashchange",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",g,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",function(){g(0,r>1)},(0,I.jT)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#r,this.importAggregator(e,()=>i.e(478).then(i.bind(i,5592)))}#r(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}var wt=i(3333);class Rt extends E{static featureName=wt.TZ;constructor(e){super(e,wt.TZ);const t=[e.init.page_action.enabled,e.init.performance.capture_marks,e.init.performance.capture_measures,e.init.user_actions.enabled,e.init.performance.resources.enabled];var r;r=e,p(u.hG,(e,t)=>z(e,t,r),r),function(e){p(u.fF,(t,r)=>q(t,r,e),e)}(e),ke(e),X(e),function(e){p(u.V1,(t,r)=>Z(t,r,e),e)}(e);const o=e.init.feature_flags.includes("user_frustrations");let s;if(y.RI&&o&&(me(this.ee),ce(this.ee),s=Pe(this.ee)),y.RI){if(e.init.user_actions.enabled&&(wt.Zp.forEach(e=>(0,I.sp)(e,e=>(0,a.p)("ua",[e],void 0,this.featureName,this.ee),!0)),wt.qN.forEach(e=>{const t=(0,x.s)(e=>{(0,a.p)("ua",[e],void 0,this.featureName,this.ee)},500,{leading:!0});(0,I.sp)(e,t)}),o)){function c(t){const r=(0,ve.D)(t);return e.beacons.includes(r.hostname+":"+r.port)}function d(){s.emit("navChange")}y.gm.addEventListener("error",()=>{(0,a.p)("uaErr",[],void 0,n.K7.genericEvents,this.ee)},(0,I.jT)(!1,this.removeOnAbort?.signal)),this.ee.on("open-xhr-start",(e,t)=>{c(e[1])||t.addEventListener("readystatechange",()=>{2===t.readyState&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)})}),this.ee.on("fetch-start",e=>{e.length>=1&&!c(Re(e[0]))&&(0,a.p)("uaXhr",[],void 0,n.K7.genericEvents,this.ee)}),s.on("pushState-end",d),s.on("replaceState-end",d),window.addEventListener("hashchange",d,(0,I.jT)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",d,(0,I.jT)(!0,this.removeOnAbort?.signal))}if(e.init.performance.resources.enabled&&y.gm.PerformanceObserver?.supportedEntryTypes.includes("resource")){new PerformanceObserver(e=>{e.getEntries().forEach(e=>{(0,a.p)("browserPerformance.resource",[e],void 0,this.featureName,this.ee)})}).observe({type:"resource",buffered:!0})}}try{this.removeOnAbort=new AbortController}catch(l){}this.abortHandler=()=>{this.removeOnAbort?.abort(),this.abortHandler=void 0},t.some(e=>e)?this.importAggregator(e,()=>i.e(478).then(i.bind(i,8019))):this.deregisterDrain()}}var xt=i(2646);const Tt=new Map;function Et(e,t,r,n){if("object"!=typeof t||!t||"string"!=typeof r||!r||"function"!=typeof t[r])return(0,l.R)(29);const i=function(e){return(e||ie.ee).get("logger")}(e),o=(0,oe.YM)(i),s=new xt.y(ie.P);s.level=n.level,s.customAttributes=n.customAttributes;const a=t[r]?.[oe.Jt]||t[r];return Tt.set(a,s),o.inPlace(t,[r],"wrap-logger-",()=>Tt.get(a)),i}var At=i(1910);class St extends E{static featureName=B.TZ;constructor(e){var t;super(e,B.TZ),t=e,p(u.$9,(e,r)=>G(e,r,t),t),function(e){p(u.Wb,(t,r,{customAttributes:n={},level:i=B.p_.INFO}={})=>{Et(e.ee,t,r,{customAttributes:n,level:i})},e)}(e),X(e);const r=this.ee;["log","error","warn","info","debug","trace"].forEach(e=>{(0,At.i)(y.gm.console[e]),Et(r,y.gm.console,e,{level:"log"===e?"info":e})}),this.ee.on("wrap-logger-end",function([e]){const{level:t,customAttributes:n}=this;(0,V.R)(r,e,n,t)}),this.importAggregator(e,()=>i.e(478).then(i.bind(i,5288)))}}new class extends r{constructor(e){var t;(super(),y.gm)?(this.features={},(0,O.bQ)(this.agentIdentifier,this),this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(_),this.runSoftNavOverSpa=[...this.desiredFeatures].some(e=>e.featureName===n.K7.softNav),(0,s.j)(this,e,e.loaderType||"agent"),t=this,p(u.cD,function(e,r,n=!1){if("string"==typeof e){if(["string","number","boolean"].includes(typeof r)||null===r)return g(t,e,r,u.cD,n);(0,l.R)(40,typeof r)}else(0,l.R)(39,typeof e)},t),function(e){p(u.Dl,function(t){if("string"==typeof t||null===t)return g(e,"enduser.id",t,u.Dl,!0);(0,l.R)(41,typeof t)},e)}(this),function(e){p(u.nb,function(t){if("string"==typeof t||null===t)return g(e,"application.version",t,u.nb,!1);(0,l.R)(42,typeof t)},e)}(this),function(e){p(u.d3,function(){e.ee.emit("manual-start-all")},e)}(this),function(e){p(u.Pv,function(t=!0){if("boolean"==typeof t){if((0,a.p)(u.Pl+u.Pv,[t],void 0,"session",e.ee),e.runtime.consented=t,t){const t=e.features.page_view_event;t.onAggregateImported.then(e=>{const r=t.featAggregate;e&&!r.sentRum&&r.sendRum()})}}else(0,l.R)(65,typeof t)},e)}(this),this.run()):(0,l.R)(21)}get config(){return{info:this.info,init:this.init,loader_config:this.loader_config,runtime:this.runtime}}get api(){return this}run(){try{const e=function(e){const t={};return o.forEach(r=>{t[r]=!!e[r]?.enabled}),t}(this.init),t=[...this.desiredFeatures];t.sort((e,t)=>n.P3[e.featureName]-n.P3[t.featureName]),t.forEach(t=>{if(!e[t.featureName]&&t.featureName!==n.K7.pageViewEvent)return;if(this.runSoftNavOverSpa&&t.featureName===n.K7.spa)return;if(!this.runSoftNavOverSpa&&t.featureName===n.K7.softNav)return;const r=function(e){switch(e){case n.K7.ajax:return[n.K7.jserrors];case n.K7.sessionTrace:return[n.K7.ajax,n.K7.pageViewEvent];case n.K7.sessionReplay:return[n.K7.sessionTrace];case n.K7.pageViewTiming:return[n.K7.pageViewEvent];default:return[]}}(t.featureName).filter(e=>!(e in this.features));r.length>0&&(0,l.R)(36,{targetFeature:t.featureName,missingDependencies:r}),this.features[t.featureName]=new t(this)})}catch(e){(0,l.R)(22,e);for(const e in this.features)this.features[e].abortHandler?.();const t=(0,O.Zm)();delete t.initializedAgents[this.agentIdentifier]?.features,delete this.sharedAggregator;return t.ee.get(this.agentIdentifier).abort(),!1}}}({features:[_e,_,j,We,Ve,k,J,Rt,St,Ze,yt],loaderType:"spa"})})()})();</script>
<link rel="icon" type="image/png" sizes="16x16" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png">
<link rel="icon" type="image/png" sizes="32x32" href="https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png">
<meta name="apple-mobile-web-app-title" content="Frontiers | Articles">
<link rel="manifest" href="/manifest.json">
<link rel="canonical" href="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/full">
<meta property="description" name="description" content="Background Breast cancer is the world's most common cancer among women. It is becoming an increasingly urgent problem in low- and middle-income countries (LM...">
<meta property="og:title" name="title" content="Frontiers | Identification of Eleven Novel BRCA Mutations in Tunisia: Impact on the Clinical Management of BRCA Related Cancers">
<meta property="og:description" name="description" content="Background Breast cancer is the world's most common cancer among women. It is becoming an increasingly urgent problem in low- and middle-income countries (LM...">
<meta name="keywords" content="BRCA cancers,Genetic Testing,novel BRCA mutations,Clinicopathological signatures,precision medicine">
<meta property="og:site_name" name="site_name" content="Frontiers">
<meta property="og:image" name="image" content="https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g001.jpg">
<meta property="og:type" name="type" content="article">
<meta property="og:url" name="url" content="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/full">
<meta name="twitter:card" content="summary_large_image">
<meta name="citation_volume" content="11">
<meta name="citation_journal_title" content="Frontiers in Oncology">
<meta name="citation_publisher" content="Frontiers">
<meta name="citation_journal_abbrev" content="Front. Oncol.">
<meta name="citation_issn" content="2234-943X">
<meta name="citation_doi" content="10.3389/fonc.2021.674965">
<meta name="citation_firstpage" content="674965">
<meta name="citation_language" content="English">
<meta name="citation_title" content="Identification of Eleven Novel BRCA Mutations in Tunisia: Impact on the Clinical Management of BRCA Related Cancers">
<meta name="citation_keywords" content="BRCA cancers; Genetic Testing; novel BRCA mutations; Clinicopathological signatures; precision medicine">
<meta name="citation_abstract" content="Background Breast cancer is the world's most common cancer among women. It is becoming an increasingly urgent problem in low- and middle-income countries (LMICs) where a large fraction of women is diagnosed with advanced-stage disease and have no access to treatment or basic palliative care. About 5-10% of all breast cancers can be attributed to hereditary genetic components and up to 25% of familial cases are due to mutations in BRCA1/2 genes. Since their discovery in 1994 and 1995, as few as 18 mutations have been identified in BRCA genes in the Tunisian population. The aim of this study is to identify additional BRCA mutations, to estimate their contribution to the hereditary breast and ovarian cancers in  Tunisia, and to investigate the clinicopathological signatures associated with BRCA mutations. Methods A total of 354 patients diagnosed with breast and ovarian cancers, including 5 male breast cancer cases, have been investigated for BRCA1/2 mutations using traditional and/or next-generation sequencing technologies. Clinicopathological signatures associated with BRCA mutations have been also investigated. Results 16 distinct mutations were detected: 10 in BRCA1 and 6 in BRCA2, of which 11 are described for the first time in Tunisia including 3 variations that have not been reported previously in public databases namely BRCA1_c.915T>A; BRCA2_c.-227-?_7805+? and BRCA2_c.249delG. Early age at onset, family history of ovarian cancer, and high tumor grade were significantly associated with BRCA status. BRCA1 carriers were more likely to be triple-negative breast cancer compared to BRCA2 carriers. A relatively high frequency of contralateral breast cancer and ovarian cancer occurrence was observed among BRCA carriers and was more frequent in patients carrying BRCA1 mutations. Conclusion Our study provides new insights into breast and ovarian cancer genetic landscape in the under-represented North African populations. The prevalence assessment of novel and recurrent BRCA1/2 pathogenic mutations will enhance the use of personalized treatment and precise screening strategies by both affected and unaffected North African cancer cases.">
<meta name="citation_article_type" content="Original Research">
<meta name="citation_pdf_url" content="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/pdf">
<meta name="citation_xml_url" content="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/xml">
<meta name="citation_fulltext_world_readable" content="yes">
<meta name="citation_online_date" content="2021/07/27">
<meta name="citation_publication_date" content="2021/08/20">
<meta name="citation_author" content="Hamdi, Yosr ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Mighri, Najah ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Boujemaa, Maroua ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Mejri, Nesrine ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Ben Nasr, Sonia ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Ben Rekaya, Mariem ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Messaoud, Olfa ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Bouaziz, Hanen ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Berrazega, Yosra ">
<meta name="citation_author_institution" content="Medical Oncology Department, Abderrahman Mami Hospital, Faculty of Medicine Tunis, University Tunis El Manar, Tunisia">
<meta name="citation_author" content="Rachdi, Haifa ">
<meta name="citation_author_institution" content="Medical Oncology Department, Abderrahman Mami Hospital, Faculty of Medicine Tunis, University Tunis El Manar, Tunisia">
<meta name="citation_author" content="Jaidane, Olfa ">
<meta name="citation_author_institution" content="Surgical Oncology Department, Salah Azaiez Institute of Cancer, Tunisia">
<meta name="citation_author" content="Daoud, Nouha ">
<meta name="citation_author_institution" content="Medical Oncology Department, Abderrahman Mami Hospital, Faculty of Medicine Tunis, University Tunis El Manar, Tunisia">
<meta name="citation_author" content="Zribi, Aref ">
<meta name="citation_author_institution" content="Department of Medical Oncology, Military Hospital of Tunis, Tunisia">
<meta name="citation_author" content="Ayari, Jihene ">
<meta name="citation_author_institution" content="Department of Medical Oncology, Military Hospital of Tunis, Tunisia">
<meta name="citation_author" content="El Benna, Houda ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Labidi, Soumaya ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Ben Hassouna, Jamel ">
<meta name="citation_author_institution" content="Surgical Oncology Department, Salah Azaiez Institute of Cancer, Tunisia">
<meta name="citation_author" content="Haddaoui, Abderazzek ">
<meta name="citation_author_institution" content="Department of Medical Oncology, Military Hospital of Tunis, Tunisia">
<meta name="citation_author" content="Rahal, Khaled ">
<meta name="citation_author_institution" content="Surgical Oncology Department, Salah Azaiez Institute of Cancer, Tunisia">
<meta name="citation_author" content="Benna, Farouk ">
<meta name="citation_author_institution" content="Department of Radiation Oncology, University of Tunis, Tunisia">
<meta name="citation_author" content="Mrad, Ridha ">
<meta name="citation_author_institution" content="Department of Human Genetics, Charles Nicolle Hospital, Tunisia">
<meta name="citation_author" content="Ben Ahmed, Slim ">
<meta name="citation_author_institution" content="Faculty of Medicine of Sousse Department of Medical Oncology Farhat Hached University Hospital University of Sousse, Tunisia">
<meta name="citation_author" content="Boussen, Hamouda ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Boubaker, Samir ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="citation_author" content="Abdelhak, Sonia ">
<meta name="citation_author_institution" content="Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia">
<meta name="dc.identifier" content="doi:10.3389/fonc.2021.674965">
<script type="application/ld+json">{"@context":"https://schema.org","@type":"ScholarlyArticle","headline":"Identification of Eleven Novel BRCA Mutations in Tunisia: Impact on the Clinical Management of BRCA Related Cancers","author":[{"@type":"Person","name":"Yosr Hamdi","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia","Laboratory of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunisia"]},{"@type":"Person","name":"Najah Mighri","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia"]},{"@type":"Person","name":"Maroua Boujemaa","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia"]},{"@type":"Person","name":"Nesrine Mejri","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia","Medical Oncology Department, Abderrahman Mami Hospital, Faculty of Medicine Tunis, University Tunis El Manar, Tunisia"]},{"@type":"Person","name":"Sonia Ben Nasr","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia","Department of Medical Oncology, Military Hospital of Tunis, Tunisia"]},{"@type":"Person","name":"Mariem Ben Rekaya","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia","UR17ES15, Oncotheranostic Biomarkers, Faculty of Medicine of Tunis, University Tunis El Manar, Tunisia"]},{"@type":"Person","name":"Olfa Messaoud","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia"]},{"@type":"Person","name":"Hanen Bouaziz","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia","Surgical Oncology Department, Salah Azaiez Institute of Cancer, Tunisia"]},{"@type":"Person","name":"Yosra Berrazega","affiliation":["Medical Oncology Department, Abderrahman Mami Hospital, Faculty of Medicine Tunis, University Tunis El Manar, Tunisia"]},{"@type":"Person","name":"Haifa Rachdi","affiliation":["Medical Oncology Department, Abderrahman Mami Hospital, Faculty of Medicine Tunis, University Tunis El Manar, Tunisia"]},{"@type":"Person","name":"Olfa Jaidane","affiliation":["Surgical Oncology Department, Salah Azaiez Institute of Cancer, Tunisia"]},{"@type":"Person","name":"Nouha Daoud","affiliation":["Medical Oncology Department, Abderrahman Mami Hospital, Faculty of Medicine Tunis, University Tunis El Manar, Tunisia"]},{"@type":"Person","name":"Aref Zribi","affiliation":["Department of Medical Oncology, Military Hospital of Tunis, Tunisia"]},{"@type":"Person","name":"Jihene Ayari","affiliation":["Department of Medical Oncology, Military Hospital of Tunis, Tunisia"]},{"@type":"Person","name":"Houda El Benna","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia","Medical Oncology Department, Abderrahman Mami Hospital, Faculty of Medicine Tunis, University Tunis El Manar, Tunisia"]},{"@type":"Person","name":"Soumaya Labidi","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia","Medical Oncology Department, Abderrahman Mami Hospital, Faculty of Medicine Tunis, University Tunis El Manar, Tunisia"]},{"@type":"Person","name":"Jamel Ben Hassouna","affiliation":["Surgical Oncology Department, Salah Azaiez Institute of Cancer, Tunisia"]},{"@type":"Person","name":"Abderazzek Haddaoui","affiliation":["Department of Medical Oncology, Military Hospital of Tunis, Tunisia"]},{"@type":"Person","name":"Khaled Rahal","affiliation":["Surgical Oncology Department, Salah Azaiez Institute of Cancer, Tunisia"]},{"@type":"Person","name":"Farouk Benna","affiliation":["Department of Radiation Oncology, University of Tunis, Tunisia"]},{"@type":"Person","name":"Ridha Mrad","affiliation":["Department of Human Genetics, Charles Nicolle Hospital, Tunisia"]},{"@type":"Person","name":"Slim Ben Ahmed","affiliation":["Faculty of Medicine of Sousse Department of Medical Oncology Farhat Hached University Hospital University of Sousse, Tunisia"]},{"@type":"Person","name":"Hamouda Boussen","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia","Medical Oncology Department, Abderrahman Mami Hospital, Faculty of Medicine Tunis, University Tunis El Manar, Tunisia"]},{"@type":"Person","name":"Samir Boubaker","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia","Laboratory of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunisia"]},{"@type":"Person","name":"Sonia Abdelhak","affiliation":["Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia"]}],"datePublished":"2021-08-20","dateModified":"2025-11-25","publisher":{"@type":"Organization","name":"Frontiers"},"isPartOf":{"@type":"PublicationIssue","datePublished":"2021","isPartOf":{"@type":"PublicationVolume","volumeNumber":"11","isPartOf":{"@type":"Periodical","name":"Frontiers in Oncology"}}},"citation":["https://doi.org/10.3389/fonc.2021.674965"],"inLanguage":"en"}</script>
<script type="module" src="/ap-2024/_nuxt/v1IBIWh4.js" crossorigin></script>
<script id="unhead:payload" type="application/json">{"title":"Frontiers | Articles"}</script></head><body  class="body--v3"><div id="__nuxt"><!--[--><!----><div theme="purple"><nav class="Ibar"><div class="Ibar__main"><div class="Ibar__wrapper"><button class="Ibar__burger" aria-label="Open Menu" data-event="iBar-btn-openMenu"></button><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/oncology" class="Ibar__journalName" data-event="iBar-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div class="Ibar__dropdown--aboutUs" parent-data-event="iBar"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=57&amp;specialtyid=0&amp;entitytype=2&amp;entityid=451" data-event="iBar-a-submit">Submit your research</a><div class="Ibar__spacer"></div><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><div><div class="Ibar__menu Ibar__menu--journal"><div class="Ibar__menu__header"><div class="Ibar__logo"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div></div><button class="Ibar__close" aria-label="Close Menu" data-event="iBarMenu-btn-closeMenu"></button></div><div class="Ibar__menu__wrapper"><div class="Ibar__menu__journal"><a href="//www.frontiersin.org/journals/oncology" data-event="iBarMenu-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/breast-cancer" data-event="iBarJournal-sections-a_id_500">Breast Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-cell-signaling" data-event="iBarJournal-sections-a_id_2606">Cancer Cell Signaling</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_513">Cancer Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-genetics" data-event="iBarJournal-sections-a_id_506">Cancer Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-imaging-and-image-directed-interventions" data-event="iBarJournal-sections-a_id_515">Cancer Imaging and Image-directed Interventions</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-immunity-and-immunotherapy" data-event="iBarJournal-sections-a_id_527">Cancer Immunity and Immunotherapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-metabolism" data-event="iBarJournal-sections-a_id_1510">Cancer Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-molecular-targets-and-therapeutics" data-event="iBarJournal-sections-a_id_507">Cancer Molecular Targets and Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-colorectal-cancer" data-event="iBarJournal-sections-a_id_2413">Gastrointestinal Cancers: Colorectal Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-gastric-and-esophageal-cancers" data-event="iBarJournal-sections-a_id_2415">Gastrointestinal Cancers: Gastric and Esophageal Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-hepato-pancreatic-biliary-cancers" data-event="iBarJournal-sections-a_id_2414">Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/genitourinary-oncology" data-event="iBarJournal-sections-a_id_503">Genitourinary Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gynecological-oncology" data-event="iBarJournal-sections-a_id_2079">Gynecological Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/head-and-neck-cancer" data-event="iBarJournal-sections-a_id_517">Head and Neck Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/hematologic-malignancies" data-event="iBarJournal-sections-a_id_505">Hematologic Malignancies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/molecular-and-cellular-oncology" data-event="iBarJournal-sections-a_id_508">Molecular and Cellular Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pediatric-oncology" data-event="iBarJournal-sections-a_id_509">Pediatric Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/radiation-oncology" data-event="iBarJournal-sections-a_id_511">Radiation Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/skin-cancer" data-event="iBarJournal-sections-a_id_1630">Skin Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/surgical-oncology" data-event="iBarJournal-sections-a_id_512">Surgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/thoracic-oncology" data-event="iBarJournal-sections-a_id_502">Thoracic Oncology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div></div><div class="Ibar__dropdown--aboutUs" parent-data-event="iBarMenu"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About us</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About us</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Who we are</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/mission" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Mission and values</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/history" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">History</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/leadership" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Leadership</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/awards" target="_self" data-event="iBar-aboutUs_0-a_whoWeAre">Awards</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Impact and progress</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/impact" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Frontiers&#39; impact</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/annual-reports" target="_self" data-event="iBar-aboutUs_1-a_impactAndProgress">Our annual reports</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Publishing model</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">How we publish</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Open access</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/peer-review" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Peer review</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-integrity" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research integrity</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/research-topics" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Research Topics</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fair-data-management" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">FAIR Data Management</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="iBar-aboutUs_2-a_publishingModel">Fee policy</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">Services</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://publishingpartnerships.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_3-a_services">Societies</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/open-access-agreements/consortia" target="_self" data-event="iBar-aboutUs_3-a_services">National consortia</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/open-access-agreements" target="_self" data-event="iBar-aboutUs_3-a_services">Institutional partnerships</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/collaborators" target="_self" data-event="iBar-aboutUs_3-a_services">Collaborators</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title">More from Frontiers</li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://forum.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Forum</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Frontiers Planet Prize</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://pressoffice.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Press office</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/sustainability" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Sustainability</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://careers.frontiersin.org/" target="_blank" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Career opportunities</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="iBar-aboutUs_4-a_moreFromFrontiers">Contact us</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><!--[--><a class="Ibar__link" href="https://www.frontiersin.org/journals" data-event="iBar-a-allJournals">All journals</a><a class="Ibar__link" href="https://www.frontiersin.org/articles" data-event="iBar-a-allArticles">All articles</a><!--]--><!----><!----><!----><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=57&amp;specialtyid=0&amp;entitytype=2&amp;entityid=451" data-event="iBarMenu-a-submit">Submit your research</a></div></div></div><!--[--><div class="Ibar__journal Ibar__journal--main"><div class="Ibar__wrapper Ibar__wrapper--journal"><a href="//www.frontiersin.org/journals/oncology" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/breast-cancer" data-event="iBarJournal-sections-a_id_500">Breast Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-cell-signaling" data-event="iBarJournal-sections-a_id_2606">Cancer Cell Signaling</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_513">Cancer Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-genetics" data-event="iBarJournal-sections-a_id_506">Cancer Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-imaging-and-image-directed-interventions" data-event="iBarJournal-sections-a_id_515">Cancer Imaging and Image-directed Interventions</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-immunity-and-immunotherapy" data-event="iBarJournal-sections-a_id_527">Cancer Immunity and Immunotherapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-metabolism" data-event="iBarJournal-sections-a_id_1510">Cancer Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-molecular-targets-and-therapeutics" data-event="iBarJournal-sections-a_id_507">Cancer Molecular Targets and Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-colorectal-cancer" data-event="iBarJournal-sections-a_id_2413">Gastrointestinal Cancers: Colorectal Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-gastric-and-esophageal-cancers" data-event="iBarJournal-sections-a_id_2415">Gastrointestinal Cancers: Gastric and Esophageal Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-hepato-pancreatic-biliary-cancers" data-event="iBarJournal-sections-a_id_2414">Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/genitourinary-oncology" data-event="iBarJournal-sections-a_id_503">Genitourinary Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gynecological-oncology" data-event="iBarJournal-sections-a_id_2079">Gynecological Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/head-and-neck-cancer" data-event="iBarJournal-sections-a_id_517">Head and Neck Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/hematologic-malignancies" data-event="iBarJournal-sections-a_id_505">Hematologic Malignancies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/molecular-and-cellular-oncology" data-event="iBarJournal-sections-a_id_508">Molecular and Cellular Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pediatric-oncology" data-event="iBarJournal-sections-a_id_509">Pediatric Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/radiation-oncology" data-event="iBarJournal-sections-a_id_511">Radiation Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/skin-cancer" data-event="iBarJournal-sections-a_id_1630">Skin Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/surgical-oncology" data-event="iBarJournal-sections-a_id_512">Surgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/thoracic-oncology" data-event="iBarJournal-sections-a_id_502">Thoracic Oncology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div></div></div><div class="Ibar__journal Ibar__journal--mix"><div class="Ibar__wrapper Ibar__wrapper--journal"><div class="Ibar__logo"><a href="//www.frontiersin.org/" aria-label="Frontiershome" data-event="iBar-a-home" class="Ibar__logo__link"><svg class="Ibar__logo__svg" viewBox="0 0 2811 590" fill="none" xmlns="http://www.w3.org/2000/svg"><path class="Ibar__logo__text" d="M633.872 234.191h-42.674v-57.246h42.674c0-19.776 2.082-35.389 5.204-48.92 4.164-13.53 9.368-23.939 17.695-31.225 8.326-8.326 18.735-13.53 32.266-16.653 13.531-3.123 29.143-5.204 47.878-5.204h21.858c7.286 0 14.572 1.04 21.857 1.04v62.451c-8.326-1.041-16.653-2.082-23.939-2.082-10.408 0-17.694 1.041-23.939 4.164-6.245 3.122-9.368 10.408-9.368 22.898v13.531h53.083v57.246h-53.083v213.372h-89.512V234.191zM794.161 176.945h86.39v47.879h1.041c6.245-17.694 16.653-30.185 31.225-39.552 14.572-9.368 31.225-13.531 49.96-13.531h10.409c3.122 0 7.286 1.041 10.408 2.082v81.185c-6.245-2.082-11.449-3.122-16.653-4.163-5.204-1.041-11.449-1.041-16.654-1.041-11.449 0-20.816 2.082-29.143 5.204-8.327 3.123-15.613 8.327-20.817 14.572-5.204 6.245-10.408 12.49-12.49 20.817-3.123 8.326-4.163 15.612-4.163 23.939v133.228h-88.472V176.945h-1.041zM989.84 312.254c0-19.776 3.122-39.552 10.41-56.205 7.28-17.695 16.65-32.266 29.14-45.797 12.49-13.531 27.06-22.899 44.76-30.185 17.69-7.285 36.43-11.449 57.24-11.449 20.82 0 39.56 4.164 57.25 11.449 17.69 7.286 32.27 17.695 45.8 30.185 12.49 12.49 22.9 28.102 29.14 45.797 7.29 17.694 10.41 36.429 10.41 56.205 0 20.817-3.12 39.552-10.41 57.246-7.29 17.695-16.65 32.266-29.14 44.756-12.49 12.49-28.11 22.899-45.8 30.185-17.69 7.286-36.43 11.449-57.25 11.449-20.81 0-40.59-4.163-57.24-11.449-17.7-7.286-32.27-17.695-44.76-30.185-12.49-12.49-21.86-28.102-29.14-44.756-7.288-17.694-10.41-36.429-10.41-57.246zm88.47 0c0 8.327 1.04 17.694 3.12 26.021 2.09 9.368 5.21 16.653 9.37 23.939 4.16 7.286 9.37 13.531 16.65 17.695 7.29 4.163 15.62 7.285 26.03 7.285 10.4 0 18.73-2.081 26.02-7.285 7.28-4.164 12.49-10.409 16.65-17.695 4.16-7.286 7.29-15.612 9.37-23.939 2.08-9.368 3.12-17.694 3.12-26.021 0-8.327-1.04-17.694-3.12-26.021-2.08-9.368-5.21-16.653-9.37-23.939-4.16-7.286-9.37-13.531-16.65-17.695-7.29-5.204-15.62-7.285-26.02-7.285-10.41 0-18.74 2.081-26.03 7.285-7.28 5.205-12.49 10.409-16.65 17.695-4.16 7.286-7.28 15.612-9.37 23.939-2.08 9.368-3.12 17.694-3.12 26.021zM1306.25 176.945h86.39v37.47h1.04c4.17-7.286 9.37-13.531 15.62-18.735 6.24-5.204 13.53-10.408 20.81-14.572 7.29-4.163 15.62-7.286 23.94-9.367 8.33-2.082 16.66-3.123 24.98-3.123 22.9 0 40.6 4.164 53.09 11.449 13.53 7.286 22.89 16.654 29.14 27.062 6.24 10.409 10.41 21.858 12.49 34.348 2.08 12.49 2.08 22.898 2.08 33.307v172.779h-88.47V316.417v-27.061c0-9.368-1.04-16.654-4.16-23.94-3.13-7.286-7.29-12.49-13.53-16.653-6.25-4.164-15.62-6.245-27.07-6.245-8.32 0-15.61 2.081-21.85 5.204-6.25 3.122-11.45 7.286-14.58 13.531-4.16 5.204-6.24 11.449-8.32 18.735s-3.12 14.572-3.12 21.858v145.717h-88.48V176.945zM1780.88 234.19h-55.17v122.819c0 10.408 3.12 17.694 8.33 20.817 6.24 3.122 13.53 5.204 22.9 5.204 4.16 0 7.28 0 11.45-1.041h11.45v65.573c-8.33 0-15.62 1.041-23.94 2.082-8.33 1.04-16.66 1.041-23.94 1.041-18.74 0-34.35-2.082-46.84-5.205-12.49-3.122-21.86-8.326-29.14-15.612-7.29-7.286-12.49-16.654-14.58-29.144-3.12-12.49-4.16-27.062-4.16-45.797V234.19h-44.76v-57.246h44.76V94.717h88.47v82.227h55.17v57.246zM1902.66 143.639h-88.48V75.984h88.48v67.655zm-89.52 33.307h88.48v270.618h-88.48V176.946zM2024.43 334.111c1.04 18.735 6.25 33.307 16.66 44.756 10.4 11.449 24.98 16.653 43.71 16.653 10.41 0 20.82-2.081 30.19-7.286 9.36-5.204 16.65-12.49 20.81-22.898h83.27c-4.16 15.613-10.41 29.144-19.78 40.593-9.36 11.449-19.77 20.817-31.22 28.102-12.49 7.286-24.98 12.491-39.55 16.654-14.57 3.122-29.15 5.204-43.72 5.204-21.86 0-41.63-3.122-60.37-9.367-18.73-6.246-34.34-15.613-46.83-28.103-12.49-12.49-22.9-27.062-30.19-45.797-7.28-17.694-10.41-38.511-10.41-60.369 0-20.817 4.17-39.552 11.45-57.246 7.29-17.694 17.7-32.266 31.23-44.756 13.53-12.49 29.14-21.858 46.83-29.144 17.7-7.286 36.43-10.408 56.21-10.408 23.94 0 45.8 4.163 63.49 12.49 17.7 8.327 33.31 19.776 44.76 35.389 11.45 15.612 20.81 32.266 26.02 52.042 5.2 19.776 8.33 41.633 7.28 64.532h-199.84v-1.041zm110.33-49.961c-1.04-15.612-6.24-28.102-15.61-39.551-9.37-10.409-21.86-16.654-37.47-16.654s-28.1 5.204-38.51 15.613c-10.41 10.408-16.66 23.939-18.74 40.592h110.33zM2254.46 176.945h86.39v47.879h1.04c6.25-17.694 16.65-30.185 31.23-39.552 14.57-9.368 31.22-13.531 49.96-13.531h10.4c3.13 0 7.29 1.041 10.41 2.082v81.185c-6.24-2.082-11.45-3.122-16.65-4.163-5.21-1.041-11.45-1.041-16.65-1.041-11.45 0-20.82 2.082-29.15 5.204-8.32 3.123-15.61 8.327-20.81 14.572-6.25 6.245-10.41 12.49-12.49 20.817-3.13 8.326-4.17 15.612-4.17 23.939v133.228h-88.47V176.945h-1.04zM2534.45 359.091c0 7.286 1.04 12.49 4.16 17.694 3.12 5.204 6.24 9.368 10.41 12.49 4.16 3.123 9.36 5.204 14.57 7.286 6.24 2.082 11.45 2.082 17.69 2.082 4.17 0 8.33 0 13.53-2.082 5.21-1.041 9.37-3.123 13.53-5.204 4.17-2.082 7.29-5.204 10.41-9.368 3.13-4.163 4.17-8.327 4.17-13.531 0-5.204-2.09-9.367-5.21-12.49-3.12-3.122-7.28-6.245-11.45-8.327-4.16-2.081-9.36-4.163-14.57-5.204-5.2-1.041-9.37-2.081-13.53-3.122-13.53-3.123-28.1-6.245-42.67-9.368-14.58-3.122-28.11-7.286-40.6-12.49-12.49-6.245-22.9-13.531-30.18-23.939-8.33-10.409-11.45-23.94-11.45-42.675 0-16.653 4.16-30.184 11.45-40.592 8.33-10.409 17.69-18.736 30.18-24.981 12.49-6.245 26.02-10.408 40.6-13.53 14.57-3.123 28.1-4.164 41.63-4.164 14.57 0 29.14 1.041 43.71 4.164 14.58 2.081 27.07 7.285 39.56 13.53 12.49 6.245 21.85 15.613 29.14 27.062 7.29 11.45 11.45 26.021 12.49 43.716h-82.23c0-10.409-4.16-18.736-11.45-23.94-7.28-4.163-16.65-7.286-28.1-7.286-4.16 0-8.32 0-12.49 1.041-4.16 1.041-8.32 1.041-12.49 2.082-4.16 1.041-7.28 3.122-9.37 6.245-2.08 3.122-4.16 6.245-4.16 11.449 0 6.245 3.12 11.449 10.41 15.613 6.24 4.163 14.57 7.286 24.98 10.408 10.41 2.082 20.82 5.204 32.27 7.286 11.44 2.082 22.89 4.163 33.3 6.245 13.53 3.123 24.98 7.286 33.31 13.531 9.37 6.245 15.61 12.49 20.82 19.776 5.2 7.286 9.36 14.572 11.45 21.858 2.08 7.285 3.12 13.53 3.12 19.776 0 17.694-4.17 33.306-11.45 45.796-8.33 12.491-17.7 21.858-30.19 30.185-12.49 7.286-26.02 12.49-41.63 16.653-15.61 3.123-31.22 5.204-45.8 5.204-15.61 0-32.26-1.04-47.87-4.163-15.62-3.122-29.15-8.327-41.64-15.612a83.855 83.855 0 01-30.18-30.185c-8.33-12.49-12.49-28.102-12.49-46.838h84.31v-2.081z" fill="#FFFFFF"></path><path d="M0 481.911V281.028l187.351-58.287v200.882L0 481.911z" fill="#8BC53F"></path><path d="M187.351 423.623V222.741l126.983 87.431v200.882l-126.983-87.431z" fill="#EBD417"></path><path d="M126.982 569.341L0 481.911l187.351-58.287 126.983 87.43-187.352 58.287z" fill="#034EA1"></path><path d="M183.188 212.331l51.001-116.574 65.573 155.085-51.001 116.574-65.573-155.085z" fill="#712E74"></path><path d="M248.761 367.415l51.001-116.574 171.739-28.102-49.96 115.533-172.78 29.143z" fill="#009FD1"></path><path d="M299.762 250.842L234.189 95.757l171.739-28.103 65.573 155.085-171.739 28.103z" fill="#F6921E"></path><path d="M187.352 222.741L59.328 198.802 44.757 71.819 172.78 95.76l14.572 126.982z" fill="#DA2128"></path><path d="M172.78 95.758L44.757 71.818l70.777-70.776 128.023 23.94-70.777 70.776z" fill="#25BCBD"></path><path d="M258.129 153.005l-70.777 69.736-14.571-126.982 70.777-70.778 14.571 128.024z" fill="#00844A"></path></svg></a></div><a href="//www.frontiersin.org/journals/oncology" class="Ibar__journalName" data-event="iBarJournal-a-journalHome"><div class="Ibar__journalName__container" logoclass="Ibar__logo--mixed"><div class="Ibar__journal__maskLogo" style="display:none;"><img class="Ibar__journal__logo" src></div><div class="Ibar__journalName"><span>Frontiers in</span><span> Oncology</span></div></div></a><div class="Ibar__spacer"></div><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> Sections</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">Sections</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><ul class="Ibar__dropdown__sections"><!--[--><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/breast-cancer" data-event="iBarJournal-sections-a_id_500">Breast Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-cell-signaling" data-event="iBarJournal-sections-a_id_2606">Cancer Cell Signaling</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-epidemiology-and-prevention" data-event="iBarJournal-sections-a_id_513">Cancer Epidemiology and Prevention</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-genetics" data-event="iBarJournal-sections-a_id_506">Cancer Genetics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-imaging-and-image-directed-interventions" data-event="iBarJournal-sections-a_id_515">Cancer Imaging and Image-directed Interventions</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-immunity-and-immunotherapy" data-event="iBarJournal-sections-a_id_527">Cancer Immunity and Immunotherapy</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-metabolism" data-event="iBarJournal-sections-a_id_1510">Cancer Metabolism</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cancer-molecular-targets-and-therapeutics" data-event="iBarJournal-sections-a_id_507">Cancer Molecular Targets and Therapeutics</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/cardio-oncology" data-event="iBarJournal-sections-a_id_1513">Cardio-Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-colorectal-cancer" data-event="iBarJournal-sections-a_id_2413">Gastrointestinal Cancers: Colorectal Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-gastric-and-esophageal-cancers" data-event="iBarJournal-sections-a_id_2415">Gastrointestinal Cancers: Gastric and Esophageal Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gastrointestinal-cancers-hepato-pancreatic-biliary-cancers" data-event="iBarJournal-sections-a_id_2414">Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/genitourinary-oncology" data-event="iBarJournal-sections-a_id_503">Genitourinary Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/gynecological-oncology" data-event="iBarJournal-sections-a_id_2079">Gynecological Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/head-and-neck-cancer" data-event="iBarJournal-sections-a_id_517">Head and Neck Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/hematologic-malignancies" data-event="iBarJournal-sections-a_id_505">Hematologic Malignancies</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/molecular-and-cellular-oncology" data-event="iBarJournal-sections-a_id_508">Molecular and Cellular Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/neuro-oncology-and-neurosurgical-oncology" data-event="iBarJournal-sections-a_id_150">Neuro-Oncology and Neurosurgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pediatric-oncology" data-event="iBarJournal-sections-a_id_509">Pediatric Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/pharmacology-of-anti-cancer-drugs" data-event="iBarJournal-sections-a_id_192">Pharmacology of Anti-Cancer Drugs</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/radiation-oncology" data-event="iBarJournal-sections-a_id_511">Radiation Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/skin-cancer" data-event="iBarJournal-sections-a_id_1630">Skin Cancer</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/surgical-oncology" data-event="iBarJournal-sections-a_id_512">Surgical Oncology</a></li><li class="Ibar__dropdown__sections__item"><a href="/journals/oncology/sections/thoracic-oncology" data-event="iBarJournal-sections-a_id_502">Thoracic Oncology</a></li><!--]--></ul><!--]--></div></div></div><!--[--><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/articles" target="_self" data-event="iBar-a-articles">Articles</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/research-topics" target="_self" data-event="iBar-a-researchTopics">Research Topics</a><a class="Ibar__link" href="//www.frontiersin.org/journals/oncology/editors" target="_self" data-event="iBar-a-editorialBoard">Editorial board</a><!--]--><div parent-data-event="iBarJournal"><div class="Ibar__dropdown"><button class="Ibar__dropdown__trigger"><!----> About journal</button><div class="Ibar__dropdown__menu"><div class="Ibar__dropdown__menu__header"><button class="Ibar__dropdown__menu__header__title" aria-label="Close Dropdown">About journal</button><button class="Ibar__close" aria-label="Close Dropdown"></button></div><!--[--><div class="Ibar__dropdown__about"><!--[--><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>Scope</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-editors" target="_self" data-event="iBar-aboutJournal_0-a_fieldChiefEditors">Field chief editors</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-scope" target="_self" data-event="iBar-aboutJournal_1-a_mission &amp;Scope">Mission &amp; scope</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-facts" target="_self" data-event="iBar-aboutJournal_2-a_facts">Facts</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-submission" target="_self" data-event="iBar-aboutJournal_3-a_journalSections">Journal sections</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-open" target="_self" data-event="iBar-aboutJournal_4-a_openAccessStatemen">Open access statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#copyright-statement" target="_self" data-event="iBar-aboutJournal_5-a_copyrightStatement">Copyright statement</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/about#about-quality" target="_self" data-event="iBar-aboutJournal_6-a_quality">Quality</a></li><!--]--></ul><ul class="Ibar__dropdown__about__block"><li class="Ibar__dropdown__about__block__title"><span>For authors</span></li><!--[--><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/why-submit" target="_self" data-event="iBar-aboutJournal_0-a_whySubmit?">Why submit?</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/article-types" target="_self" data-event="iBar-aboutJournal_1-a_articleTypes">Article types</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines" target="_self" data-event="iBar-aboutJournal_2-a_authorGuidelines">Author guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines" target="_self" data-event="iBar-aboutJournal_3-a_editorGuidelines">Editor guidelines</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees" target="_self" data-event="iBar-aboutJournal_4-a_publishingFees">Publishing fees</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist" target="_self" data-event="iBar-aboutJournal_5-a_submissionChecklis">Submission checklist</a></li><li class="Ibar__dropdown__about__block__item"><a href="https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office" target="_self" data-event="iBar-aboutJournal_6-a_contactEditorialOf">Contact editorial office</a></li><!--]--></ul><!--]--></div><!--]--></div></div></div><div class="Ibar__spacer"></div><a class="Ibar__button Ibar__submit" href="https://www.frontiersin.org/submission/submit?domainid=2&amp;fieldid=57&amp;specialtyid=0&amp;entitytype=2&amp;entityid=451" data-event="iBarJournal-a-submit"><span>Submit</span><span>your research</span></a><a class="Ibar__icon Ibar__icon--search" href="//www.frontiersin.org/search" aria-label="Search" target="_self" data-event="iBar-a-search"><span>Search</span></a><!----><!----><!----><div class="Ibar__userArea"></div></div></div><!--]--></nav><div class="ArticlePage"><!--[--><div class="Layout Layout--withAside Layout--withIbarMix"><div class="Alert Alert--info Alert--noInfo ArticleTemplateBanner"><div class="Alert__icon"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" class="FeedbackIcon"><path fill="#fff" d="M10 10h28v28H10z"></path><path fill="var(--blue50)" d="M24 2.88a21.12 21.12 0 1 0 0 42.24 21.12 21.12 0 0 0 0-42.24ZM22.08 13.4a.96.96 0 0 1 .96-.96h1.92a.96.96 0 0 1 .96.96v1.92a.96.96 0 0 1-.96.96h-1.92a.96.96 0 0 1-.96-.96V13.4Zm5.76 21.2a.96.96 0 0 1-.96.97h-5.76a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h.96v-7.68h-.96a.96.96 0 0 1-.96-.96v-1.92a.96.96 0 0 1 .96-.96h3.84a.96.96 0 0 1 .96.96v10.56h.96a.96.96 0 0 1 .96.96v1.92Z"></path></svg></div><div class="Alert__main"><p class="Alert__message">Your new experience awaits. Try the new design now and help us make it even better</p><!--[--><button type="button" class="Button Button--outline Button--grey80 Button--small ArticleTemplateBanner__switchButton" data-event="btn-action"><span>Switch to the new experience</span></button><!--]--><!----></div><ol class="Alert__info"><!--[--><!--]--></ol></div><!----><main class="Layout__main"><!----><div class="ArticleDetails"><div class="ArticleLayoutHeader"><div class="ArticleLayoutHeader__info"><p class="ArticleLayoutHeader__info__title">ORIGINAL RESEARCH article</p><p class="ArticleLayoutHeader__info__journalDate"><span>Front. Oncol.</span><span>, 20 August 2021</span></p><p class="ArticleLayoutHeader__info__journalDate"> Sec. Cancer Epidemiology and Prevention</p><p class="ArticleLayoutHeader__info__doiVolume"><span>Volume 11 - 2021 | </span><a class="ArticleLayoutHeader__info__doi" href="https://doi.org/10.3389/fonc.2021.674965">https://doi.org/10.3389/fonc.2021.674965</a></p><!----></div><!----><p class="ArticleLayoutHeader__isPartOfRT"><span class="ArticleLayoutHeader__isPartOfRT__label">This article is part of the Research Topic</span><span class="ArticleLayoutHeader__isPartOfRT__title">Cancer in Africans: The Past, the Present, and the Future</span><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View all 11 articles" href="https://www.frontiersin.org/research-topics/12906/cancer-in-africans-the-past-the-present-and-the-future/magazine" target="_self" data-event="customLink-linkType-a_viewAll11Articles"><span>View all 11 articles</span></a></span></p></div><div class="ArticleDetails__main__content"><div class="ArticleDetails__main__content__main ArticleDetails__main__content__main--fullArticle"><div class="JournalAbstract"><div class="JournalAbstract__titleWrapper"><h1>Identification of Eleven Novel <i>BRCA</i> Mutations in Tunisia: Impact on the Clinical Management of <i>BRCA</i> Related Cancers</h1><!----></div><!----></div><div class="JournalFullText"><div class="JournalAbstract"><a id="h1" name="h1"></a><div class="authors"><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/887862" class="user-id-887862"><img class="pr5" src="https://loop.frontiersin.org/images/profile/887862/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Yosr Hamdi,*">Yosr Hamdi</a><sup>1,2*</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/958051" class="user-id-958051"><img class="pr5" src="https://loop.frontiersin.org/images/profile/958051/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Najah Mighri&#x;">Najah Mighri</a><sup>1&#x2020;</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/956852" class="user-id-956852"><img class="pr5" src="https://loop.frontiersin.org/images/profile/956852/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Maroua Boujemaa&#x;">Maroua Boujemaa</a><sup>1&#x2020;</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1126033" class="user-id-1126033"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1126033/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Nesrine Mejri,">Nesrine Mejri</a><sup>1,3</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/957319" class="user-id-957319"><img class="pr5" src="https://loop.frontiersin.org/images/profile/957319/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Sonia Ben Nasr,">Sonia Ben Nasr</a><sup>1,4</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1364549" class="user-id-1364549"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1364549/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Mariem Ben Rekaya,">Mariem Ben Rekaya</a><sup>1,5</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/948209" class="user-id-948209"><img class="pr5" src="https://loop.frontiersin.org/images/profile/948209/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Olfa Messaoud">Olfa Messaoud</a><sup>1</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1130977" class="user-id-1130977"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1130977/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Hanen Bouaziz,">Hanen Bouaziz</a><sup>1,6</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Yosra Berrazega" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Yosra Berrazega<sup>3</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Haifa Rachdi" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Haifa Rachdi<sup>3</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/957930" class="user-id-957930"><img class="pr5" src="https://loop.frontiersin.org/images/profile/957930/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Olfa Jaidane">Olfa Jaidane</a><sup>6</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Nouha Daoud" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Nouha Daoud<sup>3</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Aref Zribi" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Aref Zribi<sup>4</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1125634" class="user-id-1125634"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1125634/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Jihene Ayari">Jihene Ayari</a><sup>4</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1126178" class="user-id-1126178"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1126178/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Houda El Benna,">Houda El Benna</a><sup>1,3</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Soumaya Labidi," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Soumaya Labidi<sup>1,3</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Jamel Ben Hassouna" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Jamel Ben Hassouna<sup>6</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Abderazzek Haddaoui" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Abderazzek Haddaoui<sup>4</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Khaled Rahal" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Khaled Rahal<sup>6</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Farouk Benna" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Farouk Benna<sup>7</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1252870" class="user-id-1252870"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1252870/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Ridha Mrad">Ridha Mrad</a><sup>8</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Slim Ben Ahmed" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Slim Ben Ahmed<sup>9</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/1126078" class="user-id-1126078"><img class="pr5" src="https://loop.frontiersin.org/images/profile/1126078/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Hamouda Boussen,">Hamouda Boussen</a><sup>1,3</sup></span><span class="author-wrapper notranslate"><img class="pr5" src="https://loop.frontiersin.org/cdn/images/profile/default_32.jpg" alt="Samir Boubaker," onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';">Samir Boubaker<sup>1,2</sup></span><span class="author-wrapper notranslate"><a href="https://loop.frontiersin.org/people/42850" class="user-id-42850"><img class="pr5" src="https://loop.frontiersin.org/images/profile/42850/74" onerror="this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';" alt="Sonia Abdelhak">Sonia Abdelhak</a><sup>1</sup></span></div><ul class="notes"><li><span><sup>1</sup></span>Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, Tunisia</li><li><span><sup>2</sup></span>Laboratory of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunis, Tunisia</li><li><span><sup>3</sup></span>Medical Oncology Department, Abderrahman Mami Hospital, Faculty of Medicine Tunis, University Tunis El Manar, Tunis, Tunisia</li><li><span><sup>4</sup></span>Department of Medical Oncology, Military Hospital of Tunis, Tunis, Tunisia</li><li><span><sup>5</sup></span>UR17ES15, Oncotheranostic Biomarkers, Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia</li><li><span><sup>6</sup></span>Surgical Oncology Department, Salah Azaiez Institute of Cancer, Tunis, Tunisia</li><li><span><sup>7</sup></span>Department of Radiation Oncology, University of Tunis, Tunis, Tunisia</li><li><span><sup>8</sup></span>Department of Human Genetics, Charles Nicolle Hospital, Tunis, Tunisia</li><li><span><sup>9</sup></span>Faculty of Medicine of Sousse Department of Medical Oncology Farhat Hached University Hospital University of Sousse, Sousse, Tunisia</li></ul><p><strong>Background:</strong> Breast cancer is the world&#x2019;s most common cancer among women. It is becoming an increasingly urgent problem in low- and middle-income countries (LMICs) where a large fraction of women is diagnosed with advanced-stage disease and have no access to treatment or basic palliative care. About 5-10% of all breast cancers can be attributed to hereditary genetic components and up to 25% of familial cases are due to mutations in <i>BRCA1</i>/2 genes. Since their discovery in 1994 and 1995, as few as 18 mutations have been identified in <i>BRCA</i> genes in the Tunisian population. The aim of this study is to identify additional <i>BRCA</i> mutations, to estimate their contribution to the hereditary breast and ovarian cancers in Tunisia and to investigate the clinicopathological signatures associated with <i>BRCA</i> mutations.</p><p><strong>Methods:</strong> A total of 354 patients diagnosed with breast and ovarian cancers, including 5 male breast cancer cases, have been investigated for <i>BRCA1/2</i> mutations using traditional and/or next generation sequencing technologies. Clinicopathological signatures associated with <i>BRCA</i> mutations have also been investigated.</p><p><strong>Results:</strong> In the current study, 16 distinct mutations were detected: 10 in <i>BRCA1</i> and 6 in <i>BRCA2</i>, of which 11 are described for the first time in Tunisia including 3 variations that have not been reported previously in public databases namely <i>BRCA1</i>_c.915T&gt;A; <i>BRCA2</i>_c.-227-?_7805+? and <i>BRCA2</i>_c.249delG. Early age at onset, family history of ovarian cancer and high tumor grade were significantly associated with <i>BRCA</i> status. <i>BRCA1</i> carriers were more likely to be triple negative breast cancer compared to <i>BRCA2</i> carriers. A relatively high frequency of contralateral breast cancer and ovarian cancer occurrence was observed among <i>BRCA</i> carriers and was more frequent in patients carrying <i>BRCA1</i> mutations.</p><p><strong>Conclusion:</strong> Our study provides new insights into breast and ovarian cancer genetic landscape in the under-represented North African populations. The prevalence assessment of novel and recurrent <i>BRCA1/2</i> pathogenic mutations will enhance the use of personalized treatment and precise screening strategies by both affected and unaffected North African cancer cases.</p><div class="clear"></div></div><div class="JournalFullText"><a id="h2" name="h2"></a><h2>Introduction</h2><p class="mb15">Breast cancer is the most common malignancy among women worldwide (<a href="#B1">1</a>). Incidence and mortality rates of breast cancer differ between populations (<a href="#B1">1</a>). In Tunisia, it remains the most common cancer among females and represents the first leading cause of cancer mortality among women. The mean age at diagnosis of Tunisian breast cancer cases is around 50 years old, a decade younger than Western countries (<a href="#B2">2</a>, <a href="#B3">3</a>).</p><p class="mb15"><i>BRCA1</i> and <i>BRCA2</i> are the most prominent breast cancer susceptibility genes that convey high risk of breast and ovarian cancers (<a href="#B4">4</a>). Since their discovery, a wide range of mutational spectrum have been described for both genes. So far, more than 1800 distinct <i>BRCA1</i> and 2000 <i>BRCA2</i> mutations have been reported in the Breast Cancer Information Core (BIC) database. These mutations explain around 20-30% of breast cancer genetic component and seem to be associated with different other cancers such as prostate, pancreatic, endometrial and melanoma (<a href="#B5">5</a>). The identification of novel <i>BRCA1/2</i> mutations has important clinical implications. Indeed, unaffected <i>BRCA</i> mutation carriers have various preventive options including extensive and regular surveillance, chemoprevention, and risk-reducing surgery (<a href="#B6">6</a>&#x2013;<a href="#B8">8</a>), while, affected cases carrying <i>BRCA</i> mutations could benefit from personalized therapeutic options such as platinum-based chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors (<a href="#B9">9</a>, <a href="#B10">10</a>). However, a full <i>BRCA1</i> and <i>BRCA2</i> gene screening remains a labor and time-consuming challenge due to the large gene size, diverse mutations, or variants of unknown significance (VUS) and complexity of large genomic rearrangements (LRs) and copy number variations (CNVs) requiring special technical approaches. Recent advances in high throughput sequencing technologies including Target panels and whole exome sequencing (WES) allowed rapid, sensitive, and cost-effective screening of the large <i>BRCA</i> genes. In addition, the decreased cost of genotyping and sequencing offered affordable targeted testing options.</p><p class="mb15">Sequencing thousands of cancer samples showed that the frequency of germline mutations in <i>BRCA</i> genes varies widely among populations. Some mutations are shared between different populations and others are ethnic specific (<a href="#B11">11</a>, <a href="#B12">12</a>). Indeed, in certain countries and ethnic communities, the <i>BRCA</i> mutation spectrum is limited to a few founder mutations (<a href="#B13">13</a>, <a href="#B14">14</a>). This is mainly observed in geographically, culturally, or religiously isolated populations and in countries with high rates of consanguinity and endogamy that undergo rapid expansion from a limited number of ancestors. Consequently, some alleles become more frequent which explain the high frequency of some founder mutations in these populations. The founder effect may, therefore, influence mutation prevalence and gene penetrance. Since cancer risk is a function of mutation prevalence and penetrance that seems to vary by ethnicity, investigating the prevalence, the frequency, and the penetrance of novel <i>BRCA</i> mutation in different populations will bring new insights on cancer risk and etiology.</p><p class="mb0">In Tunisia, previous studies on <i>BRCA</i> genes have focused only on breast cancer patients. In some studies, the genetic investigation concerned all the coding regions of <i>BRCA1</i> and/or <i>BRCA2</i> genes and in others only hotspot exons have been investigated. These reports have revealed a total of only 18 distinct mutations of which 12 are localized within <i>BRCA1</i> gene including 2 large rearrangements encompassing exons 5 and 20. Among the identified mutations c.211dupA, c.5266dupC in <i>BRCA1</i> and c.1310_1313delAAGA in <i>BRCA2</i> were the most recurrent mutations encountered among the hereditary breast cancer cases (<a href="#B11">11</a>, <a href="#B15">15</a>&#x2013;<a href="#B23">23</a>). Despite these efforts, the mutational spectrum of <i>BRCA1/2</i> genes is still not well established. The main goal of the present study was to identify additional novel <i>BRCA</i> mutations and to investigate the contribution of these mutations to the missing heredity of breast and ovarian cancers. We also aimed to compare breast cancer clinicopathological characteristics in BRCA+ vs <i>BRCA</i>- Tunisian breast cancer cases.</p><a id="h3" name="h3"></a><h2>Materials And Methods</h2><h3>Patients</h3><p class="mb0">A total of 354 breast and ovarian cancer patients (335 breast cancer patients and 19 ovarian cancer patients) were included in this study referred from different medical oncology departments in Tunisia including those of Abderrahman Mami Hospital, Military Hospital of Tunis, Salah Azaiez Institute of Cancer and Farhat Hachad University Hospital University of Sousse. Written informed consents were obtained from all participants. The study has been conducted according to the Declaration of Helsinki Principles and ethical approval was obtained from the biomedical ethics committee of Institut Pasteur de Tunis (2017/16/E/H&#xf4;pital A-M). Clinico-pathological characteristics and follow-up data were collected from patients&#x2019; medical records. Probands were selected based on the following selection criteria (1): Presence of at least 3 related first or second-degree breast cancer cases at any age (2), Young cancer patients aged less than 35&#xa0;years (3), Presence of at least two cases of breast or ovarian cancer, regardless of age, and at least one case of pancreatic cancer or prostate cancer in a related first- or second-degree patient (4), one case with triple negative breast cancer (TNBC) at an age &#x2264;40 years (5), one breast cancer and one ovarian cancer cases diagnosed at first or second degree relatives at any age. A study flowchart is illustrated in <a href="#f1">Figure 1</a>.</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE 1</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g001.jpg" name="" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g001.jpg" alt="www.frontiersin.org" id="f1" loading="lazy">
  </picture>
</a><p><strong>Figure 1</strong> Study flowchart.</p></div><div class="DottedLine"></div><h3>DNA Isolation</h3><p class="mb0">Total genomic DNA was isolated from peripheral blood using DNeasy blood DNA extraction Kit (Qiagen) according to the manufacturer&#x2019;s instructions. DNA purity and concentration were measured using a NanoDrop&#x2122; spectrophotometer.</p><h3>Screening for Recurrent Mutations in <i>BRCA1</i> and <i>BRCA2</i> Genes Using Sanger Sequencing</h3><p class="mb15">Before performing Next Generation Sequencing (NGS) analysis, the studied cohort was screened for at least one of the recurrent <i>BRCA1/2</i> mutations previously reported in the Tunisian population, namely exon5-c.211dupA (rs397508938), exon11-c.798_799delTT (rs80357724), exon11-c.2551delG (rs397508977), exon11-c.3331_3334delCAAG (rs80357701) and exon20-c.5266dupC (rs80357906) of the <i>BRCA1</i> gene and exon10-c.1310_1313 delAAGA (rs80359277), exon16-c.7654dupA (rs879255463) in <i>BRCA2</i> gene respectively. The reference sequences used were NM_007294.3 for <i>BRCA1</i> and NM_000059.3 for <i>BRCA2</i>.</p><p class="mb15">PCR reactions were performed on genomic DNA (gDNA), following standard protocols. Sanger sequencing has been performed using an automated sequencer (ABI 3500; Applied Biosystems, Foster City, CA) and a cycle sequencing reaction kit (Bigdye Terminator v3.1 kit, Applied Biosystems). The data were analyzed using BioEdit software version 7.2.5.</p><p class="mb15">Sanger sequencing technique was then used to validate the identified mutations resulting from NGS.</p><p class="mb0">NGS was performed on 75 breast and ovarian cancer cases. Targeted <i>BRCA1/2</i> sequencing and whole exome sequencing were performed on 60 and 15 patients respectively.</p><h3>Targeted Gene Sequencing</h3><p class="mb0">Targeted gene sequencing was performed on <i>BRCA1/2</i> for 60 breast and ovarian cancer patients with strong family history. All targeted coding exons and exon&#x2013;intron boundaries of <i>BRCA1/2</i> genes were amplified with 253 pooled primer pairs. After the targeted amplification and construction of a library through QIAGEN Library Kit v2.0, the libraries were pooled prior to emulsion PCR and bead enrichment steps that were carried out using an automated protocol on the GeneRead QIAcube (QIAGEN, Hilden, Germany) using the GeneRead Clonal Amp Q Kit (QIAGEN, Hilden, Germany), according to the manufacturer&#x2019;s protocol. Following bead enrichment, the pooled libraries were sequenced using the GeneReader platform (QIAGEN, Hilden, Germany).</p><h3>Whole Exome Sequencing</h3><p class="mb0">WES was performed for 15 breast cancer Tunisian patients. Samples were prepared according to Agilent&#x2019;s SureSelect Protocol Version 1.2 and enrichment was carried out according to Agilent SureSelect protocols. Enriched samples were sequenced on the Illumina HiSeq2000 platform using TruSeq v3 chemistry with paired-end (2 &#xd7; 100). Exome DNA sequences were mapped to their location in the build of the human genome (hg19/b37) using the Burrows&#x2013;Wheeler Aligner (BWA) package. The subsequent SAM files were converted to BAM files using Samtools. Duplicate reads were removed using Picard. GATK was then used to recalibrate the base quality scores as well as for SNP and short INDEL calling. Annotation and prioritization of potential disease-causing variants were performed using VarAFT (Variant Annotation and Filtering Tool) (<a href="http://varaf t.eu">http://varaf t.eu</a>). To annotate variants, VarAFT uses ANNOVAR, a command line tool. INDELs and SNPs annotated were filtered according to several criteria (1): considering breast cancer as autosomal dominant disease and removing variants that were found in a homozygous state (2), variants identified as intronic, intergenic, and non-coding or synonymous were discarded (3), assuming that causal variants are rare, we removed all variants with an allele frequency &gt; 1% either in ExAC (<a href="#B24">24</a>), 1000 genomes (<a href="#B25">25</a>) or ESP6500 (<a href="http://evs.gs.washington.edu/EVS/">http://evs.gs.washington.edu/EVS/</a>) (4), Using different <i>in silico</i> prediction tools, the functional impact of all identified variants has been assessed. Based on this assessment, Benign and tolerated variants were removed. Finally, significant candidate variants were obtained after filtering against their phenotypic relevance.</p><h3>Clinico-Pathological Features of <i>BRCA1</i> and <i>BRCA2</i> Carriers</h3><p class="mb0">Clinical and pathological features of <i>BRCA</i>+ vs <i>BRCA</i>- patients as well as <i>BRCA1</i> vs <i>BRCA2</i> carriers were compared and evaluated. Statistical analysis was performed using SPSS software (version 23). Quantitative variables with normal distribution were analyzed by Student&#x2019;s t test. Comparison of qualitative data was performed using Chi-square test. Fisher&#x2019;s exact test was used for the study of small sample size. Correlation is considered statistically significant between two variables if the <i>P</i> value is less than or equal to 0.05.</p><a id="h4" name="h4"></a><h2>Results</h2><h3>Epidemiological and Clinico-Pathological Features of Investigated Breast and Ovarian Cancer Patients</h3><p class="mb15">A family history of breast and ovarian cancer was present in 35.24% and 11.14% of patients respectively. In addition, 2.68% of&#xa0;patients presented both breast and ovarian cancers. Consanguineous families represent 35.31% of the studied patients. Mean age at menarche was 12.81 years. Mean age at first pregnancy was 26.62 years. Oral contraception was reported by 47.31% of patients, 25.99% of patients have never breastfed and 31.85% were premenopausal.</p><p class="mb15">The mean age at diagnosis of breast cancer was 43.10 years and 31.94% of patients were &#x2264;35 years. Among investigated patients1.49% were male breast cancer (MBC) cases. Inflammatory breast cancer (IBC) (T4d) was seen in 8.65% of patients. Invasive ductal carcinoma (IDC) was the most frequent (90.04%) while infiltrating lobular carcinoma (ILC) was observed in only 3.94% of cases. Scarff-Bloom-Richardson (SBR) grade III was the most common (47.71%). Mean Tumor size was 33.62mm. Patients with positive lymph node disease represented 53.37% of our cohort, 88.67% of patients had Ki-67&gt;14%. Luminal B tumors were the most common (56.88%) followed by triple negative breast cancer (TNBC) (23.85%), Her2+ (11.93%) and luminal A (7.34%). Distant metastases were observed in 26.34% of patients.</p><p class="mb0">For ovarian cancer cases, the mean age at diagnosis was 52.62 years and the majority with serous ovarian carcinoma.</p><h3>Genetic Analysis</h3><p class="mb0">Genetic analysis results showed that 36 out of 354 tested breast and ovarian cancer patients were <i>BRCA1/2</i> mutation carriers (31 breast cancer cases and 5 ovarian cancer patients), including 21 patients with <i>BRCA1</i> mutation and 15 patients carrying <i>BRCA2</i> mutation. A total of 16 mutations have been identified including 11 short indels, 4 single nucleotide variations (3 nonsense &amp; 1 splicing) and 1 large rearrangement.</p><h3>Identified <i>BRCA1/2</i> Pathogenic Mutations in Breast Cancer Cases</h3><p class="mb0">Within the studied breast cancer cohort, 13 pathogenic mutations have been identified: 8 in <i>BRCA1</i> and 5 in <i>BRCA2</i> genes. Among the identified mutations, 9 are described for the first time in Tunisian population (6 in <i>BRCA1</i> and 3 in <i>BRCA2</i>) <strong>(</strong><a href="#T1">Table 1</a><strong>)</strong>.</p><div class="DottedLine"></div><div class="Imageheaders">TABLE 1</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t001.jpg" name="table1" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t001.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t001.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t001.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t001.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t001.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t001.jpg" alt="www.frontiersin.org" id="T1" loading="lazy">
  </picture>
</a><p><strong>Table 1</strong> Mutations in the <i>BRCA1/2</i> genes identified in breast cancer and ovarian cancer patients by Sanger and next generation sequencing technologies.</p></div><div class="DottedLine"></div><p class="mb15 w100pc float_left mt15">Considering the <i>BRCA1</i> gene, 6 patients belonging to 5 unrelated families were carriers of the recurrent c.211dupA mutation. Three patients belonging to 2 unrelated families were positive for c.5266dupC mutation. The missense c.1612C&gt;T mutation has been identified in 2 related patients. c.19_47del, c.668dupA, c.2418dupA and c.5030_5033delCTAA mutations have been identified each in one patient. c.2433delC has been identified among 2 related patients. Except c.211dupA and c.5266dupC mutations, all remaining <i>BRCA1</i> mutations are reported for the first time in the Tunisian population.</p><p class="mb0">In the <i>BRCA2</i> gene, 3 frameshift mutations as well as 1 splicing and 1 large rearrangement mutation were detected. Our results revealed 6 patients belonging to 5 unrelated families that are double heterozygous for <i>BRCA2</i> gene. Indeed, these families were carrying two mutations classified as pathogenic in the ClinVar database namely c.632-1G&gt;A and c.1310_1313delAAGA. Four additional patients carrying only the c.1310_1313delAAGA mutation have been identified including one male breast cancer. The c.7654dupA mutation was identified in 2 related patients with a strong family history of hereditary breast and ovarian cancer. The c.1389_1390delAG mutation has been identified in 1 additional male breast cancer case. Similarly, a large rearrangement mutation of <i>BRCA2</i> gene (Del exons 1-16) has been identified in one patient. Among the identified <i>BRCA2</i> mutations, <i>BRCA2</i>-Del exons 1-16 mutation is novel and was not described in public databases. c.632-1G&gt;A and c.1389_1390delAG are described for the first time in the Tunisian population.</p><h3><i>BRCA1/2</i> Pathogenic Mutations Identified in Ovarian Cancer Cases</h3><p class="mb15">A total of 19 ovarian cancer patients were screened for <i>BRCA</i> pathogenic mutations using Sanger and/or NGS. Four distinct deleterious mutations were identified: 3 mutations in <i>BRCA1</i> gene (c.915T&gt;A, c.1612C&gt;T and c.3049G&gt;T) and one <i>BRCA2</i> mutation (c.249delG).</p><p class="mb0"><i>BRCA1</i>-c.915T&gt;A and <i>BRCA2</i>-c.249delG mutations are novel and not described in public databases. The other identified mutations are described for the first time in the Tunisian population. c.1612C&gt;T mutation was identified among 2 patients. This same mutation was also identified in 2 related breast cancer patients. Screening for additional carriers of the identified mutations, based on their geographic origin, was performed using Sanger sequencing. Consequently, the geographic origin of the identified <i>BRCA1/2</i> mutations has been clearly established (<a href="#f2">Figure 2</a>). We have also illustrated the distribution of <i>BRCA</i> mutations identified in hereditary breast and ovarian cases on <i>BRCA1</i> and <i>BRCA2</i> genes (<a href="#f3">Figure 3</a>). Breast cancer cluster regions (BCCRs) and ovarian cancer cluster regions (OCCRs) were assigned in <a href="#f3">Figure 3</a> according to the study of Rebbeck et al., 2015 (<a href="#B26">26</a>). Among <i>BRCA</i> mutations identified in breast cancer patients, <i>BRCA1_c</i>.211dupA, <i>BRCA1</i>_c.5266dupC, <i>BRCA2</i>_c.-227-?_7805+?, <i>BRCA2</i>_1310_1313delAAGA, <i>BRCA2</i>_c.1389_1390delAG and <i>BRCA2</i>_c.7654dupA occurred in BCCRs. Considering <i>BRCA</i> mutations identified in ovarian cancer patients <i>BRCA1</i>_c.1612C&gt;T and <i>BRCA1</i>_3049G&gt;T arose in OCCRs.</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE 2</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g002.jpg" name="" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g002.jpg" alt="www.frontiersin.org" id="f2" loading="lazy">
  </picture>
</a><p><strong>Figure 2</strong> Geographical distribution of the identified <i>BRCA1</i> and <i>BRCA2</i> mutations.</p></div><div class="DottedLine"></div><div class="Imageheaders">FIGURE 3</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g003.jpg" name="" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g003.jpg" alt="www.frontiersin.org" id="f3" loading="lazy">
  </picture>
</a><p><strong>Figure 3</strong> Distribution of <i>BRCA1</i> and <i>BRCA2</i> mutations identified in hereditary breast and ovarian cancer cases. The Length of mutation indicator reflects the number of observed carriers. The diagrams linearly represent BRCA1/2 protein domains (x-axis). BRCA1 domains: Zinc/Ring finger (green); BRCT_assoc: serine-rich domain associated with BRCT (red); Ethylene insensitive 3 (blue); BRCA1 C terminus domain (yellow). BRCA2 domains: BRC repeats (green); BRCA-2_helical (red); oligonucleotide/oligosaccharide-binding, domain 1 (blue); tower domain (yellow) and oligonucleotide/oligosaccharide-binding, domain 3 (purple). Black mutation indicators depict truncating mutations and purple indicators represent the other types of mutations (splicing, LR). Cluster regions (breast cancer cluster regions (BCCRs) (orange) and ovarian cancer cluster regions (OCCRs) (yellow) were assigned according to the study of Rebbeck et al. (<a href="#B26">26</a>).</p></div><div class="DottedLine"></div><h3>Polymorphisms and Variant of Unknown Significance Identified in <i>BRCA1</i> and <i>BRCA2</i> Genes</h3><p class="mb0">In addition to the pathogenic mutations that have been identified in <i>BRCA</i> genes, several SNPs and variants of unknown significance (VUS) have been observed <strong>(</strong><a href="#h14">Supplementary Table 1</a><strong>)</strong>. Among the 101 identified variants, 45.54% were coding, 50.49% were intronic and 3.96% were localized within regulatory regions. The majority of variations were classified as benign or likely benign in the ClinVar database (91.08%) and five intronic variations were not reported. One patient carried a VUS rs397507308 in <i>BRCA2</i> and 3 other patients carried 2 intronic variations (rs276174878 and rs276174816) that have conflicting interpretations of pathogenicity. Another patient diagnosed with early onset bilateral breast cancer had an in-frame variant with conflicting interpretations of pathogenicity rs80358343 (c.5017_5019delCAC) in the <i>BRCA1</i> gene.</p><h3>Clinico-Pathological Features of <i>BRCA</i> Carriers Among Breast Cancer Cohort</h3><p class="mb0">Clinico-pathological characteristics of breast cancer cases carrying <i>BRCA1</i> and <i>BRCA2</i> mutations are described in <a href="#T2">Tables 2</a>, <a href="#T3">3</a> respectively. We investigated these clinico-pathological features in <i>BRCA1/2</i> mutation carriers vs <i>BRCA negative patients</i> (<a href="#T4">Table 4</a>) and between <i>BRCA1</i> and <i>BRCA2</i> mutation carriers (<a href="#T5">Table 5</a>), as well.</p><div class="DottedLine"></div><div class="Imageheaders">TABLE 2</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t002.jpg" name="table2" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t002.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t002.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t002.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t002.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t002.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t002.jpg" alt="www.frontiersin.org" id="T2" loading="lazy">
  </picture>
</a><p><strong>Table 2</strong> Clinicopathological features of <i>BRCA1</i> carriers.</p></div><div class="DottedLine"></div><div class="Imageheaders">TABLE 3</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t003.jpg" name="table3" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t003.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t003.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t003.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t003.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t003.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t003.jpg" alt="www.frontiersin.org" id="T3" loading="lazy">
  </picture>
</a><p><strong>Table 3</strong> Clinico-pathological features of <i>BRCA2</i> carriers.</p></div><div class="DottedLine"></div><div class="Imageheaders">TABLE 4</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t004.jpg" name="table4" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t004.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t004.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t004.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t004.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t004.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t004.jpg" alt="www.frontiersin.org" id="T4" loading="lazy">
  </picture>
</a><p><strong>Table 4</strong> Epidemiological and clinico-pathological characteristics of patients carrying or not <i>BRCA1/2</i> mutations.</p></div><div class="DottedLine"></div><div class="Imageheaders">TABLE 5</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t005.jpg" name="table5" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t005.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t005.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t005.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t005.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t005.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t005.jpg" alt="www.frontiersin.org" id="T5" loading="lazy">
  </picture>
</a><p><strong>Table 5</strong> Epidemiological and clinico-pathological characteristics of patients carrying <i>BRCA1</i> and <i>BRCA2</i> mutations.</p></div><div class="DottedLine"></div><h3><i>BRCA+ vs BRCA-</i></h3><p class="mb0">Family history of ovarian cancer was significantly associated with <i>BRCA</i> positive status (p=0.004). Regarding the mean age at diagnosis <i>BRCA</i> carriers seem to be younger than <i>BRCA-</i> patients (38.37 vs 43.14) (p= 0.049). However, no significant difference has been observed between both groups regarding family history of breast cancer, personal history of cancer and consanguinity. Similarly, no significant differences have been observed between the 2 groups in histological subtype, nodal involvement, tumor stage, hormonal receptors status, HER2 status, molecular subtypes, Ki-67 index, and metastases <strong>(</strong><a href="#T4">Table 4</a><strong>)</strong>. Nevertheless, SBR grade III was found in 65.38% of patients with <i>BRCA1/2</i> mutations against a frequency of 28.57% among non-carriers, this difference appears to be statistically significant (p= 0.027).</p><h3><i>BRCA1 vs BRCA2</i></h3><p class="mb0">Association between clinico-pathological features and <i>BRCA</i> status (<i>BRCA1+, BRCA2+</i> and <i>BRCAx</i>) was shown in <a href="#f4">Figures 4</a>, <a href="#f5">5</a>. Our results showed that there were no significant differences between <i>BRCA1</i> and <i>BRCA2</i> mutated groups regarding the mean age at diagnosis, the family history of personal cancers, of breast cancer and ovarian cancer (<a href="#T5">Table 5</a>).</p><div class="DottedLine"></div><div class="Imageheaders">FIGURE 4</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g004.jpg" name="" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g004.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g004.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g004.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g004.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g004.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g004.jpg" alt="www.frontiersin.org" id="f4" loading="lazy">
  </picture>
</a><p><strong>Figure 4</strong> Distribution of clinico-pathological features of breast cancer in <i>BRCA1</i>+ and <i>BRCA2</i>+ patients.</p></div><div class="DottedLine"></div><div class="Imageheaders">FIGURE 5</div><div class="FigureDesc"><a href="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g005.jpg" name="" target="_blank">
  <picture>
    <source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g005.jpg" media="(max-width: 563px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g005.jpg" media="(max-width: 1024px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g005.jpg" media="(max-width: 1441px)"><source type="image/webp" srcset="https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g005.jpg" media=""><source type="image/jpg" srcset="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g005.jpg" media=""> <img src="https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g005.jpg" alt="www.frontiersin.org" id="f5" loading="lazy">
  </picture>
</a><p><strong>Figure 5</strong> Distribution of clinico-pathological features of breast cancer in <i>BRCA</i>+ and <i>BRCAx</i> patients.</p></div><div class="DottedLine"></div><p class="mb0">Pathology showed that the infiltrating ductal carcinoma was the most common histological type in both groups (100% and 92.86%). HER2 status, lymph node involvement, SBR grade, tumor size, Ki-67 index and metastatic status showed no statistically significant difference between both studied groups. However, <i>BRCA1</i> carriers were more likely to have triple negative breast cancer (p=0.002) and <i>BRCA2</i> carriers were more likely to have luminal B breast cancer tumors (p=0.000078). In addition, positive estrogen receptor (ER) status and positive progesterone receptor (PR) status studied separately were both associated with <i>BRCA2</i> mutated tumors (p=0.000056 and p=0.000084), respectively.</p><h3>Follow Up of <i>BRCA1</i> and <i>BRCA2</i> Carriers</h3><p class="mb0">Among <i>BRCA</i> carriers, contralateral breast cancer and ovarian cancer co-occurrence were observed respectively in 22.58% and 16.12% of cases. One patient diagnosed with early onset breast cancer has undergone a contralateral prophylactic mastectomy and is currently under regular surveillance. Both contralateral breast cancer and ovarian cancer occurrence were more frequent in <i>BRCA1</i> than <i>BRCA2</i> carriers. Also, 22.58% of the carriers have&#xa0;developed distant metastases and 5 cases died due to disease progression.</p><a id="h5" name="h5"></a><h2>Discussion</h2><p class="mb15">Detection of mutations in hereditary breast and ovarian cancer related <i>BRCA1</i> and <i>BRCA2</i> genes is an effective method of cancer prevention, early detection, and treatment. Mutations in the highly penetrant <i>BRCA</i> genes explain around a quarter of these cases (<a href="#B27">27</a>). The frequency of germline mutations identified on both genes varies depending on the geographic and ethnic distributions. In some populations, a wide spectrum of different mutations is present, whereas in other groups specific recurrent <i>BRCA</i> mutations have been reported that may be due to the founder mutation effect (<a href="#B28">28</a>&#x2013;<a href="#B32">32</a>).</p><p class="mb15">Our previous studies, investigating breast cancer loci and Nucleotide Excision Repair pathway, have shown that the Tunisian population is an admixed and intermediate population between Sub-Saharan Africans and Europeans (<a href="#B33">33</a>, <a href="#B34">34</a>). This genetic diversity reflects the inter-ethnic variability in the frequency distribution of the studied polymorphisms. Indeed, allele frequencies of several variants were found to be statistically different between Tunisian and other populations including rs2046210 and rs941764 that site in breast cancer susceptibility loci (<a href="#B33">33</a>). These findings are in favor of the genetic heterogeneity to breast cancer predisposition in the Tunisian population. So far, only 18 deleterious <i>BRCA</i> mutations have been reported. In the current study, 16 <i>BRCA</i> mutations, including 11 novel variations, have been identified in a cohort of 354 Tunisian breast and ovarian cancer patients. For breast cancer cases, high fractions of young patients (31.94%), cases with family history of breast cancer (35.24%), Triple negative breast cancer (24.31%) and high tumor grade (47.41%) have been observed. As reported in previous studies, the high fractions of early onset, triple negative cases and also the presence of family history of breast cancer may be associated with germline <i>BRCA</i> mutations (<a href="#B35">35</a>, <a href="#B36">36</a>). Indeed, it is now well documented that breast cancer patients in North Africa are almost 10 years younger than patients from western countries (<a href="#B37">37</a>). In Tunisia, around 11% of breast cancer cases are under 35 years old (<a href="#B38">38</a>). In fact, at a young age, the human organism usually functions as well as it ever will. However, interactions between some&#xa0;genetic and environmental factors (GxE) may cause a physiological decline of some organism systems leading to early disease presentation. Therefore, the influence of specific genetic background, differences in variant penetrance and frequency between populations along with environmental factors&#xa0;may explain this early onset of the disease. Large cohorts of young breast cancer patients&#xa0;should be studied to elucidate these GxE factors.</p><p class="mb15">For ovarian cancer cases, the mean age at diagnosis was 52.62 years and the majority presented with serous ovarian carcinoma. Previous studies have shown that among all patients diagnosed with serous ovarian carcinoma, which is the most common subtype, over 15% will have germline <i>BRCA</i> mutations (<a href="#B39">39</a>).</p><p class="mb15">Among the 16 distinct deleterious mutations that have been observed c.19_47del, c.668dupA, c.915T&gt;A, c.1612C&gt;T, c.2418dupA, c.2433delC, c.3049G&gt;T and c.5030_5033delCTAA in <i>BRCA1</i> and c.-227-?_7805+? (Del exons 1-16), c.249delG, c.632-1G&gt;A, c.1389_1390delAG in <i>BRCA2</i>, are reported for the first time in the Tunisian population. We have also identified an inframe deletion reported to have a conflicting interpretation of pathogenicity effect in early onset bilateral breast cancer patient <i>BRCA1</i>_c.5017_5019delCAC. This variation has been described in multiple breast and ovarian cancer cases, with some families showing incomplete co-segregation of the variation (<a href="#B40">40</a>&#x2013;<a href="#B42">42</a>).</p><p class="mb15">Among <i>BRCA</i> mutations identified in breast cancer patients <i>BRCA1_c</i>.211dupA, <i>BRCA1</i>_c.5266dupC,<i>BRCA2</i>_c.-227-?_7805+?,<i>BRCA2</i>_1310_1313delAAGA, <i>BRCA2</i>_c.1389_1390delAG and <i>BRCA2</i>_c.7654dupA occurred in BCCRs that are considered to be associated with an increased likelihood of&#xa0;breast cancer compared to ovarian cancer. Considering <i>BRCA</i> mutations identified in ovarian cancer patients <i>BRCA1</i>_c.1612C&gt;T and <i>BRCA1</i>_3049G&gt;T arose in OCCRs. Other mutations, namely c.19_47del, c.668dupA, c.915T&gt;A, c.2418dupA, c.2433delC, c.5030_5033delCTAA in <i>BRCA1</i> and c.249delG, c.632-1G&gt;A in <i>BRCA2</i> do not overlap with previously reported breast or ovarian cancer cluster regions. This could be explained by ethnic differences in <i>BRCA</i> mutation spectrum or it may indicate shared cluster regions for both breast and ovarian cancer.</p><p class="mb15">In the <i>BRCA1</i> gene, the c.19_47del mutation was identified in one breast cancer patient. This mutation was previously described only in the Algerian population (<a href="#B43">43</a>). The c.2433delC mutation was described in Korean breast and ovarian patients (<a href="#B44">44</a>, <a href="#B45">45</a>), and in Mexican patients (<a href="#B46">46</a>, <a href="#B47">47</a>). The pathogenic c.1612C&gt;T mutation was identified in 4 breast and ovarian cancer patients. This mutation has been identified in Brazilian population (<a href="#B48">48</a>), in ovarian cancer patients from Israeli population (<a href="#B49">49</a>) and in Macedonian population (<a href="#B50">50</a>). We also detected the c.668dupA mutation in one patient. This latter has not been reported in previous studies neither in Tunisia nor in other populations. Nevertheless, it is already listed and classified as pathogenic in ClinVar and predicted to result in the substitution of Alanine to Glycine (p.Ala224Glyfs) which leads to BRCA1 protein truncation. Another new mutation was identified in <i>BRCA1</i> gene, c.2418dupA, that was reported by our group for the first time in the Tunisian population and was not reported previously in other populations (<a href="#B51">51</a>). c.3049G&gt;T has been identified in one ovarian cancer patient. This mutation has been reported in Thai patients with non-mucinous epithelial ovarian cancer (<a href="#B52">52</a>). The c.5030_5033delCTAA mutation was identified among one patient with breast and ovarian cancers and it is reported in Brazilian population (<a href="#B48">48</a>). The c.915T&gt;A mutation is novel and not described in public databases.</p><p class="mb15">In addition to the identification of rare and novel <i>BRCA1</i> mutations, other mutations seem to be recurrent and/or were described in previous Tunisian reports. The c.211dupA mutation was shared by 6 patients belonging to the same geographical origin. This mutation has so far been reported only in hereditary breast/ovarian cancer families of Tunisian origin, particularly in the North-East region, suggesting a founder effect. In order to unravel the genetic specificities of this mutation and to trace&#xa0;its&#xa0;origin a haplotype analysis has been conducted by our group&#xa0;on the North Eastern region (<a href="#B51">51</a>). Results have determined the founder haplotype segregating with this mutation and have revealed that it arose in the period of colonization approximately 130 years ago.</p><p class="mb15">The c.5266dupC mutation has been identified among two families. This mutation was previously described in 8 Tunisian breast cancer families (<a href="#B11">11</a>, <a href="#B16">16</a>, <a href="#B17">17</a>, <a href="#B20">20</a>). It was originally described as an Ashkenazi founder mutation. Haplotype analysis has shown that this mutation arose approximately 1800 years ago in Northern Europe (<a href="#B53">53</a>). Then, it has been reported in several other populations such as, Italian, Russian Slovenian and Greek (<a href="#B54">54</a>).</p><p class="mb15">Interestingly for <i>BRCA2</i> gene, 6 breast cancer patients were double heterozygous carrying the two deleterious mutations c.632-1G&gt;A and c.1310_1313delAAGA, and 4 other unrelated patients carried only the c.1310_1313delAAGA mutation including one male breast cancer (MBC). c.632-1G&gt;A mutation appears to be rare in other populations since it was only reported in one patient with prostate cancer in the UK (<a href="#B55">55</a>). However, c.1310_1313delAAGA seems to be a founder mutation in Maghrebin countries (<a href="#B16">16</a>, <a href="#B17">17</a>, <a href="#B56">56</a>, <a href="#B57">57</a>). It has been also identified in patients with Lebanese (<a href="#B58">58</a>), European (<a href="#B59">59</a>&#x2013;<a href="#B62">62</a>), African (<a href="#B63">63</a>), Asian (<a href="#B64">64</a>) and Latino ancestry (<a href="#B65">65</a>) as well as in Caribbean cohorts (<a href="#B66">66</a>, <a href="#B67">67</a>). These results show the genetic heterogeneity of breast and ovarian cancers in Tunisian patients and the admixed origins of <i>BRCA</i> mutations in Tunisia.</p><p class="mb15">In addition, 5 male breast cancer cases were investigated among which 2 carried <i>BRCA2</i> mutations (c.1310_1313delAAGA and c.1389_1390delAG). Male breast cancer is a rare disease accounting for less than 1% of all breast cancer cases and it was previously shown that nearly 90% of MBC arising in <i>BRCA</i> mutation carriers are found to harbor a <i>BRCA2</i> mutation (<a href="#B68">68</a>). Unfortunately, being a man with &#x201c;a women&#x2019;s disease&#x201d; makes MBC a disease surrounded by social taboo and lack of awareness especially in underdeveloped countries. Indeed, the treatment of MBC has been extrapolated from the knowledge of female breast cancer, despite the multiple differences in the pathogenesis, biology and genetics of these two disease entities. These evidence make MBC a gender issue that requires&#xa0;more attention from the scientific community.</p><p class="mb15">The introduction of the c.1310_1313delAAGA mutation, that have been encountered in diverse populations, in the Tunisian population could be explained by the immigration of Andalusians in Tunisia which has been intensified after the fall of Granada in 1492 and lasted for two centuries before the total expulsion of all Andalusian Moriscos from the Iberian Peninsula in 1610. The diverse geographical distribution of this mutation may further suggest independent origins as shown for the 4184del4 <i>BRCA1</i> mutation reported to have at least three independent origins in the study of Neuhausen et al. (<a href="#B69">69</a>). The c.7654dupA <i>BRCA2</i> gene mutation which was identified in a unique family with a strong family history of breast and ovarian cancer is reported previously and exclusively in Algerian population (<a href="#B70">70</a>) and could be therefore specific to North African countries.</p><p class="mb15">Through this report and despite the identification of novel mutations in Tunisian population, it is clear that the genetic susceptibility to breast cancer is explained in a vast majority of cases by recurrent mutations. Indeed, more than 44.44% of carriers harbor <i>BRCA1</i>-c.211dupA or <i>BRCA2</i>-1310_1313deAAGA mutations which highlights the importance of screening these mutations in the treatment workflow of cases with early onset or strong family history of breast cancer. In fact, identifying germline <i>BRCA1</i> and <i>BRCA2</i> pathogenic mutations is a crucial component in the medical management of affected patients. Regular surveillance and/or prophylactic mastectomy of the second breast or prophylactic salpingo oophorectomies, which have been shown to reduce the risk of developing cancer, are recommended to these carriers. Moreover, relatives who test positive for a germline <i>BRCA</i> pathogenic mutation may take appropriate action to prevent cancer or have cancer diagnosed as early as possible for better treatment options (<a href="#B59">59</a>).</p><p class="mb15">In addition, mutations in the <i>BRCA</i> genes and their associations with clinico-pathological features were reported in several studies (<a href="#B71">71</a>&#x2013;<a href="#B74">74</a>). However, in Tunisia this aspect was not previously investigated. This point was raised in the present study and our results showed that patients with <i>BRCA1</i> and <i>BRCA2</i> mutations were similar with regard to several epidemiological and clinico-pathological parameters. Nevertheless, <i>BRCA1</i> carriers were more likely to be triple negative breast cancer compared to <i>BRCA2</i> carriers (p=0.002) and <i>BRCA2</i> carriers were more likely to be luminal B breast cancer tumors (p=0.000078). Consistent with our findings, various previous studies reported that there is a much higher rate of TNBC among <i>BRCA1</i> mutation carriers (<a href="#B75">75</a>, <a href="#B76">76</a>) and <i>BRCA2</i>-related breast cancer is often luminal (<a href="#B77">77</a>). Additionally, positive ER was significantly associated with <i>BRCA2+</i> tumors (p=0.000056). PR status was significantly different between <i>BRCA1</i> and <i>BRCA2</i> mutation carriers; <i>BRCA2</i> carriers are more likely to develop progesterone receptor (PR) positive tumors and PR-negative breast cancer are associated with <i>BRCA1</i> mutation carriers (p=0.000084). It was reported that the ER positivity was predominantly seen in <i>BRCA2</i> mutation carriers, which is consistent with our findings (<a href="#B71">71</a>, <a href="#B78">78</a>). Furthermore, a previous report has found that <i>BRCA2</i>-associated cancers are mainly PR positive (<a href="#B79">79</a>). Other studies have raised some pathological differences between <i>BRCA1/2</i> mutation carriers and <i>BRCAx</i> patients. In our study, <i>BRCA</i> carriers seem to be younger than <i>BRCA-negative</i> patients (p=0.049). Furthermore, patients with a positive family history of ovarian cancer are more likely to be <i>BRCA</i> positive (p=0.004). We also observed a significant predominance of SBR grade III tumors among <i>BRCA1/2</i> mutations carriers (p= 0.027). These findings are in line with previous literature&#xa0; (<a href="#B35">35</a>, <a href="#B80">80</a>, <a href="#B81">81</a>).</p><p class="mb15">Furthermore, we have assessed disease outcomes in <i>BRCA</i> carriers, and we have observed a relatively high proportion of contralateral breast cancer and ovarian cancer occurrence that were more frequently observed in <i>BRCA1</i> carriers. Previous reports have demonstrated that women carrying a pathogenic mutation in the <i>BRCA1</i> or <i>BRCA2</i> genes have an increased risk of developing a second primary cancer in the contralateral breast. The cumulative risk 20 years after breast cancer diagnosis was estimated to be 40% for <i>BRCA1</i> carriers and about 26% for <i>BRCA2</i> carriers (<a href="#B82">82</a>). In accordance with our findings, it was shown also that the occurrence of both breast and ovarian cancer in a woman is associated with a high likelihood of a germline <i>BRCA1</i> mutation (<a href="#B83">83</a>).</p><p class="mb15">Besides the <i>BRCA</i> genetic mutations that have been identified in our study, mutations on other high to moderate breast cancer genes such as <i>TP53</i>, <i>ATM, BLM</i> and <i>CHEK2</i>&#xa0;have been also identified for the first time in North African populations (data not shown). All these findings reflect the genetic heterogeneity of cancer predisposition in Tunisia and highlights the importance of the use of NGS to identify clinically actionable genetic variants that have a crucial role in disease management. Therefore,&#xa0;technological advances in terms of array and DNA sequencing technologies made the route towards the examination of genetic risk largely clear. However, practical challenges related to marked population-specific differences still exist. In this context, Manolio and colleagues conveniently classified <i>LRRK2</i> as a high penetrant gene associated with Parkinson disease (<a href="#B84">84</a>) with G2019S mutation being the main cause of Parkinson familial cases. Recently the international LRRK2 consortium reported a worldwide frequency of 1% of <i>LRRK2</i> G2019S, 30&#x2013;40% in Arab patients from North Africa and 10&#x2013;30% in Ashkenazi Jews, but is very rare in Asians (<a href="#B85">85</a>, <a href="#B86">86</a>). As a variant&#xb4;s frequency has a direct impact on its penetrance, this example shows the ethnic-dependent penetrance of some important variants involved in complex diseases and the role of consanguinity and endogamy in shaping the genetic susceptibility to these diseases. Therefore, the same reflection can be applied on high and low penetrant breast cancer variants in order&#xa0;to review their penetrance in underrepresented populations such as North Africans. A disproportionate distribution of the identified mutations is observed between the Northern and Southern regions of Tunisia (<a href="#f2">Figure 2</a>), with the vast majority found in the North. This can be explained by a selection bias because most of the recruited participants come from Northern governorates, but it can also be explained by the very high consanguinity rates in the South that reaches 98% in some cities and that may have an impact on <i>BRCA</i> mutations frequency and prevalence.</p><p class="mb15">Additional limitations of our study have been observed. Indeed, to our best knowledge, this work represents the largest BRCA1/2 study in Africa. However, we believe that the sample size is still small and larger cohorts are needed to trace a clear and complete BRCA1/2 mutational spectrum in Tunisia. In addition, because of the limited resources dedicated to this work, we were not able to perform a complete sequencing of both genes for the whole cohort. Therefore, the frequency and prevalence of the identified mutations need to be assessed in larger studies. Clearly, the prevalence assessment of <i>BRCA1</i> and <i>BRCA2</i> mutations also rely on the quality of both cohort selection criteria and mutation ascertainment methods. The identification of novel BRCA mutations and the assessment of their penetrance in a specific population will help to implement more affordable and cost effective targeted genetic testing strategies.</p><p class="mb0">Finally, up until now, most data on <i>BRCA1</i>/2 mutations associated with high risk for hereditary breast and ovarian cancer do not cover the North African populations. Accordingly, the novel mutations identified in this study will help to improve knowledge on the genetic component of hereditary breast and ovarian cancer in the North African region and will lead to a better clinical management of cancer patients. In addition, we are aiming to share genetic and phenotypic data with larger multi-ethnic Consortia of <i>BRCA1/2</i> mutation carriers such as the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) (<a href="#B87">87</a>). This will make our findings more broadly useful and will give us a global overview of the similarities and differences that the Tunisian population has compared to other ethnicities.</p><a id="h6" name="h6"></a><h2>Conclusion</h2><p class="mb0">In conclusion we have identified 16 distinct <i>BRCA</i> mutations in breast and ovarian cancer patients including 11 novel mutations in the Tunisian population. The recognition of the <i>BRCA</i> mutational spectrum and its geographical distribution in Tunisia is of keen interest for the scientific and medical communities as it helps to develop precise risk assessment tools, accurate genetic testing, cost-effective approaches for prevention and early detection of the disease as well as personalized treatments of <i>BRCA</i> related cancers for both affected and unaffected cancer cases.</p><a id="h7" name="h7"></a><h2>Data Availability Statement</h2><p class="mb0">The minimal dataset that would be necessary to interpret, replicate and build upon the findings reported in this study are included in this article and in its supplementary files. All identified mutations with their related details have been shared in the public database ClinVar under the following link &#x201c;<a href="https://www.ncbi.nlm.nih.gov/clinvar/submitters/507986/">https://www.ncbi.nlm.nih.gov/clinvar/submitters/507986/</a>&#x201d;. Any additional datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p><a id="h8" name="h8"></a><h2>Ethics Statement</h2><p class="mb0">The studies involving human participants were reviewed and approved by The Biomedical Ethics Committee of Institut Pasteur de Tunis (2017/16/E/H&#xf4;pital A-M). The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from participants for the publication of any potentially identifiable images or data included in this article.</p><a id="h9" name="h9"></a><h2>Author Contributions</h2><p class="mb0">YH prepared the study concept and design, supervised the study, did data analysis, data interpretation, drafted, and critically revised the manuscript. NMi and MB did the experiments, participated in participant recruitment, and participated in drafting and reviewing the manuscript. NMe contributed to clinical data analysis and reviewed the manuscript. SN contributed to participants recruitment and reviewed the manuscript. MR and OM contributed to data collection and reviewed the manuscript. HanB, YB, HR, OJ, ND, AZ, JA, HEB, SL and JBH contributed to the clinical investigation and recruitment of patients. AH, KR, FB, RM, SBA and HamB critically revised the clinicopathological section and the whole manuscript. SB and SA contributed to the study concept, design and supervision and critically revised the manuscript. All authors contributed to the article and approved the submitted version.</p><a id="h10" name="h10"></a><h2>Funding</h2><p class="mb0">This work was supported by the Tunisian Ministry of Higher Education and Scientific Research (LR16IPT05) and the Tunisian Ministry of Public Health (PEC-4-TUN). MB and MBR are recipient of a MOBIDOC fellowship funded by the EU through the EMORI and PASRI programs managed by the ANPR.</p><a id="h11" name="h11"></a><h2>Conflict of Interest</h2><p class="mb0">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p><a id="h12" name="h12"></a><h2>Publisher&#x2019;s Note</h2><p class="mb15">All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p><a id="h13" name="h13"></a><h2>Acknowledgments</h2><p class="mb0">This manuscript is dedicated to the memory of Prof. Farouk Benna, an imminent radiotherapist who died from Covid19 when ensuring his medical activity. We would like to thank Dr. Zied Zidi, Dr Ghazi Jerbi, Dr Samir Khalfallah, Dr Monia Hechiche, Dr Achraf Chaari, Dr Olfa gharbi, Dr Monia Hechiche, Dr Sami Bellil, Dr Ichraf Jbir, Dr Olfa Daldoul Ben Fraj, Dr Bassem Allani/Dr David Khayat, Dr Tarek Bouzid, Dr El Fatmi Rym/Dr Mokrani Amina, Dr Samia Chatti Dey, Dr Hatem Chaaba, Dr Med Ali Ayadi, Dr Lotfi Kochbati, Dr Fethi Messoudi and Dr Chadha Elward Abdelhedi&#xa0;for their contribution in this work. We are also grateful to all participants and their family members for their participation in the study.</p><a id="h14" name="h14"></a><h2>Supplementary Material</h2><p class="mb15">The Supplementary Material for this article can be found online at: <a href="https://www.frontiersin.org/articles/10.3389/fonc.2021.674965/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fonc.2021.674965/full#supplementary-material</a></p><a id="h15" name="h15"></a><h2>Abbreviations</h2><p class="mb15">BCCRs, Breast Cancer Cluster Regions; ER, Estrogen receptor; gDNA, Genomic DNA; GxE, Genetic and Environmental factors; IDC, Invasive Ductal Carcinoma; LMICs, Low- and middle-income countries; OCCRs, Ovarian cancer cluster regions; PR, Progesterone receptor; SBR, Scarff-Bloom-Richardson; TNBC, Triple Negative Breast Cancer; VUS, Variants of Unknown Significance; WES, Whole Exome Sequencing.</p><a id="h16" name="h16"></a><h2>References</h2><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B1" id="B1"></a> 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. <i>CA: Cancer J Clin</i> (2018) 68(6):394&#x2013;424. doi: 10.3322/caac.21492</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/30207593/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3322/caac.21492" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=F+Bray&amp;author=J+Ferlay&amp;author=I+Soerjomataram&amp;author=RL+Siegel&amp;author=LA+Torre&amp;author=A+Jemal&amp;publication_year=2018&amp;title=Global%20Cancer%20Statistics%202018%3A%20GLOBOCAN%20Estimates%20of%20Incidence%20and%20Mortality%20Worldwide%20for%2036%20Cancers%20in%20185%20Countries&amp;journal=CA:+Cancer+J+Clin&amp;volume=68&amp;pages=394" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B2" id="B2"></a> 2. Chalabi N, Bernard-Gallon DJ, Bignon YJ, Breast Med C, Kwiatkowski F, Agier M, et al. Comparative Clinical and Transcriptomal Profiles of Breast Cancer Between French and South Mediterranean Patients Show Minor But Significative Biological Differences. <i>Cancer Genomics Proteomics</i> (2008) 5(5):253&#x2013;61.
</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/19129556/" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?author=N+Chalabi&amp;author=DJ+Bernard-Gallon&amp;author=YJ+Bignon&amp;author=C+Breast%20Med&amp;author=F+Kwiatkowski&amp;author=M+Agier&amp;publication_year=2008&amp;title=Comparative%20Clinical%20and%20Transcriptomal%20Profiles%20of%20Breast%20Cancer%20Between%20French%20and%20South%20Mediterranean%20Patients%20Show%20Minor%20But%20Significative%20Biological%20Differences&amp;journal=Cancer+Genomics+Proteomics&amp;volume=5&amp;pages=253-61" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B3" id="B3"></a> 3. Boussen H, Bouzaiene H, Ben Hassouna J, Dhiab T, Khomsi F, Benna F, et al. Inflammatory Breast Cancer in Tunisia: Epidemiological and Clinical Trends. <i>Cancer</i> (2010) 116(11 Suppl):2730&#x2013;5. doi: 10.1002/cncr.25175</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/20503401/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/cncr.25175" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H+Boussen&amp;author=H+Bouzaiene&amp;author=J+Ben%20Hassouna&amp;author=T+Dhiab&amp;author=F+Khomsi&amp;author=F+Benna&amp;publication_year=2010&amp;title=Inflammatory%20Breast%20Cancer%20in%20Tunisia%3A%20Epidemiological%20and%20Clinical%20Trends&amp;journal=Cancer&amp;volume=116&amp;pages=2730-5" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B4" id="B4"></a> 4. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average Risks of Breast and Ovarian Cancer Associated With BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. <i>Am J Hum Genet</i> (2003) 72(5):1117&#x2013;30. doi: 10.1086/375033</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/12677558/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1086/375033" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Antoniou&amp;author=PD+Pharoah&amp;author=S+Narod&amp;author=HA+Risch&amp;author=JE+Eyfjord&amp;author=JL+Hopper&amp;publication_year=2003&amp;title=Average%20Risks%20of%20Breast%20and%20Ovarian%20Cancer%20Associated%20With%20BRCA1%20or%20BRCA2%20Mutations%20Detected%20in%20Case%20Series%20Unselected%20for%20Family%20History%3A%20A%20Combined%20Analysis%20of%2022%20Studies&amp;journal=Am+J+Hum+Genet&amp;volume=72&amp;pages=1117-30" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B5" id="B5"></a> 5. Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, et al. Cancers Associated With BRCA 1 and BRCA 2 Mutations Other Than Breast and Ovarian. <i>Cancer</i> (2015) 121(2):269&#x2013;75. doi: 10.1002/cncr.29041</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25224030/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/cncr.29041" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Mersch&amp;author=MA+Jackson&amp;author=M+Park&amp;author=D+Nebgen&amp;author=SK+Peterson&amp;author=C+Singletary&amp;publication_year=2015&amp;title=Cancers%20Associated%20With%20BRCA%201%20and%20BRCA%202%20Mutations%20Other%20Than%20Breast%20and%20Ovarian&amp;journal=Cancer&amp;volume=121&amp;pages=269-75" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B6" id="B6"></a> 6. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality. <i>JAMA</i> (2010) 304(9):967&#x2013;75. doi: 10.1001/jama.2010.1237</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/20810374/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1001/jama.2010.1237" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SM+Domchek&amp;author=TM+Friebel&amp;author=CF+Singer&amp;author=DG+Evans&amp;author=HT+Lynch&amp;author=C+Isaacs&amp;publication_year=2010&amp;title=Association%20of%20Risk-Reducing%20Surgery%20in%20BRCA1%20or%20BRCA2%20Mutation%20Carriers%20With%20Cancer%20Risk%20and%20Mortality&amp;journal=JAMA&amp;volume=304&amp;pages=967-75" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B7" id="B7"></a> 7. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations. <i>N Engl J Med</i> (2002) 346(21):1616&#x2013;22. doi: 10.1056/NEJMoa012158</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/12023993/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1056/NEJMoa012158" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=TR+Rebbeck&amp;author=HT+Lynch&amp;author=SL+Neuhausen&amp;author=SA+Narod&amp;author=L+Van%27t%20Veer&amp;author=JE+Garber&amp;publication_year=2002&amp;title=Prophylactic%20Oophorectomy%20in%20Carriers%20of%20BRCA1%20or%20BRCA2%20Mutations&amp;journal=N+Engl+J+Med&amp;volume=346&amp;pages=1616-22" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B8" id="B8"></a> 8. Menkiszak J, Chudecka-Glaz A, Gronwald J, Cymbaluk-Ploska A, Celewicz A, Swiniarska M, et al. Prophylactic Salpingo-Oophorectomy in BRCA1 Mutation Carriers and Postoperative Incidence of Peritoneal and Breast Cancers. <i>J Ovarian Res</i> (2016) 9:11. doi: 10.1186/s13048-016-0220-4</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/26928677/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s13048-016-0220-4" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Menkiszak&amp;author=A+Chudecka-Glaz&amp;author=J+Gronwald&amp;author=A+Cymbaluk-Ploska&amp;author=A+Celewicz&amp;author=M+Swiniarska&amp;publication_year=2016&amp;title=Prophylactic%20Salpingo-Oophorectomy%20in%20BRCA1%20Mutation%20Carriers%20and%20Postoperative%20Incidence%20of%20Peritoneal%20and%20Breast%20Cancers&amp;journal=J+Ovarian+Res&amp;volume=9&amp;pages=11" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B9" id="B9"></a> 9. Turner NC, Tutt AN. Platinum Chemotherapy for BRCA1-Related Breast Cancer: Do We Need More Evidence? <i>Breast Cancer Res</i> (2012) 14(6):115. doi: 10.1186/bcr3332</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/23146216/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/bcr3332" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=NC+Turner&amp;author=AN+Tutt&amp;publication_year=2012&amp;title=Platinum%20Chemotherapy%20for%20BRCA1-Related%20Breast%20Cancer%3A%20Do%20We%20Need%20More%20Evidence&amp;journal=Breast+Cancer+Res&amp;volume=14&amp;pages=115" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B10" id="B10"></a> 10. Mateo J, Lord CJ, Serra V, Tutt A, Balmana J, Castroviejo-Bermejo M, et al. A Decade of Clinical Development of PARP Inhibitors in Perspective. <i>Ann Oncol</i> (2019) 30(9):1437&#x2013;47. doi: 10.1093/annonc/mdz192</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/31218365/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/annonc/mdz192" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Mateo&amp;author=CJ+Lord&amp;author=V+Serra&amp;author=A+Tutt&amp;author=J+Balmana&amp;author=M+Castroviejo-Bermejo&amp;publication_year=2019&amp;title=A%20Decade%20of%20Clinical%20Development%20of%20PARP%20Inhibitors%20in%20Perspective&amp;journal=Ann+Oncol&amp;volume=30&amp;pages=1437-47" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B11" id="B11"></a> 11. Mahfoudh W, Bouaouina N, Ahmed SB, Gabbouj S, Shan J, Mathew R, et al. Hereditary Breast Cancer in Middle Eastern and North African (MENA) Populations: Identification of Novel, Recurrent and Founder BRCA1 Mutations in the Tunisian Population. <i>Mol Biol Rep</i> (2012) 39(2):1037&#x2013;46. doi: 10.1007/s11033-011-0829-8</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/21603858/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s11033-011-0829-8" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=W+Mahfoudh&amp;author=N+Bouaouina&amp;author=SB+Ahmed&amp;author=S+Gabbouj&amp;author=J+Shan&amp;author=R+Mathew&amp;publication_year=2012&amp;title=Hereditary%20Breast%20Cancer%20in%20Middle%20Eastern%20and%20North%20African%20%28MENA%29%20Populations%3A%20Identification%20of%20Novel%2C%20Recurrent%20and%20Founder%20BRCA1%20Mutations%20in%20the%20Tunisian%20Population&amp;journal=Mol+Biol+Rep&amp;volume=39&amp;pages=1037-46" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B12" id="B12"></a> 12. Kadouri L, Hubert A, Rotenberg Y, Hamburger T, Sagi M, Nechushtan C, et al. Cancer Risks in Carriers of the BRCA1/2 Ashkenazi Founder Mutations. <i>J Med Genet</i> (2007) 44(7):467&#x2013;71. doi: 10.1136/jmg.2006.048173</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/17307836/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1136/jmg.2006.048173" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L+Kadouri&amp;author=A+Hubert&amp;author=Y+Rotenberg&amp;author=T+Hamburger&amp;author=M+Sagi&amp;author=C+Nechushtan&amp;publication_year=2007&amp;title=Cancer%20Risks%20in%20Carriers%20of%20the%20BRCA1%2F2%20Ashkenazi%20Founder%20Mutations&amp;journal=J+Med+Genet&amp;volume=44&amp;pages=467-71" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B13" id="B13"></a> 13. Fackenthal JD, Olopade OI. Breast Cancer Risk Associated With BRCA1 and BRCA2 in Diverse Populations. <i>Nat Rev Cancer</i> (2007) 7(12):937&#x2013;48. doi: 10.1038/nrc2054</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/18034184/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nrc2054" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=JD+Fackenthal&amp;author=OI+Olopade&amp;publication_year=2007&amp;title=Breast%20Cancer%20Risk%20Associated%20With%20BRCA1%20and%20BRCA2%20in%20Diverse%20Populations&amp;journal=Nat+Rev+Cancer&amp;volume=7&amp;pages=937-48" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B14" id="B14"></a> 14. Ramus SJ, Gayther SA. The Contribution of BRCA1 and BRCA2 to Ovarian Cancer. <i>Mol Oncol</i> (2009) 3(2):138&#x2013;50. doi: 10.1016/j.molonc.2009.02.001</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/19383375/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.molonc.2009.02.001" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SJ+Ramus&amp;author=SA+Gayther&amp;publication_year=2009&amp;title=The%20Contribution%20of%20BRCA1%20and%20BRCA2%20to%20Ovarian%20Cancer&amp;journal=Mol+Oncol&amp;volume=3&amp;pages=138-50" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B15" id="B15"></a> 15. Mestiri S, Monastiri K, Ben SA, Bouaouina N, Presneau N, Bignon Y, et al. Mutational Analysis of Breast/Ovarian Cancer Hereditary Predisposition Gene BRCA1 in Tunisian Women. <i>Arch l'Institut Pasteur Tunis</i> (2000) 77(1-4):11&#x2013;5.
</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="http://scholar.google.com/scholar_lookup?author=S+Mestiri&amp;author=K+Monastiri&amp;author=SA+Ben&amp;author=N+Bouaouina&amp;author=N+Presneau&amp;author=Y+Bignon&amp;publication_year=2000&amp;title=Mutational%20Analysis%20of%20Breast%2FOvarian%20Cancer%20Hereditary%20Predisposition%20Gene%20BRCA1%20in%20Tunisian%20Women&amp;journal=Arch+l'Institut+Pasteur+Tunis&amp;volume=77&amp;pages=11-5" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B16" id="B16"></a> 16. Troudi W, Uhrhammer N, Sibille C, Dahan C, Mahfoudh W, Bouchlaka Souissi C, et al. Contribution of the BRCA1 and BRCA2 Mutations to Breast Cancer in Tunisia. <i>J Hum Genet</i> (2007) 52(11):915&#x2013;20. doi: 10.1007/s10038-007-0195-5</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/17922257/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10038-007-0195-5" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=W+Troudi&amp;author=N+Uhrhammer&amp;author=C+Sibille&amp;author=C+Dahan&amp;author=W+Mahfoudh&amp;author=C+Bouchlaka%20Souissi&amp;publication_year=2007&amp;title=Contribution%20of%20the%20BRCA1%20and%20BRCA2%20Mutations%20to%20Breast%20Cancer%20in%20Tunisia&amp;journal=J+Hum+Genet&amp;volume=52&amp;pages=915-20" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B17" id="B17"></a> 17. Fourati A, Louchez MM, Fournier J, Gamoudi A, Rahal K, El May MV, et al. Screening for Common Mutations in BRCA1 and BRCA2 Genes: Interest in Genetic Testing of Tunisian Families With Breast and/or Ovarian Cancer. <i>Bull Cancer</i> (2014) 101(11):E36&#x2013;40. doi: 10.1684/bdc.2014.2049</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25418591/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1684/bdc.2014.2049" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Fourati&amp;author=MM+Louchez&amp;author=J+Fournier&amp;author=A+Gamoudi&amp;author=K+Rahal&amp;author=MV+El%20May&amp;publication_year=2014&amp;title=Screening%20for%20Common%20Mutations%20in%20BRCA1%20and%20BRCA2%20Genes%3A%20Interest%20in%20Genetic%20Testing%20of%20Tunisian%20Families%20With%20Breast%20and%2For%20Ovarian%20Cancer&amp;journal=Bull+Cancer&amp;volume=101&amp;pages=E36-40" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B18" id="B18"></a> 18. Msolly A. BRCA1 and BRCA2 Mutations Are They Related to Breast Cancer in a Sample of Tunisian Population? <i>Cancer Ther Oncol Int J</i> (2015) 1(1):1&#x2013;5. doi: 10.19080/CTOIJ.2015.01.555551</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.19080/CTOIJ.2015.01.555551" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Msolly&amp;publication_year=2015&amp;title=BRCA1%20and%20BRCA2%20Mutations%20Are%20They%20Related%20to%20Breast%20Cancer%20in%20a%20Sample%20of%20Tunisian%20Population&amp;journal=Cancer+Ther+Oncol+Int+J&amp;volume=1&amp;pages=1" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B19" id="B19"></a> 19. Riahi A, Chabouni-Bouhamed H, Kharrat M. Prevalence of BRCA1 and BRCA2 Large Genomic Rearrangements in Tunisian High Risk Breast/Ovarian Cancer Families: Implications for Genetic Testing. <i>Cancer Genet</i> (2017) 210:22&#x2013;7. doi: 10.1016/j.cancergen.2016.11.002</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/28212807/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.cancergen.2016.11.002" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Riahi&amp;author=H+Chabouni-Bouhamed&amp;author=M+Kharrat&amp;publication_year=2017&amp;title=Prevalence%20of%20BRCA1%20and%20BRCA2%20Large%20Genomic%20Rearrangements%20in%20Tunisian%20High%20Risk%20Breast%2FOvarian%20Cancer%20Families%3A%20Implications%20for%20Genetic%20Testing&amp;journal=Cancer+Genet&amp;volume=210&amp;pages=22-7" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B20" id="B20"></a> 20. Riahi A, Kharrat M, Ghourabi ME, Khomsi F, Gamoudi A, Lariani I, et al. Mutation Spectrum and Prevalence of BRCA1 and BRCA2 Genes in Patients With Familial and Early-Onset Breast/Ovarian Cancer From Tunisia. <i>Clin Genet</i> (2015) 87(2):155&#x2013;60. doi: 10.1111/cge.12337</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/24372583/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/cge.12337" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Riahi&amp;author=M+Kharrat&amp;author=ME+Ghourabi&amp;author=F+Khomsi&amp;author=A+Gamoudi&amp;author=I+Lariani&amp;publication_year=2015&amp;title=Mutation%20Spectrum%20and%20Prevalence%20of%20BRCA1%20and%20BRCA2%20Genes%20in%20Patients%20With%20Familial%20and%20Early-Onset%20Breast%2FOvarian%20Cancer%20From%20Tunisia&amp;journal=Clin+Genet&amp;volume=87&amp;pages=155-60" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B21" id="B21"></a> 21. Hadiji-Abbes N, Trifa F, Choura M, Khabir A, Sellami-Boudawara T, Frikha M, et al. A Novel BRCA2 in Frame Deletion in a Tunisian Woman With Early Onset Sporadic Breast Cancer. <i>Pathol Biol (Paris)</i> (2015) 63(4-5):185&#x2013;9. doi: 10.1016/j.patbio.2015.07.009</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/26320393/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.patbio.2015.07.009" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=N+Hadiji-Abbes&amp;author=F+Trifa&amp;author=M+Choura&amp;author=A+Khabir&amp;author=T+Sellami-Boudawara&amp;author=M+Frikha&amp;publication_year=2015&amp;title=A%20Novel%20BRCA2%20in%20Frame%20Deletion%20in%20a%20Tunisian%20Woman%20With%20Early%20Onset%20Sporadic%20Breast%20Cancer&amp;journal=Pathol+Biol+(Paris)&amp;volume=63&amp;pages=185-9" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B22" id="B22"></a> 22. Mahfoudh W, Bettaieb I, Ghedira R, Snoussi K, Bouzid N, Klayech Z, et al. Contribution of BRCA1 5382insc Mutation in Triple Negative Breast Cancer in Tunisia. <i>J Trans Med</i> (2019) 17(1):123. doi: 10.1186/s12967-019-1873-8</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.1186/s12967-019-1873-8" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=W+Mahfoudh&amp;author=I+Bettaieb&amp;author=R+Ghedira&amp;author=K+Snoussi&amp;author=N+Bouzid&amp;author=Z+Klayech&amp;publication_year=2019&amp;title=Contribution%20of%20BRCA1%205382insc%20Mutation%20in%20Triple%20Negative%20Breast%20Cancer%20in%20Tunisia&amp;journal=J+Trans+Med&amp;volume=17&amp;pages=123" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B23" id="B23"></a> 23. Ben Kridis-Rejeb W, Ben Ayed-Guerfali D, Ammous-Boukhris N, Ayadi W, Kifagi C, Charfi S, et al. Identification of Novel Candidate Genes by Exome Sequencing in Tunisian Familial Male Breast Cancer Patients. <i>Mol Biol Rep</i> (2020) 47(9):6507&#x2013;16. doi: 10.1007/s11033-020-05703-0</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/32901360/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s11033-020-05703-0" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=W+Ben%20Kridis-Rejeb&amp;author=D+Ben%20Ayed-Guerfali&amp;author=N+Ammous-Boukhris&amp;author=W+Ayadi&amp;author=C+Kifagi&amp;author=S+Charfi&amp;publication_year=2020&amp;title=Identification%20of%20Novel%20Candidate%20Genes%20by%20Exome%20Sequencing%20in%20Tunisian%20Familial%20Male%20Breast%20Cancer%20Patients&amp;journal=Mol+Biol+Rep&amp;volume=47&amp;pages=6507-16" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B24" id="B24"></a> 24. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of Protein-Coding Genetic Variation in 60,706 Humans. <i>Nature</i> (2016) 536(7616):285&#x2013;91. doi: 10.1038/nature19057</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/27535533/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nature19057" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Lek&amp;author=KJ+Karczewski&amp;author=EV+Minikel&amp;author=KE+Samocha&amp;author=E+Banks&amp;author=T+Fennell&amp;publication_year=2016&amp;title=Analysis%20of%20Protein-Coding%20Genetic%20Variation%20in%2060%2C706%20Humans&amp;journal=Nature&amp;volume=536&amp;pages=285-91" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B25" id="B25"></a> 25. Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A Global Reference for Human Genetic Variation. <i>Nature</i> (2015) 526(7571):68&#x2013;74. doi: 10.1038/nature15393</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/26432245/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nature15393" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C+Genomes%20Project&amp;author=A+Auton&amp;author=LD+Brooks&amp;author=RM+Durbin&amp;author=EP+Garrison&amp;author=HM+Kang&amp;publication_year=2015&amp;title=A%20Global%20Reference%20for%20Human%20Genetic%20Variation&amp;journal=Nature&amp;volume=526&amp;pages=68" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B26" id="B26"></a> 26. Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, et al. Association of Type and Location of BRCA1 and BRCA2 Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA</i> (2015) 313(13):1347&#x2013;61. doi: 10.1001/jama.2014.5985</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25849179/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1001/jama.2014.5985" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=TR+Rebbeck&amp;author=N+Mitra&amp;author=F+Wan&amp;author=OM+Sinilnikova&amp;author=S+Healey&amp;author=L+McGuffog&amp;publication_year=2015&amp;title=Association%20of%20Type%20and%20Location%20of%20BRCA1%20and%20BRCA2%20Mutations%20With%20Risk%20of%20Breast%20and%20Ovarian%20Cancer&amp;journal=JAMA&amp;volume=313&amp;pages=1347-61" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B27" id="B27"></a> 27. Melchor L, Benitez J. The Complex Genetic Landscape of Familial Breast Cancer. <i>Hum Genet</i> (2013) 132(8):845&#x2013;63. doi: 10.1007/s00439-013-1299-y</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/23552954/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s00439-013-1299-y" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L+Melchor&amp;author=J+Benitez&amp;publication_year=2013&amp;title=The%20Complex%20Genetic%20Landscape%20of%20Familial%20Breast%20Cancer&amp;journal=Hum+Genet&amp;volume=132&amp;pages=845-63" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B28" id="B28"></a> 28. Laraqui A, Uhrhammer N, Rhaffouli HE, Sekhsokh Y, Lahlou-Amine I, Bajjou T, et al. BRCA Genetic Screening in Middle Eastern and North African: Mutational Spectrum and Founder BRCA1 Mutation (C.798_799deltt) in North African. <i>Dis Markers</i> (2015) 2015:194293. doi: 10.1155/2015/194293</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25814778/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1155/2015/194293" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Laraqui&amp;author=N+Uhrhammer&amp;author=HE+Rhaffouli&amp;author=Y+Sekhsokh&amp;author=I+Lahlou-Amine&amp;author=T+Bajjou&amp;publication_year=2015&amp;title=BRCA%20Genetic%20Screening%20in%20Middle%20Eastern%20and%20North%20African%3A%20Mutational%20Spectrum%20and%20Founder%20BRCA1%20Mutation%20%28C.798_799deltt%29%20in%20North%20African&amp;journal=Dis+Markers&amp;volume=2015&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B29" id="B29"></a> 29. Laitman Y, Friebel TM, Yannoukakos D, Fostira F, Konstantopoulou I, Figlioli G, et al. The Spectrum of BRCA1 and BRCA2 Pathogenic Sequence Variants in Middle Eastern, North African, and South European Countries. <i>Hum Mutat</i> (2019) 40(11):e1&#x2013;e23. doi: 10.1002/humu.23842</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/31209999/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/humu.23842" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=Y+Laitman&amp;author=TM+Friebel&amp;author=D+Yannoukakos&amp;author=F+Fostira&amp;author=I+Konstantopoulou&amp;author=G+Figlioli&amp;publication_year=2019&amp;title=The%20Spectrum%20of%20BRCA1%20and%20BRCA2%20Pathogenic%20Sequence%20Variants%20in%20Middle%20Eastern%2C%20North%20African%2C%20and%20South%20European%20Countries&amp;journal=Hum+Mutat&amp;volume=40&amp;pages=e1" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B30" id="B30"></a> 30. Behl S, Hamel N, de Ladurantaye M, Lepage S, Lapointe R, Mes-Masson AM, et al. Founder BRCA1/BRCA2/PALB2 Pathogenic Variants in French-Canadian Breast Cancer Cases and Controls. <i>Sci Rep</i> (2020) 10(1):6491. doi: 10.1038/s41598-020-63100-w</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/32300229/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41598-020-63100-w" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Behl&amp;author=N+Hamel&amp;author=M+de%20Ladurantaye&amp;author=S+Lepage&amp;author=R+Lapointe&amp;author=AM+Mes-Masson&amp;publication_year=2020&amp;title=Founder%20BRCA1%2FBRCA2%2FPALB2%20Pathogenic%20Variants%20in%20French-Canadian%20Breast%20Cancer%20Cases%20and%20Controls&amp;journal=Sci+Rep&amp;volume=10&amp;pages=6491" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B31" id="B31"></a> 31. Oosthuizen J, Kotze MJ, van der Merwe N, Myburgh EJ, Bester P, van der Merwe NC. Globally Rare BRCA2 Variants With Founder Haplotypes in the South African Population: Implications for Point-Of-Care Testing Based on a Single-Institution BRCA1/2 Next-Generation Sequencing Study. <i>Front Oncol</i> (2020) 10:619469. doi: 10.3389/fonc.2020.619469</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/33643918/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3389/fonc.2020.619469" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Oosthuizen&amp;author=MJ+Kotze&amp;author=N+van%20der%20Merwe&amp;author=EJ+Myburgh&amp;author=P+Bester&amp;author=NC+van%20der%20Merwe&amp;publication_year=2020&amp;title=Globally%20Rare%20BRCA2%20Variants%20With%20Founder%20Haplotypes%20in%20the%20South%20African%20Population%3A%20Implications%20for%20Point-Of-Care%20Testing%20Based%20on%20a%20Single-Institution%20BRCA1%2F2%20Next-Generation%20Sequencing%20Study&amp;journal=Front+Oncol&amp;volume=10&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B32" id="B32"></a> 32. Tennen RI, Laskey SB, Koelsch BL, McIntyre MH, Tung JY. Identifying Ashkenazi Jewish BRCA1/2 Founder Variants in Individuals Who Do Not Self-Report Jewish Ancestry. <i>Sci Rep</i> (2020) 10(1):7669. doi: 10.1038/s41598-020-63466-x</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/32376921/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41598-020-63466-x" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=RI+Tennen&amp;author=SB+Laskey&amp;author=BL+Koelsch&amp;author=MH+McIntyre&amp;author=JY+Tung&amp;publication_year=2020&amp;title=Identifying%20Ashkenazi%20Jewish%20BRCA1%2F2%20Founder%20Variants%20in%20Individuals%20Who%20Do%20Not%20Self-Report%20Jewish%20Ancestry&amp;journal=Sci+Rep&amp;volume=10&amp;pages=7669" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B33" id="B33"></a> 33. Hamdi Y, Ben Rekaya M, Jingxuan S, Nagara M, Messaoud O, Benammar Elgaaied A, et al. A Genome Wide SNP Genotyping Study in the Tunisian Population: Specific Reporting on a Subset of Common Breast Cancer Risk Loci. <i>BMC Cancer</i> (2018) 18(1):1295. doi: 10.1186/s12885-018-5133-8</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/30594178/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s12885-018-5133-8" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=Y+Hamdi&amp;author=M+Ben%20Rekaya&amp;author=S+Jingxuan&amp;author=M+Nagara&amp;author=O+Messaoud&amp;author=A+Benammar%20Elgaaied&amp;publication_year=2018&amp;title=A%20Genome%20Wide%20SNP%20Genotyping%20Study%20in%20the%20Tunisian%20Population%3A%20Specific%20Reporting%20on%20a%20Subset%20of%20Common%20Breast%20Cancer%20Risk%20Loci&amp;journal=BMC+Cancer&amp;volume=18&amp;pages=1295" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B34" id="B34"></a> 34. Hamdi Y, Jerbi M, Romdhane L, Ben Rekaya M, El Benna H, Chouchane L, et al. Genetic Diversity and Functional Effect of Common Polymorphisms in Genes Involved in the First Heterodimeric Complex of the Nucleotide Excision Repair Pathway. <i>DNA Repair (Amst)</i> (2020) 86:102770. doi: 10.1016/j.dnarep.2019.102770</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/31865061/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.dnarep.2019.102770" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=Y+Hamdi&amp;author=M+Jerbi&amp;author=L+Romdhane&amp;author=M+Ben%20Rekaya&amp;author=H+El%20Benna&amp;author=L+Chouchane&amp;publication_year=2020&amp;title=Genetic%20Diversity%20and%20Functional%20Effect%20of%20Common%20Polymorphisms%20in%20Genes%20Involved%20in%20the%20First%20Heterodimeric%20Complex%20of%20the%20Nucleotide%20Excision%20Repair%20Pathway&amp;journal=DNA+Repair+(Amst)&amp;volume=86&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B35" id="B35"></a> 35. Fang M, Zhu L, Li H, Li X, Wu Y, Wu K, et al. Characterization of Mutations in BRCA1/2 and the Relationship With Clinic-Pathological Features of Breast Cancer in a Hereditarily High-Risk Sample of Chinese Population. <i>Oncol Lett</i> (2018) 15(3):3068&#x2013;74. doi: 10.3892/ol.2017.7717</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/29435039/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3892/ol.2017.7717" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Fang&amp;author=L+Zhu&amp;author=H+Li&amp;author=X+Li&amp;author=Y+Wu&amp;author=K+Wu&amp;publication_year=2018&amp;title=Characterization%20of%20Mutations%20in%20BRCA1%2F2%20and%20the%20Relationship%20With%20Clinic-Pathological%20Features%20of%20Breast%20Cancer%20in%20a%20Hereditarily%20High-Risk%20Sample%20of%20Chinese%20Population&amp;journal=Oncol+Lett&amp;volume=15&amp;pages=3068-74" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B36" id="B36"></a> 36. Godet I, Gilkes DM. BRCA1 and BRCA2 Mutations and Treatment Strategies for Breast Cancer. <i>Integr Cancer Sci Ther</i> (2017) 4(1):10. doi: 10.15761/ICST.1000228</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://doi.org/10.15761/ICST.1000228" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=I+Godet&amp;author=DM+Gilkes&amp;publication_year=2017&amp;title=BRCA1%20and%20BRCA2%20Mutations%20and%20Treatment%20Strategies%20for%20Breast%20Cancer&amp;journal=Integr+Cancer+Sci+Ther&amp;volume=4&amp;pages=10" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B37" id="B37"></a> 37. Chouchane L, Boussen H, Sastry KSR. Breast Cancer in Arab Populations: Molecular Characteristics and Disease Management Implications. <i>Lancet Oncol</i> (2013) 14(10):e417&#x2013;e24. doi: 10.1016/S1470-2045(13)70165-7</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/23993386/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/S1470-2045(13)70165-7" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=L+Chouchane&amp;author=H+Boussen&amp;author=KSR+Sastry&amp;publication_year=2013&amp;title=Breast%20Cancer%20in%20Arab%20Populations%3A%20Molecular%20Characteristics%20and%20Disease%20Management%20Implications&amp;journal=Lancet+Oncol&amp;volume=14&amp;pages=e417-e24" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B38" id="B38"></a> 38. Zehani S, Maalej M, Hsairi M, Hechiche M, Romdhane B, Boussen H, et al. Breast Cancer in Tunisia: Epidemiologic Characteristics and Trends in Incidence. <i>La Tunisie Medicale</i> (2009) 87(7):417&#x2013;25.
</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/20063673/" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Zehani&amp;author=M+Maalej&amp;author=M+Hsairi&amp;author=M+Hechiche&amp;author=B+Romdhane&amp;author=H+Boussen&amp;publication_year=2009&amp;title=Breast%20Cancer%20in%20Tunisia%3A%20Epidemiologic%20Characteristics%20and%20Trends%20in%20Incidence&amp;journal=La+Tunisie+Medicale&amp;volume=87&amp;pages=417-25" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B39" id="B39"></a> 39. Neff RT, Senter L, Salani R. BRCA Mutation in Ovarian Cancer: Testing, Implications and Treatment Considerations. <i>Ther Adv Med Oncol</i> (2017) 9(8):519&#x2013;31. doi: 10.1177/1758834017714993</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/28794804/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1177/1758834017714993" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=RT+Neff&amp;author=L+Senter&amp;author=R+Salani&amp;publication_year=2017&amp;title=BRCA%20Mutation%20in%20Ovarian%20Cancer%3A%20Testing%2C%20Implications%20and%20Treatment%20Considerations&amp;journal=Ther+Adv+Med+Oncol&amp;volume=9&amp;pages=519-31" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B40" id="B40"></a> 40. Meindl A, German Consortium for Hereditary B, Ovarian C. Comprehensive Analysis of 989 Patients With Breast or Ovarian Cancer Provides BRCA1 and BRCA2 Mutation Profiles and Frequencies for the German Population. <i>Int J Cancer</i> (2002) 97(4):472&#x2013;80. doi: 10.1002/ijc.1626</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/11802209/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/ijc.1626" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Meindl&amp;author=German%20Consortium%20for%20Hereditary%20B&amp;author=Ovarian%20C&amp;publication_year=2002&amp;title=Comprehensive%20Analysis%20of%20989%20Patients%20With%20Breast%20or%20Ovarian%20Cancer%20Provides%20BRCA1%20and%20BRCA2%20Mutation%20Profiles%20and%20Frequencies%20for%20the%20German%20Population&amp;journal=Int+J+Cancer&amp;volume=97&amp;pages=472-80" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B41" id="B41"></a> 41. Lim MC, Kang S, Seo SS, Kong SY, Lee BY, Lee SK, et al. BRCA1 and BRCA2 Germline Mutations in Korean Ovarian Cancer Patients. <i>J Cancer Res Clin Oncol</i> (2009) 135(11):1593&#x2013;9. doi: 10.1007/s00432-009-0607-3</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/19499246/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s00432-009-0607-3" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MC+Lim&amp;author=S+Kang&amp;author=SS+Seo&amp;author=SY+Kong&amp;author=BY+Lee&amp;author=SK+Lee&amp;publication_year=2009&amp;title=BRCA1%20and%20BRCA2%20Germline%20Mutations%20in%20Korean%20Ovarian%20Cancer%20Patients&amp;journal=J+Cancer+Res+Clin+Oncol&amp;volume=135&amp;pages=1593-9" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B42" id="B42"></a> 42. Zuntini R, Cortesi L, Calistri D, Pippucci T, Martelli PL, Casadio R, et al. BRCA1 P. His1673del Is a Pathogenic Mutation Associated With a Predominant Ovarian Cancer Phenotype. <i>Oncotarget</i> (2017) 8(14):22640. doi: 10.18632/oncotarget.15151</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/28186987/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.18632/oncotarget.15151" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R+Zuntini&amp;author=L+Cortesi&amp;author=D+Calistri&amp;author=T+Pippucci&amp;author=PL+Martelli&amp;author=R+Casadio&amp;publication_year=2017&amp;title=BRCA1%20P.%20His1673del%20Is%20a%20Pathogenic%20Mutation%20Associated%20With%20a%20Predominant%20Ovarian%20Cancer%20Phenotype&amp;journal=Oncotarget&amp;volume=8&amp;pages=22640" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B43" id="B43"></a> 43. Cherbal F, Bakour R, Adane S, Boualga K. BRCA1 and BRCA2 Germline Mutation Spectrum in Hereditary Breast/Ovarian Cancer Families From Maghrebian Countries. <i>Breast Dis</i> (2012) 34(1):1&#x2013;8. doi: 10.3233/BD-130348</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/23697973/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3233/BD-130348" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=F+Cherbal&amp;author=R+Bakour&amp;author=S+Adane&amp;author=K+Boualga&amp;publication_year=2012&amp;title=BRCA1%20and%20BRCA2%20Germline%20Mutation%20Spectrum%20in%20Hereditary%20Breast%2FOvarian%20Cancer%20Families%20From%20Maghrebian%20Countries&amp;journal=Breast+Dis&amp;volume=34&amp;pages=1" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B44" id="B44"></a> 44. Ahn SH, Son BH, Yoon KS, Noh DY, Han W, Kim SW, et al. BRCA1 and BRCA2 Germline Mutations in Korean Breast Cancer Patients at High Risk of Carrying Mutations. <i>Cancer Lett</i> (2007) 245(1-2):90&#x2013;5. doi: 10.1016/j.canlet.2005.12.031</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/16455195/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.canlet.2005.12.031" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SH+Ahn&amp;author=BH+Son&amp;author=KS+Yoon&amp;author=DY+Noh&amp;author=W+Han&amp;author=SW+Kim&amp;publication_year=2007&amp;title=BRCA1%20and%20BRCA2%20Germline%20Mutations%20in%20Korean%20Breast%20Cancer%20Patients%20at%20High%20Risk%20of%20Carrying%20Mutations&amp;journal=Cancer+Lett&amp;volume=245&amp;pages=90-5" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B45" id="B45"></a> 45. Kim H, Cho DY, Choi DH, Choi SY, Shin I, Park W, et al. Characteristics and Spectrum of BRCA1 and BRCA2 Mutations in 3,922 Korean Patients With Breast and Ovarian Cancer. <i>Breast Cancer Res Treat</i> (2012) 134(3):1315&#x2013;26. doi: 10.1007/s10549-012-2159-5</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/22798144/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10549-012-2159-5" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H+Kim&amp;author=DY+Cho&amp;author=DH+Choi&amp;author=SY+Choi&amp;author=I+Shin&amp;author=W+Park&amp;publication_year=2012&amp;title=Characteristics%20and%20Spectrum%20of%20BRCA1%20and%20BRCA2%20Mutations%20in%203%2C922%20Korean%20Patients%20With%20Breast%20and%20Ovarian%20Cancer&amp;journal=Breast+Cancer+Res+Treat&amp;volume=134&amp;pages=1315-26" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B46" id="B46"></a> 46. Weitzel JN, Clague J, Martir-Negron A, Ogaz R, Herzog J, Ricker C, et al. Prevalence and Type of BRCA Mutations in Hispanics Undergoing Genetic Cancer Risk Assessment in the Southwestern United States: A Report From the Clinical Cancer Genetics Community Research Network. <i>J Clin Oncol</i> (2013) 31(2):210&#x2013;6. doi: 10.1200/JCO.2011.41.0027</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/23233716/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1200/JCO.2011.41.0027" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=JN+Weitzel&amp;author=J+Clague&amp;author=A+Martir-Negron&amp;author=R+Ogaz&amp;author=J+Herzog&amp;author=C+Ricker&amp;publication_year=2013&amp;title=Prevalence%20and%20Type%20of%20BRCA%20Mutations%20in%20Hispanics%20Undergoing%20Genetic%20Cancer%20Risk%20Assessment%20in%20the%20Southwestern%20United%20States%3A%20A%20Report%20From%20the%20Clinical%20Cancer%20Genetics%20Community%20Research%20Network&amp;journal=J+Clin+Oncol&amp;volume=31&amp;pages=210-6" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B47" id="B47"></a> 47. Torres-Mejia G, Royer R, Llacuachaqui M, Akbari MR, Giuliano AR, Martinez-Matsushita L, et al. Recurrent BRCA1 and BRCA2 Mutations in Mexican Women With Breast Cancer. <i>Cancer Epidemiol Biomarkers Prev</i> (2015) 24(3):498&#x2013;505. doi: 10.1158/1055-9965.EPI-13-0980</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25371446/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1158/1055-9965.EPI-13-0980" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=G+Torres-Mejia&amp;author=R+Royer&amp;author=M+Llacuachaqui&amp;author=MR+Akbari&amp;author=AR+Giuliano&amp;author=L+Martinez-Matsushita&amp;publication_year=2015&amp;title=Recurrent%20BRCA1%20and%20BRCA2%20Mutations%20in%20Mexican%20Women%20With%20Breast%20Cancer&amp;journal=Cancer+Epidemiol+Biomarkers+Prev&amp;volume=24&amp;pages=498" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B48" id="B48"></a> 48. Palmero EI, Carraro DM, Alemar B, Moreira MAM, Ribeiro-Dos-Santos A, Abe-Sandes K, et al. The Germline Mutational Landscape of BRCA1 and BRCA2 in Brazil. <i>Sci Rep</i> (2018) 8(1):9188. doi: 10.1038/s41598-018-27315-2</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/29907814/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/s41598-018-27315-2" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=EI+Palmero&amp;author=DM+Carraro&amp;author=B+Alemar&amp;author=MAM+Moreira&amp;author=A+Ribeiro-Dos-Santos&amp;author=K+Abe-Sandes&amp;publication_year=2018&amp;title=The%20Germline%20Mutational%20Landscape%20of%20BRCA1%20and%20BRCA2%20in%20Brazil&amp;journal=Sci+Rep&amp;volume=8&amp;pages=9188" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B49" id="B49"></a> 49. Barnes-Kedar I, Bernstein-Molho R, Ginzach N, Hartmajer S, Shapira T, Magal N, et al. The Yield of Full BRCA1/2 Genotyping in Israeli High-Risk Breast/Ovarian Cancer Patients Who Do Not Carry the Predominant Mutations. <i>Breast Cancer Res Treat</i> (2018) 172(1):151&#x2013;7. doi: 10.1007/s10549-018-4887-7</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/30014164/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10549-018-4887-7" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=I+Barnes-Kedar&amp;author=R+Bernstein-Molho&amp;author=N+Ginzach&amp;author=S+Hartmajer&amp;author=T+Shapira&amp;author=N+Magal&amp;publication_year=2018&amp;title=The%20Yield%20of%20Full%20BRCA1%2F2%20Genotyping%20in%20Israeli%20High-Risk%20Breast%2FOvarian%20Cancer%20Patients%20Who%20Do%20Not%20Carry%20the%20Predominant%20Mutations&amp;journal=Breast+Cancer+Res+Treat&amp;volume=172&amp;pages=151-7" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B50" id="B50"></a> 50. Jakimovska M, Maleva Kostovska I, Popovska-Jankovic K, Kubelka-Sabit K, Karadjozov M, Stojanovska L, et al. BRCA1 and BRCA2 Germline Variants in Breast Cancer Patients From the Republic of Macedonia. <i>Breast Cancer Res Treat</i> (2018) 168(3):745&#x2013;53. doi: 10.1007/s10549-017-4642-5</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/29335924/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10549-017-4642-5" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Jakimovska&amp;author=I+Maleva%20Kostovska&amp;author=K+Popovska-Jankovic&amp;author=K+Kubelka-Sabit&amp;author=M+Karadjozov&amp;author=L+Stojanovska&amp;publication_year=2018&amp;title=BRCA1%20and%20BRCA2%20Germline%20Variants%20in%20Breast%20Cancer%20Patients%20From%20the%20Republic%20of%20Macedonia&amp;journal=Breast+Cancer+Res+Treat&amp;volume=168&amp;pages=745-53" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B51" id="B51"></a> 51. Mighri N, Hamdi Y, Boujemaa M, Othman H, Ben Nasr S, El Benna H, et al. Identification of Novel BRCA1 and RAD50 Mutations Associated With Breast Cancer Predisposition in Tunisian Patients. <i>Front Genet</i> (2020) 11:552971. doi: 10.3389/fgene.2020.552971</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/33240314/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.3389/fgene.2020.552971" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=N+Mighri&amp;author=Y+Hamdi&amp;author=M+Boujemaa&amp;author=H+Othman&amp;author=S+Ben%20Nasr&amp;author=H+El%20Benna&amp;publication_year=2020&amp;title=Identification%20of%20Novel%20BRCA1%20and%20RAD50%20Mutations%20Associated%20With%20Breast%20Cancer%20Predisposition%20in%20Tunisian%20Patients&amp;journal=Front+Genet&amp;volume=11&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B52" id="B52"></a> 52. Manchana T, Phoolcharoen N, Tantbirojn P. BRCA Mutation in High Grade Epithelial Ovarian Cancers. <i>Gynecol Oncol Rep</i> (2019) 29:102&#x2013;5. doi: 10.1016/j.gore.2019.07.007</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/31467961/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.gore.2019.07.007" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=T+Manchana&amp;author=N+Phoolcharoen&amp;author=P+Tantbirojn&amp;publication_year=2019&amp;title=BRCA%20Mutation%20in%20High%20Grade%20Epithelial%20Ovarian%20Cancers&amp;journal=Gynecol+Oncol+Rep&amp;volume=29&amp;pages=102-5" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B53" id="B53"></a> 53. Hamel N, Feng BJ, Foretova L, Stoppa-Lyonnet D, Narod SA, Imyanitov E, et al. On the Origin and Diffusion of BRCA1 C.5266dupc (5382insc) in European Populations. <i>Eur J Hum Genet</i> (2011) 19(3):300&#x2013;6. doi: 10.1038/ejhg.2010.203</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/21119707/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/ejhg.2010.203" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=N+Hamel&amp;author=BJ+Feng&amp;author=L+Foretova&amp;author=D+Stoppa-Lyonnet&amp;author=SA+Narod&amp;author=E+Imyanitov&amp;publication_year=2011&amp;title=On%20the%20Origin%20and%20Diffusion%20of%20BRCA1%20C.5266dupc%20%285382insc%29%20in%20European%20Populations&amp;journal=Eur+J+Hum+Genet&amp;volume=19&amp;pages=300-6" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B54" id="B54"></a> 54. Janavicius R. Founder BRCA1/2 Mutations in the Europe: Implications for Hereditary Breast-Ovarian Cancer Prevention and Control. <i>EPMA J</i> (2010) 1(3):397&#x2013;412. doi: 10.1007/s13167-010-0037-y</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/23199084/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s13167-010-0037-y" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=R+Janavicius&amp;publication_year=2010&amp;title=Founder%20BRCA1%2F2%20Mutations%20in%20the%20Europe%3A%20Implications%20for%20Hereditary%20Breast-Ovarian%20Cancer%20Prevention%20and%20Control&amp;journal=EPMA+J&amp;volume=1&amp;pages=397" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B55" id="B55"></a> 55. Edwards SM, Evans DGR, Hope Q, Norman A, Barbachano Y, Bullock S, et al. Prostate Cancer in BRCA2 Germline Mutation Carriers is Associated With Poorer Prognosis. <i>Br J Cancer</i> (2010) 103(6):918&#x2013;24. doi: 10.1038/sj.bjc.6605822</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/20736950/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/sj.bjc.6605822" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SM+Edwards&amp;author=DGR+Evans&amp;author=Q+Hope&amp;author=A+Norman&amp;author=Y+Barbachano&amp;author=S+Bullock&amp;publication_year=2010&amp;title=Prostate%20Cancer%20in%20BRCA2%20Germline%20Mutation%20Carriers%20is%20Associated%20With%20Poorer%20Prognosis&amp;journal=Br+J+Cancer&amp;volume=103&amp;pages=918-24" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B56" id="B56"></a> 56. Laarabi FZ, Ratbi I, Elalaoui SC, Mezzouar L, Doubaj Y, Bouguenouch L, et al. High Frequency of the Recurrent C.1310_1313delaaga BRCA2 Mutation in the North-East of Morocco and Implication for Hereditary Breast-Ovarian Cancer Prevention and Control. <i>BMC Res Notes</i> (2017) 10(1):188. doi: 10.1186/s13104-017-2511-2</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/28577564/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s13104-017-2511-2" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=FZ+Laarabi&amp;author=I+Ratbi&amp;author=SC+Elalaoui&amp;author=L+Mezzouar&amp;author=Y+Doubaj&amp;author=L+Bouguenouch&amp;publication_year=2017&amp;title=High%20Frequency%20of%20the%20Recurrent%20C.1310_1313delaaga%20BRCA2%20Mutation%20in%20the%20North-East%20of%20Morocco%20and%20Implication%20for%20Hereditary%20Breast-Ovarian%20Cancer%20Prevention%20and%20Control&amp;journal=BMC+Res+Notes&amp;volume=10&amp;pages=188" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B57" id="B57"></a> 57. Cherbal F, Bakour R, Adane S, Boualga K, Benais-Pont G, Maillet P. BRCA1 and BRCA2 Germline Mutations Screening in Algerian Breast/Ovarian Cancer Families. <i>Dis Markers</i> (2010) 28(6):377&#x2013;84. doi: 10.1155/2010/585278</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/20683152/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1155/2010/585278" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=F+Cherbal&amp;author=R+Bakour&amp;author=S+Adane&amp;author=K+Boualga&amp;author=G+Benais-Pont&amp;author=P+Maillet&amp;publication_year=2010&amp;title=BRCA1%20and%20BRCA2%20Germline%20Mutations%20Screening%20in%20Algerian%20Breast%2FOvarian%20Cancer%20Families&amp;journal=Dis+Markers&amp;volume=28&amp;pages=377-84" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B58" id="B58"></a> 58. El Saghir NS, Zgheib NK, Assi HA, Khoury KE, Bidet Y, Jaber SM, et al. BRCA1 and BRCA2 Mutations in Ethnic Lebanese Arab Women With High Hereditary Risk Breast Cancer. <i>Oncologist</i> (2015) 20(4):357&#x2013;64. doi: 10.1634/theoncologist.2014-0364</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25777348/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1634/theoncologist.2014-0364" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=NS+El%20Saghir&amp;author=NK+Zgheib&amp;author=HA+Assi&amp;author=KE+Khoury&amp;author=Y+Bidet&amp;author=SM+Jaber&amp;publication_year=2015&amp;title=BRCA1%20and%20BRCA2%20Mutations%20in%20Ethnic%20Lebanese%20Arab%20Women%20With%20High%20Hereditary%20Risk%20Breast%20Cancer&amp;journal=Oncologist&amp;volume=20&amp;pages=357-64" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B59" id="B59"></a> 59. Caputo S, Benboudjema L, Sinilnikova O, Rouleau E, Beroud C, Lidereau R, et al. Description and Analysis of Genetic Variants in French Hereditary Breast and Ovarian Cancer Families Recorded in the UMD-BRCA1/BRCA2 Databases. <i>Nucleic Acids Res</i> (2012) 40(Database issue):D992&#x2013;1002. doi: 10.1093/nar/gkr1160</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/22144684/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1093/nar/gkr1160" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Caputo&amp;author=L+Benboudjema&amp;author=O+Sinilnikova&amp;author=E+Rouleau&amp;author=C+Beroud&amp;author=R+Lidereau&amp;publication_year=2012&amp;title=Description%20and%20Analysis%20of%20Genetic%20Variants%20in%20French%20Hereditary%20Breast%20and%20Ovarian%20Cancer%20Families%20Recorded%20in%20the%20UMD-BRCA1%2FBRCA2%20Databases&amp;journal=Nucleic+Acids+Res&amp;volume=40&amp;pages=D992" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B60" id="B60"></a> 60. Vos JR, Teixeira N, van der Kolk DM, Mourits MJ, Rookus MA, van Leeuwen FE, et al. Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female BRCA Mutation Carriers in the Netherlands. <i>Cancer Epidemiol Biomarkers Prev</i> (2014) 23(11):2482&#x2013;91. doi: 10.1158/1055-9965.EPI-13-1279</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25103822/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1158/1055-9965.EPI-13-1279" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=JR+Vos&amp;author=N+Teixeira&amp;author=DM+van%20der%20Kolk&amp;author=MJ+Mourits&amp;author=MA+Rookus&amp;author=FE+van%20Leeuwen&amp;publication_year=2014&amp;title=Variation%20in%20Mutation%20Spectrum%20Partly%20Explains%20Regional%20Differences%20in%20the%20Breast%20Cancer%20Risk%20of%20Female%20BRCA%20Mutation%20Carriers%20in%20the%20Netherlands&amp;journal=Cancer+Epidemiol+Biomarkers+Prev&amp;volume=23&amp;pages=2482-91" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B61" id="B61"></a> 61. Meisel C, Sadowski CE, Kohlstedt D, Keller K, Staritz F, Grubling N, et al. Spectrum of Genetic Variants of BRCA1 and BRCA2 in a German Single Center Study. <i>Arch Gynecol Obstet</i> (2017) 295(5):1227&#x2013;38. doi: 10.1007/s00404-017-4330-z</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/28324225/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s00404-017-4330-z" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=C+Meisel&amp;author=CE+Sadowski&amp;author=D+Kohlstedt&amp;author=K+Keller&amp;author=F+Staritz&amp;author=N+Grubling&amp;publication_year=2017&amp;title=Spectrum%20of%20Genetic%20Variants%20of%20BRCA1%20and%20BRCA2%20in%20a%20German%20Single%20Center%20Study&amp;journal=Arch+Gynecol+Obstet&amp;volume=295&amp;pages=1227-38" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B62" id="B62"></a> 62. Thomassen M, Hansen TV, Borg A, Lianee HT, Wikman F, Pedersen IS, et al. BRCA1 and BRCA2 Mutations in Danish Families With Hereditary Breast and/or Ovarian Cancer. <i>Acta Oncol</i> (2008) 47(4):772&#x2013;7. doi: 10.1080/02841860802004974</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/18465347/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1080/02841860802004974" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Thomassen&amp;author=TV+Hansen&amp;author=A+Borg&amp;author=HT+Lianee&amp;author=F+Wikman&amp;author=IS+Pedersen&amp;publication_year=2008&amp;title=BRCA1%20and%20BRCA2%20Mutations%20in%20Danish%20Families%20With%20Hereditary%20Breast%20and%2For%20Ovarian%20Cancer&amp;journal=Acta+Oncol&amp;volume=47&amp;pages=772-7" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B63" id="B63"></a> 63. Zhang J, Fackenthal JD, Zheng Y, Huo D, Hou N, Niu Q, et al. Recurrent BRCA1 and BRCA2 Mutations in Breast Cancer Patients of African Ancestry. <i>Breast Cancer Res Treat</i> (2012) 134(2):889&#x2013;94. doi: 10.1007/s10549-012-2136-z</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/22739995/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10549-012-2136-z" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=J+Zhang&amp;author=JD+Fackenthal&amp;author=Y+Zheng&amp;author=D+Huo&amp;author=N+Hou&amp;author=Q+Niu&amp;publication_year=2012&amp;title=Recurrent%20BRCA1%20and%20BRCA2%20Mutations%20in%20Breast%20Cancer%20Patients%20of%20African%20Ancestry&amp;journal=Breast+Cancer+Res+Treat&amp;volume=134&amp;pages=889-94" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B64" id="B64"></a> 64. Jang JH, Lee JE, Kwon MJ, Ki CS, Kim JW, Nam SJ, et al. Spectra of BRCA1 and BRCA2 Mutations in Korean Patients With Breast Cancer: The Importance of Whole-Gene Sequencing. <i>J Hum Genet</i> (2012) 57(3):212&#x2013;5. doi: 10.1038/jhg.2011.139</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/22217648/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/jhg.2011.139" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=JH+Jang&amp;author=JE+Lee&amp;author=MJ+Kwon&amp;author=CS+Ki&amp;author=JW+Kim&amp;author=SJ+Nam&amp;publication_year=2012&amp;title=Spectra%20of%20BRCA1%20and%20BRCA2%20Mutations%20in%20Korean%20Patients%20With%20Breast%20Cancer%3A%20The%20Importance%20of%20Whole-Gene%20Sequencing&amp;journal=J+Hum+Genet&amp;volume=57&amp;pages=212-5" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B65" id="B65"></a> 65. Cruz-Correa M, Perez-Mayoral J, Dutil J, Echenique M, Mosquera R, Rivera-Roman K, et al. Hereditary Cancer Syndromes in Latino Populations: Genetic Characterization and Surveillance Guidelines. <i>Hered Cancer Clin Pract</i> (2017) 15:3. doi: 10.1186/s13053-017-0063-z</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/28127413/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s13053-017-0063-z" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=M+Cruz-Correa&amp;author=J+Perez-Mayoral&amp;author=J+Dutil&amp;author=M+Echenique&amp;author=R+Mosquera&amp;author=K+Rivera-Roman&amp;publication_year=2017&amp;title=Hereditary%20Cancer%20Syndromes%20in%20Latino%20Populations%3A%20Genetic%20Characterization%20and%20Surveillance%20Guidelines&amp;journal=Hered+Cancer+Clin+Pract&amp;volume=15&amp;pages=3" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B66" id="B66"></a> 66. Akbari MR, Donenberg T, Lunn J, Curling D, Turnquest T, Krill-Jackson E, et al. The Spectrum of BRCA1 and BRCA2 Mutations in Breast Cancer Patients in the Bahamas. <i>Clin Genet</i> (2014) 85(1):64&#x2013;7. doi: 10.1111/cge.12132</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/23458327/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1111/cge.12132" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MR+Akbari&amp;author=T+Donenberg&amp;author=J+Lunn&amp;author=D+Curling&amp;author=T+Turnquest&amp;author=E+Krill-Jackson&amp;publication_year=2014&amp;title=The%20Spectrum%20of%20BRCA1%20and%20BRCA2%20Mutations%20in%20Breast%20Cancer%20Patients%20in%20the%20Bahamas&amp;journal=Clin+Genet&amp;volume=85&amp;pages=64-7" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B67" id="B67"></a> 67. Donenberg T, Ahmed H, Royer R, Zhang S, Narod SA, George S, et al. A Survey of BRCA1, BRCA2, and PALB2 Mutations in Women With Breast Cancer in Trinidad and Tobago. <i>Breast Cancer Res Treat</i> (2016) 159(1):131&#x2013;8. doi: 10.1007/s10549-016-3870-4</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/27469594/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10549-016-3870-4" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=T+Donenberg&amp;author=H+Ahmed&amp;author=R+Royer&amp;author=S+Zhang&amp;author=SA+Narod&amp;author=S+George&amp;publication_year=2016&amp;title=A%20Survey%20of%20BRCA1%2C%20BRCA2%2C%20and%20PALB2%20Mutations%20in%20Women%20With%20Breast%20Cancer%20in%20Trinidad%20and%20Tobago&amp;journal=Breast+Cancer+Res+Treat&amp;volume=159&amp;pages=131-8" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B68" id="B68"></a> 68. Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, et al. Male Breast Cancer in BRCA1 and BRCA2 Mutation Carriers: Pathology Data From the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Res</i> (2016) 18(1):15. doi: 10.1186/s13058-016-0671-y</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/26857456/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s13058-016-0671-y" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=V+Silvestri&amp;author=D+Barrowdale&amp;author=AM+Mulligan&amp;author=SL+Neuhausen&amp;author=S+Fox&amp;author=BY+Karlan&amp;publication_year=2016&amp;title=Male%20Breast%20Cancer%20in%20BRCA1%20and%20BRCA2%20Mutation%20Carriers%3A%20Pathology%20Data%20From%20the%20Consortium%20of%20Investigators%20of%20Modifiers%20of%20BRCA1%2F2&amp;journal=Breast+Cancer+Res&amp;volume=18&amp;pages=15" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B69" id="B69"></a> 69. Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offit K, Caligo A, et al. Haplotype and Phenotype Analysis of Six Recurrent BRCA1 Mutations in 61 Families: Results of an International Study. <i>Am J Hum Genet</i> (1996) 58(2):271.
</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/8571953/" target="_blank">PubMed Abstract</a> | <a href="http://scholar.google.com/scholar_lookup?author=SL+Neuhausen&amp;author=S+Mazoyer&amp;author=L+Friedman&amp;author=M+Stratton&amp;author=K+Offit&amp;author=A+Caligo&amp;publication_year=1996&amp;title=Haplotype%20and%20Phenotype%20Analysis%20of%20Six%20Recurrent%20BRCA1%20Mutations%20in%2061%20Families%3A%20Results%20of%20an%20International%20Study&amp;journal=Am+J+Hum+Genet&amp;volume=58&amp;pages=271" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B70" id="B70"></a> 70. Henouda S, Bensalem A, Reggad R, Serrar N, Rouabah L, Pujol P. Contribution of BRCA1 and BRCA2 Germline Mutations to Early Algerian Breast Cancer. <i>Dis Markers</i> (2016) 2016:7869095. doi: 10.1155/2016/7869095</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/26997744/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1155/2016/7869095" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Henouda&amp;author=A+Bensalem&amp;author=R+Reggad&amp;author=N+Serrar&amp;author=L+Rouabah&amp;author=P+Pujol&amp;publication_year=2016&amp;title=Contribution%20of%20BRCA1%20and%20BRCA2%20Germline%20Mutations%20to%20Early%20Algerian%20Breast%20Cancer&amp;journal=Dis+Markers&amp;volume=2016&amp;" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B71" id="B71"></a> 71. Veronesi A, de Giacomi C, Magri MD, Lombardi D, Zanetti M, Scuderi C, et al. Familial Breast Cancer: Characteristics and Outcome of BRCA 1-2 Positive and Negative Cases. <i>BMC Cancer</i> (2005) 5:70. doi: 10.1186/1471-2407-5-70</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/15996267/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/1471-2407-5-70" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Veronesi&amp;author=C+de%20Giacomi&amp;author=MD+Magri&amp;author=D+Lombardi&amp;author=M+Zanetti&amp;author=C+Scuderi&amp;publication_year=2005&amp;title=Familial%20Breast%20Cancer%3A%20Characteristics%20and%20Outcome%20of%20BRCA%201-2%20Positive%20and%20Negative%20Cases&amp;journal=BMC+Cancer&amp;volume=5&amp;pages=70" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B72" id="B72"></a> 72. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, et al. Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast Cancer. <i>J Clin Oncol</i> (2008) 26(26):4282&#x2013;8. doi: 10.1200/JCO.2008.16.6231</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/18779615/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1200/JCO.2008.16.6231" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=DP+Atchley&amp;author=CT+Albarracin&amp;author=A+Lopez&amp;author=V+Valero&amp;author=CI+Amos&amp;author=AM+Gonzalez-Angulo&amp;publication_year=2008&amp;title=Clinical%20and%20Pathologic%20Characteristics%20of%20Patients%20With%20BRCA-Positive%20and%20BRCA-Negative%20Breast%20Cancer&amp;journal=J+Clin+Oncol&amp;volume=26&amp;pages=4282-8" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B73" id="B73"></a> 73. Jouhadi H, Tazzite A, Azeddoug H, Naim A, Nadifi S, Benider A. Clinical and Pathological Features of BRCA1/2 Tumors in a Sample of High-Risk Moroccan Breast Cancer Patients. <i>BMC Res Notes</i> (2016) 9:248. doi: 10.1186/s13104-016-2057-8</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/27129401/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/s13104-016-2057-8" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=H+Jouhadi&amp;author=A+Tazzite&amp;author=H+Azeddoug&amp;author=A+Naim&amp;author=S+Nadifi&amp;author=A+Benider&amp;publication_year=2016&amp;title=Clinical%20and%20Pathological%20Features%20of%20BRCA1%2F2%20Tumors%20in%20a%20Sample%20of%20High-Risk%20Moroccan%20Breast%20Cancer%20Patients&amp;journal=BMC+Res+Notes&amp;volume=9&amp;pages=248" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B74" id="B74"></a> 74. Atci MM, Geredeli C, Ay S, Sakin A, Erturk B, Secmeler S, et al. Clinical and Pathological Characteristics of Patients With High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study. <i>Eur J Breast Health</i> (2021) 17(2):123&#x2013;7. doi: 10.4274/ejbh.galenos.2020.6346</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/33870111/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.4274/ejbh.galenos.2020.6346" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MM+Atci&amp;author=C+Geredeli&amp;author=S+Ay&amp;author=A+Sakin&amp;author=B+Erturk&amp;author=S+Secmeler&amp;publication_year=2021&amp;title=Clinical%20and%20Pathological%20Characteristics%20of%20Patients%20With%20High-Risk%20Breast%20Cancer%20Based%20on%20BRCA%20Mutation%20Profiles%3A%20A%20Retrospective%20Study&amp;journal=Eur+J+Breast+Health&amp;volume=17&amp;pages=123-7" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B75" id="B75"></a> 75. Lee E, McKean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, Bernstein L, et al. Characteristics of Triple-Negative Breast Cancer in Patients With a BRCA1 Mutation: Results From a Population-Based Study of Young Women. <i>J Clin Oncol</i> (2011) 29(33):4373&#x2013;80. doi: 10.1200/JCO.2010.33.6446</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/22010008/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1200/JCO.2010.33.6446" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=E+Lee&amp;author=R+McKean-Cowdin&amp;author=H+Ma&amp;author=DV+Spicer&amp;author=D+Van%20Den%20Berg&amp;author=L+Bernstein&amp;publication_year=2011&amp;title=Characteristics%20of%20Triple-Negative%20Breast%20Cancer%20in%20Patients%20With%20a%20BRCA1%20Mutation%3A%20Results%20From%20a%20Population-Based%20Study%20of%20Young%20Women&amp;journal=J+Clin+Oncol&amp;volume=29&amp;pages=4373-80" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B76" id="B76"></a> 76. Muendlein A, Rohde BH, Gasser K, Haid A, Rauch S, Kinz E, et al. Evaluation of BRCA1/2 Mutational Status Among German and Austrian Women With Triple-Negative Breast Cancer. <i>J Cancer Res Clin Oncol</i> (2015) 141(11):2005&#x2013;12. doi: 10.1007/s00432-015-1986-2</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/25971625/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s00432-015-1986-2" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=A+Muendlein&amp;author=BH+Rohde&amp;author=K+Gasser&amp;author=A+Haid&amp;author=S+Rauch&amp;author=E+Kinz&amp;publication_year=2015&amp;title=Evaluation%20of%20BRCA1%2F2%20Mutational%20Status%20Among%20German%20and%20Austrian%20Women%20With%20Triple-Negative%20Breast%20Cancer&amp;journal=J+Cancer+Res+Clin+Oncol&amp;volume=141&amp;pages=2005-12" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B77" id="B77"></a> 77. Stefansson OA, Jonasson JG, Olafsdottir K, Bjarnason H, Th Johannsson O, Bodvarsdottir SK, et al. Genomic and Phenotypic Analysis of BRCA2 Mutated Breast Cancers Reveals Co-Occurring Changes Linked to Progression. <i>Breast Cancer Res</i> (2011) 13(5):R95. doi: 10.1186/bcr3020</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/21958427/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/bcr3020" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=OA+Stefansson&amp;author=JG+Jonasson&amp;author=K+Olafsdottir&amp;author=H+Bjarnason&amp;author=O+Th%20Johannsson&amp;author=SK+Bodvarsdottir&amp;publication_year=2011&amp;title=Genomic%20and%20Phenotypic%20Analysis%20of%20BRCA2%20Mutated%20Breast%20Cancers%20Reveals%20Co-Occurring%20Changes%20Linked%20to%20Progression&amp;journal=Breast+Cancer+Res&amp;volume=13&amp;pages=R95" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B78" id="B78"></a> 78. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, et al. Prediction of BRCA1 Status in Patients With Breast Cancer Using Estrogen Receptor and Basal Phenotype. <i>Clin Cancer Res</i> (2005) 11(14):5175&#x2013;80. doi: 10.1158/1078-0432.CCR-04-2424</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/16033833/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1158/1078-0432.CCR-04-2424" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=SR+Lakhani&amp;author=JS+Reis-Filho&amp;author=L+Fulford&amp;author=F+Penault-Llorca&amp;author=M+van%20der%20Vijver&amp;author=S+Parry&amp;publication_year=2005&amp;title=Prediction%20of%20BRCA1%20Status%20in%20Patients%20With%20Breast%20Cancer%20Using%20Estrogen%20Receptor%20and%20Basal%20Phenotype&amp;journal=Clin+Cancer+Res&amp;volume=11&amp;pages=5175-80" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B79" id="B79"></a> 79. Keeney MG, Couch FJ, Visscher DW, Lindor NM. Non-BRCA Familial Breast Cancer: Review of Reported Pathology and Molecular Findings. <i>Pathology</i> (2017) 49(4):363&#x2013;70. doi: 10.1016/j.pathol.2017.03.002</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/28450088/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.pathol.2017.03.002" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MG+Keeney&amp;author=FJ+Couch&amp;author=DW+Visscher&amp;author=NM+Lindor&amp;publication_year=2017&amp;title=Non-BRCA%20Familial%20Breast%20Cancer%3A%20Review%20of%20Reported%20Pathology%20and%20Molecular%20Findings&amp;journal=Pathology&amp;volume=49&amp;pages=363-70" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B80" id="B80"></a> 80. Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, et al. Frequencies of BRCA1 and BRCA2 Mutations Among 1,342 Unselected Patients With Invasive Ovarian Cancer. <i>Gynecol Oncol</i> (2011) 121(2):353&#x2013;7. doi: 10.1016/j.ygyno.2011.01.020</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/21324516/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/j.ygyno.2011.01.020" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Zhang&amp;author=R+Royer&amp;author=S+Li&amp;author=JR+McLaughlin&amp;author=B+Rosen&amp;author=HA+Risch&amp;publication_year=2011&amp;title=Frequencies%20of%20BRCA1%20and%20BRCA2%20Mutations%20Among%201%2C342%20Unselected%20Patients%20With%20Invasive%20Ovarian%20Cancer&amp;journal=Gynecol+Oncol&amp;volume=121&amp;pages=353-7" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B81" id="B81"></a> 81. Lang GT, Shi JX, Hu X, Zhang CH, Shan L, Song CG, et al. The Spectrum of BRCA Mutations and Characteristics of BRCA-Associated Breast Cancers in China: Screening of 2,991 Patients and 1,043 Controls by Next-Generation Sequencing. <i>Int J Cancer</i> (2017) 141(1):129&#x2013;42. doi: 10.1002/ijc.30692</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/28294317/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1002/ijc.30692" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=GT+Lang&amp;author=JX+Shi&amp;author=X+Hu&amp;author=CH+Zhang&amp;author=L+Shan&amp;author=CG+Song&amp;publication_year=2017&amp;title=The%20Spectrum%20of%20BRCA%20Mutations%20and%20Characteristics%20of%20BRCA-Associated%20Breast%20Cancers%20in%20China%3A%20Screening%20of%202%2C991%20Patients%20and%201%2C043%20Controls%20by%20Next-Generation%20Sequencing&amp;journal=Int+J+Cancer&amp;volume=141&amp;pages=129-42" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B82" id="B82"></a> 82. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom M-J, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. <i>Jama</i> (2017) 317(23):2402&#x2013;16. doi: 10.1001/jama.2017.7112</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/28632866/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1001/jama.2017.7112" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=KB+Kuchenbaecker&amp;author=JL+Hopper&amp;author=DR+Barnes&amp;author=K-A+Phillips&amp;author=TM+Mooij&amp;author=M-J+Roos-Blom&amp;publication_year=2017&amp;title=Risks%20of%20Breast%2C%20Ovarian%2C%20and%20Contralateral%20Breast%20Cancer%20for%20BRCA1%20and%20BRCA2%20Mutation%20Carriers&amp;journal=Jama&amp;volume=317&amp;pages=2402-16" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B83" id="B83"></a> 83. Einbeigi Z, Bergman A, Meis-Kindblom JM, Flodin A, Bjursell C, Martinsson T, et al. Occurrence of Both Breast and Ovarian Cancer in a Woman Is a Marker for the BRCA Gene Mutations: A Population-Based Study From Western Sweden. <i>Familial Cancer</i> (2007) 6(1):35&#x2013;41. doi: 10.1007/s10689-006-9101-0</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/16944270/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1007/s10689-006-9101-0" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=Z+Einbeigi&amp;author=A+Bergman&amp;author=JM+Meis-Kindblom&amp;author=A+Flodin&amp;author=C+Bjursell&amp;author=T+Martinsson&amp;publication_year=2007&amp;title=Occurrence%20of%20Both%20Breast%20and%20Ovarian%20Cancer%20in%20a%20Woman%20Is%20a%20Marker%20for%20the%20BRCA%20Gene%20Mutations%3A%20A%20Population-Based%20Study%20From%20Western%20Sweden&amp;journal=Familial+Cancer&amp;volume=6&amp;pages=35" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B84" id="B84"></a> 84. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the Missing Heritability of Complex Diseases. <i>Nature</i> (2009) 461(7265):747&#x2013;53. doi: 10.1038/nature08494</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/19812666/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1038/nature08494" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=TA+Manolio&amp;author=FS+Collins&amp;author=NJ+Cox&amp;author=DB+Goldstein&amp;author=LA+Hindorff&amp;author=DJ+Hunter&amp;publication_year=2009&amp;title=Finding%20the%20Missing%20Heritability%20of%20Complex%20Diseases&amp;journal=Nature&amp;volume=461&amp;pages=747-53" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B85" id="B85"></a> 85. Lesage S, Belarbi S, Troiano A, Condroyer C, Hecham N, Pollak P, et al. Is the Common LRRK2 G2019S Mutation Related to Dyskinesias in North African Parkinson Disease? <i>Neurology</i> (2008) 71(19):1550&#x2013;2. doi: 10.1212/01.wnl.0000338460.89796.06</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/18981379/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1212/01.wnl.0000338460.89796.06" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=S+Lesage&amp;author=S+Belarbi&amp;author=A+Troiano&amp;author=C+Condroyer&amp;author=N+Hecham&amp;author=P+Pollak&amp;publication_year=2008&amp;title=Is%20the%20Common%20LRRK2%20G2019S%20Mutation%20Related%20to%20Dyskinesias%20in%20North%20African%20Parkinson%20Disease&amp;journal=Neurology&amp;volume=71&amp;pages=1550-2" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B86" id="B86"></a> 86. Hulihan MM, Ishihara-Paul L, Kachergus J, Warren L, Amouri R, Elango R, et al. LRRK2 Gly2019Ser Penetrance in Arab-Berber Patients From Tunisia: A Case-Control Genetic Study. <i>Lancet Neurol</i> (2008) 7(7):591&#x2013;4. doi: 10.1016/S1474-4422(08)70116-9</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/18539535/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1016/S1474-4422(08)70116-9" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=MM+Hulihan&amp;author=L+Ishihara-Paul&amp;author=J+Kachergus&amp;author=L+Warren&amp;author=R+Amouri&amp;author=R+Elango&amp;publication_year=2008&amp;title=LRRK2%20Gly2019Ser%20Penetrance%20in%20Arab-Berber%20Patients%20From%20Tunisia%3A%20A%20Case-Control%20Genetic%20Study&amp;journal=Lancet+Neurol&amp;volume=7&amp;pages=591-4" target="_blank">Google Scholar</a></p></div><div class="References" style="margin-bottom:0.5em; margin-left:2em;"><p class="ReferencesCopy1" style="margin-left:0.7em; text-indent:-1.1em;"><a name="B87" id="B87"></a> 87. Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE, et al. An International Initiative to Identify Genetic Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). <i>Breast Cancer Res</i> (2007) 9(2):104. doi: 10.1186/bcr1670</p><p class="ReferencesCopy2" style="margin-left:1em;"><a href="https://pubmed.ncbi.nlm.nih.gov/17466083/" target="_blank">PubMed Abstract</a> | <a href="https://doi.org/10.1186/bcr1670" target="_blank">CrossRef Full Text</a> | <a href="http://scholar.google.com/scholar_lookup?author=G+Chenevix-Trench&amp;author=RL+Milne&amp;author=AC+Antoniou&amp;author=FJ+Couch&amp;author=DF+Easton&amp;author=DE+Goldgar&amp;publication_year=2007&amp;title=An%20International%20Initiative%20to%20Identify%20Genetic%20Modifiers%20of%20Cancer%20Risk%20in%20BRCA1%20and%20BRCA2%20Mutation%20Carriers%3A%20The%20Consortium%20of%20Investigators%20of%20Modifiers%20of%20BRCA1%20and%20BRCA2%20%28CIMBA%29&amp;journal=Breast+Cancer+Res&amp;volume=9&amp;pages=104" target="_blank">Google Scholar</a></p></div></div><div class="thinLineM20"></div><div class="AbstractSummary"><p><span>Keywords:</span> <i>BRCA</i> cancers, genetic testing, novel <i>BRCA</i> mutations, clinicopathological signatures, precision medicine</p><p><span>Citation:</span> Hamdi Y, Mighri N, Boujemaa M, Mejri N, Ben Nasr S, Ben Rekaya M, Messaoud O, Bouaziz H, Berrazega Y, Rachdi H, Jaidane O, Daoud N, Zribi A, Ayari J, El Benna H, Labidi S, Ben Hassouna J, Haddaoui A, Rahal K, Benna F, Mrad R, Ben Ahmed S, Boussen H, Boubaker S and Abdelhak S (2021) Identification of Eleven Novel <i>BRCA</i> Mutations in Tunisia: Impact on the Clinical Management of <i>BRCA</i> Related Cancers. <i>Front. Oncol.</i> 11:674965. doi: 10.3389/fonc.2021.674965</p><p id="timestamps"><span>Received:</span> 02 March 2021; <span>Accepted:</span> 27 July 2021;<br><span>Published:</span> 20 August 2021.</p><div><p>Edited by:</p><a href="https://loop.frontiersin.org/people/896430">Zodwa Dlamini</a>, University of Pretoria, South Africa</div><div><p>Reviewed by:</p><a href="https://loop.frontiersin.org/people/739327">Yan Du</a>, Fudan University, China<br><a href="https://loop.frontiersin.org/people/125219">Umamaheswaran Gurusamy</a>, University of California, San Francisco, United States</div><p><span>Copyright</span> &#xa9; 2021 Hamdi, Mighri, Boujemaa, Mejri, Ben Nasr, Ben Rekaya, Messaoud, Bouaziz, Berrazega, Rachdi, Jaidane, Daoud, Zribi, Ayari, El Benna, Labidi, Ben Hassouna, Haddaoui, Rahal, Benna, Mrad, Ben Ahmed, Boussen, Boubaker and Abdelhak. This is an open-access article distributed under the terms of the <a rel="license" href="http://creativecommons.org/licenses/by/4.0/" target="_blank">Creative Commons Attribution License (CC BY)</a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p><p><span>*Correspondence:</span> Yosr Hamdi, <a id="encmail">eW9zci5oYW1kaUBwYXN0ZXVyLnRu</a></p><p><span><sup>&#x2020;</sup></span>These authors have contributed equally to this work</p><div class="clear"></div></div></div></div><p class="AbstractSummary__disclaimer"><span>Disclaimer: </span> All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. </p></div></div><!----></main><aside class="Layout__aside"><div class="ArticleDetails__wrapper"><div class="ArticleDetails__aside"><div class="ArticleDetails__aside__responsiveButtons"><div class="ActionsDropDown" id="FloatingButtonsEl"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--icon ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fonc.2021.674965" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="ArticleDetails__aside__responsiveButtons__items"><span></span><div class="ArticleDetailsShare__responsive"><button class="ArticleDetailsShare__trigger" aria-label="Open share options"></button><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div></div><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeIconButton ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><!----></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Export citation</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div></div></div><div class="TotalViews"><div class="TotalViews__data"><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">4K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Total views</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">1,6K</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Downloads</div></div></div><div class="TotalViews__data__metrics"><div class="TotalViews__data__metrics__number">11</div><div class="TotalViews__data__metrics__text"><div class="TotalViews__data__metrics__label">Citations</div></div></div><div class="ImpactMetricsInfoPopover"><button aria-label="Open impact metrics info" class="ImpactMetricsInfoPopover__button"></button><div class="ImpactMetricsInfoPopover__tooltip"><button aria-label="Close impact metrics info" class="ImpactMetricsInfoPopover__tooltip__closeButton"></button><div class="ImpactMetricsInfoPopover__tooltip__text"> Citation numbers are available from Dimensions </div></div></div></div><div class="TotalViews__viewImpactLink"><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View article impact" href="http://loop-impact.frontiersin.org/impact/article/674965#totalviews/views" target="_blank" data-event="customLink-link-a_viewArticleImpact"><span>View article impact</span></a></span></div><div class="TotalViews__altmetric"><div data-badge-popover="bottom" data-badge-type="donut" data-doi="10.3389/fonc.2021.674965" data-condensed="true" data-link-target="new" class="altmetric-embed"></div><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--medium Link--icon Link--chevronRight Link--right" aria-label="View altmetric score" href="https://www.altmetric.com/details/doi/10.3389/fonc.2021.674965" target="_blank" data-event="customLink-link-a_viewAltmetricScore"><span>View altmetric score</span></a></span></div></div><div class="ArticleDetailsShare"><p class="ArticleDetailsShare__title">Share on</p><ul class="ArticleDetailsShare__list"><!--[--><li class="ArticleDetailsShare__item"><a href="https://www.twitter.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/full" target="_blank" class="ArticleDetailsShare__link--x ArticleDetailsShare__link" title="Share on X" aria-label="Share on X"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.linkedin.com/share?url=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/full" target="_blank" class="ArticleDetailsShare__link--linkedin ArticleDetailsShare__link" title="Share on Linkedin" aria-label="Share on Linkedin"></a></li><li class="ArticleDetailsShare__item"><a href="https://www.facebook.com/sharer/sharer.php?u=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/full" target="_blank" class="ArticleDetailsShare__link--facebook ArticleDetailsShare__link" title="Share on Facebook" aria-label="Share on Facebook"></a></li><!--]--></ul></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Edited by</div><!--[--><a href="https://loop.frontiersin.org/people/896430/overview" data-event="editorInfo-a-zodwaDlamini" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">Z</span><span class="notranslate">D</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Zodwa  Dlamini</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Pan African Cancer Research Institute (PACRI), South Africa</div></div></a><!--]--></div></div><div class="ArticleDetailsEditors"><div class="ArticleDetailsEditors__editors"><div class="ArticleDetailsEditors__title">Reviewed by</div><!--[--><a href="https://loop.frontiersin.org/people/125219/overview" data-event="editorInfo-a-umamaheswaranGurusamy" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">U</span><span class="notranslate">G</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Umamaheswaran  Gurusamy</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Abigail Wexner Research Institute, Nationwide Children&#39;s Hospital, United States</div></div></a><a href="https://loop.frontiersin.org/people/739327/overview" data-event="editorInfo-a-yanDu" class="ArticleDetailsEditors__ediorInfo"><div class="Avatar Avatar--size-32 Avatar--text Avatar--grey"><!--[--><span class="notranslate">Y</span><span class="notranslate">D</span><!--]--></div><div class="ArticleDetailsEditors__ediorInfo__info"><div class="ArticleDetailsEditors__ediorInfo__name notranslate">Yan  Du</div><div class="ArticleDetailsEditors__ediorInfo__affiliation notranslate">Obstetrics and Gynecology Hospital, Fudan University, China</div></div></a><!--]--></div></div><div class="ArticleDetailsGlossary ArticleDetailsGlossary--open"><button class="ArticleDetailsGlossary__header"><div class="ArticleDetailsGlossary__header__title">Table of contents</div><div class="ArticleDetailsGlossary__header__arrow"></div></button><div class="ArticleDetailsGlossary__content"><ul class="flyoutJournal"><li><a href="#h1">Abstract</a></li><li><a href="#h2">Introduction</a></li><li><a href="#h3">Materials And Methods</a></li><li><a href="#h4">Results</a></li><li><a href="#h5">Discussion</a></li><li><a href="#h6">Conclusion</a></li><li><a href="#h7">Data Availability Statement</a></li><li><a href="#h8">Ethics Statement</a></li><li><a href="#h9">Author Contributions</a></li><li><a href="#h10">Funding</a></li><li><a href="#h11">Conflict of Interest</a></li><li><a href="#h12">Publisher&#x2019;s Note</a></li><li><a href="#h13">Acknowledgments</a></li><li><a href="#h14">Supplementary Material</a></li><li><a href="#h15">Abbreviations</a></li><li><a href="#h16">References</a></li></ul></div></div><span></span><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--typeOutline ActionsDropDown__button--iconQuote ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Export citation</span></button><div class="ActionsDropDown__menuWrapper"><!----><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/endNote" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-endNote">EndNote</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/reference" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-referenceManager">Reference Manager</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/text" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-simpleTextFile">Simple Text file</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/bibTex" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-bibTex">BibTex</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><div class="CheckForUpdates"><button data-target="crossmark" class="CheckForUpdates__link" data-event="checkForUpdates-btn-openModal"><img class="CheckForUpdates__link__img" src="/ap-2024/images/crossmark.svg" alt="Crossmark icon"><div class="CheckForUpdates__link__text">Check for updates</div></button></div><div class="AnnouncementCard"><p class="AnnouncementCard__title">Frontiers&#39; impact</p><article class="CardA"><div class="CardA__wrapper CardA__wrapper--vertical"><figure class="FrontiersImage CardA__img"><picture class="FrontiersImage"><!--[--><source srcset="https://images-provider.frontiersin.org/api/ipx/w=440&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 563px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=320x400&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1024px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=268x280&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media="(max-width: 1441px)"><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=webp/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><source srcset="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" media><!--]--><img src="https://images-provider.frontiersin.org/api/ipx/s=366x408&amp;fit=outside&amp;f=jpg/https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png" class="is-inside-mask" alt loading="eager"></picture><!----></figure><div class="CardA__info"><!--[--><h2 class="CardA__title">Articles published with Frontiers have received 12 million total citations</h2><p class="CardA__text">Your research is the real superpower - learn how we maximise its impact through our leading community journals</p><br><span class="Link__wrapper"><a class="Link Link--linkType Link--maincolor Link--small Link--icon Link--chevronRight Link--right" aria-label="Explore our impact metrics" href="https://www.frontiersin.org/about/impact" target="_self" data-event="customLink-linkType-a_exploreOurImpactMe"><span>Explore our impact metrics</span></a></span><!--]--></div></div></article></div><!----><!----></div><div><div class="Modal Modal--noFooter"><button aria-label="Close modal" class="Modal__overlay" data-event="modal-overlay-close"></button><div class="Modal__container"><div class="Modal__header"><p class="Modal__title">Supplementary Material</p><button aria-label="Close modal" class="Modal__close" data-event="modal-button-close"></button></div><div class="Modal__body"><!--[--><div class="SupplementalData"><ul class="SupplementalData__list"><!--[--><!--]--></ul></div><!--]--><!----></div><!----><!----></div></div></div><div><div class="FloatingButtons"><!----><div class="ActionsDropDown"><button aria-label="Open dropdown" class="ActionsDropDown__button--type ActionsDropDown__button--iconDownload ActionsDropDown__button--color ActionsDropDown__button" data-event="actionsDropDown-button-toggle"><span class="ActionsDropDown__button__label">Download article</span></button><div class="ActionsDropDown__menuWrapper"><div class="ActionsDropDown__mobileTitle">Download</div><ul class="ActionsDropDown__menu"><!--[--><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/pdf" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-pdf">Download PDF</a></li><li><a href="http://www.readcube.com/articles/10.3389/fonc.2021.674965" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-readCube">ReadCube</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/epub" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-epub">EPUB</a></li><li><a href="https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/xml" target="_blank" rel="noopener noreferrer" class="ActionsDropDown__option" data-event="actionsDropDown-a-nlmXml">XML</a></li><!--]--></ul><button class="ActionsDropDown__mobileClose" aria-label="Close modal" data-event="actionsDropDown-button-close"></button></div></div><!----></div></div></div></aside></div><div class=""><!----></div><!--]--></div><!----><footer class="Footer"><div class="Footer__wrapper"><div class="Footer__sections"><ul class="Accordion"><!--[--><!--[--><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Guidelines</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/guidelines/author-guidelines" target="_self" data-event="footer-block_0-a_authorGuidelines">Author guidelines</a></li><li><a href="https://www.frontiersin.org/for-authors/author-services" target="_self" data-event="footer-block_0-a_servicesForAuthors">Services for authors</a></li><li><a href="https://www.frontiersin.org/guidelines/policies-and-publication-ethics" target="_self" data-event="footer-block_0-a_policiesAndPublicationE">Policies and publication ethics</a></li><li><a href="https://www.frontiersin.org/guidelines/editor-guidelines" target="_self" data-event="footer-block_0-a_editorGuidelines">Editor guidelines</a></li><li><a href="https://www.frontiersin.org/about/fee-policy" target="_self" data-event="footer-block_0-a_feePolicy">Fee policy</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Explore</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://www.frontiersin.org/articles" target="_self" data-event="footer-block_1-a_articles">Articles</a></li><li><a href="https://www.frontiersin.org/research-topics" target="_self" data-event="footer-block_1-a_researchTopics">Research Topics </a></li><li><a href="https://www.frontiersin.org/journals" target="_self" data-event="footer-block_1-a_journals">Journals</a></li><li><a href="https://www.frontiersin.org/about/how-we-publish" target="_self" data-event="footer-block_1-a_howWePublish">How we publish</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Outreach</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://forum.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForum">Frontiers Forum </a></li><li><a href="https://policylabs.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersPolicyLabs">Frontiers Policy Labs </a></li><li><a href="https://kids.frontiersin.org/" target="_blank" data-event="footer-block_2-a_frontiersForYoungMinds">Frontiers for Young Minds</a></li><li><a href="https://www.frontiersin.org/about/frontiers-planet-prize" target="_self" data-event="footer-block_2-a_frontiersPlanetPrize">Frontiers Planet Prize</a></li><!--]--></ul><!--]--></div></li><li class="Accordion__item"><button class="Accordion__headline"><!----><!--[--><div class="Accordion__title">Connect</div><div class="Accordion__space"></div><!--]--><div class="Accordion__arrow"></div></button><div class="Accordion__content Accordion__content--fadeOut" style="height:0px;"><!--[--><ul><!--[--><li><a href="https://helpcenter.frontiersin.org" target="_blank" data-event="footer-block_3-a_helpCenter">Help center</a></li><li><a href="https://subscription-management.frontiersin.org/emails/preferences#block0" target="_blank" data-event="footer-block_3-a_emailsAndAlerts">Emails and alerts </a></li><li><a href="https://www.frontiersin.org/about/contact" target="_self" data-event="footer-block_3-a_contactUs">Contact us </a></li><li><a href="https://www.frontiersin.org/submission/submit" target="_self" data-event="footer-block_3-a_submit">Submit</a></li><li><a href="https://careers.frontiersin.org/" target="_blank" data-event="footer-block_3-a_careerOpportunities">Career opportunities</a></li><!--]--></ul><!--]--></div></li><!--]--><!--]--></ul><div class="Footer__socialLinks"><div class="Footer__socialLinks__title">Follow us</div><!--[--><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--facebook Link--right" aria-label="Frontiers Facebook" href="https://www.facebook.com/Frontiersin" target="_blank" data-event="footer-facebook-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--twitter Link--right" aria-label="Frontiers Twitter" href="https://twitter.com/frontiersin" target="_blank" data-event="footer-twitter-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--linkedin Link--right" aria-label="Frontiers LinkedIn" href="https://www.linkedin.com/company/frontiers" target="_blank" data-event="footer-linkedIn-a_true"><span></span></a></span><span class="Link__wrapper"><a class="Link Link--linkType Link--grey Link--medium Link--icon Link--instagram Link--right" aria-label="Frontiers Instagram" href="https://www.instagram.com/frontiersin_" target="_blank" data-event="footer-instagram-a_true"><span></span></a></span><!--]--></div></div><div class="Footer__copyright"><div><span> 2025 Frontiers Media SA. All rights reserved.</span></div><div><a href="https://www.frontiersin.org/legal/privacy-policy" target="_blank">Privacy policy</a><span>|</span><a href="https://www.frontiersin.org/legal/terms-and-conditions" target="_blank">Terms and conditions</a></div></div></div></footer><div class="SnackbarWrapper"><div class="SnackbarManager"><!--[--><!--]--></div></div></div><noscript><iframe
            src="https://tag-manager.frontiersin.org/ns.html?id=GTM-M322FV2&gtm_auth=owVbWxfaJr21yQv1fe1cAQ&gtm_preview=env-1&gtm_cookies_win=x"
            height="0"
            width="0"
            style="display: none; visibility: hidden">
          </iframe></noscript><!--]--></div><div id="teleports"></div><script type="application/json" id="__NUXT_DATA__" data-ssr="true">[["ShallowReactive",1],{"data":2,"state":4,"once":10,"_errors":11,"serverRendered":13,"path":14,"pinia":15},["ShallowReactive",3],{},["Reactive",5],{"$ssite-config":6},{"env":7,"name":8,"url":9},"production","Frontiers articles","https://article-pages-2024.frontiersin.org/",["Set"],["ShallowReactive",12],{},true,"/journals/oncology/articles/10.3389/fonc.2021.674965/full",["Reactive",16],{"main":17,"user":532,"article":533,"articleHub":1040,"mainHeader":1044},{"ibar":18,"footer":284,"newsletterComponent":-1,"snackbarItem":366,"toggleShowSnackbar":367,"contentfulJournal":368,"graphJournal":433,"settingsFeaturesSwitchers":437,"templateToggleBanner":438,"tenantConfig":497},{"tenantLogo":19,"journalLogo":19,"aboutUs":20,"submitUrl":113,"showSubmitButton":13,"journal":114,"sectionTerm":215,"aboutJournal":216,"mainLinks":265,"journalLinks":272,"helpCenterLink":281},"",[21,38,47,71,87],{"title":22,"links":23},"Who we are",[24,29,32,35],{"text":25,"url":26,"target":27,"ariaLabel":28},"Mission and values","https://www.frontiersin.org/about/mission","_self",null,{"text":30,"url":31,"target":27,"ariaLabel":28},"History","https://www.frontiersin.org/about/history",{"text":33,"url":34,"target":27,"ariaLabel":28},"Leadership","https://www.frontiersin.org/about/leadership",{"text":36,"url":37,"target":27,"ariaLabel":28},"Awards","https://www.frontiersin.org/about/awards",{"title":39,"links":40},"Impact and progress",[41,44],{"text":42,"url":43,"target":27,"ariaLabel":28},"Frontiers' impact","https://www.frontiersin.org/about/impact",{"text":45,"url":46,"target":27,"ariaLabel":28},"Our annual reports","https://www.frontiersin.org/about/annual-reports",{"title":48,"links":49},"Publishing model",[50,53,56,59,62,65,68],{"text":51,"url":52,"target":27,"ariaLabel":28},"How we publish","https://www.frontiersin.org/about/how-we-publish",{"text":54,"url":55,"target":27,"ariaLabel":28},"Open access","https://www.frontiersin.org/about/open-access",{"text":57,"url":58,"target":27,"ariaLabel":28},"Peer review","https://www.frontiersin.org/about/peer-review",{"text":60,"url":61,"target":27,"ariaLabel":28},"Research integrity","https://www.frontiersin.org/about/research-integrity",{"text":63,"url":64,"target":27,"ariaLabel":28},"Research Topics","https://www.frontiersin.org/about/research-topics",{"text":66,"url":67,"target":27,"ariaLabel":28},"FAIR Data Management","https://www.frontiersin.org/about/fair-data-management",{"text":69,"url":70,"target":27,"ariaLabel":28},"Fee policy","https://www.frontiersin.org/about/fee-policy",{"title":72,"links":73},"Services",[74,78,81,84],{"text":75,"url":76,"target":77,"ariaLabel":28},"Societies","https://publishingpartnerships.frontiersin.org/","_blank",{"text":79,"url":80,"target":27,"ariaLabel":28},"National consortia","https://www.frontiersin.org/open-access-agreements/consortia",{"text":82,"url":83,"target":27,"ariaLabel":28},"Institutional partnerships","https://www.frontiersin.org/about/open-access-agreements",{"text":85,"url":86,"target":27,"ariaLabel":28},"Collaborators","https://www.frontiersin.org/about/collaborators",{"title":88,"links":89},"More from Frontiers",[90,94,97,101,105,109],{"text":91,"url":92,"target":77,"ariaLabel":93},"Frontiers Forum","https://forum.frontiersin.org/","this link will take you to the Frontiers Forum website",{"text":95,"url":96,"target":27,"ariaLabel":28},"Frontiers Planet Prize","https://www.frontiersin.org/about/frontiers-planet-prize",{"text":98,"url":99,"target":77,"ariaLabel":100},"Press office","https://pressoffice.frontiersin.org/","this link will take you to the Frontiers press office website",{"text":102,"url":103,"target":27,"ariaLabel":104},"Sustainability","https://www.frontiersin.org/about/sustainability","link to information about Frontiers' sustainability",{"text":106,"url":107,"target":77,"ariaLabel":108},"Career opportunities","https://careers.frontiersin.org/","this link will take you to the Frontiers careers website",{"text":110,"url":111,"target":27,"ariaLabel":112},"Contact us","https://www.frontiersin.org/about/contact","this link will take you to the help pages to contact our support team","https://www.frontiersin.org/submission/submit?domainid=2&fieldid=57&specialtyid=0&entitytype=2&entityid=451",{"id":115,"name":116,"slug":117,"sections":118},451,"Frontiers in Oncology","oncology",[119,123,127,131,135,139,143,147,151,155,159,163,167,171,175,179,183,187,191,195,199,203,207,211],{"id":120,"name":121,"slug":122},500,"Breast Cancer","breast-cancer",{"id":124,"name":125,"slug":126},2606,"Cancer Cell Signaling","cancer-cell-signaling",{"id":128,"name":129,"slug":130},513,"Cancer Epidemiology and Prevention","cancer-epidemiology-and-prevention",{"id":132,"name":133,"slug":134},506,"Cancer Genetics","cancer-genetics",{"id":136,"name":137,"slug":138},515,"Cancer Imaging and Image-directed Interventions","cancer-imaging-and-image-directed-interventions",{"id":140,"name":141,"slug":142},527,"Cancer Immunity and Immunotherapy","cancer-immunity-and-immunotherapy",{"id":144,"name":145,"slug":146},1510,"Cancer Metabolism","cancer-metabolism",{"id":148,"name":149,"slug":150},507,"Cancer Molecular Targets and Therapeutics","cancer-molecular-targets-and-therapeutics",{"id":152,"name":153,"slug":154},1513,"Cardio-Oncology","cardio-oncology",{"id":156,"name":157,"slug":158},2413,"Gastrointestinal Cancers: Colorectal Cancer","gastrointestinal-cancers-colorectal-cancer",{"id":160,"name":161,"slug":162},2415,"Gastrointestinal Cancers: Gastric and Esophageal Cancers","gastrointestinal-cancers-gastric-and-esophageal-cancers",{"id":164,"name":165,"slug":166},2414,"Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers","gastrointestinal-cancers-hepato-pancreatic-biliary-cancers",{"id":168,"name":169,"slug":170},503,"Genitourinary Oncology","genitourinary-oncology",{"id":172,"name":173,"slug":174},2079,"Gynecological Oncology","gynecological-oncology",{"id":176,"name":177,"slug":178},517,"Head and Neck Cancer","head-and-neck-cancer",{"id":180,"name":181,"slug":182},505,"Hematologic Malignancies","hematologic-malignancies",{"id":184,"name":185,"slug":186},508,"Molecular and Cellular Oncology","molecular-and-cellular-oncology",{"id":188,"name":189,"slug":190},150,"Neuro-Oncology and Neurosurgical Oncology","neuro-oncology-and-neurosurgical-oncology",{"id":192,"name":193,"slug":194},509,"Pediatric Oncology","pediatric-oncology",{"id":196,"name":197,"slug":198},192,"Pharmacology of Anti-Cancer Drugs","pharmacology-of-anti-cancer-drugs",{"id":200,"name":201,"slug":202},511,"Radiation Oncology","radiation-oncology",{"id":204,"name":205,"slug":206},1630,"Skin Cancer","skin-cancer",{"id":208,"name":209,"slug":210},512,"Surgical Oncology","surgical-oncology",{"id":212,"name":213,"slug":214},502,"Thoracic Oncology","thoracic-oncology","Sections",[217,241],{"title":218,"links":219},"Scope",[220,223,226,229,232,235,238],{"text":221,"url":222,"target":27,"ariaLabel":28},"Field chief editors","https://www.frontiersin.org/journals/oncology/about#about-editors",{"text":224,"url":225,"target":27,"ariaLabel":28},"Mission & scope","https://www.frontiersin.org/journals/oncology/about#about-scope",{"text":227,"url":228,"target":27,"ariaLabel":28},"Facts","https://www.frontiersin.org/journals/oncology/about#about-facts",{"text":230,"url":231,"target":27,"ariaLabel":28},"Journal sections","https://www.frontiersin.org/journals/oncology/about#about-submission",{"text":233,"url":234,"target":27,"ariaLabel":28},"Open access statement","https://www.frontiersin.org/journals/oncology/about#about-open",{"text":236,"url":237,"target":27,"ariaLabel":28},"Copyright statement","https://www.frontiersin.org/journals/oncology/about#copyright-statement",{"text":239,"url":240,"target":27,"ariaLabel":28},"Quality","https://www.frontiersin.org/journals/oncology/about#about-quality",{"title":242,"links":243},"For authors",[244,247,250,253,256,259,262],{"text":245,"url":246,"target":27,"ariaLabel":28},"Why submit?","https://www.frontiersin.org/journals/oncology/for-authors/why-submit",{"text":248,"url":249,"target":27,"ariaLabel":28},"Article types","https://www.frontiersin.org/journals/oncology/for-authors/article-types",{"text":251,"url":252,"target":27,"ariaLabel":28},"Author guidelines","https://www.frontiersin.org/journals/oncology/for-authors/author-guidelines",{"text":254,"url":255,"target":27,"ariaLabel":28},"Editor guidelines","https://www.frontiersin.org/journals/oncology/for-authors/editor-guidelines",{"text":257,"url":258,"target":27,"ariaLabel":28},"Publishing fees","https://www.frontiersin.org/journals/oncology/for-authors/publishing-fees",{"text":260,"url":261,"target":27,"ariaLabel":28},"Submission checklist","https://www.frontiersin.org/journals/oncology/for-authors/submission-checklist",{"text":263,"url":264,"target":27,"ariaLabel":28},"Contact editorial office","https://www.frontiersin.org/journals/oncology/for-authors/contact-editorial-office",[266,269],{"text":267,"url":268,"target":27,"ariaLabel":28},"All journals","https://www.frontiersin.org/journals",{"text":270,"url":271,"target":27,"ariaLabel":28},"All articles","https://www.frontiersin.org/articles",[273,276,278],{"text":274,"url":275,"target":27,"ariaLabel":28},"Articles","articles",{"text":63,"url":277,"target":27,"ariaLabel":28},"research-topics",{"text":279,"url":280,"target":27,"ariaLabel":28},"Editorial board","editors",{"text":282,"url":283,"target":77,"ariaLabel":282},"Help center","https://helpcenter.frontiersin.org",{"blocks":285,"socialLinks":339,"copyright":363,"termsAndConditionsUrl":364,"privacyPolicyUrl":365},[286,300,310,324],{"title":287,"links":288},"Guidelines",[289,291,294,297,299],{"text":251,"url":290,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/author-guidelines",{"text":292,"url":293,"target":27,"ariaLabel":28},"Services for authors","https://www.frontiersin.org/for-authors/author-services",{"text":295,"url":296,"target":27,"ariaLabel":28},"Policies and publication ethics","https://www.frontiersin.org/guidelines/policies-and-publication-ethics",{"text":254,"url":298,"target":27,"ariaLabel":28},"https://www.frontiersin.org/guidelines/editor-guidelines",{"text":69,"url":70,"target":27,"ariaLabel":28},{"title":301,"links":302},"Explore",[303,304,307,309],{"text":274,"url":271,"target":27,"ariaLabel":28},{"text":305,"url":306,"target":27,"ariaLabel":28},"Research Topics ","https://www.frontiersin.org/research-topics",{"text":308,"url":268,"target":27,"ariaLabel":28},"Journals",{"text":51,"url":52,"target":27,"ariaLabel":28},{"title":311,"links":312},"Outreach",[313,316,319,323],{"text":314,"url":92,"target":77,"ariaLabel":315},"Frontiers Forum ","Frontiers Forum website",{"text":317,"url":318,"target":77,"ariaLabel":28},"Frontiers Policy Labs ","https://policylabs.frontiersin.org/",{"text":320,"url":321,"target":77,"ariaLabel":322},"Frontiers for Young Minds","https://kids.frontiersin.org/","Frontiers for Young Minds journal",{"text":95,"url":96,"target":27,"ariaLabel":28},{"title":325,"links":326},"Connect",[327,328,332,335,338],{"text":282,"url":283,"target":77,"ariaLabel":282},{"text":329,"url":330,"target":77,"ariaLabel":331},"Emails and alerts ","https://subscription-management.frontiersin.org/emails/preferences#block0","Subscribe to Frontiers emails",{"text":333,"url":111,"target":27,"ariaLabel":334},"Contact us ","Subscribe to newsletter",{"text":336,"url":337,"target":27,"ariaLabel":28},"Submit","https://www.frontiersin.org/submission/submit",{"text":106,"url":107,"target":77,"ariaLabel":28},[340,348,353,358],{"link":341,"type":344,"color":345,"icon":346,"size":347,"hiddenText":13},{"text":342,"url":343,"target":77,"ariaLabel":342},"Frontiers Facebook","https://www.facebook.com/Frontiersin","Link","Grey","Facebook","Medium",{"link":349,"type":344,"color":345,"icon":352,"size":347,"hiddenText":13},{"text":350,"url":351,"target":77,"ariaLabel":28},"Frontiers Twitter","https://twitter.com/frontiersin","Twitter",{"link":354,"type":344,"color":345,"icon":357,"size":347,"hiddenText":13},{"text":355,"url":356,"target":77,"ariaLabel":28},"Frontiers LinkedIn","https://www.linkedin.com/company/frontiers","LinkedIn",{"link":359,"type":344,"color":345,"icon":362,"size":347,"hiddenText":13},{"text":360,"url":361,"target":77,"ariaLabel":28},"Frontiers Instagram","https://www.instagram.com/frontiersin_","Instagram","Frontiers Media SA. All rights reserved.","https://www.frontiersin.org/legal/terms-and-conditions","https://www.frontiersin.org/legal/privacy-policy",{},false,{"__typename":369,"identifier":115,"name":116,"slug":117,"banner":370,"description":426,"mission":427,"palette":428,"impactFactor":429,"citeScore":430,"citations":431,"showTagline":28,"twitter":432},"Journal",[371],{"id":372,"src":373,"name":374,"tags":375,"type":384,"width":385,"height":386,"idHash":387,"archive":388,"brandId":389,"limited":388,"fileSize":390,"isPublic":391,"original":392,"copyright":393,"extension":394,"thumbnails":396,"dateCreated":404,"description":405,"orientation":406,"userCreated":407,"watermarked":388,"dateModified":404,"datePublished":408,"ecsArchiveFiles":409,"propertyOptions":410,"property_Channel":415,"property_Sub-Type":417,"property_Asset_Type":419,"activeOriginalFocusPoint":421,"property_Office_Department":424},"A08FCA58-05EE-4283-A13E51F93BB73C97","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/webimage-6A59331A-8816-4B2C-BC3F6EF168F6183E.jpg","FONC_Main Visual_Purple_Website",[376,377,378,379,380,381,382,383],"body part","dead","anatomy","defending","protection","skin","treatment","cell","image",7200,4050,"7f2922f165e2e1ba",0,"22C10171-81B3-4DA6-99342F272A32E8BB",9449881,1,"https://brand.frontiersin.org/m/7f2922f165e2e1ba/original/FONC_Main-Visual_Purple_Website.jpeg","Copyright (c) 2021 Design_Cells/Shutterstock.  No use without permission.",[395],"jpeg",{"mini":397,"thul":398,"webimage":373,"Guidelines":399,"WebsiteJpg_XL":400,"WebsiteWebP_L":401,"WebsiteWebP_M":402,"WebsiteWebP_XL":403},"https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/mini-5795EAF1-94A7-4623-B52EAC7FC8A5098F.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/thul-301BCB38-FCF6-4517-9359D5382707B640.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/Guidelines-FONC_Main Visual_Purple_Website.png","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteJpg_XL-FONC_Main Visual_Purple_Website.jpg","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteWebP_L-FONC_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteWebP_M-FONC_Main Visual_Purple_Website.webp","https://d2csxpduxe849s.cloudfront.net/media/E32629C6-9347-4F84-81FEAEF7BFA342B3/A08FCA58-05EE-4283-A13E51F93BB73C97/352DFCCB-44FF-4821-962507007B815780/WebsiteWebP_XL-FONC_Main Visual_Purple_Website.webp","2022-06-27T10:00:39Z","Cancer cell, cell grow out of control and become invasive. 3d illustration","landscape","Caroline Sutter","2022-06-27T09:27:09Z",[],[411,412,413,414],"414FB2D4-2283-43FD-BE14E534ECA67928","6C18119B-14BD-4951-B437696F4357BD33","7C692885-DB25-4858-B1FB4FF47B241E9B","D88C0047-EC30-4506-A7DF28A4D765E1CF",[416],"frontiersin_org",[418],"Main_Visual",[420],"Photography",{"x":422,"y":423},3600,2025,[425],"Publishing","Explore global oncology research advancing cancer diagnosis, treatment, and management across diverse populations and healthcare systems.","\u003Cp>Frontiers in Oncology is a broad-scope, multidisciplinary journal covering all areas of cancer research to advance our knowledge of cancer epidemiology to improve diagnosis, therapeutics, and management strategies.\u003C/p>\n\n\u003Cp>The journal is led by Field Chief Editor Prof Giuseppe Giaccone (Cornell University and Amgen, USA), and Assistant Field Chief Editor Prof Sharon Pine (University of Colorado, USA). Indexed in PubMed Central (PMC), Scopus, Web of Science (SCIE), and the DOAJ, Frontiers in Oncology welcomes clinical and experimental research contributions in the various domains of cancer research, which bridge the gap between basic research and clinical applications. Topics include, but are not limited to:\u003C/p>\n\u003Cul>\n  \u003Cli>breast cancer\u003C/li>\n  \u003Cli>cancer cell signaling\u003C/li>\n  \u003Cli>cancer epidemiology and prevention\u003C/li>\n  \u003Cli>cancer genetics\u003C/li>\n  \u003Cli>cancer imaging and image-directed interventions\u003C/li>\n  \u003Cli>cancer immunity and immunotherapy\u003C/li>\n  \u003Cli>cancer metabolism\u003C/li>\n  \u003Cli>cancer molecular targets and therapeutics\u003C/li>\n  \u003Cli>cardio-oncology\u003C/li>\n  \u003Cli>gastrointestinal cancers\u003C/li>\n  \u003Cli>genitourinary oncology\u003C/li>\n  \u003Cli>gynecological oncology\u003C/li>\n  \u003Cli>head and neck cancer\u003C/li>\n  \u003Cli>hematologic malignancies\u003C/li>\n  \u003Cli>molecular and cellular oncology\u003C/li>\n  \u003Cli>neuro-oncology and neurosurgical oncology\u003C/li>\n  \u003Cli>pediatric oncology\u003C/li>\n  \u003Cli>pharmacology of anti-cancer drugs\u003C/li>\n  \u003Cli>radiation oncology\u003C/li>\n  \u003Cli>skin cancer\u003C/li>\n  \u003Cli>surgical oncology\u003C/li>\n  \u003Cli>thoracic oncology.\u003C/li>\n\u003C/ul>\n\n\u003Cp>In particular, the journal welcomes submissions which support and advance the UNs Sustainable Development Goals (SDGs), notable SDG 3: ensure healthy lives and promote well-being for all at all ages.\u003C/p>\n\n\u003Cp>Frontiers' journals require that manuscripts primarily comprising solely of bioinformatics analyses, computational studies of public data, or findings from Mendelian Randomisation studies must include appropriate validation. Acceptable forms of validation include:\u003Cp>\n\u003Cul>\n  \u003Cli>independent clinical or patient cohorts that are not publicly available\u003C/li>\n  \u003Cli>biological validation of the main conclusions, either \u003Cem>in vitro\u003C/em> or \u003Cem>in vivo\u003C/em>\u003C/li>\n  \u003Cli>multi-database queries (bibliometric studies only)\u003C/li>\n\u003C/ul>\n\n\u003Cp>Manuscripts lacking robust validation will be considered unsuitable for publication, as they do not meet the required evidence standards necessary for scientific conclusions. Please refer to the \u003Ca href=\"https://www.frontiersin.org/guidelines/policies-and-publication-ethics#standards-for-research-methodology\">Frontiers Standards for research methodology policy\u003C/a>, for more information.\u003C/p>\n\n\u003Cp>Frontiers in Oncology is committed to advancing developments in the field of cancer research by allowing unrestricted access to articles, and communicating scientific knowledge to researchers and the public alike, to enable the scientific breakthroughs of the future.\u003C/p>","purple","4.7","5.2","464146","@FrontOncology",{"id":115,"name":116,"slug":117,"abbreviation":434,"isOnline":13,"isOpenForSubmissions":13,"citeScore":435,"impactFactor":436},"fonc",6.9,3.3,{"displayTitlePillLabels":13,"displayRelatedArticlesBox":13,"showEditors":13,"showReviewers":13,"showLoopImpactLink":13,"enableFigshare":367},{"isPublic":13,"allowCompanyUsers":367,"whiteListEmails":439,"enableAllJournals":13,"whiteListJournals":461},[440,441,442,443,444,445,446,447,448,445,449,450,451,452,453,454,455,456,457,458,459,460],"Y2FybG9zLmxvcmNhQGZyb250aWVyc2luLm9yZw==","ZGFuaWVsLmx1ekBmcm9udGllcnNpbi5vcmc=","bGF1cmEudGVuYUBmcm9udGllcnNpbi5vcmc=","cmFmYWVsLnJpYW5jaG9AZnJvbnRpZXJzaW4ub3Jn","amFtZXMuc21hbGxib25lQGZyb250aWVyc2luLm9yZw==","ZnJhbi5tb3Jlbm9AZnJvbnRpZXJzaW4ub3Jn","c2FtdWVsLmZlcm5hbmRlekBmcm9udGllcnNpbi5vcmc=","YmFyYmFyYS5jYXJjYW5naXVAZnJvbnRpZXJzaW4ub3Jn","aXZhbi5zYW50YW1hcmlhQGZyb250aWVyc2luLm9yZw==","aHVlLnRyYW5AZnJvbnRpZXJzaW4ub3Jn","Z29uY2Fsby52YXJnYXNAZnJvbnRpZXJzaW4ub3Jn","bHVjaWUuc2VubkBmcm9udGllcnNpbi5vcmc=","bG9ybi5mcmFzZXJAZnJvbnRpZXJzaW4ub3Jn","ZWxzYS5jYXJyb25AZnJvbnRpZXJzaW4ub3Jn","bWFhcnRlbi52YW5kaWpja0Bmcm9udGllcnNpbi5vcmc=","YmluZGh1LmtyaXNobmFuQGZyb250aWVyc2luLm9yZw==","bWF0dGhldy5hdHR3YXRlcnNAZnJvbnRpZXJzaW4ub3Jn","Z2l1bGlhLnZhbHNlY2NoaUBmcm9udGllcnNpbi5vcmc=","ZmFiaWFuLmRlbGxhbW9ydGVAZnJvbnRpZXJzaW4ub3Jn","dmlqYXlhbi5wcEBwaXRzb2x1dGlvbnMuY29t","Z3VpbGxhdW1lLnNldXJhdEBmcm9udGllcnNpbi5vcmc=",[462,463,464,465,466,467,391,468,469,470,471,472,473,474,475,476,477,478,479,480,481,115,482,483,484,485,486,487,488,489,490,491,492,493,494,495,496],2232,1729,2357,2456,2176,2333,1843,602,106,616,310,657,3123,1468,2137,628,1566,2726,2086,1490,141,1335,2655,1238,604,698,1547,176,1440,403,1239,755,2136,609,1534,{"spaceId":391,"name":391,"availableJournalPages":498,"announcement":502},[275,280,277,499,500,501],"volumes","about","community-reviewers",{"__typename":503,"sys":504,"preHeader":42,"title":506,"description":507,"image":508,"link":530},"Announcement",{"id":505},"5ITtnTtQgAzPPGH6rX0AlM","Articles published with Frontiers have received 12 million total citations","Your research is the real superpower - learn how we maximise its impact through our leading community journals",[509],{"archive":388,"brandId":389,"copyright":28,"dateCreated":510,"dateModified":511,"datePublished":512,"description":28,"extension":513,"fileSize":515,"height":516,"id":517,"isPublic":388,"limited":388,"name":518,"orientation":406,"original":28,"thumbnails":519,"type":384,"watermarked":388,"width":526,"videoPreviewURLs":527,"tags":528,"textMetaproperties":529,"src":520},"2025-06-18T12:58:01Z","2025-06-18T14:15:34Z","2025-06-18T12:57:32Z",[514],"png",1365026,920,"7C5269C4-3C83-4591-951A74D15B95DAEA","Impact metrics banner for article pages",{"webimage":520,"thul":521,"mini":522,"WebsiteWebP_L":523,"WebsiteWebP_M":524,"Guidelines":525},"https://brand.frontiersin.org/m/59ee6275cb9a849c/webimage-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/thul-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/m/59ee6275cb9a849c/mini-Impact-metrics-banner-for-article-pages.png","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_L/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/WebsiteWebP_M/Impact-metrics-banner-for-article-pages.webp","https://brand.frontiersin.org/asset/7c5269c4-3c83-4591-951a-74d15b95daea/Guidelines/Impact-metrics-banner-for-article-pages.png",1600,[],[],[],{"text":531,"url":43,"target":27,"ariaLabel":28},"Explore our impact metrics",{"loggedUserInfo":-1},{"currentArticle":534,"isPreviewPage":367,"hasSupplementalData":367,"showCrossmarkWidget":13,"articleTemplate":812,"currentArticlePageMetaInfo":813,"xmlParsedArticleContent":-1,"xmlParsingError":-1},{"id":535,"doi":536,"title":537,"acceptanceDate":538,"receptionDate":539,"publicationDate":540,"lastModifiedDate":541,"isPublished":13,"abstract":542,"researchTopic":543,"articleType":549,"stage":552,"keywords":554,"authors":560,"editors":741,"reviewers":751,"journal":770,"section":778,"impactMetrics":780,"volume":546,"articleVolume":783,"relatedArticles":784,"isPublishedV2":367,"contents":785,"files":789},674965,"10.3389/fonc.2021.674965","Identification of Eleven Novel BRCA Mutations in Tunisia: Impact on the Clinical Management of BRCA Related Cancers",["Date","2021-07-27T15:38:03.000Z"],["Date","2021-03-02T08:41:19.000Z"],["Date","2021-08-20T00:00:00.000Z"],["Date","2025-11-25T04:33:14.910Z"],"Background Breast cancer is the world's most common cancer among women. It is becoming an increasingly urgent problem in low- and middle-income countries (LMICs) where a large fraction of women is diagnosed with advanced-stage disease and have no access to treatment or basic palliative care. About 5-10% of all breast cancers can be attributed to hereditary genetic components and up to 25% of familial cases are due to mutations in BRCA1/2 genes. Since their discovery in 1994 and 1995, as few as 18 mutations have been identified in BRCA genes in the Tunisian population. The aim of this study is to identify additional BRCA mutations, to estimate their contribution to the hereditary breast and ovarian cancers in  Tunisia, and to investigate the clinicopathological signatures associated with BRCA mutations. Methods A total of 354 patients diagnosed with breast and ovarian cancers, including 5 male breast cancer cases, have been investigated for BRCA1/2 mutations using traditional and/or next-generation sequencing technologies. Clinicopathological signatures associated with BRCA mutations have been also investigated. Results 16 distinct mutations were detected: 10 in BRCA1 and 6 in BRCA2, of which 11 are described for the first time in Tunisia including 3 variations that have not been reported previously in public databases namely BRCA1_c.915T>A; BRCA2_c.-227-?_7805+? and BRCA2_c.249delG. Early age at onset, family history of ovarian cancer, and high tumor grade were significantly associated with BRCA status. BRCA1 carriers were more likely to be triple-negative breast cancer compared to BRCA2 carriers. A relatively high frequency of contralateral breast cancer and ovarian cancer occurrence was observed among BRCA carriers and was more frequent in patients carrying BRCA1 mutations. Conclusion Our study provides new insights into breast and ovarian cancer genetic landscape in the under-represented North African populations. The prevalence assessment of novel and recurrent BRCA1/2 pathogenic mutations will enhance the use of personalized treatment and precise screening strategies by both affected and unaffected North African cancer cases.",{"id":544,"title":545,"articlesCount":546,"isMagazinePage":13,"slug":547,"isOpenForSubmission":367,"views":548},12906,"Cancer in Africans: The Past, the Present, and the Future",11,"cancer-in-africans-the-past-the-present-and-the-future",96322,{"id":550,"name":551},24,"Original Research",{"id":553,"name":19},18,[555,556,557,558,559],"BRCA cancers","Genetic Testing","novel BRCA mutations","Clinicopathological signatures","precision medicine",[561,573,580,587,596,605,614,621,630,636,642,647,653,659,666,674,681,687,693,699,706,714,721,729,736],{"id":562,"firstName":563,"middleName":19,"lastName":564,"givenNames":565,"isCorresponding":13,"isProfilePublic":13,"userId":562,"email":566,"affiliations":567},887862,"Yosr","Hamdi","Yosr ","yosr.hamdi@pasteur.utm.tn",[568,571],{"organizationName":569,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar","Tunisia",{"organizationName":572,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Laboratory of Human and Experimental Pathology, Institut Pasteur de Tunis",{"id":574,"firstName":575,"middleName":19,"lastName":576,"givenNames":577,"isCorresponding":367,"isProfilePublic":13,"userId":574,"email":-1,"affiliations":578},958051,"Najah","Mighri","Najah ",[579],{"organizationName":569,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"id":581,"firstName":582,"middleName":19,"lastName":583,"givenNames":584,"isCorresponding":367,"isProfilePublic":13,"userId":581,"email":-1,"affiliations":585},956852,"Maroua","Boujemaa","Maroua ",[586],{"organizationName":569,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"id":588,"firstName":589,"middleName":19,"lastName":590,"givenNames":591,"isCorresponding":367,"isProfilePublic":13,"userId":588,"email":-1,"affiliations":592},1126033,"Nesrine","Mejri","Nesrine ",[593,594],{"organizationName":569,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":595,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Medical Oncology Department, Abderrahman Mami Hospital, Faculty of Medicine Tunis, University Tunis El Manar",{"id":597,"firstName":598,"middleName":19,"lastName":599,"givenNames":600,"isCorresponding":367,"isProfilePublic":13,"userId":597,"email":-1,"affiliations":601},957319,"Sonia","Ben Nasr","Sonia ",[602,603],{"organizationName":569,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":604,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Department of Medical Oncology, Military Hospital of Tunis",{"id":606,"firstName":607,"middleName":19,"lastName":608,"givenNames":609,"isCorresponding":367,"isProfilePublic":13,"userId":606,"email":-1,"affiliations":610},1364549,"Mariem","Ben Rekaya","Mariem ",[611,612],{"organizationName":569,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":613,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"UR17ES15, Oncotheranostic Biomarkers, Faculty of Medicine of Tunis, University Tunis El Manar",{"id":615,"firstName":616,"middleName":19,"lastName":617,"givenNames":618,"isCorresponding":367,"isProfilePublic":13,"userId":615,"email":-1,"affiliations":619},948209,"Olfa","Messaoud","Olfa ",[620],{"organizationName":569,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"id":622,"firstName":623,"middleName":19,"lastName":624,"givenNames":625,"isCorresponding":367,"isProfilePublic":13,"userId":622,"email":-1,"affiliations":626},1130977,"Hanen","Bouaziz","Hanen ",[627,628],{"organizationName":569,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":629,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Surgical Oncology Department, Salah Azaiez Institute of Cancer",{"id":388,"firstName":631,"middleName":19,"lastName":632,"givenNames":633,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":634},"Yosra","Berrazega","Yosra ",[635],{"organizationName":595,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"id":388,"firstName":637,"middleName":19,"lastName":638,"givenNames":639,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":640},"Haifa","Rachdi","Haifa ",[641],{"organizationName":595,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"id":643,"firstName":616,"middleName":19,"lastName":644,"givenNames":618,"isCorresponding":367,"isProfilePublic":13,"userId":643,"email":-1,"affiliations":645},957930,"Jaidane",[646],{"organizationName":629,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"id":388,"firstName":648,"middleName":19,"lastName":649,"givenNames":650,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":651},"Nouha","Daoud","Nouha ",[652],{"organizationName":595,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"id":388,"firstName":654,"middleName":19,"lastName":655,"givenNames":656,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":657},"Aref","Zribi","Aref ",[658],{"organizationName":604,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"id":660,"firstName":661,"middleName":19,"lastName":662,"givenNames":663,"isCorresponding":367,"isProfilePublic":13,"userId":660,"email":-1,"affiliations":664},1125634,"Jihene","Ayari","Jihene ",[665],{"organizationName":604,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"id":667,"firstName":668,"middleName":19,"lastName":669,"givenNames":670,"isCorresponding":367,"isProfilePublic":13,"userId":667,"email":-1,"affiliations":671},1126178,"Houda","El Benna","Houda ",[672,673],{"organizationName":569,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":595,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"id":388,"firstName":675,"middleName":19,"lastName":676,"givenNames":677,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":678},"Soumaya","Labidi","Soumaya ",[679,680],{"organizationName":569,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":595,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"id":388,"firstName":682,"middleName":19,"lastName":683,"givenNames":684,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":685},"Jamel","Ben Hassouna","Jamel ",[686],{"organizationName":629,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"id":388,"firstName":688,"middleName":19,"lastName":689,"givenNames":690,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":691},"Abderazzek","Haddaoui","Abderazzek ",[692],{"organizationName":604,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"id":388,"firstName":694,"middleName":19,"lastName":695,"givenNames":696,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":697},"Khaled","Rahal","Khaled ",[698],{"organizationName":629,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"id":388,"firstName":700,"middleName":19,"lastName":701,"givenNames":702,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":703},"Farouk","Benna","Farouk ",[704],{"organizationName":705,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Department of Radiation Oncology, University of Tunis",{"id":707,"firstName":708,"middleName":19,"lastName":709,"givenNames":710,"isCorresponding":367,"isProfilePublic":13,"userId":707,"email":-1,"affiliations":711},1252870,"Ridha","Mrad","Ridha ",[712],{"organizationName":713,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Department of Human Genetics, Charles Nicolle Hospital",{"id":388,"firstName":715,"middleName":19,"lastName":716,"givenNames":717,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":718},"Slim","Ben Ahmed","Slim ",[719],{"organizationName":720,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},"Faculty of Medicine of Sousse Department of Medical Oncology Farhat Hached University Hospital University of Sousse",{"id":722,"firstName":723,"middleName":19,"lastName":724,"givenNames":725,"isCorresponding":367,"isProfilePublic":13,"userId":722,"email":-1,"affiliations":726},1126078,"Hamouda","Boussen","Hamouda ",[727,728],{"organizationName":569,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":595,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"id":388,"firstName":730,"middleName":19,"lastName":731,"givenNames":732,"isCorresponding":367,"isProfilePublic":367,"userId":388,"email":-1,"affiliations":733},"Samir","Boubaker","Samir ",[734,735],{"organizationName":569,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"organizationName":572,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},{"id":737,"firstName":598,"middleName":19,"lastName":738,"givenNames":600,"isCorresponding":367,"isProfilePublic":13,"userId":737,"email":-1,"affiliations":739},42850,"Abdelhak",[740],{"organizationName":569,"countryName":570,"cityName":19,"stateName":19,"zipCode":19},[742],{"id":743,"firstName":744,"middleName":19,"lastName":745,"givenNames":746,"isCorresponding":367,"isProfilePublic":13,"userId":743,"email":-1,"affiliations":747},896430,"Zodwa","Dlamini","Zodwa ",[748],{"organizationName":749,"countryName":750,"cityName":19,"stateName":19,"zipCode":19},"Pan African Cancer Research Institute (PACRI)","South Africa",[752,761],{"id":753,"firstName":754,"middleName":19,"lastName":755,"givenNames":756,"isCorresponding":367,"isProfilePublic":13,"userId":753,"email":-1,"affiliations":757},125219,"Umamaheswaran","Gurusamy","Umamaheswaran ",[758],{"organizationName":759,"countryName":760,"cityName":19,"stateName":19,"zipCode":19},"Abigail Wexner Research Institute, Nationwide Children's Hospital","United States",{"id":762,"firstName":763,"middleName":19,"lastName":764,"givenNames":765,"isCorresponding":367,"isProfilePublic":13,"userId":762,"email":-1,"affiliations":766},739327,"Yan","Du","Yan ",[767],{"organizationName":768,"countryName":769,"cityName":19,"stateName":19,"zipCode":19},"Obstetrics and Gynecology Hospital, Fudan University","China",{"id":115,"slug":117,"name":116,"shortName":771,"electronicISSN":772,"field":773,"specialtyId":28,"journalSectionPaths":776},"Front. Oncol.","2234-943X",{"id":774,"domainId":775},57,2,[777],{"section":778},{"id":128,"name":129,"slug":130,"specialtyId":779},1234,{"views":781,"downloads":782,"citations":546},4020,1583,"Volume 11 - 2021",[],{"titleHtml":786,"fullTextHtml":787,"menuHtml":788},"Identification of Eleven Novel \u003Ci>BRCA\u003C/i> Mutations in Tunisia: Impact on the Clinical Management of \u003Ci>BRCA\u003C/i> Related Cancers","\u003Cdiv class=\"JournalAbstract\">\u003Ca id=\"h1\" name=\"h1\">\u003C/a>\u003Cdiv class=\"authors\">\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/887862\" class=\"user-id-887862\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/887862/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Yosr Hamdi,*\">Yosr Hamdi\u003C/a>\u003Csup>1,2*\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/958051\" class=\"user-id-958051\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/958051/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Najah Mighri&#x;\">Najah Mighri\u003C/a>\u003Csup>1&#x2020;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/956852\" class=\"user-id-956852\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/956852/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Maroua Boujemaa&#x;\">Maroua Boujemaa\u003C/a>\u003Csup>1&#x2020;\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1126033\" class=\"user-id-1126033\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1126033/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Nesrine Mejri,\">Nesrine Mejri\u003C/a>\u003Csup>1,3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/957319\" class=\"user-id-957319\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/957319/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Sonia Ben Nasr,\">Sonia Ben Nasr\u003C/a>\u003Csup>1,4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1364549\" class=\"user-id-1364549\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1364549/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Mariem Ben Rekaya,\">Mariem Ben Rekaya\u003C/a>\u003Csup>1,5\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/948209\" class=\"user-id-948209\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/948209/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Olfa Messaoud\">Olfa Messaoud\u003C/a>\u003Csup>1\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1130977\" class=\"user-id-1130977\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1130977/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Hanen Bouaziz,\">Hanen Bouaziz\u003C/a>\u003Csup>1,6\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Yosra Berrazega\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Yosra Berrazega\u003Csup>3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Haifa Rachdi\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Haifa Rachdi\u003Csup>3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/957930\" class=\"user-id-957930\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/957930/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Olfa Jaidane\">Olfa Jaidane\u003C/a>\u003Csup>6\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Nouha Daoud\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Nouha Daoud\u003Csup>3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Aref Zribi\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Aref Zribi\u003Csup>4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1125634\" class=\"user-id-1125634\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1125634/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Jihene Ayari\">Jihene Ayari\u003C/a>\u003Csup>4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1126178\" class=\"user-id-1126178\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1126178/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Houda El Benna,\">Houda El Benna\u003C/a>\u003Csup>1,3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Soumaya Labidi,\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Soumaya Labidi\u003Csup>1,3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Jamel Ben Hassouna\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Jamel Ben Hassouna\u003Csup>6\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Abderazzek Haddaoui\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Abderazzek Haddaoui\u003Csup>4\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Khaled Rahal\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Khaled Rahal\u003Csup>6\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Farouk Benna\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Farouk Benna\u003Csup>7\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1252870\" class=\"user-id-1252870\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1252870/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Ridha Mrad\">Ridha Mrad\u003C/a>\u003Csup>8\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Slim Ben Ahmed\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Slim Ben Ahmed\u003Csup>9\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/1126078\" class=\"user-id-1126078\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/1126078/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Hamouda Boussen,\">Hamouda Boussen\u003C/a>\u003Csup>1,3\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/cdn/images/profile/default_32.jpg\" alt=\"Samir Boubaker,\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\">Samir Boubaker\u003Csup>1,2\u003C/sup>\u003C/span>\u003Cspan class=\"author-wrapper notranslate\">\u003Ca href=\"https://loop.frontiersin.org/people/42850\" class=\"user-id-42850\">\u003Cimg class=\"pr5\" src=\"https://loop.frontiersin.org/images/profile/42850/74\" onerror=\"this.onerror=null;this.src='https://loop.frontiersin.org/cdn/images/profile/default_32.jpg';\" alt=\"Sonia Abdelhak\">Sonia Abdelhak\u003C/a>\u003Csup>1\u003C/sup>\u003C/span>\u003C/div>\u003Cul class=\"notes\">\u003Cli>\u003Cspan>\u003Csup>1\u003C/sup>\u003C/span>Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, Tunisia\u003C/li>\u003Cli>\u003Cspan>\u003Csup>2\u003C/sup>\u003C/span>Laboratory of Human and Experimental Pathology, Institut Pasteur de Tunis, Tunis, Tunisia\u003C/li>\u003Cli>\u003Cspan>\u003Csup>3\u003C/sup>\u003C/span>Medical Oncology Department, Abderrahman Mami Hospital, Faculty of Medicine Tunis, University Tunis El Manar, Tunis, Tunisia\u003C/li>\u003Cli>\u003Cspan>\u003Csup>4\u003C/sup>\u003C/span>Department of Medical Oncology, Military Hospital of Tunis, Tunis, Tunisia\u003C/li>\u003Cli>\u003Cspan>\u003Csup>5\u003C/sup>\u003C/span>UR17ES15, Oncotheranostic Biomarkers, Faculty of Medicine of Tunis, University Tunis El Manar, Tunis, Tunisia\u003C/li>\u003Cli>\u003Cspan>\u003Csup>6\u003C/sup>\u003C/span>Surgical Oncology Department, Salah Azaiez Institute of Cancer, Tunis, Tunisia\u003C/li>\u003Cli>\u003Cspan>\u003Csup>7\u003C/sup>\u003C/span>Department of Radiation Oncology, University of Tunis, Tunis, Tunisia\u003C/li>\u003Cli>\u003Cspan>\u003Csup>8\u003C/sup>\u003C/span>Department of Human Genetics, Charles Nicolle Hospital, Tunis, Tunisia\u003C/li>\u003Cli>\u003Cspan>\u003Csup>9\u003C/sup>\u003C/span>Faculty of Medicine of Sousse Department of Medical Oncology Farhat Hached University Hospital University of Sousse, Sousse, Tunisia\u003C/li>\u003C/ul>\u003Cp>\u003Cstrong>Background:\u003C/strong> Breast cancer is the world&#x2019;s most common cancer among women. It is becoming an increasingly urgent problem in low- and middle-income countries (LMICs) where a large fraction of women is diagnosed with advanced-stage disease and have no access to treatment or basic palliative care. About 5-10% of all breast cancers can be attributed to hereditary genetic components and up to 25% of familial cases are due to mutations in \u003Ci>BRCA1\u003C/i>/2 genes. Since their discovery in 1994 and 1995, as few as 18 mutations have been identified in \u003Ci>BRCA\u003C/i> genes in the Tunisian population. The aim of this study is to identify additional \u003Ci>BRCA\u003C/i> mutations, to estimate their contribution to the hereditary breast and ovarian cancers in Tunisia and to investigate the clinicopathological signatures associated with \u003Ci>BRCA\u003C/i> mutations.\u003C/p>\u003Cp>\u003Cstrong>Methods:\u003C/strong> A total of 354 patients diagnosed with breast and ovarian cancers, including 5 male breast cancer cases, have been investigated for \u003Ci>BRCA1/2\u003C/i> mutations using traditional and/or next generation sequencing technologies. Clinicopathological signatures associated with \u003Ci>BRCA\u003C/i> mutations have also been investigated.\u003C/p>\u003Cp>\u003Cstrong>Results:\u003C/strong> In the current study, 16 distinct mutations were detected: 10 in \u003Ci>BRCA1\u003C/i> and 6 in \u003Ci>BRCA2\u003C/i>, of which 11 are described for the first time in Tunisia including 3 variations that have not been reported previously in public databases namely \u003Ci>BRCA1\u003C/i>_c.915T&gt;A; \u003Ci>BRCA2\u003C/i>_c.-227-?_7805+? and \u003Ci>BRCA2\u003C/i>_c.249delG. Early age at onset, family history of ovarian cancer and high tumor grade were significantly associated with \u003Ci>BRCA\u003C/i> status. \u003Ci>BRCA1\u003C/i> carriers were more likely to be triple negative breast cancer compared to \u003Ci>BRCA2\u003C/i> carriers. A relatively high frequency of contralateral breast cancer and ovarian cancer occurrence was observed among \u003Ci>BRCA\u003C/i> carriers and was more frequent in patients carrying \u003Ci>BRCA1\u003C/i> mutations.\u003C/p>\u003Cp>\u003Cstrong>Conclusion:\u003C/strong> Our study provides new insights into breast and ovarian cancer genetic landscape in the under-represented North African populations. The prevalence assessment of novel and recurrent \u003Ci>BRCA1/2\u003C/i> pathogenic mutations will enhance the use of personalized treatment and precise screening strategies by both affected and unaffected North African cancer cases.\u003C/p>\u003Cdiv class=\"clear\">\u003C/div>\u003C/div>\u003Cdiv class=\"JournalFullText\">\u003Ca id=\"h2\" name=\"h2\">\u003C/a>\u003Ch2>Introduction\u003C/h2>\u003Cp class=\"mb15\">Breast cancer is the most common malignancy among women worldwide (\u003Ca href=\"#B1\">1\u003C/a>). Incidence and mortality rates of breast cancer differ between populations (\u003Ca href=\"#B1\">1\u003C/a>). In Tunisia, it remains the most common cancer among females and represents the first leading cause of cancer mortality among women. The mean age at diagnosis of Tunisian breast cancer cases is around 50 years old, a decade younger than Western countries (\u003Ca href=\"#B2\">2\u003C/a>, \u003Ca href=\"#B3\">3\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">\u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> are the most prominent breast cancer susceptibility genes that convey high risk of breast and ovarian cancers (\u003Ca href=\"#B4\">4\u003C/a>). Since their discovery, a wide range of mutational spectrum have been described for both genes. So far, more than 1800 distinct \u003Ci>BRCA1\u003C/i> and 2000 \u003Ci>BRCA2\u003C/i> mutations have been reported in the Breast Cancer Information Core (BIC) database. These mutations explain around 20-30% of breast cancer genetic component and seem to be associated with different other cancers such as prostate, pancreatic, endometrial and melanoma (\u003Ca href=\"#B5\">5\u003C/a>). The identification of novel \u003Ci>BRCA1/2\u003C/i> mutations has important clinical implications. Indeed, unaffected \u003Ci>BRCA\u003C/i> mutation carriers have various preventive options including extensive and regular surveillance, chemoprevention, and risk-reducing surgery (\u003Ca href=\"#B6\">6\u003C/a>&#x2013;\u003Ca href=\"#B8\">8\u003C/a>), while, affected cases carrying \u003Ci>BRCA\u003C/i> mutations could benefit from personalized therapeutic options such as platinum-based chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors (\u003Ca href=\"#B9\">9\u003C/a>, \u003Ca href=\"#B10\">10\u003C/a>). However, a full \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> gene screening remains a labor and time-consuming challenge due to the large gene size, diverse mutations, or variants of unknown significance (VUS) and complexity of large genomic rearrangements (LRs) and copy number variations (CNVs) requiring special technical approaches. Recent advances in high throughput sequencing technologies including Target panels and whole exome sequencing (WES) allowed rapid, sensitive, and cost-effective screening of the large \u003Ci>BRCA\u003C/i> genes. In addition, the decreased cost of genotyping and sequencing offered affordable targeted testing options.\u003C/p>\u003Cp class=\"mb15\">Sequencing thousands of cancer samples showed that the frequency of germline mutations in \u003Ci>BRCA\u003C/i> genes varies widely among populations. Some mutations are shared between different populations and others are ethnic specific (\u003Ca href=\"#B11\">11\u003C/a>, \u003Ca href=\"#B12\">12\u003C/a>). Indeed, in certain countries and ethnic communities, the \u003Ci>BRCA\u003C/i> mutation spectrum is limited to a few founder mutations (\u003Ca href=\"#B13\">13\u003C/a>, \u003Ca href=\"#B14\">14\u003C/a>). This is mainly observed in geographically, culturally, or religiously isolated populations and in countries with high rates of consanguinity and endogamy that undergo rapid expansion from a limited number of ancestors. Consequently, some alleles become more frequent which explain the high frequency of some founder mutations in these populations. The founder effect may, therefore, influence mutation prevalence and gene penetrance. Since cancer risk is a function of mutation prevalence and penetrance that seems to vary by ethnicity, investigating the prevalence, the frequency, and the penetrance of novel \u003Ci>BRCA\u003C/i> mutation in different populations will bring new insights on cancer risk and etiology.\u003C/p>\u003Cp class=\"mb0\">In Tunisia, previous studies on \u003Ci>BRCA\u003C/i> genes have focused only on breast cancer patients. In some studies, the genetic investigation concerned all the coding regions of \u003Ci>BRCA1\u003C/i> and/or \u003Ci>BRCA2\u003C/i> genes and in others only hotspot exons have been investigated. These reports have revealed a total of only 18 distinct mutations of which 12 are localized within \u003Ci>BRCA1\u003C/i> gene including 2 large rearrangements encompassing exons 5 and 20. Among the identified mutations c.211dupA, c.5266dupC in \u003Ci>BRCA1\u003C/i> and c.1310_1313delAAGA in \u003Ci>BRCA2\u003C/i> were the most recurrent mutations encountered among the hereditary breast cancer cases (\u003Ca href=\"#B11\">11\u003C/a>, \u003Ca href=\"#B15\">15\u003C/a>&#x2013;\u003Ca href=\"#B23\">23\u003C/a>). Despite these efforts, the mutational spectrum of \u003Ci>BRCA1/2\u003C/i> genes is still not well established. The main goal of the present study was to identify additional novel \u003Ci>BRCA\u003C/i> mutations and to investigate the contribution of these mutations to the missing heredity of breast and ovarian cancers. We also aimed to compare breast cancer clinicopathological characteristics in BRCA+ vs \u003Ci>BRCA\u003C/i>- Tunisian breast cancer cases.\u003C/p>\u003Ca id=\"h3\" name=\"h3\">\u003C/a>\u003Ch2>Materials And Methods\u003C/h2>\u003Ch3>Patients\u003C/h3>\u003Cp class=\"mb0\">A total of 354 breast and ovarian cancer patients (335 breast cancer patients and 19 ovarian cancer patients) were included in this study referred from different medical oncology departments in Tunisia including those of Abderrahman Mami Hospital, Military Hospital of Tunis, Salah Azaiez Institute of Cancer and Farhat Hachad University Hospital University of Sousse. Written informed consents were obtained from all participants. The study has been conducted according to the Declaration of Helsinki Principles and ethical approval was obtained from the biomedical ethics committee of Institut Pasteur de Tunis (2017/16/E/H&#xf4;pital A-M). Clinico-pathological characteristics and follow-up data were collected from patients&#x2019; medical records. Probands were selected based on the following selection criteria (1): Presence of at least 3 related first or second-degree breast cancer cases at any age (2), Young cancer patients aged less than 35&#xa0;years (3), Presence of at least two cases of breast or ovarian cancer, regardless of age, and at least one case of pancreatic cancer or prostate cancer in a related first- or second-degree patient (4), one case with triple negative breast cancer (TNBC) at an age &#x2264;40 years (5), one breast cancer and one ovarian cancer cases diagnosed at first or second degree relatives at any age. A study flowchart is illustrated in \u003Ca href=\"#f1\">Figure 1\u003C/a>.\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE 1\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g001.jpg\" name=\"\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g001.jpg\" alt=\"www.frontiersin.org\" id=\"f1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>Figure 1\u003C/strong> Study flowchart.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Ch3>DNA Isolation\u003C/h3>\u003Cp class=\"mb0\">Total genomic DNA was isolated from peripheral blood using DNeasy blood DNA extraction Kit (Qiagen) according to the manufacturer&#x2019;s instructions. DNA purity and concentration were measured using a NanoDrop&#x2122; spectrophotometer.\u003C/p>\u003Ch3>Screening for Recurrent Mutations in \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> Genes Using Sanger Sequencing\u003C/h3>\u003Cp class=\"mb15\">Before performing Next Generation Sequencing (NGS) analysis, the studied cohort was screened for at least one of the recurrent \u003Ci>BRCA1/2\u003C/i> mutations previously reported in the Tunisian population, namely exon5-c.211dupA (rs397508938), exon11-c.798_799delTT (rs80357724), exon11-c.2551delG (rs397508977), exon11-c.3331_3334delCAAG (rs80357701) and exon20-c.5266dupC (rs80357906) of the \u003Ci>BRCA1\u003C/i> gene and exon10-c.1310_1313 delAAGA (rs80359277), exon16-c.7654dupA (rs879255463) in \u003Ci>BRCA2\u003C/i> gene respectively. The reference sequences used were NM_007294.3 for \u003Ci>BRCA1\u003C/i> and NM_000059.3 for \u003Ci>BRCA2\u003C/i>.\u003C/p>\u003Cp class=\"mb15\">PCR reactions were performed on genomic DNA (gDNA), following standard protocols. Sanger sequencing has been performed using an automated sequencer (ABI 3500; Applied Biosystems, Foster City, CA) and a cycle sequencing reaction kit (Bigdye Terminator v3.1 kit, Applied Biosystems). The data were analyzed using BioEdit software version 7.2.5.\u003C/p>\u003Cp class=\"mb15\">Sanger sequencing technique was then used to validate the identified mutations resulting from NGS.\u003C/p>\u003Cp class=\"mb0\">NGS was performed on 75 breast and ovarian cancer cases. Targeted \u003Ci>BRCA1/2\u003C/i> sequencing and whole exome sequencing were performed on 60 and 15 patients respectively.\u003C/p>\u003Ch3>Targeted Gene Sequencing\u003C/h3>\u003Cp class=\"mb0\">Targeted gene sequencing was performed on \u003Ci>BRCA1/2\u003C/i> for 60 breast and ovarian cancer patients with strong family history. All targeted coding exons and exon&#x2013;intron boundaries of \u003Ci>BRCA1/2\u003C/i> genes were amplified with 253 pooled primer pairs. After the targeted amplification and construction of a library through QIAGEN Library Kit v2.0, the libraries were pooled prior to emulsion PCR and bead enrichment steps that were carried out using an automated protocol on the GeneRead QIAcube (QIAGEN, Hilden, Germany) using the GeneRead Clonal Amp Q Kit (QIAGEN, Hilden, Germany), according to the manufacturer&#x2019;s protocol. Following bead enrichment, the pooled libraries were sequenced using the GeneReader platform (QIAGEN, Hilden, Germany).\u003C/p>\u003Ch3>Whole Exome Sequencing\u003C/h3>\u003Cp class=\"mb0\">WES was performed for 15 breast cancer Tunisian patients. Samples were prepared according to Agilent&#x2019;s SureSelect Protocol Version 1.2 and enrichment was carried out according to Agilent SureSelect protocols. Enriched samples were sequenced on the Illumina HiSeq2000 platform using TruSeq v3 chemistry with paired-end (2 &#xd7; 100). Exome DNA sequences were mapped to their location in the build of the human genome (hg19/b37) using the Burrows&#x2013;Wheeler Aligner (BWA) package. The subsequent SAM files were converted to BAM files using Samtools. Duplicate reads were removed using Picard. GATK was then used to recalibrate the base quality scores as well as for SNP and short INDEL calling. Annotation and prioritization of potential disease-causing variants were performed using VarAFT (Variant Annotation and Filtering Tool) (\u003Ca href=\"http://varaf t.eu\">http://varaf t.eu\u003C/a>). To annotate variants, VarAFT uses ANNOVAR, a command line tool. INDELs and SNPs annotated were filtered according to several criteria (1): considering breast cancer as autosomal dominant disease and removing variants that were found in a homozygous state (2), variants identified as intronic, intergenic, and non-coding or synonymous were discarded (3), assuming that causal variants are rare, we removed all variants with an allele frequency &gt; 1% either in ExAC (\u003Ca href=\"#B24\">24\u003C/a>), 1000 genomes (\u003Ca href=\"#B25\">25\u003C/a>) or ESP6500 (\u003Ca href=\"http://evs.gs.washington.edu/EVS/\">http://evs.gs.washington.edu/EVS/\u003C/a>) (4), Using different \u003Ci>in silico\u003C/i> prediction tools, the functional impact of all identified variants has been assessed. Based on this assessment, Benign and tolerated variants were removed. Finally, significant candidate variants were obtained after filtering against their phenotypic relevance.\u003C/p>\u003Ch3>Clinico-Pathological Features of \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> Carriers\u003C/h3>\u003Cp class=\"mb0\">Clinical and pathological features of \u003Ci>BRCA\u003C/i>+ vs \u003Ci>BRCA\u003C/i>- patients as well as \u003Ci>BRCA1\u003C/i> vs \u003Ci>BRCA2\u003C/i> carriers were compared and evaluated. Statistical analysis was performed using SPSS software (version 23). Quantitative variables with normal distribution were analyzed by Student&#x2019;s t test. Comparison of qualitative data was performed using Chi-square test. Fisher&#x2019;s exact test was used for the study of small sample size. Correlation is considered statistically significant between two variables if the \u003Ci>P\u003C/i> value is less than or equal to 0.05.\u003C/p>\u003Ca id=\"h4\" name=\"h4\">\u003C/a>\u003Ch2>Results\u003C/h2>\u003Ch3>Epidemiological and Clinico-Pathological Features of Investigated Breast and Ovarian Cancer Patients\u003C/h3>\u003Cp class=\"mb15\">A family history of breast and ovarian cancer was present in 35.24% and 11.14% of patients respectively. In addition, 2.68% of&#xa0;patients presented both breast and ovarian cancers. Consanguineous families represent 35.31% of the studied patients. Mean age at menarche was 12.81 years. Mean age at first pregnancy was 26.62 years. Oral contraception was reported by 47.31% of patients, 25.99% of patients have never breastfed and 31.85% were premenopausal.\u003C/p>\u003Cp class=\"mb15\">The mean age at diagnosis of breast cancer was 43.10 years and 31.94% of patients were &#x2264;35 years. Among investigated patients1.49% were male breast cancer (MBC) cases. Inflammatory breast cancer (IBC) (T4d) was seen in 8.65% of patients. Invasive ductal carcinoma (IDC) was the most frequent (90.04%) while infiltrating lobular carcinoma (ILC) was observed in only 3.94% of cases. Scarff-Bloom-Richardson (SBR) grade III was the most common (47.71%). Mean Tumor size was 33.62mm. Patients with positive lymph node disease represented 53.37% of our cohort, 88.67% of patients had Ki-67&gt;14%. Luminal B tumors were the most common (56.88%) followed by triple negative breast cancer (TNBC) (23.85%), Her2+ (11.93%) and luminal A (7.34%). Distant metastases were observed in 26.34% of patients.\u003C/p>\u003Cp class=\"mb0\">For ovarian cancer cases, the mean age at diagnosis was 52.62 years and the majority with serous ovarian carcinoma.\u003C/p>\u003Ch3>Genetic Analysis\u003C/h3>\u003Cp class=\"mb0\">Genetic analysis results showed that 36 out of 354 tested breast and ovarian cancer patients were \u003Ci>BRCA1/2\u003C/i> mutation carriers (31 breast cancer cases and 5 ovarian cancer patients), including 21 patients with \u003Ci>BRCA1\u003C/i> mutation and 15 patients carrying \u003Ci>BRCA2\u003C/i> mutation. A total of 16 mutations have been identified including 11 short indels, 4 single nucleotide variations (3 nonsense &amp; 1 splicing) and 1 large rearrangement.\u003C/p>\u003Ch3>Identified \u003Ci>BRCA1/2\u003C/i> Pathogenic Mutations in Breast Cancer Cases\u003C/h3>\u003Cp class=\"mb0\">Within the studied breast cancer cohort, 13 pathogenic mutations have been identified: 8 in \u003Ci>BRCA1\u003C/i> and 5 in \u003Ci>BRCA2\u003C/i> genes. Among the identified mutations, 9 are described for the first time in Tunisian population (6 in \u003Ci>BRCA1\u003C/i> and 3 in \u003Ci>BRCA2\u003C/i>) \u003Cstrong>(\u003C/strong>\u003Ca href=\"#T1\">Table 1\u003C/a>\u003Cstrong>)\u003C/strong>.\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">TABLE 1\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t001.jpg\" name=\"table1\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t001.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t001.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t001.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t001.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t001.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t001.jpg\" alt=\"www.frontiersin.org\" id=\"T1\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>Table 1\u003C/strong> Mutations in the \u003Ci>BRCA1/2\u003C/i> genes identified in breast cancer and ovarian cancer patients by Sanger and next generation sequencing technologies.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cp class=\"mb15 w100pc float_left mt15\">Considering the \u003Ci>BRCA1\u003C/i> gene, 6 patients belonging to 5 unrelated families were carriers of the recurrent c.211dupA mutation. Three patients belonging to 2 unrelated families were positive for c.5266dupC mutation. The missense c.1612C&gt;T mutation has been identified in 2 related patients. c.19_47del, c.668dupA, c.2418dupA and c.5030_5033delCTAA mutations have been identified each in one patient. c.2433delC has been identified among 2 related patients. Except c.211dupA and c.5266dupC mutations, all remaining \u003Ci>BRCA1\u003C/i> mutations are reported for the first time in the Tunisian population.\u003C/p>\u003Cp class=\"mb0\">In the \u003Ci>BRCA2\u003C/i> gene, 3 frameshift mutations as well as 1 splicing and 1 large rearrangement mutation were detected. Our results revealed 6 patients belonging to 5 unrelated families that are double heterozygous for \u003Ci>BRCA2\u003C/i> gene. Indeed, these families were carrying two mutations classified as pathogenic in the ClinVar database namely c.632-1G&gt;A and c.1310_1313delAAGA. Four additional patients carrying only the c.1310_1313delAAGA mutation have been identified including one male breast cancer. The c.7654dupA mutation was identified in 2 related patients with a strong family history of hereditary breast and ovarian cancer. The c.1389_1390delAG mutation has been identified in 1 additional male breast cancer case. Similarly, a large rearrangement mutation of \u003Ci>BRCA2\u003C/i> gene (Del exons 1-16) has been identified in one patient. Among the identified \u003Ci>BRCA2\u003C/i> mutations, \u003Ci>BRCA2\u003C/i>-Del exons 1-16 mutation is novel and was not described in public databases. c.632-1G&gt;A and c.1389_1390delAG are described for the first time in the Tunisian population.\u003C/p>\u003Ch3>\u003Ci>BRCA1/2\u003C/i> Pathogenic Mutations Identified in Ovarian Cancer Cases\u003C/h3>\u003Cp class=\"mb15\">A total of 19 ovarian cancer patients were screened for \u003Ci>BRCA\u003C/i> pathogenic mutations using Sanger and/or NGS. Four distinct deleterious mutations were identified: 3 mutations in \u003Ci>BRCA1\u003C/i> gene (c.915T&gt;A, c.1612C&gt;T and c.3049G&gt;T) and one \u003Ci>BRCA2\u003C/i> mutation (c.249delG).\u003C/p>\u003Cp class=\"mb0\">\u003Ci>BRCA1\u003C/i>-c.915T&gt;A and \u003Ci>BRCA2\u003C/i>-c.249delG mutations are novel and not described in public databases. The other identified mutations are described for the first time in the Tunisian population. c.1612C&gt;T mutation was identified among 2 patients. This same mutation was also identified in 2 related breast cancer patients. Screening for additional carriers of the identified mutations, based on their geographic origin, was performed using Sanger sequencing. Consequently, the geographic origin of the identified \u003Ci>BRCA1/2\u003C/i> mutations has been clearly established (\u003Ca href=\"#f2\">Figure 2\u003C/a>). We have also illustrated the distribution of \u003Ci>BRCA\u003C/i> mutations identified in hereditary breast and ovarian cases on \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> genes (\u003Ca href=\"#f3\">Figure 3\u003C/a>). Breast cancer cluster regions (BCCRs) and ovarian cancer cluster regions (OCCRs) were assigned in \u003Ca href=\"#f3\">Figure 3\u003C/a> according to the study of Rebbeck et al., 2015 (\u003Ca href=\"#B26\">26\u003C/a>). Among \u003Ci>BRCA\u003C/i> mutations identified in breast cancer patients, \u003Ci>BRCA1_c\u003C/i>.211dupA, \u003Ci>BRCA1\u003C/i>_c.5266dupC, \u003Ci>BRCA2\u003C/i>_c.-227-?_7805+?, \u003Ci>BRCA2\u003C/i>_1310_1313delAAGA, \u003Ci>BRCA2\u003C/i>_c.1389_1390delAG and \u003Ci>BRCA2\u003C/i>_c.7654dupA occurred in BCCRs. Considering \u003Ci>BRCA\u003C/i> mutations identified in ovarian cancer patients \u003Ci>BRCA1\u003C/i>_c.1612C&gt;T and \u003Ci>BRCA1\u003C/i>_3049G&gt;T arose in OCCRs.\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE 2\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g002.jpg\" name=\"\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g002.jpg\" alt=\"www.frontiersin.org\" id=\"f2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>Figure 2\u003C/strong> Geographical distribution of the identified \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> mutations.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE 3\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g003.jpg\" name=\"\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g003.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g003.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g003.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g003.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g003.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g003.jpg\" alt=\"www.frontiersin.org\" id=\"f3\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>Figure 3\u003C/strong> Distribution of \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> mutations identified in hereditary breast and ovarian cancer cases. The Length of mutation indicator reflects the number of observed carriers. The diagrams linearly represent BRCA1/2 protein domains (x-axis). BRCA1 domains: Zinc/Ring finger (green); BRCT_assoc: serine-rich domain associated with BRCT (red); Ethylene insensitive 3 (blue); BRCA1 C terminus domain (yellow). BRCA2 domains: BRC repeats (green); BRCA-2_helical (red); oligonucleotide/oligosaccharide-binding, domain 1 (blue); tower domain (yellow) and oligonucleotide/oligosaccharide-binding, domain 3 (purple). Black mutation indicators depict truncating mutations and purple indicators represent the other types of mutations (splicing, LR). Cluster regions (breast cancer cluster regions (BCCRs) (orange) and ovarian cancer cluster regions (OCCRs) (yellow) were assigned according to the study of Rebbeck et al. (\u003Ca href=\"#B26\">26\u003C/a>).\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Ch3>Polymorphisms and Variant of Unknown Significance Identified in \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> Genes\u003C/h3>\u003Cp class=\"mb0\">In addition to the pathogenic mutations that have been identified in \u003Ci>BRCA\u003C/i> genes, several SNPs and variants of unknown significance (VUS) have been observed \u003Cstrong>(\u003C/strong>\u003Ca href=\"#h14\">Supplementary Table 1\u003C/a>\u003Cstrong>)\u003C/strong>. Among the 101 identified variants, 45.54% were coding, 50.49% were intronic and 3.96% were localized within regulatory regions. The majority of variations were classified as benign or likely benign in the ClinVar database (91.08%) and five intronic variations were not reported. One patient carried a VUS rs397507308 in \u003Ci>BRCA2\u003C/i> and 3 other patients carried 2 intronic variations (rs276174878 and rs276174816) that have conflicting interpretations of pathogenicity. Another patient diagnosed with early onset bilateral breast cancer had an in-frame variant with conflicting interpretations of pathogenicity rs80358343 (c.5017_5019delCAC) in the \u003Ci>BRCA1\u003C/i> gene.\u003C/p>\u003Ch3>Clinico-Pathological Features of \u003Ci>BRCA\u003C/i> Carriers Among Breast Cancer Cohort\u003C/h3>\u003Cp class=\"mb0\">Clinico-pathological characteristics of breast cancer cases carrying \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> mutations are described in \u003Ca href=\"#T2\">Tables 2\u003C/a>, \u003Ca href=\"#T3\">3\u003C/a> respectively. We investigated these clinico-pathological features in \u003Ci>BRCA1/2\u003C/i> mutation carriers vs \u003Ci>BRCA negative patients\u003C/i> (\u003Ca href=\"#T4\">Table 4\u003C/a>) and between \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> mutation carriers (\u003Ca href=\"#T5\">Table 5\u003C/a>), as well.\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">TABLE 2\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t002.jpg\" name=\"table2\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t002.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t002.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t002.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t002.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t002.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t002.jpg\" alt=\"www.frontiersin.org\" id=\"T2\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>Table 2\u003C/strong> Clinicopathological features of \u003Ci>BRCA1\u003C/i> carriers.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">TABLE 3\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t003.jpg\" name=\"table3\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t003.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t003.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t003.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t003.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t003.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t003.jpg\" alt=\"www.frontiersin.org\" id=\"T3\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>Table 3\u003C/strong> Clinico-pathological features of \u003Ci>BRCA2\u003C/i> carriers.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">TABLE 4\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t004.jpg\" name=\"table4\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t004.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t004.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t004.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t004.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t004.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t004.jpg\" alt=\"www.frontiersin.org\" id=\"T4\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>Table 4\u003C/strong> Epidemiological and clinico-pathological characteristics of patients carrying or not \u003Ci>BRCA1/2\u003C/i> mutations.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">TABLE 5\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t005.jpg\" name=\"table5\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t005.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t005.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t005.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t005.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t005.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-t005.jpg\" alt=\"www.frontiersin.org\" id=\"T5\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>Table 5\u003C/strong> Epidemiological and clinico-pathological characteristics of patients carrying \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> mutations.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Ch3>\u003Ci>BRCA+ vs BRCA-\u003C/i>\u003C/h3>\u003Cp class=\"mb0\">Family history of ovarian cancer was significantly associated with \u003Ci>BRCA\u003C/i> positive status (p=0.004). Regarding the mean age at diagnosis \u003Ci>BRCA\u003C/i> carriers seem to be younger than \u003Ci>BRCA-\u003C/i> patients (38.37 vs 43.14) (p= 0.049). However, no significant difference has been observed between both groups regarding family history of breast cancer, personal history of cancer and consanguinity. Similarly, no significant differences have been observed between the 2 groups in histological subtype, nodal involvement, tumor stage, hormonal receptors status, HER2 status, molecular subtypes, Ki-67 index, and metastases \u003Cstrong>(\u003C/strong>\u003Ca href=\"#T4\">Table 4\u003C/a>\u003Cstrong>)\u003C/strong>. Nevertheless, SBR grade III was found in 65.38% of patients with \u003Ci>BRCA1/2\u003C/i> mutations against a frequency of 28.57% among non-carriers, this difference appears to be statistically significant (p= 0.027).\u003C/p>\u003Ch3>\u003Ci>BRCA1 vs BRCA2\u003C/i>\u003C/h3>\u003Cp class=\"mb0\">Association between clinico-pathological features and \u003Ci>BRCA\u003C/i> status (\u003Ci>BRCA1+, BRCA2+\u003C/i> and \u003Ci>BRCAx\u003C/i>) was shown in \u003Ca href=\"#f4\">Figures 4\u003C/a>, \u003Ca href=\"#f5\">5\u003C/a>. Our results showed that there were no significant differences between \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> mutated groups regarding the mean age at diagnosis, the family history of personal cancers, of breast cancer and ovarian cancer (\u003Ca href=\"#T5\">Table 5\u003C/a>).\u003C/p>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE 4\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g004.jpg\" name=\"\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g004.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g004.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g004.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g004.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g004.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g004.jpg\" alt=\"www.frontiersin.org\" id=\"f4\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>Figure 4\u003C/strong> Distribution of clinico-pathological features of breast cancer in \u003Ci>BRCA1\u003C/i>+ and \u003Ci>BRCA2\u003C/i>+ patients.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cdiv class=\"Imageheaders\">FIGURE 5\u003C/div>\u003Cdiv class=\"FigureDesc\">\u003Ca href=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g005.jpg\" name=\"\" target=\"_blank\">\n  \u003Cpicture>\n    \u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=480&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g005.jpg\" media=\"(max-width: 563px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=370&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g005.jpg\" media=\"(max-width: 1024px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=290&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g005.jpg\" media=\"(max-width: 1441px)\">\u003Csource type=\"image/webp\" srcset=\"https://images-provider.frontiersin.org/api/ipx/w=410&f=webp/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g005.jpg\" media=\"\">\u003Csource type=\"image/jpg\" srcset=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g005.jpg\" media=\"\"> \u003Cimg src=\"https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g005.jpg\" alt=\"www.frontiersin.org\" id=\"f5\" loading=\"lazy\">\n  \u003C/picture>\n\u003C/a>\u003Cp>\u003Cstrong>Figure 5\u003C/strong> Distribution of clinico-pathological features of breast cancer in \u003Ci>BRCA\u003C/i>+ and \u003Ci>BRCAx\u003C/i> patients.\u003C/p>\u003C/div>\u003Cdiv class=\"DottedLine\">\u003C/div>\u003Cp class=\"mb0\">Pathology showed that the infiltrating ductal carcinoma was the most common histological type in both groups (100% and 92.86%). HER2 status, lymph node involvement, SBR grade, tumor size, Ki-67 index and metastatic status showed no statistically significant difference between both studied groups. However, \u003Ci>BRCA1\u003C/i> carriers were more likely to have triple negative breast cancer (p=0.002) and \u003Ci>BRCA2\u003C/i> carriers were more likely to have luminal B breast cancer tumors (p=0.000078). In addition, positive estrogen receptor (ER) status and positive progesterone receptor (PR) status studied separately were both associated with \u003Ci>BRCA2\u003C/i> mutated tumors (p=0.000056 and p=0.000084), respectively.\u003C/p>\u003Ch3>Follow Up of \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> Carriers\u003C/h3>\u003Cp class=\"mb0\">Among \u003Ci>BRCA\u003C/i> carriers, contralateral breast cancer and ovarian cancer co-occurrence were observed respectively in 22.58% and 16.12% of cases. One patient diagnosed with early onset breast cancer has undergone a contralateral prophylactic mastectomy and is currently under regular surveillance. Both contralateral breast cancer and ovarian cancer occurrence were more frequent in \u003Ci>BRCA1\u003C/i> than \u003Ci>BRCA2\u003C/i> carriers. Also, 22.58% of the carriers have&#xa0;developed distant metastases and 5 cases died due to disease progression.\u003C/p>\u003Ca id=\"h5\" name=\"h5\">\u003C/a>\u003Ch2>Discussion\u003C/h2>\u003Cp class=\"mb15\">Detection of mutations in hereditary breast and ovarian cancer related \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> genes is an effective method of cancer prevention, early detection, and treatment. Mutations in the highly penetrant \u003Ci>BRCA\u003C/i> genes explain around a quarter of these cases (\u003Ca href=\"#B27\">27\u003C/a>). The frequency of germline mutations identified on both genes varies depending on the geographic and ethnic distributions. In some populations, a wide spectrum of different mutations is present, whereas in other groups specific recurrent \u003Ci>BRCA\u003C/i> mutations have been reported that may be due to the founder mutation effect (\u003Ca href=\"#B28\">28\u003C/a>&#x2013;\u003Ca href=\"#B32\">32\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">Our previous studies, investigating breast cancer loci and Nucleotide Excision Repair pathway, have shown that the Tunisian population is an admixed and intermediate population between Sub-Saharan Africans and Europeans (\u003Ca href=\"#B33\">33\u003C/a>, \u003Ca href=\"#B34\">34\u003C/a>). This genetic diversity reflects the inter-ethnic variability in the frequency distribution of the studied polymorphisms. Indeed, allele frequencies of several variants were found to be statistically different between Tunisian and other populations including rs2046210 and rs941764 that site in breast cancer susceptibility loci (\u003Ca href=\"#B33\">33\u003C/a>). These findings are in favor of the genetic heterogeneity to breast cancer predisposition in the Tunisian population. So far, only 18 deleterious \u003Ci>BRCA\u003C/i> mutations have been reported. In the current study, 16 \u003Ci>BRCA\u003C/i> mutations, including 11 novel variations, have been identified in a cohort of 354 Tunisian breast and ovarian cancer patients. For breast cancer cases, high fractions of young patients (31.94%), cases with family history of breast cancer (35.24%), Triple negative breast cancer (24.31%) and high tumor grade (47.41%) have been observed. As reported in previous studies, the high fractions of early onset, triple negative cases and also the presence of family history of breast cancer may be associated with germline \u003Ci>BRCA\u003C/i> mutations (\u003Ca href=\"#B35\">35\u003C/a>, \u003Ca href=\"#B36\">36\u003C/a>). Indeed, it is now well documented that breast cancer patients in North Africa are almost 10 years younger than patients from western countries (\u003Ca href=\"#B37\">37\u003C/a>). In Tunisia, around 11% of breast cancer cases are under 35 years old (\u003Ca href=\"#B38\">38\u003C/a>). In fact, at a young age, the human organism usually functions as well as it ever will. However, interactions between some&#xa0;genetic and environmental factors (GxE) may cause a physiological decline of some organism systems leading to early disease presentation. Therefore, the influence of specific genetic background, differences in variant penetrance and frequency between populations along with environmental factors&#xa0;may explain this early onset of the disease. Large cohorts of young breast cancer patients&#xa0;should be studied to elucidate these GxE factors.\u003C/p>\u003Cp class=\"mb15\">For ovarian cancer cases, the mean age at diagnosis was 52.62 years and the majority presented with serous ovarian carcinoma. Previous studies have shown that among all patients diagnosed with serous ovarian carcinoma, which is the most common subtype, over 15% will have germline \u003Ci>BRCA\u003C/i> mutations (\u003Ca href=\"#B39\">39\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">Among the 16 distinct deleterious mutations that have been observed c.19_47del, c.668dupA, c.915T&gt;A, c.1612C&gt;T, c.2418dupA, c.2433delC, c.3049G&gt;T and c.5030_5033delCTAA in \u003Ci>BRCA1\u003C/i> and c.-227-?_7805+? (Del exons 1-16), c.249delG, c.632-1G&gt;A, c.1389_1390delAG in \u003Ci>BRCA2\u003C/i>, are reported for the first time in the Tunisian population. We have also identified an inframe deletion reported to have a conflicting interpretation of pathogenicity effect in early onset bilateral breast cancer patient \u003Ci>BRCA1\u003C/i>_c.5017_5019delCAC. This variation has been described in multiple breast and ovarian cancer cases, with some families showing incomplete co-segregation of the variation (\u003Ca href=\"#B40\">40\u003C/a>&#x2013;\u003Ca href=\"#B42\">42\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">Among \u003Ci>BRCA\u003C/i> mutations identified in breast cancer patients \u003Ci>BRCA1_c\u003C/i>.211dupA, \u003Ci>BRCA1\u003C/i>_c.5266dupC,\u003Ci>BRCA2\u003C/i>_c.-227-?_7805+?,\u003Ci>BRCA2\u003C/i>_1310_1313delAAGA, \u003Ci>BRCA2\u003C/i>_c.1389_1390delAG and \u003Ci>BRCA2\u003C/i>_c.7654dupA occurred in BCCRs that are considered to be associated with an increased likelihood of&#xa0;breast cancer compared to ovarian cancer. Considering \u003Ci>BRCA\u003C/i> mutations identified in ovarian cancer patients \u003Ci>BRCA1\u003C/i>_c.1612C&gt;T and \u003Ci>BRCA1\u003C/i>_3049G&gt;T arose in OCCRs. Other mutations, namely c.19_47del, c.668dupA, c.915T&gt;A, c.2418dupA, c.2433delC, c.5030_5033delCTAA in \u003Ci>BRCA1\u003C/i> and c.249delG, c.632-1G&gt;A in \u003Ci>BRCA2\u003C/i> do not overlap with previously reported breast or ovarian cancer cluster regions. This could be explained by ethnic differences in \u003Ci>BRCA\u003C/i> mutation spectrum or it may indicate shared cluster regions for both breast and ovarian cancer.\u003C/p>\u003Cp class=\"mb15\">In the \u003Ci>BRCA1\u003C/i> gene, the c.19_47del mutation was identified in one breast cancer patient. This mutation was previously described only in the Algerian population (\u003Ca href=\"#B43\">43\u003C/a>). The c.2433delC mutation was described in Korean breast and ovarian patients (\u003Ca href=\"#B44\">44\u003C/a>, \u003Ca href=\"#B45\">45\u003C/a>), and in Mexican patients (\u003Ca href=\"#B46\">46\u003C/a>, \u003Ca href=\"#B47\">47\u003C/a>). The pathogenic c.1612C&gt;T mutation was identified in 4 breast and ovarian cancer patients. This mutation has been identified in Brazilian population (\u003Ca href=\"#B48\">48\u003C/a>), in ovarian cancer patients from Israeli population (\u003Ca href=\"#B49\">49\u003C/a>) and in Macedonian population (\u003Ca href=\"#B50\">50\u003C/a>). We also detected the c.668dupA mutation in one patient. This latter has not been reported in previous studies neither in Tunisia nor in other populations. Nevertheless, it is already listed and classified as pathogenic in ClinVar and predicted to result in the substitution of Alanine to Glycine (p.Ala224Glyfs) which leads to BRCA1 protein truncation. Another new mutation was identified in \u003Ci>BRCA1\u003C/i> gene, c.2418dupA, that was reported by our group for the first time in the Tunisian population and was not reported previously in other populations (\u003Ca href=\"#B51\">51\u003C/a>). c.3049G&gt;T has been identified in one ovarian cancer patient. This mutation has been reported in Thai patients with non-mucinous epithelial ovarian cancer (\u003Ca href=\"#B52\">52\u003C/a>). The c.5030_5033delCTAA mutation was identified among one patient with breast and ovarian cancers and it is reported in Brazilian population (\u003Ca href=\"#B48\">48\u003C/a>). The c.915T&gt;A mutation is novel and not described in public databases.\u003C/p>\u003Cp class=\"mb15\">In addition to the identification of rare and novel \u003Ci>BRCA1\u003C/i> mutations, other mutations seem to be recurrent and/or were described in previous Tunisian reports. The c.211dupA mutation was shared by 6 patients belonging to the same geographical origin. This mutation has so far been reported only in hereditary breast/ovarian cancer families of Tunisian origin, particularly in the North-East region, suggesting a founder effect. In order to unravel the genetic specificities of this mutation and to trace&#xa0;its&#xa0;origin a haplotype analysis has been conducted by our group&#xa0;on the North Eastern region (\u003Ca href=\"#B51\">51\u003C/a>). Results have determined the founder haplotype segregating with this mutation and have revealed that it arose in the period of colonization approximately 130 years ago.\u003C/p>\u003Cp class=\"mb15\">The c.5266dupC mutation has been identified among two families. This mutation was previously described in 8 Tunisian breast cancer families (\u003Ca href=\"#B11\">11\u003C/a>, \u003Ca href=\"#B16\">16\u003C/a>, \u003Ca href=\"#B17\">17\u003C/a>, \u003Ca href=\"#B20\">20\u003C/a>). It was originally described as an Ashkenazi founder mutation. Haplotype analysis has shown that this mutation arose approximately 1800 years ago in Northern Europe (\u003Ca href=\"#B53\">53\u003C/a>). Then, it has been reported in several other populations such as, Italian, Russian Slovenian and Greek (\u003Ca href=\"#B54\">54\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">Interestingly for \u003Ci>BRCA2\u003C/i> gene, 6 breast cancer patients were double heterozygous carrying the two deleterious mutations c.632-1G&gt;A and c.1310_1313delAAGA, and 4 other unrelated patients carried only the c.1310_1313delAAGA mutation including one male breast cancer (MBC). c.632-1G&gt;A mutation appears to be rare in other populations since it was only reported in one patient with prostate cancer in the UK (\u003Ca href=\"#B55\">55\u003C/a>). However, c.1310_1313delAAGA seems to be a founder mutation in Maghrebin countries (\u003Ca href=\"#B16\">16\u003C/a>, \u003Ca href=\"#B17\">17\u003C/a>, \u003Ca href=\"#B56\">56\u003C/a>, \u003Ca href=\"#B57\">57\u003C/a>). It has been also identified in patients with Lebanese (\u003Ca href=\"#B58\">58\u003C/a>), European (\u003Ca href=\"#B59\">59\u003C/a>&#x2013;\u003Ca href=\"#B62\">62\u003C/a>), African (\u003Ca href=\"#B63\">63\u003C/a>), Asian (\u003Ca href=\"#B64\">64\u003C/a>) and Latino ancestry (\u003Ca href=\"#B65\">65\u003C/a>) as well as in Caribbean cohorts (\u003Ca href=\"#B66\">66\u003C/a>, \u003Ca href=\"#B67\">67\u003C/a>). These results show the genetic heterogeneity of breast and ovarian cancers in Tunisian patients and the admixed origins of \u003Ci>BRCA\u003C/i> mutations in Tunisia.\u003C/p>\u003Cp class=\"mb15\">In addition, 5 male breast cancer cases were investigated among which 2 carried \u003Ci>BRCA2\u003C/i> mutations (c.1310_1313delAAGA and c.1389_1390delAG). Male breast cancer is a rare disease accounting for less than 1% of all breast cancer cases and it was previously shown that nearly 90% of MBC arising in \u003Ci>BRCA\u003C/i> mutation carriers are found to harbor a \u003Ci>BRCA2\u003C/i> mutation (\u003Ca href=\"#B68\">68\u003C/a>). Unfortunately, being a man with &#x201c;a women&#x2019;s disease&#x201d; makes MBC a disease surrounded by social taboo and lack of awareness especially in underdeveloped countries. Indeed, the treatment of MBC has been extrapolated from the knowledge of female breast cancer, despite the multiple differences in the pathogenesis, biology and genetics of these two disease entities. These evidence make MBC a gender issue that requires&#xa0;more attention from the scientific community.\u003C/p>\u003Cp class=\"mb15\">The introduction of the c.1310_1313delAAGA mutation, that have been encountered in diverse populations, in the Tunisian population could be explained by the immigration of Andalusians in Tunisia which has been intensified after the fall of Granada in 1492 and lasted for two centuries before the total expulsion of all Andalusian Moriscos from the Iberian Peninsula in 1610. The diverse geographical distribution of this mutation may further suggest independent origins as shown for the 4184del4 \u003Ci>BRCA1\u003C/i> mutation reported to have at least three independent origins in the study of Neuhausen et al. (\u003Ca href=\"#B69\">69\u003C/a>). The c.7654dupA \u003Ci>BRCA2\u003C/i> gene mutation which was identified in a unique family with a strong family history of breast and ovarian cancer is reported previously and exclusively in Algerian population (\u003Ca href=\"#B70\">70\u003C/a>) and could be therefore specific to North African countries.\u003C/p>\u003Cp class=\"mb15\">Through this report and despite the identification of novel mutations in Tunisian population, it is clear that the genetic susceptibility to breast cancer is explained in a vast majority of cases by recurrent mutations. Indeed, more than 44.44% of carriers harbor \u003Ci>BRCA1\u003C/i>-c.211dupA or \u003Ci>BRCA2\u003C/i>-1310_1313deAAGA mutations which highlights the importance of screening these mutations in the treatment workflow of cases with early onset or strong family history of breast cancer. In fact, identifying germline \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> pathogenic mutations is a crucial component in the medical management of affected patients. Regular surveillance and/or prophylactic mastectomy of the second breast or prophylactic salpingo oophorectomies, which have been shown to reduce the risk of developing cancer, are recommended to these carriers. Moreover, relatives who test positive for a germline \u003Ci>BRCA\u003C/i> pathogenic mutation may take appropriate action to prevent cancer or have cancer diagnosed as early as possible for better treatment options (\u003Ca href=\"#B59\">59\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">In addition, mutations in the \u003Ci>BRCA\u003C/i> genes and their associations with clinico-pathological features were reported in several studies (\u003Ca href=\"#B71\">71\u003C/a>&#x2013;\u003Ca href=\"#B74\">74\u003C/a>). However, in Tunisia this aspect was not previously investigated. This point was raised in the present study and our results showed that patients with \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> mutations were similar with regard to several epidemiological and clinico-pathological parameters. Nevertheless, \u003Ci>BRCA1\u003C/i> carriers were more likely to be triple negative breast cancer compared to \u003Ci>BRCA2\u003C/i> carriers (p=0.002) and \u003Ci>BRCA2\u003C/i> carriers were more likely to be luminal B breast cancer tumors (p=0.000078). Consistent with our findings, various previous studies reported that there is a much higher rate of TNBC among \u003Ci>BRCA1\u003C/i> mutation carriers (\u003Ca href=\"#B75\">75\u003C/a>, \u003Ca href=\"#B76\">76\u003C/a>) and \u003Ci>BRCA2\u003C/i>-related breast cancer is often luminal (\u003Ca href=\"#B77\">77\u003C/a>). Additionally, positive ER was significantly associated with \u003Ci>BRCA2+\u003C/i> tumors (p=0.000056). PR status was significantly different between \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> mutation carriers; \u003Ci>BRCA2\u003C/i> carriers are more likely to develop progesterone receptor (PR) positive tumors and PR-negative breast cancer are associated with \u003Ci>BRCA1\u003C/i> mutation carriers (p=0.000084). It was reported that the ER positivity was predominantly seen in \u003Ci>BRCA2\u003C/i> mutation carriers, which is consistent with our findings (\u003Ca href=\"#B71\">71\u003C/a>, \u003Ca href=\"#B78\">78\u003C/a>). Furthermore, a previous report has found that \u003Ci>BRCA2\u003C/i>-associated cancers are mainly PR positive (\u003Ca href=\"#B79\">79\u003C/a>). Other studies have raised some pathological differences between \u003Ci>BRCA1/2\u003C/i> mutation carriers and \u003Ci>BRCAx\u003C/i> patients. In our study, \u003Ci>BRCA\u003C/i> carriers seem to be younger than \u003Ci>BRCA-negative\u003C/i> patients (p=0.049). Furthermore, patients with a positive family history of ovarian cancer are more likely to be \u003Ci>BRCA\u003C/i> positive (p=0.004). We also observed a significant predominance of SBR grade III tumors among \u003Ci>BRCA1/2\u003C/i> mutations carriers (p= 0.027). These findings are in line with previous literature&#xa0; (\u003Ca href=\"#B35\">35\u003C/a>, \u003Ca href=\"#B80\">80\u003C/a>, \u003Ca href=\"#B81\">81\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">Furthermore, we have assessed disease outcomes in \u003Ci>BRCA\u003C/i> carriers, and we have observed a relatively high proportion of contralateral breast cancer and ovarian cancer occurrence that were more frequently observed in \u003Ci>BRCA1\u003C/i> carriers. Previous reports have demonstrated that women carrying a pathogenic mutation in the \u003Ci>BRCA1\u003C/i> or \u003Ci>BRCA2\u003C/i> genes have an increased risk of developing a second primary cancer in the contralateral breast. The cumulative risk 20 years after breast cancer diagnosis was estimated to be 40% for \u003Ci>BRCA1\u003C/i> carriers and about 26% for \u003Ci>BRCA2\u003C/i> carriers (\u003Ca href=\"#B82\">82\u003C/a>). In accordance with our findings, it was shown also that the occurrence of both breast and ovarian cancer in a woman is associated with a high likelihood of a germline \u003Ci>BRCA1\u003C/i> mutation (\u003Ca href=\"#B83\">83\u003C/a>).\u003C/p>\u003Cp class=\"mb15\">Besides the \u003Ci>BRCA\u003C/i> genetic mutations that have been identified in our study, mutations on other high to moderate breast cancer genes such as \u003Ci>TP53\u003C/i>, \u003Ci>ATM, BLM\u003C/i> and \u003Ci>CHEK2\u003C/i>&#xa0;have been also identified for the first time in North African populations (data not shown). All these findings reflect the genetic heterogeneity of cancer predisposition in Tunisia and highlights the importance of the use of NGS to identify clinically actionable genetic variants that have a crucial role in disease management. Therefore,&#xa0;technological advances in terms of array and DNA sequencing technologies made the route towards the examination of genetic risk largely clear. However, practical challenges related to marked population-specific differences still exist. In this context, Manolio and colleagues conveniently classified \u003Ci>LRRK2\u003C/i> as a high penetrant gene associated with Parkinson disease (\u003Ca href=\"#B84\">84\u003C/a>) with G2019S mutation being the main cause of Parkinson familial cases. Recently the international LRRK2 consortium reported a worldwide frequency of 1% of \u003Ci>LRRK2\u003C/i> G2019S, 30&#x2013;40% in Arab patients from North Africa and 10&#x2013;30% in Ashkenazi Jews, but is very rare in Asians (\u003Ca href=\"#B85\">85\u003C/a>, \u003Ca href=\"#B86\">86\u003C/a>). As a variant&#xb4;s frequency has a direct impact on its penetrance, this example shows the ethnic-dependent penetrance of some important variants involved in complex diseases and the role of consanguinity and endogamy in shaping the genetic susceptibility to these diseases. Therefore, the same reflection can be applied on high and low penetrant breast cancer variants in order&#xa0;to review their penetrance in underrepresented populations such as North Africans. A disproportionate distribution of the identified mutations is observed between the Northern and Southern regions of Tunisia (\u003Ca href=\"#f2\">Figure 2\u003C/a>), with the vast majority found in the North. This can be explained by a selection bias because most of the recruited participants come from Northern governorates, but it can also be explained by the very high consanguinity rates in the South that reaches 98% in some cities and that may have an impact on \u003Ci>BRCA\u003C/i> mutations frequency and prevalence.\u003C/p>\u003Cp class=\"mb15\">Additional limitations of our study have been observed. Indeed, to our best knowledge, this work represents the largest BRCA1/2 study in Africa. However, we believe that the sample size is still small and larger cohorts are needed to trace a clear and complete BRCA1/2 mutational spectrum in Tunisia. In addition, because of the limited resources dedicated to this work, we were not able to perform a complete sequencing of both genes for the whole cohort. Therefore, the frequency and prevalence of the identified mutations need to be assessed in larger studies. Clearly, the prevalence assessment of \u003Ci>BRCA1\u003C/i> and \u003Ci>BRCA2\u003C/i> mutations also rely on the quality of both cohort selection criteria and mutation ascertainment methods. The identification of novel BRCA mutations and the assessment of their penetrance in a specific population will help to implement more affordable and cost effective targeted genetic testing strategies.\u003C/p>\u003Cp class=\"mb0\">Finally, up until now, most data on \u003Ci>BRCA1\u003C/i>/2 mutations associated with high risk for hereditary breast and ovarian cancer do not cover the North African populations. Accordingly, the novel mutations identified in this study will help to improve knowledge on the genetic component of hereditary breast and ovarian cancer in the North African region and will lead to a better clinical management of cancer patients. In addition, we are aiming to share genetic and phenotypic data with larger multi-ethnic Consortia of \u003Ci>BRCA1/2\u003C/i> mutation carriers such as the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) (\u003Ca href=\"#B87\">87\u003C/a>). This will make our findings more broadly useful and will give us a global overview of the similarities and differences that the Tunisian population has compared to other ethnicities.\u003C/p>\u003Ca id=\"h6\" name=\"h6\">\u003C/a>\u003Ch2>Conclusion\u003C/h2>\u003Cp class=\"mb0\">In conclusion we have identified 16 distinct \u003Ci>BRCA\u003C/i> mutations in breast and ovarian cancer patients including 11 novel mutations in the Tunisian population. The recognition of the \u003Ci>BRCA\u003C/i> mutational spectrum and its geographical distribution in Tunisia is of keen interest for the scientific and medical communities as it helps to develop precise risk assessment tools, accurate genetic testing, cost-effective approaches for prevention and early detection of the disease as well as personalized treatments of \u003Ci>BRCA\u003C/i> related cancers for both affected and unaffected cancer cases.\u003C/p>\u003Ca id=\"h7\" name=\"h7\">\u003C/a>\u003Ch2>Data Availability Statement\u003C/h2>\u003Cp class=\"mb0\">The minimal dataset that would be necessary to interpret, replicate and build upon the findings reported in this study are included in this article and in its supplementary files. All identified mutations with their related details have been shared in the public database ClinVar under the following link &#x201c;\u003Ca href=\"https://www.ncbi.nlm.nih.gov/clinvar/submitters/507986/\">https://www.ncbi.nlm.nih.gov/clinvar/submitters/507986/\u003C/a>&#x201d;. Any additional datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.\u003C/p>\u003Ca id=\"h8\" name=\"h8\">\u003C/a>\u003Ch2>Ethics Statement\u003C/h2>\u003Cp class=\"mb0\">The studies involving human participants were reviewed and approved by The Biomedical Ethics Committee of Institut Pasteur de Tunis (2017/16/E/H&#xf4;pital A-M). The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from participants for the publication of any potentially identifiable images or data included in this article.\u003C/p>\u003Ca id=\"h9\" name=\"h9\">\u003C/a>\u003Ch2>Author Contributions\u003C/h2>\u003Cp class=\"mb0\">YH prepared the study concept and design, supervised the study, did data analysis, data interpretation, drafted, and critically revised the manuscript. NMi and MB did the experiments, participated in participant recruitment, and participated in drafting and reviewing the manuscript. NMe contributed to clinical data analysis and reviewed the manuscript. SN contributed to participants recruitment and reviewed the manuscript. MR and OM contributed to data collection and reviewed the manuscript. HanB, YB, HR, OJ, ND, AZ, JA, HEB, SL and JBH contributed to the clinical investigation and recruitment of patients. AH, KR, FB, RM, SBA and HamB critically revised the clinicopathological section and the whole manuscript. SB and SA contributed to the study concept, design and supervision and critically revised the manuscript. All authors contributed to the article and approved the submitted version.\u003C/p>\u003Ca id=\"h10\" name=\"h10\">\u003C/a>\u003Ch2>Funding\u003C/h2>\u003Cp class=\"mb0\">This work was supported by the Tunisian Ministry of Higher Education and Scientific Research (LR16IPT05) and the Tunisian Ministry of Public Health (PEC-4-TUN). MB and MBR are recipient of a MOBIDOC fellowship funded by the EU through the EMORI and PASRI programs managed by the ANPR.\u003C/p>\u003Ca id=\"h11\" name=\"h11\">\u003C/a>\u003Ch2>Conflict of Interest\u003C/h2>\u003Cp class=\"mb0\">The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\u003C/p>\u003Ca id=\"h12\" name=\"h12\">\u003C/a>\u003Ch2>Publisher&#x2019;s Note\u003C/h2>\u003Cp class=\"mb15\">All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.\u003C/p>\u003Ca id=\"h13\" name=\"h13\">\u003C/a>\u003Ch2>Acknowledgments\u003C/h2>\u003Cp class=\"mb0\">This manuscript is dedicated to the memory of Prof. Farouk Benna, an imminent radiotherapist who died from Covid19 when ensuring his medical activity. We would like to thank Dr. Zied Zidi, Dr Ghazi Jerbi, Dr Samir Khalfallah, Dr Monia Hechiche, Dr Achraf Chaari, Dr Olfa gharbi, Dr Monia Hechiche, Dr Sami Bellil, Dr Ichraf Jbir, Dr Olfa Daldoul Ben Fraj, Dr Bassem Allani/Dr David Khayat, Dr Tarek Bouzid, Dr El Fatmi Rym/Dr Mokrani Amina, Dr Samia Chatti Dey, Dr Hatem Chaaba, Dr Med Ali Ayadi, Dr Lotfi Kochbati, Dr Fethi Messoudi and Dr Chadha Elward Abdelhedi&#xa0;for their contribution in this work. We are also grateful to all participants and their family members for their participation in the study.\u003C/p>\u003Ca id=\"h14\" name=\"h14\">\u003C/a>\u003Ch2>Supplementary Material\u003C/h2>\u003Cp class=\"mb15\">The Supplementary Material for this article can be found online at: \u003Ca href=\"https://www.frontiersin.org/articles/10.3389/fonc.2021.674965/full#supplementary-material\">https://www.frontiersin.org/articles/10.3389/fonc.2021.674965/full#supplementary-material\u003C/a>\u003C/p>\u003Ca id=\"h15\" name=\"h15\">\u003C/a>\u003Ch2>Abbreviations\u003C/h2>\u003Cp class=\"mb15\">BCCRs, Breast Cancer Cluster Regions; ER, Estrogen receptor; gDNA, Genomic DNA; GxE, Genetic and Environmental factors; IDC, Invasive Ductal Carcinoma; LMICs, Low- and middle-income countries; OCCRs, Ovarian cancer cluster regions; PR, Progesterone receptor; SBR, Scarff-Bloom-Richardson; TNBC, Triple Negative Breast Cancer; VUS, Variants of Unknown Significance; WES, Whole Exome Sequencing.\u003C/p>\u003Ca id=\"h16\" name=\"h16\">\u003C/a>\u003Ch2>References\u003C/h2>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B1\" id=\"B1\">\u003C/a> 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. \u003Ci>CA: Cancer J Clin\u003C/i> (2018) 68(6):394&#x2013;424. doi: 10.3322/caac.21492\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30207593/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3322/caac.21492\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=F+Bray&amp;author=J+Ferlay&amp;author=I+Soerjomataram&amp;author=RL+Siegel&amp;author=LA+Torre&amp;author=A+Jemal&amp;publication_year=2018&amp;title=Global%20Cancer%20Statistics%202018%3A%20GLOBOCAN%20Estimates%20of%20Incidence%20and%20Mortality%20Worldwide%20for%2036%20Cancers%20in%20185%20Countries&amp;journal=CA:+Cancer+J+Clin&amp;volume=68&amp;pages=394\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B2\" id=\"B2\">\u003C/a> 2. Chalabi N, Bernard-Gallon DJ, Bignon YJ, Breast Med C, Kwiatkowski F, Agier M, et al. Comparative Clinical and Transcriptomal Profiles of Breast Cancer Between French and South Mediterranean Patients Show Minor But Significative Biological Differences. \u003Ci>Cancer Genomics Proteomics\u003C/i> (2008) 5(5):253&#x2013;61.\n\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/19129556/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=N+Chalabi&amp;author=DJ+Bernard-Gallon&amp;author=YJ+Bignon&amp;author=C+Breast%20Med&amp;author=F+Kwiatkowski&amp;author=M+Agier&amp;publication_year=2008&amp;title=Comparative%20Clinical%20and%20Transcriptomal%20Profiles%20of%20Breast%20Cancer%20Between%20French%20and%20South%20Mediterranean%20Patients%20Show%20Minor%20But%20Significative%20Biological%20Differences&amp;journal=Cancer+Genomics+Proteomics&amp;volume=5&amp;pages=253-61\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B3\" id=\"B3\">\u003C/a> 3. Boussen H, Bouzaiene H, Ben Hassouna J, Dhiab T, Khomsi F, Benna F, et al. Inflammatory Breast Cancer in Tunisia: Epidemiological and Clinical Trends. \u003Ci>Cancer\u003C/i> (2010) 116(11 Suppl):2730&#x2013;5. doi: 10.1002/cncr.25175\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/20503401/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/cncr.25175\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H+Boussen&amp;author=H+Bouzaiene&amp;author=J+Ben%20Hassouna&amp;author=T+Dhiab&amp;author=F+Khomsi&amp;author=F+Benna&amp;publication_year=2010&amp;title=Inflammatory%20Breast%20Cancer%20in%20Tunisia%3A%20Epidemiological%20and%20Clinical%20Trends&amp;journal=Cancer&amp;volume=116&amp;pages=2730-5\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B4\" id=\"B4\">\u003C/a> 4. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average Risks of Breast and Ovarian Cancer Associated With BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. \u003Ci>Am J Hum Genet\u003C/i> (2003) 72(5):1117&#x2013;30. doi: 10.1086/375033\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/12677558/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1086/375033\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Antoniou&amp;author=PD+Pharoah&amp;author=S+Narod&amp;author=HA+Risch&amp;author=JE+Eyfjord&amp;author=JL+Hopper&amp;publication_year=2003&amp;title=Average%20Risks%20of%20Breast%20and%20Ovarian%20Cancer%20Associated%20With%20BRCA1%20or%20BRCA2%20Mutations%20Detected%20in%20Case%20Series%20Unselected%20for%20Family%20History%3A%20A%20Combined%20Analysis%20of%2022%20Studies&amp;journal=Am+J+Hum+Genet&amp;volume=72&amp;pages=1117-30\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B5\" id=\"B5\">\u003C/a> 5. Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, et al. Cancers Associated With BRCA 1 and BRCA 2 Mutations Other Than Breast and Ovarian. \u003Ci>Cancer\u003C/i> (2015) 121(2):269&#x2013;75. doi: 10.1002/cncr.29041\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25224030/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/cncr.29041\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+Mersch&amp;author=MA+Jackson&amp;author=M+Park&amp;author=D+Nebgen&amp;author=SK+Peterson&amp;author=C+Singletary&amp;publication_year=2015&amp;title=Cancers%20Associated%20With%20BRCA%201%20and%20BRCA%202%20Mutations%20Other%20Than%20Breast%20and%20Ovarian&amp;journal=Cancer&amp;volume=121&amp;pages=269-75\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B6\" id=\"B6\">\u003C/a> 6. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and Mortality. \u003Ci>JAMA\u003C/i> (2010) 304(9):967&#x2013;75. doi: 10.1001/jama.2010.1237\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/20810374/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1001/jama.2010.1237\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=SM+Domchek&amp;author=TM+Friebel&amp;author=CF+Singer&amp;author=DG+Evans&amp;author=HT+Lynch&amp;author=C+Isaacs&amp;publication_year=2010&amp;title=Association%20of%20Risk-Reducing%20Surgery%20in%20BRCA1%20or%20BRCA2%20Mutation%20Carriers%20With%20Cancer%20Risk%20and%20Mortality&amp;journal=JAMA&amp;volume=304&amp;pages=967-75\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B7\" id=\"B7\">\u003C/a> 7. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, et al. Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations. \u003Ci>N Engl J Med\u003C/i> (2002) 346(21):1616&#x2013;22. doi: 10.1056/NEJMoa012158\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/12023993/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1056/NEJMoa012158\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=TR+Rebbeck&amp;author=HT+Lynch&amp;author=SL+Neuhausen&amp;author=SA+Narod&amp;author=L+Van%27t%20Veer&amp;author=JE+Garber&amp;publication_year=2002&amp;title=Prophylactic%20Oophorectomy%20in%20Carriers%20of%20BRCA1%20or%20BRCA2%20Mutations&amp;journal=N+Engl+J+Med&amp;volume=346&amp;pages=1616-22\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B8\" id=\"B8\">\u003C/a> 8. Menkiszak J, Chudecka-Glaz A, Gronwald J, Cymbaluk-Ploska A, Celewicz A, Swiniarska M, et al. Prophylactic Salpingo-Oophorectomy in BRCA1 Mutation Carriers and Postoperative Incidence of Peritoneal and Breast Cancers. \u003Ci>J Ovarian Res\u003C/i> (2016) 9:11. doi: 10.1186/s13048-016-0220-4\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26928677/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s13048-016-0220-4\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+Menkiszak&amp;author=A+Chudecka-Glaz&amp;author=J+Gronwald&amp;author=A+Cymbaluk-Ploska&amp;author=A+Celewicz&amp;author=M+Swiniarska&amp;publication_year=2016&amp;title=Prophylactic%20Salpingo-Oophorectomy%20in%20BRCA1%20Mutation%20Carriers%20and%20Postoperative%20Incidence%20of%20Peritoneal%20and%20Breast%20Cancers&amp;journal=J+Ovarian+Res&amp;volume=9&amp;pages=11\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B9\" id=\"B9\">\u003C/a> 9. Turner NC, Tutt AN. Platinum Chemotherapy for BRCA1-Related Breast Cancer: Do We Need More Evidence? \u003Ci>Breast Cancer Res\u003C/i> (2012) 14(6):115. doi: 10.1186/bcr3332\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23146216/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/bcr3332\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=NC+Turner&amp;author=AN+Tutt&amp;publication_year=2012&amp;title=Platinum%20Chemotherapy%20for%20BRCA1-Related%20Breast%20Cancer%3A%20Do%20We%20Need%20More%20Evidence&amp;journal=Breast+Cancer+Res&amp;volume=14&amp;pages=115\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B10\" id=\"B10\">\u003C/a> 10. Mateo J, Lord CJ, Serra V, Tutt A, Balmana J, Castroviejo-Bermejo M, et al. A Decade of Clinical Development of PARP Inhibitors in Perspective. \u003Ci>Ann Oncol\u003C/i> (2019) 30(9):1437&#x2013;47. doi: 10.1093/annonc/mdz192\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31218365/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/annonc/mdz192\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+Mateo&amp;author=CJ+Lord&amp;author=V+Serra&amp;author=A+Tutt&amp;author=J+Balmana&amp;author=M+Castroviejo-Bermejo&amp;publication_year=2019&amp;title=A%20Decade%20of%20Clinical%20Development%20of%20PARP%20Inhibitors%20in%20Perspective&amp;journal=Ann+Oncol&amp;volume=30&amp;pages=1437-47\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B11\" id=\"B11\">\u003C/a> 11. Mahfoudh W, Bouaouina N, Ahmed SB, Gabbouj S, Shan J, Mathew R, et al. Hereditary Breast Cancer in Middle Eastern and North African (MENA) Populations: Identification of Novel, Recurrent and Founder BRCA1 Mutations in the Tunisian Population. \u003Ci>Mol Biol Rep\u003C/i> (2012) 39(2):1037&#x2013;46. doi: 10.1007/s11033-011-0829-8\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/21603858/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s11033-011-0829-8\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=W+Mahfoudh&amp;author=N+Bouaouina&amp;author=SB+Ahmed&amp;author=S+Gabbouj&amp;author=J+Shan&amp;author=R+Mathew&amp;publication_year=2012&amp;title=Hereditary%20Breast%20Cancer%20in%20Middle%20Eastern%20and%20North%20African%20%28MENA%29%20Populations%3A%20Identification%20of%20Novel%2C%20Recurrent%20and%20Founder%20BRCA1%20Mutations%20in%20the%20Tunisian%20Population&amp;journal=Mol+Biol+Rep&amp;volume=39&amp;pages=1037-46\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B12\" id=\"B12\">\u003C/a> 12. Kadouri L, Hubert A, Rotenberg Y, Hamburger T, Sagi M, Nechushtan C, et al. Cancer Risks in Carriers of the BRCA1/2 Ashkenazi Founder Mutations. \u003Ci>J Med Genet\u003C/i> (2007) 44(7):467&#x2013;71. doi: 10.1136/jmg.2006.048173\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/17307836/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1136/jmg.2006.048173\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=L+Kadouri&amp;author=A+Hubert&amp;author=Y+Rotenberg&amp;author=T+Hamburger&amp;author=M+Sagi&amp;author=C+Nechushtan&amp;publication_year=2007&amp;title=Cancer%20Risks%20in%20Carriers%20of%20the%20BRCA1%2F2%20Ashkenazi%20Founder%20Mutations&amp;journal=J+Med+Genet&amp;volume=44&amp;pages=467-71\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B13\" id=\"B13\">\u003C/a> 13. Fackenthal JD, Olopade OI. Breast Cancer Risk Associated With BRCA1 and BRCA2 in Diverse Populations. \u003Ci>Nat Rev Cancer\u003C/i> (2007) 7(12):937&#x2013;48. doi: 10.1038/nrc2054\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/18034184/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nrc2054\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=JD+Fackenthal&amp;author=OI+Olopade&amp;publication_year=2007&amp;title=Breast%20Cancer%20Risk%20Associated%20With%20BRCA1%20and%20BRCA2%20in%20Diverse%20Populations&amp;journal=Nat+Rev+Cancer&amp;volume=7&amp;pages=937-48\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B14\" id=\"B14\">\u003C/a> 14. Ramus SJ, Gayther SA. The Contribution of BRCA1 and BRCA2 to Ovarian Cancer. \u003Ci>Mol Oncol\u003C/i> (2009) 3(2):138&#x2013;50. doi: 10.1016/j.molonc.2009.02.001\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/19383375/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.molonc.2009.02.001\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=SJ+Ramus&amp;author=SA+Gayther&amp;publication_year=2009&amp;title=The%20Contribution%20of%20BRCA1%20and%20BRCA2%20to%20Ovarian%20Cancer&amp;journal=Mol+Oncol&amp;volume=3&amp;pages=138-50\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B15\" id=\"B15\">\u003C/a> 15. Mestiri S, Monastiri K, Ben SA, Bouaouina N, Presneau N, Bignon Y, et al. Mutational Analysis of Breast/Ovarian Cancer Hereditary Predisposition Gene BRCA1 in Tunisian Women. \u003Ci>Arch l'Institut Pasteur Tunis\u003C/i> (2000) 77(1-4):11&#x2013;5.\n\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+Mestiri&amp;author=K+Monastiri&amp;author=SA+Ben&amp;author=N+Bouaouina&amp;author=N+Presneau&amp;author=Y+Bignon&amp;publication_year=2000&amp;title=Mutational%20Analysis%20of%20Breast%2FOvarian%20Cancer%20Hereditary%20Predisposition%20Gene%20BRCA1%20in%20Tunisian%20Women&amp;journal=Arch+l'Institut+Pasteur+Tunis&amp;volume=77&amp;pages=11-5\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B16\" id=\"B16\">\u003C/a> 16. Troudi W, Uhrhammer N, Sibille C, Dahan C, Mahfoudh W, Bouchlaka Souissi C, et al. Contribution of the BRCA1 and BRCA2 Mutations to Breast Cancer in Tunisia. \u003Ci>J Hum Genet\u003C/i> (2007) 52(11):915&#x2013;20. doi: 10.1007/s10038-007-0195-5\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/17922257/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10038-007-0195-5\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=W+Troudi&amp;author=N+Uhrhammer&amp;author=C+Sibille&amp;author=C+Dahan&amp;author=W+Mahfoudh&amp;author=C+Bouchlaka%20Souissi&amp;publication_year=2007&amp;title=Contribution%20of%20the%20BRCA1%20and%20BRCA2%20Mutations%20to%20Breast%20Cancer%20in%20Tunisia&amp;journal=J+Hum+Genet&amp;volume=52&amp;pages=915-20\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B17\" id=\"B17\">\u003C/a> 17. Fourati A, Louchez MM, Fournier J, Gamoudi A, Rahal K, El May MV, et al. Screening for Common Mutations in BRCA1 and BRCA2 Genes: Interest in Genetic Testing of Tunisian Families With Breast and/or Ovarian Cancer. \u003Ci>Bull Cancer\u003C/i> (2014) 101(11):E36&#x2013;40. doi: 10.1684/bdc.2014.2049\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25418591/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1684/bdc.2014.2049\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Fourati&amp;author=MM+Louchez&amp;author=J+Fournier&amp;author=A+Gamoudi&amp;author=K+Rahal&amp;author=MV+El%20May&amp;publication_year=2014&amp;title=Screening%20for%20Common%20Mutations%20in%20BRCA1%20and%20BRCA2%20Genes%3A%20Interest%20in%20Genetic%20Testing%20of%20Tunisian%20Families%20With%20Breast%20and%2For%20Ovarian%20Cancer&amp;journal=Bull+Cancer&amp;volume=101&amp;pages=E36-40\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B18\" id=\"B18\">\u003C/a> 18. Msolly A. BRCA1 and BRCA2 Mutations Are They Related to Breast Cancer in a Sample of Tunisian Population? \u003Ci>Cancer Ther Oncol Int J\u003C/i> (2015) 1(1):1&#x2013;5. doi: 10.19080/CTOIJ.2015.01.555551\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.19080/CTOIJ.2015.01.555551\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Msolly&amp;publication_year=2015&amp;title=BRCA1%20and%20BRCA2%20Mutations%20Are%20They%20Related%20to%20Breast%20Cancer%20in%20a%20Sample%20of%20Tunisian%20Population&amp;journal=Cancer+Ther+Oncol+Int+J&amp;volume=1&amp;pages=1\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B19\" id=\"B19\">\u003C/a> 19. Riahi A, Chabouni-Bouhamed H, Kharrat M. Prevalence of BRCA1 and BRCA2 Large Genomic Rearrangements in Tunisian High Risk Breast/Ovarian Cancer Families: Implications for Genetic Testing. \u003Ci>Cancer Genet\u003C/i> (2017) 210:22&#x2013;7. doi: 10.1016/j.cancergen.2016.11.002\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28212807/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.cancergen.2016.11.002\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Riahi&amp;author=H+Chabouni-Bouhamed&amp;author=M+Kharrat&amp;publication_year=2017&amp;title=Prevalence%20of%20BRCA1%20and%20BRCA2%20Large%20Genomic%20Rearrangements%20in%20Tunisian%20High%20Risk%20Breast%2FOvarian%20Cancer%20Families%3A%20Implications%20for%20Genetic%20Testing&amp;journal=Cancer+Genet&amp;volume=210&amp;pages=22-7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B20\" id=\"B20\">\u003C/a> 20. Riahi A, Kharrat M, Ghourabi ME, Khomsi F, Gamoudi A, Lariani I, et al. Mutation Spectrum and Prevalence of BRCA1 and BRCA2 Genes in Patients With Familial and Early-Onset Breast/Ovarian Cancer From Tunisia. \u003Ci>Clin Genet\u003C/i> (2015) 87(2):155&#x2013;60. doi: 10.1111/cge.12337\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/24372583/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/cge.12337\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Riahi&amp;author=M+Kharrat&amp;author=ME+Ghourabi&amp;author=F+Khomsi&amp;author=A+Gamoudi&amp;author=I+Lariani&amp;publication_year=2015&amp;title=Mutation%20Spectrum%20and%20Prevalence%20of%20BRCA1%20and%20BRCA2%20Genes%20in%20Patients%20With%20Familial%20and%20Early-Onset%20Breast%2FOvarian%20Cancer%20From%20Tunisia&amp;journal=Clin+Genet&amp;volume=87&amp;pages=155-60\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B21\" id=\"B21\">\u003C/a> 21. Hadiji-Abbes N, Trifa F, Choura M, Khabir A, Sellami-Boudawara T, Frikha M, et al. A Novel BRCA2 in Frame Deletion in a Tunisian Woman With Early Onset Sporadic Breast Cancer. \u003Ci>Pathol Biol (Paris)\u003C/i> (2015) 63(4-5):185&#x2013;9. doi: 10.1016/j.patbio.2015.07.009\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26320393/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.patbio.2015.07.009\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=N+Hadiji-Abbes&amp;author=F+Trifa&amp;author=M+Choura&amp;author=A+Khabir&amp;author=T+Sellami-Boudawara&amp;author=M+Frikha&amp;publication_year=2015&amp;title=A%20Novel%20BRCA2%20in%20Frame%20Deletion%20in%20a%20Tunisian%20Woman%20With%20Early%20Onset%20Sporadic%20Breast%20Cancer&amp;journal=Pathol+Biol+(Paris)&amp;volume=63&amp;pages=185-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B22\" id=\"B22\">\u003C/a> 22. Mahfoudh W, Bettaieb I, Ghedira R, Snoussi K, Bouzid N, Klayech Z, et al. Contribution of BRCA1 5382insc Mutation in Triple Negative Breast Cancer in Tunisia. \u003Ci>J Trans Med\u003C/i> (2019) 17(1):123. doi: 10.1186/s12967-019-1873-8\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.1186/s12967-019-1873-8\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=W+Mahfoudh&amp;author=I+Bettaieb&amp;author=R+Ghedira&amp;author=K+Snoussi&amp;author=N+Bouzid&amp;author=Z+Klayech&amp;publication_year=2019&amp;title=Contribution%20of%20BRCA1%205382insc%20Mutation%20in%20Triple%20Negative%20Breast%20Cancer%20in%20Tunisia&amp;journal=J+Trans+Med&amp;volume=17&amp;pages=123\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B23\" id=\"B23\">\u003C/a> 23. Ben Kridis-Rejeb W, Ben Ayed-Guerfali D, Ammous-Boukhris N, Ayadi W, Kifagi C, Charfi S, et al. Identification of Novel Candidate Genes by Exome Sequencing in Tunisian Familial Male Breast Cancer Patients. \u003Ci>Mol Biol Rep\u003C/i> (2020) 47(9):6507&#x2013;16. doi: 10.1007/s11033-020-05703-0\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32901360/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s11033-020-05703-0\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=W+Ben%20Kridis-Rejeb&amp;author=D+Ben%20Ayed-Guerfali&amp;author=N+Ammous-Boukhris&amp;author=W+Ayadi&amp;author=C+Kifagi&amp;author=S+Charfi&amp;publication_year=2020&amp;title=Identification%20of%20Novel%20Candidate%20Genes%20by%20Exome%20Sequencing%20in%20Tunisian%20Familial%20Male%20Breast%20Cancer%20Patients&amp;journal=Mol+Biol+Rep&amp;volume=47&amp;pages=6507-16\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B24\" id=\"B24\">\u003C/a> 24. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of Protein-Coding Genetic Variation in 60,706 Humans. \u003Ci>Nature\u003C/i> (2016) 536(7616):285&#x2013;91. doi: 10.1038/nature19057\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27535533/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nature19057\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Lek&amp;author=KJ+Karczewski&amp;author=EV+Minikel&amp;author=KE+Samocha&amp;author=E+Banks&amp;author=T+Fennell&amp;publication_year=2016&amp;title=Analysis%20of%20Protein-Coding%20Genetic%20Variation%20in%2060%2C706%20Humans&amp;journal=Nature&amp;volume=536&amp;pages=285-91\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B25\" id=\"B25\">\u003C/a> 25. Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A Global Reference for Human Genetic Variation. \u003Ci>Nature\u003C/i> (2015) 526(7571):68&#x2013;74. doi: 10.1038/nature15393\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26432245/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nature15393\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=C+Genomes%20Project&amp;author=A+Auton&amp;author=LD+Brooks&amp;author=RM+Durbin&amp;author=EP+Garrison&amp;author=HM+Kang&amp;publication_year=2015&amp;title=A%20Global%20Reference%20for%20Human%20Genetic%20Variation&amp;journal=Nature&amp;volume=526&amp;pages=68\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B26\" id=\"B26\">\u003C/a> 26. Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, et al. Association of Type and Location of BRCA1 and BRCA2 Mutations With Risk of Breast and Ovarian Cancer. \u003Ci>JAMA\u003C/i> (2015) 313(13):1347&#x2013;61. doi: 10.1001/jama.2014.5985\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25849179/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1001/jama.2014.5985\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=TR+Rebbeck&amp;author=N+Mitra&amp;author=F+Wan&amp;author=OM+Sinilnikova&amp;author=S+Healey&amp;author=L+McGuffog&amp;publication_year=2015&amp;title=Association%20of%20Type%20and%20Location%20of%20BRCA1%20and%20BRCA2%20Mutations%20With%20Risk%20of%20Breast%20and%20Ovarian%20Cancer&amp;journal=JAMA&amp;volume=313&amp;pages=1347-61\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B27\" id=\"B27\">\u003C/a> 27. Melchor L, Benitez J. The Complex Genetic Landscape of Familial Breast Cancer. \u003Ci>Hum Genet\u003C/i> (2013) 132(8):845&#x2013;63. doi: 10.1007/s00439-013-1299-y\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23552954/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s00439-013-1299-y\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=L+Melchor&amp;author=J+Benitez&amp;publication_year=2013&amp;title=The%20Complex%20Genetic%20Landscape%20of%20Familial%20Breast%20Cancer&amp;journal=Hum+Genet&amp;volume=132&amp;pages=845-63\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B28\" id=\"B28\">\u003C/a> 28. Laraqui A, Uhrhammer N, Rhaffouli HE, Sekhsokh Y, Lahlou-Amine I, Bajjou T, et al. BRCA Genetic Screening in Middle Eastern and North African: Mutational Spectrum and Founder BRCA1 Mutation (C.798_799deltt) in North African. \u003Ci>Dis Markers\u003C/i> (2015) 2015:194293. doi: 10.1155/2015/194293\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25814778/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1155/2015/194293\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Laraqui&amp;author=N+Uhrhammer&amp;author=HE+Rhaffouli&amp;author=Y+Sekhsokh&amp;author=I+Lahlou-Amine&amp;author=T+Bajjou&amp;publication_year=2015&amp;title=BRCA%20Genetic%20Screening%20in%20Middle%20Eastern%20and%20North%20African%3A%20Mutational%20Spectrum%20and%20Founder%20BRCA1%20Mutation%20%28C.798_799deltt%29%20in%20North%20African&amp;journal=Dis+Markers&amp;volume=2015&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B29\" id=\"B29\">\u003C/a> 29. Laitman Y, Friebel TM, Yannoukakos D, Fostira F, Konstantopoulou I, Figlioli G, et al. The Spectrum of BRCA1 and BRCA2 Pathogenic Sequence Variants in Middle Eastern, North African, and South European Countries. \u003Ci>Hum Mutat\u003C/i> (2019) 40(11):e1&#x2013;e23. doi: 10.1002/humu.23842\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31209999/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/humu.23842\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=Y+Laitman&amp;author=TM+Friebel&amp;author=D+Yannoukakos&amp;author=F+Fostira&amp;author=I+Konstantopoulou&amp;author=G+Figlioli&amp;publication_year=2019&amp;title=The%20Spectrum%20of%20BRCA1%20and%20BRCA2%20Pathogenic%20Sequence%20Variants%20in%20Middle%20Eastern%2C%20North%20African%2C%20and%20South%20European%20Countries&amp;journal=Hum+Mutat&amp;volume=40&amp;pages=e1\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B30\" id=\"B30\">\u003C/a> 30. Behl S, Hamel N, de Ladurantaye M, Lepage S, Lapointe R, Mes-Masson AM, et al. Founder BRCA1/BRCA2/PALB2 Pathogenic Variants in French-Canadian Breast Cancer Cases and Controls. \u003Ci>Sci Rep\u003C/i> (2020) 10(1):6491. doi: 10.1038/s41598-020-63100-w\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32300229/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41598-020-63100-w\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+Behl&amp;author=N+Hamel&amp;author=M+de%20Ladurantaye&amp;author=S+Lepage&amp;author=R+Lapointe&amp;author=AM+Mes-Masson&amp;publication_year=2020&amp;title=Founder%20BRCA1%2FBRCA2%2FPALB2%20Pathogenic%20Variants%20in%20French-Canadian%20Breast%20Cancer%20Cases%20and%20Controls&amp;journal=Sci+Rep&amp;volume=10&amp;pages=6491\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B31\" id=\"B31\">\u003C/a> 31. Oosthuizen J, Kotze MJ, van der Merwe N, Myburgh EJ, Bester P, van der Merwe NC. Globally Rare BRCA2 Variants With Founder Haplotypes in the South African Population: Implications for Point-Of-Care Testing Based on a Single-Institution BRCA1/2 Next-Generation Sequencing Study. \u003Ci>Front Oncol\u003C/i> (2020) 10:619469. doi: 10.3389/fonc.2020.619469\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33643918/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3389/fonc.2020.619469\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+Oosthuizen&amp;author=MJ+Kotze&amp;author=N+van%20der%20Merwe&amp;author=EJ+Myburgh&amp;author=P+Bester&amp;author=NC+van%20der%20Merwe&amp;publication_year=2020&amp;title=Globally%20Rare%20BRCA2%20Variants%20With%20Founder%20Haplotypes%20in%20the%20South%20African%20Population%3A%20Implications%20for%20Point-Of-Care%20Testing%20Based%20on%20a%20Single-Institution%20BRCA1%2F2%20Next-Generation%20Sequencing%20Study&amp;journal=Front+Oncol&amp;volume=10&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B32\" id=\"B32\">\u003C/a> 32. Tennen RI, Laskey SB, Koelsch BL, McIntyre MH, Tung JY. Identifying Ashkenazi Jewish BRCA1/2 Founder Variants in Individuals Who Do Not Self-Report Jewish Ancestry. \u003Ci>Sci Rep\u003C/i> (2020) 10(1):7669. doi: 10.1038/s41598-020-63466-x\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/32376921/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41598-020-63466-x\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=RI+Tennen&amp;author=SB+Laskey&amp;author=BL+Koelsch&amp;author=MH+McIntyre&amp;author=JY+Tung&amp;publication_year=2020&amp;title=Identifying%20Ashkenazi%20Jewish%20BRCA1%2F2%20Founder%20Variants%20in%20Individuals%20Who%20Do%20Not%20Self-Report%20Jewish%20Ancestry&amp;journal=Sci+Rep&amp;volume=10&amp;pages=7669\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B33\" id=\"B33\">\u003C/a> 33. Hamdi Y, Ben Rekaya M, Jingxuan S, Nagara M, Messaoud O, Benammar Elgaaied A, et al. A Genome Wide SNP Genotyping Study in the Tunisian Population: Specific Reporting on a Subset of Common Breast Cancer Risk Loci. \u003Ci>BMC Cancer\u003C/i> (2018) 18(1):1295. doi: 10.1186/s12885-018-5133-8\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30594178/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s12885-018-5133-8\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=Y+Hamdi&amp;author=M+Ben%20Rekaya&amp;author=S+Jingxuan&amp;author=M+Nagara&amp;author=O+Messaoud&amp;author=A+Benammar%20Elgaaied&amp;publication_year=2018&amp;title=A%20Genome%20Wide%20SNP%20Genotyping%20Study%20in%20the%20Tunisian%20Population%3A%20Specific%20Reporting%20on%20a%20Subset%20of%20Common%20Breast%20Cancer%20Risk%20Loci&amp;journal=BMC+Cancer&amp;volume=18&amp;pages=1295\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B34\" id=\"B34\">\u003C/a> 34. Hamdi Y, Jerbi M, Romdhane L, Ben Rekaya M, El Benna H, Chouchane L, et al. Genetic Diversity and Functional Effect of Common Polymorphisms in Genes Involved in the First Heterodimeric Complex of the Nucleotide Excision Repair Pathway. \u003Ci>DNA Repair (Amst)\u003C/i> (2020) 86:102770. doi: 10.1016/j.dnarep.2019.102770\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31865061/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.dnarep.2019.102770\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=Y+Hamdi&amp;author=M+Jerbi&amp;author=L+Romdhane&amp;author=M+Ben%20Rekaya&amp;author=H+El%20Benna&amp;author=L+Chouchane&amp;publication_year=2020&amp;title=Genetic%20Diversity%20and%20Functional%20Effect%20of%20Common%20Polymorphisms%20in%20Genes%20Involved%20in%20the%20First%20Heterodimeric%20Complex%20of%20the%20Nucleotide%20Excision%20Repair%20Pathway&amp;journal=DNA+Repair+(Amst)&amp;volume=86&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B35\" id=\"B35\">\u003C/a> 35. Fang M, Zhu L, Li H, Li X, Wu Y, Wu K, et al. Characterization of Mutations in BRCA1/2 and the Relationship With Clinic-Pathological Features of Breast Cancer in a Hereditarily High-Risk Sample of Chinese Population. \u003Ci>Oncol Lett\u003C/i> (2018) 15(3):3068&#x2013;74. doi: 10.3892/ol.2017.7717\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29435039/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3892/ol.2017.7717\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Fang&amp;author=L+Zhu&amp;author=H+Li&amp;author=X+Li&amp;author=Y+Wu&amp;author=K+Wu&amp;publication_year=2018&amp;title=Characterization%20of%20Mutations%20in%20BRCA1%2F2%20and%20the%20Relationship%20With%20Clinic-Pathological%20Features%20of%20Breast%20Cancer%20in%20a%20Hereditarily%20High-Risk%20Sample%20of%20Chinese%20Population&amp;journal=Oncol+Lett&amp;volume=15&amp;pages=3068-74\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B36\" id=\"B36\">\u003C/a> 36. Godet I, Gilkes DM. BRCA1 and BRCA2 Mutations and Treatment Strategies for Breast Cancer. \u003Ci>Integr Cancer Sci Ther\u003C/i> (2017) 4(1):10. doi: 10.15761/ICST.1000228\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://doi.org/10.15761/ICST.1000228\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=I+Godet&amp;author=DM+Gilkes&amp;publication_year=2017&amp;title=BRCA1%20and%20BRCA2%20Mutations%20and%20Treatment%20Strategies%20for%20Breast%20Cancer&amp;journal=Integr+Cancer+Sci+Ther&amp;volume=4&amp;pages=10\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B37\" id=\"B37\">\u003C/a> 37. Chouchane L, Boussen H, Sastry KSR. Breast Cancer in Arab Populations: Molecular Characteristics and Disease Management Implications. \u003Ci>Lancet Oncol\u003C/i> (2013) 14(10):e417&#x2013;e24. doi: 10.1016/S1470-2045(13)70165-7\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23993386/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/S1470-2045(13)70165-7\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=L+Chouchane&amp;author=H+Boussen&amp;author=KSR+Sastry&amp;publication_year=2013&amp;title=Breast%20Cancer%20in%20Arab%20Populations%3A%20Molecular%20Characteristics%20and%20Disease%20Management%20Implications&amp;journal=Lancet+Oncol&amp;volume=14&amp;pages=e417-e24\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B38\" id=\"B38\">\u003C/a> 38. Zehani S, Maalej M, Hsairi M, Hechiche M, Romdhane B, Boussen H, et al. Breast Cancer in Tunisia: Epidemiologic Characteristics and Trends in Incidence. \u003Ci>La Tunisie Medicale\u003C/i> (2009) 87(7):417&#x2013;25.\n\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/20063673/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+Zehani&amp;author=M+Maalej&amp;author=M+Hsairi&amp;author=M+Hechiche&amp;author=B+Romdhane&amp;author=H+Boussen&amp;publication_year=2009&amp;title=Breast%20Cancer%20in%20Tunisia%3A%20Epidemiologic%20Characteristics%20and%20Trends%20in%20Incidence&amp;journal=La+Tunisie+Medicale&amp;volume=87&amp;pages=417-25\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B39\" id=\"B39\">\u003C/a> 39. Neff RT, Senter L, Salani R. BRCA Mutation in Ovarian Cancer: Testing, Implications and Treatment Considerations. \u003Ci>Ther Adv Med Oncol\u003C/i> (2017) 9(8):519&#x2013;31. doi: 10.1177/1758834017714993\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28794804/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1177/1758834017714993\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=RT+Neff&amp;author=L+Senter&amp;author=R+Salani&amp;publication_year=2017&amp;title=BRCA%20Mutation%20in%20Ovarian%20Cancer%3A%20Testing%2C%20Implications%20and%20Treatment%20Considerations&amp;journal=Ther+Adv+Med+Oncol&amp;volume=9&amp;pages=519-31\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B40\" id=\"B40\">\u003C/a> 40. Meindl A, German Consortium for Hereditary B, Ovarian C. Comprehensive Analysis of 989 Patients With Breast or Ovarian Cancer Provides BRCA1 and BRCA2 Mutation Profiles and Frequencies for the German Population. \u003Ci>Int J Cancer\u003C/i> (2002) 97(4):472&#x2013;80. doi: 10.1002/ijc.1626\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/11802209/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/ijc.1626\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Meindl&amp;author=German%20Consortium%20for%20Hereditary%20B&amp;author=Ovarian%20C&amp;publication_year=2002&amp;title=Comprehensive%20Analysis%20of%20989%20Patients%20With%20Breast%20or%20Ovarian%20Cancer%20Provides%20BRCA1%20and%20BRCA2%20Mutation%20Profiles%20and%20Frequencies%20for%20the%20German%20Population&amp;journal=Int+J+Cancer&amp;volume=97&amp;pages=472-80\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B41\" id=\"B41\">\u003C/a> 41. Lim MC, Kang S, Seo SS, Kong SY, Lee BY, Lee SK, et al. BRCA1 and BRCA2 Germline Mutations in Korean Ovarian Cancer Patients. \u003Ci>J Cancer Res Clin Oncol\u003C/i> (2009) 135(11):1593&#x2013;9. doi: 10.1007/s00432-009-0607-3\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/19499246/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s00432-009-0607-3\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MC+Lim&amp;author=S+Kang&amp;author=SS+Seo&amp;author=SY+Kong&amp;author=BY+Lee&amp;author=SK+Lee&amp;publication_year=2009&amp;title=BRCA1%20and%20BRCA2%20Germline%20Mutations%20in%20Korean%20Ovarian%20Cancer%20Patients&amp;journal=J+Cancer+Res+Clin+Oncol&amp;volume=135&amp;pages=1593-9\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B42\" id=\"B42\">\u003C/a> 42. Zuntini R, Cortesi L, Calistri D, Pippucci T, Martelli PL, Casadio R, et al. BRCA1 P. His1673del Is a Pathogenic Mutation Associated With a Predominant Ovarian Cancer Phenotype. \u003Ci>Oncotarget\u003C/i> (2017) 8(14):22640. doi: 10.18632/oncotarget.15151\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28186987/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.18632/oncotarget.15151\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R+Zuntini&amp;author=L+Cortesi&amp;author=D+Calistri&amp;author=T+Pippucci&amp;author=PL+Martelli&amp;author=R+Casadio&amp;publication_year=2017&amp;title=BRCA1%20P.%20His1673del%20Is%20a%20Pathogenic%20Mutation%20Associated%20With%20a%20Predominant%20Ovarian%20Cancer%20Phenotype&amp;journal=Oncotarget&amp;volume=8&amp;pages=22640\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B43\" id=\"B43\">\u003C/a> 43. Cherbal F, Bakour R, Adane S, Boualga K. BRCA1 and BRCA2 Germline Mutation Spectrum in Hereditary Breast/Ovarian Cancer Families From Maghrebian Countries. \u003Ci>Breast Dis\u003C/i> (2012) 34(1):1&#x2013;8. doi: 10.3233/BD-130348\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23697973/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3233/BD-130348\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=F+Cherbal&amp;author=R+Bakour&amp;author=S+Adane&amp;author=K+Boualga&amp;publication_year=2012&amp;title=BRCA1%20and%20BRCA2%20Germline%20Mutation%20Spectrum%20in%20Hereditary%20Breast%2FOvarian%20Cancer%20Families%20From%20Maghrebian%20Countries&amp;journal=Breast+Dis&amp;volume=34&amp;pages=1\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B44\" id=\"B44\">\u003C/a> 44. Ahn SH, Son BH, Yoon KS, Noh DY, Han W, Kim SW, et al. BRCA1 and BRCA2 Germline Mutations in Korean Breast Cancer Patients at High Risk of Carrying Mutations. \u003Ci>Cancer Lett\u003C/i> (2007) 245(1-2):90&#x2013;5. doi: 10.1016/j.canlet.2005.12.031\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16455195/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.canlet.2005.12.031\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=SH+Ahn&amp;author=BH+Son&amp;author=KS+Yoon&amp;author=DY+Noh&amp;author=W+Han&amp;author=SW+Kim&amp;publication_year=2007&amp;title=BRCA1%20and%20BRCA2%20Germline%20Mutations%20in%20Korean%20Breast%20Cancer%20Patients%20at%20High%20Risk%20of%20Carrying%20Mutations&amp;journal=Cancer+Lett&amp;volume=245&amp;pages=90-5\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B45\" id=\"B45\">\u003C/a> 45. Kim H, Cho DY, Choi DH, Choi SY, Shin I, Park W, et al. Characteristics and Spectrum of BRCA1 and BRCA2 Mutations in 3,922 Korean Patients With Breast and Ovarian Cancer. \u003Ci>Breast Cancer Res Treat\u003C/i> (2012) 134(3):1315&#x2013;26. doi: 10.1007/s10549-012-2159-5\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/22798144/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10549-012-2159-5\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H+Kim&amp;author=DY+Cho&amp;author=DH+Choi&amp;author=SY+Choi&amp;author=I+Shin&amp;author=W+Park&amp;publication_year=2012&amp;title=Characteristics%20and%20Spectrum%20of%20BRCA1%20and%20BRCA2%20Mutations%20in%203%2C922%20Korean%20Patients%20With%20Breast%20and%20Ovarian%20Cancer&amp;journal=Breast+Cancer+Res+Treat&amp;volume=134&amp;pages=1315-26\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B46\" id=\"B46\">\u003C/a> 46. Weitzel JN, Clague J, Martir-Negron A, Ogaz R, Herzog J, Ricker C, et al. Prevalence and Type of BRCA Mutations in Hispanics Undergoing Genetic Cancer Risk Assessment in the Southwestern United States: A Report From the Clinical Cancer Genetics Community Research Network. \u003Ci>J Clin Oncol\u003C/i> (2013) 31(2):210&#x2013;6. doi: 10.1200/JCO.2011.41.0027\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23233716/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1200/JCO.2011.41.0027\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=JN+Weitzel&amp;author=J+Clague&amp;author=A+Martir-Negron&amp;author=R+Ogaz&amp;author=J+Herzog&amp;author=C+Ricker&amp;publication_year=2013&amp;title=Prevalence%20and%20Type%20of%20BRCA%20Mutations%20in%20Hispanics%20Undergoing%20Genetic%20Cancer%20Risk%20Assessment%20in%20the%20Southwestern%20United%20States%3A%20A%20Report%20From%20the%20Clinical%20Cancer%20Genetics%20Community%20Research%20Network&amp;journal=J+Clin+Oncol&amp;volume=31&amp;pages=210-6\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B47\" id=\"B47\">\u003C/a> 47. Torres-Mejia G, Royer R, Llacuachaqui M, Akbari MR, Giuliano AR, Martinez-Matsushita L, et al. Recurrent BRCA1 and BRCA2 Mutations in Mexican Women With Breast Cancer. \u003Ci>Cancer Epidemiol Biomarkers Prev\u003C/i> (2015) 24(3):498&#x2013;505. doi: 10.1158/1055-9965.EPI-13-0980\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25371446/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1158/1055-9965.EPI-13-0980\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=G+Torres-Mejia&amp;author=R+Royer&amp;author=M+Llacuachaqui&amp;author=MR+Akbari&amp;author=AR+Giuliano&amp;author=L+Martinez-Matsushita&amp;publication_year=2015&amp;title=Recurrent%20BRCA1%20and%20BRCA2%20Mutations%20in%20Mexican%20Women%20With%20Breast%20Cancer&amp;journal=Cancer+Epidemiol+Biomarkers+Prev&amp;volume=24&amp;pages=498\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B48\" id=\"B48\">\u003C/a> 48. Palmero EI, Carraro DM, Alemar B, Moreira MAM, Ribeiro-Dos-Santos A, Abe-Sandes K, et al. The Germline Mutational Landscape of BRCA1 and BRCA2 in Brazil. \u003Ci>Sci Rep\u003C/i> (2018) 8(1):9188. doi: 10.1038/s41598-018-27315-2\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29907814/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/s41598-018-27315-2\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=EI+Palmero&amp;author=DM+Carraro&amp;author=B+Alemar&amp;author=MAM+Moreira&amp;author=A+Ribeiro-Dos-Santos&amp;author=K+Abe-Sandes&amp;publication_year=2018&amp;title=The%20Germline%20Mutational%20Landscape%20of%20BRCA1%20and%20BRCA2%20in%20Brazil&amp;journal=Sci+Rep&amp;volume=8&amp;pages=9188\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B49\" id=\"B49\">\u003C/a> 49. Barnes-Kedar I, Bernstein-Molho R, Ginzach N, Hartmajer S, Shapira T, Magal N, et al. The Yield of Full BRCA1/2 Genotyping in Israeli High-Risk Breast/Ovarian Cancer Patients Who Do Not Carry the Predominant Mutations. \u003Ci>Breast Cancer Res Treat\u003C/i> (2018) 172(1):151&#x2013;7. doi: 10.1007/s10549-018-4887-7\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/30014164/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10549-018-4887-7\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=I+Barnes-Kedar&amp;author=R+Bernstein-Molho&amp;author=N+Ginzach&amp;author=S+Hartmajer&amp;author=T+Shapira&amp;author=N+Magal&amp;publication_year=2018&amp;title=The%20Yield%20of%20Full%20BRCA1%2F2%20Genotyping%20in%20Israeli%20High-Risk%20Breast%2FOvarian%20Cancer%20Patients%20Who%20Do%20Not%20Carry%20the%20Predominant%20Mutations&amp;journal=Breast+Cancer+Res+Treat&amp;volume=172&amp;pages=151-7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B50\" id=\"B50\">\u003C/a> 50. Jakimovska M, Maleva Kostovska I, Popovska-Jankovic K, Kubelka-Sabit K, Karadjozov M, Stojanovska L, et al. BRCA1 and BRCA2 Germline Variants in Breast Cancer Patients From the Republic of Macedonia. \u003Ci>Breast Cancer Res Treat\u003C/i> (2018) 168(3):745&#x2013;53. doi: 10.1007/s10549-017-4642-5\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/29335924/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10549-017-4642-5\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Jakimovska&amp;author=I+Maleva%20Kostovska&amp;author=K+Popovska-Jankovic&amp;author=K+Kubelka-Sabit&amp;author=M+Karadjozov&amp;author=L+Stojanovska&amp;publication_year=2018&amp;title=BRCA1%20and%20BRCA2%20Germline%20Variants%20in%20Breast%20Cancer%20Patients%20From%20the%20Republic%20of%20Macedonia&amp;journal=Breast+Cancer+Res+Treat&amp;volume=168&amp;pages=745-53\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B51\" id=\"B51\">\u003C/a> 51. Mighri N, Hamdi Y, Boujemaa M, Othman H, Ben Nasr S, El Benna H, et al. Identification of Novel BRCA1 and RAD50 Mutations Associated With Breast Cancer Predisposition in Tunisian Patients. \u003Ci>Front Genet\u003C/i> (2020) 11:552971. doi: 10.3389/fgene.2020.552971\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33240314/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.3389/fgene.2020.552971\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=N+Mighri&amp;author=Y+Hamdi&amp;author=M+Boujemaa&amp;author=H+Othman&amp;author=S+Ben%20Nasr&amp;author=H+El%20Benna&amp;publication_year=2020&amp;title=Identification%20of%20Novel%20BRCA1%20and%20RAD50%20Mutations%20Associated%20With%20Breast%20Cancer%20Predisposition%20in%20Tunisian%20Patients&amp;journal=Front+Genet&amp;volume=11&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B52\" id=\"B52\">\u003C/a> 52. Manchana T, Phoolcharoen N, Tantbirojn P. BRCA Mutation in High Grade Epithelial Ovarian Cancers. \u003Ci>Gynecol Oncol Rep\u003C/i> (2019) 29:102&#x2013;5. doi: 10.1016/j.gore.2019.07.007\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/31467961/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.gore.2019.07.007\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=T+Manchana&amp;author=N+Phoolcharoen&amp;author=P+Tantbirojn&amp;publication_year=2019&amp;title=BRCA%20Mutation%20in%20High%20Grade%20Epithelial%20Ovarian%20Cancers&amp;journal=Gynecol+Oncol+Rep&amp;volume=29&amp;pages=102-5\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B53\" id=\"B53\">\u003C/a> 53. Hamel N, Feng BJ, Foretova L, Stoppa-Lyonnet D, Narod SA, Imyanitov E, et al. On the Origin and Diffusion of BRCA1 C.5266dupc (5382insc) in European Populations. \u003Ci>Eur J Hum Genet\u003C/i> (2011) 19(3):300&#x2013;6. doi: 10.1038/ejhg.2010.203\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/21119707/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/ejhg.2010.203\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=N+Hamel&amp;author=BJ+Feng&amp;author=L+Foretova&amp;author=D+Stoppa-Lyonnet&amp;author=SA+Narod&amp;author=E+Imyanitov&amp;publication_year=2011&amp;title=On%20the%20Origin%20and%20Diffusion%20of%20BRCA1%20C.5266dupc%20%285382insc%29%20in%20European%20Populations&amp;journal=Eur+J+Hum+Genet&amp;volume=19&amp;pages=300-6\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B54\" id=\"B54\">\u003C/a> 54. Janavicius R. Founder BRCA1/2 Mutations in the Europe: Implications for Hereditary Breast-Ovarian Cancer Prevention and Control. \u003Ci>EPMA J\u003C/i> (2010) 1(3):397&#x2013;412. doi: 10.1007/s13167-010-0037-y\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23199084/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s13167-010-0037-y\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=R+Janavicius&amp;publication_year=2010&amp;title=Founder%20BRCA1%2F2%20Mutations%20in%20the%20Europe%3A%20Implications%20for%20Hereditary%20Breast-Ovarian%20Cancer%20Prevention%20and%20Control&amp;journal=EPMA+J&amp;volume=1&amp;pages=397\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B55\" id=\"B55\">\u003C/a> 55. Edwards SM, Evans DGR, Hope Q, Norman A, Barbachano Y, Bullock S, et al. Prostate Cancer in BRCA2 Germline Mutation Carriers is Associated With Poorer Prognosis. \u003Ci>Br J Cancer\u003C/i> (2010) 103(6):918&#x2013;24. doi: 10.1038/sj.bjc.6605822\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/20736950/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/sj.bjc.6605822\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=SM+Edwards&amp;author=DGR+Evans&amp;author=Q+Hope&amp;author=A+Norman&amp;author=Y+Barbachano&amp;author=S+Bullock&amp;publication_year=2010&amp;title=Prostate%20Cancer%20in%20BRCA2%20Germline%20Mutation%20Carriers%20is%20Associated%20With%20Poorer%20Prognosis&amp;journal=Br+J+Cancer&amp;volume=103&amp;pages=918-24\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B56\" id=\"B56\">\u003C/a> 56. Laarabi FZ, Ratbi I, Elalaoui SC, Mezzouar L, Doubaj Y, Bouguenouch L, et al. High Frequency of the Recurrent C.1310_1313delaaga BRCA2 Mutation in the North-East of Morocco and Implication for Hereditary Breast-Ovarian Cancer Prevention and Control. \u003Ci>BMC Res Notes\u003C/i> (2017) 10(1):188. doi: 10.1186/s13104-017-2511-2\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28577564/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s13104-017-2511-2\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=FZ+Laarabi&amp;author=I+Ratbi&amp;author=SC+Elalaoui&amp;author=L+Mezzouar&amp;author=Y+Doubaj&amp;author=L+Bouguenouch&amp;publication_year=2017&amp;title=High%20Frequency%20of%20the%20Recurrent%20C.1310_1313delaaga%20BRCA2%20Mutation%20in%20the%20North-East%20of%20Morocco%20and%20Implication%20for%20Hereditary%20Breast-Ovarian%20Cancer%20Prevention%20and%20Control&amp;journal=BMC+Res+Notes&amp;volume=10&amp;pages=188\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B57\" id=\"B57\">\u003C/a> 57. Cherbal F, Bakour R, Adane S, Boualga K, Benais-Pont G, Maillet P. BRCA1 and BRCA2 Germline Mutations Screening in Algerian Breast/Ovarian Cancer Families. \u003Ci>Dis Markers\u003C/i> (2010) 28(6):377&#x2013;84. doi: 10.1155/2010/585278\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/20683152/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1155/2010/585278\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=F+Cherbal&amp;author=R+Bakour&amp;author=S+Adane&amp;author=K+Boualga&amp;author=G+Benais-Pont&amp;author=P+Maillet&amp;publication_year=2010&amp;title=BRCA1%20and%20BRCA2%20Germline%20Mutations%20Screening%20in%20Algerian%20Breast%2FOvarian%20Cancer%20Families&amp;journal=Dis+Markers&amp;volume=28&amp;pages=377-84\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B58\" id=\"B58\">\u003C/a> 58. El Saghir NS, Zgheib NK, Assi HA, Khoury KE, Bidet Y, Jaber SM, et al. BRCA1 and BRCA2 Mutations in Ethnic Lebanese Arab Women With High Hereditary Risk Breast Cancer. \u003Ci>Oncologist\u003C/i> (2015) 20(4):357&#x2013;64. doi: 10.1634/theoncologist.2014-0364\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25777348/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1634/theoncologist.2014-0364\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=NS+El%20Saghir&amp;author=NK+Zgheib&amp;author=HA+Assi&amp;author=KE+Khoury&amp;author=Y+Bidet&amp;author=SM+Jaber&amp;publication_year=2015&amp;title=BRCA1%20and%20BRCA2%20Mutations%20in%20Ethnic%20Lebanese%20Arab%20Women%20With%20High%20Hereditary%20Risk%20Breast%20Cancer&amp;journal=Oncologist&amp;volume=20&amp;pages=357-64\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B59\" id=\"B59\">\u003C/a> 59. Caputo S, Benboudjema L, Sinilnikova O, Rouleau E, Beroud C, Lidereau R, et al. Description and Analysis of Genetic Variants in French Hereditary Breast and Ovarian Cancer Families Recorded in the UMD-BRCA1/BRCA2 Databases. \u003Ci>Nucleic Acids Res\u003C/i> (2012) 40(Database issue):D992&#x2013;1002. doi: 10.1093/nar/gkr1160\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/22144684/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1093/nar/gkr1160\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+Caputo&amp;author=L+Benboudjema&amp;author=O+Sinilnikova&amp;author=E+Rouleau&amp;author=C+Beroud&amp;author=R+Lidereau&amp;publication_year=2012&amp;title=Description%20and%20Analysis%20of%20Genetic%20Variants%20in%20French%20Hereditary%20Breast%20and%20Ovarian%20Cancer%20Families%20Recorded%20in%20the%20UMD-BRCA1%2FBRCA2%20Databases&amp;journal=Nucleic+Acids+Res&amp;volume=40&amp;pages=D992\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B60\" id=\"B60\">\u003C/a> 60. Vos JR, Teixeira N, van der Kolk DM, Mourits MJ, Rookus MA, van Leeuwen FE, et al. Variation in Mutation Spectrum Partly Explains Regional Differences in the Breast Cancer Risk of Female BRCA Mutation Carriers in the Netherlands. \u003Ci>Cancer Epidemiol Biomarkers Prev\u003C/i> (2014) 23(11):2482&#x2013;91. doi: 10.1158/1055-9965.EPI-13-1279\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25103822/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1158/1055-9965.EPI-13-1279\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=JR+Vos&amp;author=N+Teixeira&amp;author=DM+van%20der%20Kolk&amp;author=MJ+Mourits&amp;author=MA+Rookus&amp;author=FE+van%20Leeuwen&amp;publication_year=2014&amp;title=Variation%20in%20Mutation%20Spectrum%20Partly%20Explains%20Regional%20Differences%20in%20the%20Breast%20Cancer%20Risk%20of%20Female%20BRCA%20Mutation%20Carriers%20in%20the%20Netherlands&amp;journal=Cancer+Epidemiol+Biomarkers+Prev&amp;volume=23&amp;pages=2482-91\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B61\" id=\"B61\">\u003C/a> 61. Meisel C, Sadowski CE, Kohlstedt D, Keller K, Staritz F, Grubling N, et al. Spectrum of Genetic Variants of BRCA1 and BRCA2 in a German Single Center Study. \u003Ci>Arch Gynecol Obstet\u003C/i> (2017) 295(5):1227&#x2013;38. doi: 10.1007/s00404-017-4330-z\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28324225/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s00404-017-4330-z\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=C+Meisel&amp;author=CE+Sadowski&amp;author=D+Kohlstedt&amp;author=K+Keller&amp;author=F+Staritz&amp;author=N+Grubling&amp;publication_year=2017&amp;title=Spectrum%20of%20Genetic%20Variants%20of%20BRCA1%20and%20BRCA2%20in%20a%20German%20Single%20Center%20Study&amp;journal=Arch+Gynecol+Obstet&amp;volume=295&amp;pages=1227-38\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B62\" id=\"B62\">\u003C/a> 62. Thomassen M, Hansen TV, Borg A, Lianee HT, Wikman F, Pedersen IS, et al. BRCA1 and BRCA2 Mutations in Danish Families With Hereditary Breast and/or Ovarian Cancer. \u003Ci>Acta Oncol\u003C/i> (2008) 47(4):772&#x2013;7. doi: 10.1080/02841860802004974\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/18465347/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1080/02841860802004974\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Thomassen&amp;author=TV+Hansen&amp;author=A+Borg&amp;author=HT+Lianee&amp;author=F+Wikman&amp;author=IS+Pedersen&amp;publication_year=2008&amp;title=BRCA1%20and%20BRCA2%20Mutations%20in%20Danish%20Families%20With%20Hereditary%20Breast%20and%2For%20Ovarian%20Cancer&amp;journal=Acta+Oncol&amp;volume=47&amp;pages=772-7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B63\" id=\"B63\">\u003C/a> 63. Zhang J, Fackenthal JD, Zheng Y, Huo D, Hou N, Niu Q, et al. Recurrent BRCA1 and BRCA2 Mutations in Breast Cancer Patients of African Ancestry. \u003Ci>Breast Cancer Res Treat\u003C/i> (2012) 134(2):889&#x2013;94. doi: 10.1007/s10549-012-2136-z\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/22739995/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10549-012-2136-z\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=J+Zhang&amp;author=JD+Fackenthal&amp;author=Y+Zheng&amp;author=D+Huo&amp;author=N+Hou&amp;author=Q+Niu&amp;publication_year=2012&amp;title=Recurrent%20BRCA1%20and%20BRCA2%20Mutations%20in%20Breast%20Cancer%20Patients%20of%20African%20Ancestry&amp;journal=Breast+Cancer+Res+Treat&amp;volume=134&amp;pages=889-94\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B64\" id=\"B64\">\u003C/a> 64. Jang JH, Lee JE, Kwon MJ, Ki CS, Kim JW, Nam SJ, et al. Spectra of BRCA1 and BRCA2 Mutations in Korean Patients With Breast Cancer: The Importance of Whole-Gene Sequencing. \u003Ci>J Hum Genet\u003C/i> (2012) 57(3):212&#x2013;5. doi: 10.1038/jhg.2011.139\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/22217648/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/jhg.2011.139\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=JH+Jang&amp;author=JE+Lee&amp;author=MJ+Kwon&amp;author=CS+Ki&amp;author=JW+Kim&amp;author=SJ+Nam&amp;publication_year=2012&amp;title=Spectra%20of%20BRCA1%20and%20BRCA2%20Mutations%20in%20Korean%20Patients%20With%20Breast%20Cancer%3A%20The%20Importance%20of%20Whole-Gene%20Sequencing&amp;journal=J+Hum+Genet&amp;volume=57&amp;pages=212-5\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B65\" id=\"B65\">\u003C/a> 65. Cruz-Correa M, Perez-Mayoral J, Dutil J, Echenique M, Mosquera R, Rivera-Roman K, et al. Hereditary Cancer Syndromes in Latino Populations: Genetic Characterization and Surveillance Guidelines. \u003Ci>Hered Cancer Clin Pract\u003C/i> (2017) 15:3. doi: 10.1186/s13053-017-0063-z\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28127413/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s13053-017-0063-z\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=M+Cruz-Correa&amp;author=J+Perez-Mayoral&amp;author=J+Dutil&amp;author=M+Echenique&amp;author=R+Mosquera&amp;author=K+Rivera-Roman&amp;publication_year=2017&amp;title=Hereditary%20Cancer%20Syndromes%20in%20Latino%20Populations%3A%20Genetic%20Characterization%20and%20Surveillance%20Guidelines&amp;journal=Hered+Cancer+Clin+Pract&amp;volume=15&amp;pages=3\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B66\" id=\"B66\">\u003C/a> 66. Akbari MR, Donenberg T, Lunn J, Curling D, Turnquest T, Krill-Jackson E, et al. The Spectrum of BRCA1 and BRCA2 Mutations in Breast Cancer Patients in the Bahamas. \u003Ci>Clin Genet\u003C/i> (2014) 85(1):64&#x2013;7. doi: 10.1111/cge.12132\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/23458327/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1111/cge.12132\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MR+Akbari&amp;author=T+Donenberg&amp;author=J+Lunn&amp;author=D+Curling&amp;author=T+Turnquest&amp;author=E+Krill-Jackson&amp;publication_year=2014&amp;title=The%20Spectrum%20of%20BRCA1%20and%20BRCA2%20Mutations%20in%20Breast%20Cancer%20Patients%20in%20the%20Bahamas&amp;journal=Clin+Genet&amp;volume=85&amp;pages=64-7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B67\" id=\"B67\">\u003C/a> 67. Donenberg T, Ahmed H, Royer R, Zhang S, Narod SA, George S, et al. A Survey of BRCA1, BRCA2, and PALB2 Mutations in Women With Breast Cancer in Trinidad and Tobago. \u003Ci>Breast Cancer Res Treat\u003C/i> (2016) 159(1):131&#x2013;8. doi: 10.1007/s10549-016-3870-4\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27469594/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10549-016-3870-4\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=T+Donenberg&amp;author=H+Ahmed&amp;author=R+Royer&amp;author=S+Zhang&amp;author=SA+Narod&amp;author=S+George&amp;publication_year=2016&amp;title=A%20Survey%20of%20BRCA1%2C%20BRCA2%2C%20and%20PALB2%20Mutations%20in%20Women%20With%20Breast%20Cancer%20in%20Trinidad%20and%20Tobago&amp;journal=Breast+Cancer+Res+Treat&amp;volume=159&amp;pages=131-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B68\" id=\"B68\">\u003C/a> 68. Silvestri V, Barrowdale D, Mulligan AM, Neuhausen SL, Fox S, Karlan BY, et al. Male Breast Cancer in BRCA1 and BRCA2 Mutation Carriers: Pathology Data From the Consortium of Investigators of Modifiers of BRCA1/2. \u003Ci>Breast Cancer Res\u003C/i> (2016) 18(1):15. doi: 10.1186/s13058-016-0671-y\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26857456/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s13058-016-0671-y\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=V+Silvestri&amp;author=D+Barrowdale&amp;author=AM+Mulligan&amp;author=SL+Neuhausen&amp;author=S+Fox&amp;author=BY+Karlan&amp;publication_year=2016&amp;title=Male%20Breast%20Cancer%20in%20BRCA1%20and%20BRCA2%20Mutation%20Carriers%3A%20Pathology%20Data%20From%20the%20Consortium%20of%20Investigators%20of%20Modifiers%20of%20BRCA1%2F2&amp;journal=Breast+Cancer+Res&amp;volume=18&amp;pages=15\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B69\" id=\"B69\">\u003C/a> 69. Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offit K, Caligo A, et al. Haplotype and Phenotype Analysis of Six Recurrent BRCA1 Mutations in 61 Families: Results of an International Study. \u003Ci>Am J Hum Genet\u003C/i> (1996) 58(2):271.\n\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/8571953/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=SL+Neuhausen&amp;author=S+Mazoyer&amp;author=L+Friedman&amp;author=M+Stratton&amp;author=K+Offit&amp;author=A+Caligo&amp;publication_year=1996&amp;title=Haplotype%20and%20Phenotype%20Analysis%20of%20Six%20Recurrent%20BRCA1%20Mutations%20in%2061%20Families%3A%20Results%20of%20an%20International%20Study&amp;journal=Am+J+Hum+Genet&amp;volume=58&amp;pages=271\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B70\" id=\"B70\">\u003C/a> 70. Henouda S, Bensalem A, Reggad R, Serrar N, Rouabah L, Pujol P. Contribution of BRCA1 and BRCA2 Germline Mutations to Early Algerian Breast Cancer. \u003Ci>Dis Markers\u003C/i> (2016) 2016:7869095. doi: 10.1155/2016/7869095\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/26997744/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1155/2016/7869095\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+Henouda&amp;author=A+Bensalem&amp;author=R+Reggad&amp;author=N+Serrar&amp;author=L+Rouabah&amp;author=P+Pujol&amp;publication_year=2016&amp;title=Contribution%20of%20BRCA1%20and%20BRCA2%20Germline%20Mutations%20to%20Early%20Algerian%20Breast%20Cancer&amp;journal=Dis+Markers&amp;volume=2016&amp;\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B71\" id=\"B71\">\u003C/a> 71. Veronesi A, de Giacomi C, Magri MD, Lombardi D, Zanetti M, Scuderi C, et al. Familial Breast Cancer: Characteristics and Outcome of BRCA 1-2 Positive and Negative Cases. \u003Ci>BMC Cancer\u003C/i> (2005) 5:70. doi: 10.1186/1471-2407-5-70\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/15996267/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/1471-2407-5-70\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Veronesi&amp;author=C+de%20Giacomi&amp;author=MD+Magri&amp;author=D+Lombardi&amp;author=M+Zanetti&amp;author=C+Scuderi&amp;publication_year=2005&amp;title=Familial%20Breast%20Cancer%3A%20Characteristics%20and%20Outcome%20of%20BRCA%201-2%20Positive%20and%20Negative%20Cases&amp;journal=BMC+Cancer&amp;volume=5&amp;pages=70\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B72\" id=\"B72\">\u003C/a> 72. Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, et al. Clinical and Pathologic Characteristics of Patients With BRCA-Positive and BRCA-Negative Breast Cancer. \u003Ci>J Clin Oncol\u003C/i> (2008) 26(26):4282&#x2013;8. doi: 10.1200/JCO.2008.16.6231\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/18779615/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1200/JCO.2008.16.6231\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=DP+Atchley&amp;author=CT+Albarracin&amp;author=A+Lopez&amp;author=V+Valero&amp;author=CI+Amos&amp;author=AM+Gonzalez-Angulo&amp;publication_year=2008&amp;title=Clinical%20and%20Pathologic%20Characteristics%20of%20Patients%20With%20BRCA-Positive%20and%20BRCA-Negative%20Breast%20Cancer&amp;journal=J+Clin+Oncol&amp;volume=26&amp;pages=4282-8\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B73\" id=\"B73\">\u003C/a> 73. Jouhadi H, Tazzite A, Azeddoug H, Naim A, Nadifi S, Benider A. Clinical and Pathological Features of BRCA1/2 Tumors in a Sample of High-Risk Moroccan Breast Cancer Patients. \u003Ci>BMC Res Notes\u003C/i> (2016) 9:248. doi: 10.1186/s13104-016-2057-8\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/27129401/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/s13104-016-2057-8\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=H+Jouhadi&amp;author=A+Tazzite&amp;author=H+Azeddoug&amp;author=A+Naim&amp;author=S+Nadifi&amp;author=A+Benider&amp;publication_year=2016&amp;title=Clinical%20and%20Pathological%20Features%20of%20BRCA1%2F2%20Tumors%20in%20a%20Sample%20of%20High-Risk%20Moroccan%20Breast%20Cancer%20Patients&amp;journal=BMC+Res+Notes&amp;volume=9&amp;pages=248\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B74\" id=\"B74\">\u003C/a> 74. Atci MM, Geredeli C, Ay S, Sakin A, Erturk B, Secmeler S, et al. Clinical and Pathological Characteristics of Patients With High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study. \u003Ci>Eur J Breast Health\u003C/i> (2021) 17(2):123&#x2013;7. doi: 10.4274/ejbh.galenos.2020.6346\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/33870111/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.4274/ejbh.galenos.2020.6346\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MM+Atci&amp;author=C+Geredeli&amp;author=S+Ay&amp;author=A+Sakin&amp;author=B+Erturk&amp;author=S+Secmeler&amp;publication_year=2021&amp;title=Clinical%20and%20Pathological%20Characteristics%20of%20Patients%20With%20High-Risk%20Breast%20Cancer%20Based%20on%20BRCA%20Mutation%20Profiles%3A%20A%20Retrospective%20Study&amp;journal=Eur+J+Breast+Health&amp;volume=17&amp;pages=123-7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B75\" id=\"B75\">\u003C/a> 75. Lee E, McKean-Cowdin R, Ma H, Spicer DV, Van Den Berg D, Bernstein L, et al. Characteristics of Triple-Negative Breast Cancer in Patients With a BRCA1 Mutation: Results From a Population-Based Study of Young Women. \u003Ci>J Clin Oncol\u003C/i> (2011) 29(33):4373&#x2013;80. doi: 10.1200/JCO.2010.33.6446\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/22010008/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1200/JCO.2010.33.6446\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=E+Lee&amp;author=R+McKean-Cowdin&amp;author=H+Ma&amp;author=DV+Spicer&amp;author=D+Van%20Den%20Berg&amp;author=L+Bernstein&amp;publication_year=2011&amp;title=Characteristics%20of%20Triple-Negative%20Breast%20Cancer%20in%20Patients%20With%20a%20BRCA1%20Mutation%3A%20Results%20From%20a%20Population-Based%20Study%20of%20Young%20Women&amp;journal=J+Clin+Oncol&amp;volume=29&amp;pages=4373-80\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B76\" id=\"B76\">\u003C/a> 76. Muendlein A, Rohde BH, Gasser K, Haid A, Rauch S, Kinz E, et al. Evaluation of BRCA1/2 Mutational Status Among German and Austrian Women With Triple-Negative Breast Cancer. \u003Ci>J Cancer Res Clin Oncol\u003C/i> (2015) 141(11):2005&#x2013;12. doi: 10.1007/s00432-015-1986-2\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/25971625/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s00432-015-1986-2\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=A+Muendlein&amp;author=BH+Rohde&amp;author=K+Gasser&amp;author=A+Haid&amp;author=S+Rauch&amp;author=E+Kinz&amp;publication_year=2015&amp;title=Evaluation%20of%20BRCA1%2F2%20Mutational%20Status%20Among%20German%20and%20Austrian%20Women%20With%20Triple-Negative%20Breast%20Cancer&amp;journal=J+Cancer+Res+Clin+Oncol&amp;volume=141&amp;pages=2005-12\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B77\" id=\"B77\">\u003C/a> 77. Stefansson OA, Jonasson JG, Olafsdottir K, Bjarnason H, Th Johannsson O, Bodvarsdottir SK, et al. Genomic and Phenotypic Analysis of BRCA2 Mutated Breast Cancers Reveals Co-Occurring Changes Linked to Progression. \u003Ci>Breast Cancer Res\u003C/i> (2011) 13(5):R95. doi: 10.1186/bcr3020\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/21958427/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/bcr3020\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=OA+Stefansson&amp;author=JG+Jonasson&amp;author=K+Olafsdottir&amp;author=H+Bjarnason&amp;author=O+Th%20Johannsson&amp;author=SK+Bodvarsdottir&amp;publication_year=2011&amp;title=Genomic%20and%20Phenotypic%20Analysis%20of%20BRCA2%20Mutated%20Breast%20Cancers%20Reveals%20Co-Occurring%20Changes%20Linked%20to%20Progression&amp;journal=Breast+Cancer+Res&amp;volume=13&amp;pages=R95\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B78\" id=\"B78\">\u003C/a> 78. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, et al. Prediction of BRCA1 Status in Patients With Breast Cancer Using Estrogen Receptor and Basal Phenotype. \u003Ci>Clin Cancer Res\u003C/i> (2005) 11(14):5175&#x2013;80. doi: 10.1158/1078-0432.CCR-04-2424\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16033833/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1158/1078-0432.CCR-04-2424\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=SR+Lakhani&amp;author=JS+Reis-Filho&amp;author=L+Fulford&amp;author=F+Penault-Llorca&amp;author=M+van%20der%20Vijver&amp;author=S+Parry&amp;publication_year=2005&amp;title=Prediction%20of%20BRCA1%20Status%20in%20Patients%20With%20Breast%20Cancer%20Using%20Estrogen%20Receptor%20and%20Basal%20Phenotype&amp;journal=Clin+Cancer+Res&amp;volume=11&amp;pages=5175-80\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B79\" id=\"B79\">\u003C/a> 79. Keeney MG, Couch FJ, Visscher DW, Lindor NM. Non-BRCA Familial Breast Cancer: Review of Reported Pathology and Molecular Findings. \u003Ci>Pathology\u003C/i> (2017) 49(4):363&#x2013;70. doi: 10.1016/j.pathol.2017.03.002\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28450088/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.pathol.2017.03.002\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MG+Keeney&amp;author=FJ+Couch&amp;author=DW+Visscher&amp;author=NM+Lindor&amp;publication_year=2017&amp;title=Non-BRCA%20Familial%20Breast%20Cancer%3A%20Review%20of%20Reported%20Pathology%20and%20Molecular%20Findings&amp;journal=Pathology&amp;volume=49&amp;pages=363-70\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B80\" id=\"B80\">\u003C/a> 80. Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, et al. Frequencies of BRCA1 and BRCA2 Mutations Among 1,342 Unselected Patients With Invasive Ovarian Cancer. \u003Ci>Gynecol Oncol\u003C/i> (2011) 121(2):353&#x2013;7. doi: 10.1016/j.ygyno.2011.01.020\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/21324516/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/j.ygyno.2011.01.020\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+Zhang&amp;author=R+Royer&amp;author=S+Li&amp;author=JR+McLaughlin&amp;author=B+Rosen&amp;author=HA+Risch&amp;publication_year=2011&amp;title=Frequencies%20of%20BRCA1%20and%20BRCA2%20Mutations%20Among%201%2C342%20Unselected%20Patients%20With%20Invasive%20Ovarian%20Cancer&amp;journal=Gynecol+Oncol&amp;volume=121&amp;pages=353-7\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B81\" id=\"B81\">\u003C/a> 81. Lang GT, Shi JX, Hu X, Zhang CH, Shan L, Song CG, et al. The Spectrum of BRCA Mutations and Characteristics of BRCA-Associated Breast Cancers in China: Screening of 2,991 Patients and 1,043 Controls by Next-Generation Sequencing. \u003Ci>Int J Cancer\u003C/i> (2017) 141(1):129&#x2013;42. doi: 10.1002/ijc.30692\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28294317/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1002/ijc.30692\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=GT+Lang&amp;author=JX+Shi&amp;author=X+Hu&amp;author=CH+Zhang&amp;author=L+Shan&amp;author=CG+Song&amp;publication_year=2017&amp;title=The%20Spectrum%20of%20BRCA%20Mutations%20and%20Characteristics%20of%20BRCA-Associated%20Breast%20Cancers%20in%20China%3A%20Screening%20of%202%2C991%20Patients%20and%201%2C043%20Controls%20by%20Next-Generation%20Sequencing&amp;journal=Int+J+Cancer&amp;volume=141&amp;pages=129-42\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B82\" id=\"B82\">\u003C/a> 82. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K-A, Mooij TM, Roos-Blom M-J, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. \u003Ci>Jama\u003C/i> (2017) 317(23):2402&#x2013;16. doi: 10.1001/jama.2017.7112\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/28632866/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1001/jama.2017.7112\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=KB+Kuchenbaecker&amp;author=JL+Hopper&amp;author=DR+Barnes&amp;author=K-A+Phillips&amp;author=TM+Mooij&amp;author=M-J+Roos-Blom&amp;publication_year=2017&amp;title=Risks%20of%20Breast%2C%20Ovarian%2C%20and%20Contralateral%20Breast%20Cancer%20for%20BRCA1%20and%20BRCA2%20Mutation%20Carriers&amp;journal=Jama&amp;volume=317&amp;pages=2402-16\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B83\" id=\"B83\">\u003C/a> 83. Einbeigi Z, Bergman A, Meis-Kindblom JM, Flodin A, Bjursell C, Martinsson T, et al. Occurrence of Both Breast and Ovarian Cancer in a Woman Is a Marker for the BRCA Gene Mutations: A Population-Based Study From Western Sweden. \u003Ci>Familial Cancer\u003C/i> (2007) 6(1):35&#x2013;41. doi: 10.1007/s10689-006-9101-0\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/16944270/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1007/s10689-006-9101-0\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=Z+Einbeigi&amp;author=A+Bergman&amp;author=JM+Meis-Kindblom&amp;author=A+Flodin&amp;author=C+Bjursell&amp;author=T+Martinsson&amp;publication_year=2007&amp;title=Occurrence%20of%20Both%20Breast%20and%20Ovarian%20Cancer%20in%20a%20Woman%20Is%20a%20Marker%20for%20the%20BRCA%20Gene%20Mutations%3A%20A%20Population-Based%20Study%20From%20Western%20Sweden&amp;journal=Familial+Cancer&amp;volume=6&amp;pages=35\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B84\" id=\"B84\">\u003C/a> 84. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the Missing Heritability of Complex Diseases. \u003Ci>Nature\u003C/i> (2009) 461(7265):747&#x2013;53. doi: 10.1038/nature08494\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/19812666/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1038/nature08494\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=TA+Manolio&amp;author=FS+Collins&amp;author=NJ+Cox&amp;author=DB+Goldstein&amp;author=LA+Hindorff&amp;author=DJ+Hunter&amp;publication_year=2009&amp;title=Finding%20the%20Missing%20Heritability%20of%20Complex%20Diseases&amp;journal=Nature&amp;volume=461&amp;pages=747-53\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B85\" id=\"B85\">\u003C/a> 85. Lesage S, Belarbi S, Troiano A, Condroyer C, Hecham N, Pollak P, et al. Is the Common LRRK2 G2019S Mutation Related to Dyskinesias in North African Parkinson Disease? \u003Ci>Neurology\u003C/i> (2008) 71(19):1550&#x2013;2. doi: 10.1212/01.wnl.0000338460.89796.06\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/18981379/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1212/01.wnl.0000338460.89796.06\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=S+Lesage&amp;author=S+Belarbi&amp;author=A+Troiano&amp;author=C+Condroyer&amp;author=N+Hecham&amp;author=P+Pollak&amp;publication_year=2008&amp;title=Is%20the%20Common%20LRRK2%20G2019S%20Mutation%20Related%20to%20Dyskinesias%20in%20North%20African%20Parkinson%20Disease&amp;journal=Neurology&amp;volume=71&amp;pages=1550-2\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B86\" id=\"B86\">\u003C/a> 86. Hulihan MM, Ishihara-Paul L, Kachergus J, Warren L, Amouri R, Elango R, et al. LRRK2 Gly2019Ser Penetrance in Arab-Berber Patients From Tunisia: A Case-Control Genetic Study. \u003Ci>Lancet Neurol\u003C/i> (2008) 7(7):591&#x2013;4. doi: 10.1016/S1474-4422(08)70116-9\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/18539535/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1016/S1474-4422(08)70116-9\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=MM+Hulihan&amp;author=L+Ishihara-Paul&amp;author=J+Kachergus&amp;author=L+Warren&amp;author=R+Amouri&amp;author=R+Elango&amp;publication_year=2008&amp;title=LRRK2%20Gly2019Ser%20Penetrance%20in%20Arab-Berber%20Patients%20From%20Tunisia%3A%20A%20Case-Control%20Genetic%20Study&amp;journal=Lancet+Neurol&amp;volume=7&amp;pages=591-4\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003Cdiv class=\"References\" style=\"margin-bottom:0.5em; margin-left:2em;\">\u003Cp class=\"ReferencesCopy1\" style=\"margin-left:0.7em; text-indent:-1.1em;\">\u003Ca name=\"B87\" id=\"B87\">\u003C/a> 87. Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE, et al. An International Initiative to Identify Genetic Modifiers of Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). \u003Ci>Breast Cancer Res\u003C/i> (2007) 9(2):104. doi: 10.1186/bcr1670\u003C/p>\u003Cp class=\"ReferencesCopy2\" style=\"margin-left:1em;\">\u003Ca href=\"https://pubmed.ncbi.nlm.nih.gov/17466083/\" target=\"_blank\">PubMed Abstract\u003C/a> | \u003Ca href=\"https://doi.org/10.1186/bcr1670\" target=\"_blank\">CrossRef Full Text\u003C/a> | \u003Ca href=\"http://scholar.google.com/scholar_lookup?author=G+Chenevix-Trench&amp;author=RL+Milne&amp;author=AC+Antoniou&amp;author=FJ+Couch&amp;author=DF+Easton&amp;author=DE+Goldgar&amp;publication_year=2007&amp;title=An%20International%20Initiative%20to%20Identify%20Genetic%20Modifiers%20of%20Cancer%20Risk%20in%20BRCA1%20and%20BRCA2%20Mutation%20Carriers%3A%20The%20Consortium%20of%20Investigators%20of%20Modifiers%20of%20BRCA1%20and%20BRCA2%20%28CIMBA%29&amp;journal=Breast+Cancer+Res&amp;volume=9&amp;pages=104\" target=\"_blank\">Google Scholar\u003C/a>\u003C/p>\u003C/div>\u003C/div>\u003Cdiv class=\"thinLineM20\">\u003C/div>\u003Cdiv class=\"AbstractSummary\">\u003Cp>\u003Cspan>Keywords:\u003C/span> \u003Ci>BRCA\u003C/i> cancers, genetic testing, novel \u003Ci>BRCA\u003C/i> mutations, clinicopathological signatures, precision medicine\u003C/p>\u003Cp>\u003Cspan>Citation:\u003C/span> Hamdi Y, Mighri N, Boujemaa M, Mejri N, Ben Nasr S, Ben Rekaya M, Messaoud O, Bouaziz H, Berrazega Y, Rachdi H, Jaidane O, Daoud N, Zribi A, Ayari J, El Benna H, Labidi S, Ben Hassouna J, Haddaoui A, Rahal K, Benna F, Mrad R, Ben Ahmed S, Boussen H, Boubaker S and Abdelhak S (2021) Identification of Eleven Novel \u003Ci>BRCA\u003C/i> Mutations in Tunisia: Impact on the Clinical Management of \u003Ci>BRCA\u003C/i> Related Cancers. \u003Ci>Front. Oncol.\u003C/i> 11:674965. doi: 10.3389/fonc.2021.674965\u003C/p>\u003Cp id=\"timestamps\">\u003Cspan>Received:\u003C/span> 02 March 2021; \u003Cspan>Accepted:\u003C/span> 27 July 2021;\u003Cbr>\u003Cspan>Published:\u003C/span> 20 August 2021.\u003C/p>\u003Cdiv>\u003Cp>Edited by:\u003C/p>\u003Ca href=\"https://loop.frontiersin.org/people/896430\">Zodwa Dlamini\u003C/a>, University of Pretoria, South Africa\u003C/div>\u003Cdiv>\u003Cp>Reviewed by:\u003C/p>\u003Ca href=\"https://loop.frontiersin.org/people/739327\">Yan Du\u003C/a>, Fudan University, China\u003Cbr>\u003Ca href=\"https://loop.frontiersin.org/people/125219\">Umamaheswaran Gurusamy\u003C/a>, University of California, San Francisco, United States\u003C/div>\u003Cp>\u003Cspan>Copyright\u003C/span> &#xa9; 2021 Hamdi, Mighri, Boujemaa, Mejri, Ben Nasr, Ben Rekaya, Messaoud, Bouaziz, Berrazega, Rachdi, Jaidane, Daoud, Zribi, Ayari, El Benna, Labidi, Ben Hassouna, Haddaoui, Rahal, Benna, Mrad, Ben Ahmed, Boussen, Boubaker and Abdelhak. This is an open-access article distributed under the terms of the \u003Ca rel=\"license\" href=\"http://creativecommons.org/licenses/by/4.0/\" target=\"_blank\">Creative Commons Attribution License (CC BY)\u003C/a>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.\u003C/p>\u003Cp>\u003Cspan>*Correspondence:\u003C/span> Yosr Hamdi, \u003Ca id=\"encmail\">eW9zci5oYW1kaUBwYXN0ZXVyLnRu\u003C/a>\u003C/p>\u003Cp>\u003Cspan>\u003Csup>&#x2020;\u003C/sup>\u003C/span>These authors have contributed equally to this work\u003C/p>\u003Cdiv class=\"clear\">\u003C/div>\u003C/div>","\u003Cul class=\"flyoutJournal\">\u003Cli>\u003Ca href=\"#h1\">Abstract\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h2\">Introduction\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h3\">Materials And Methods\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h4\">Results\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h5\">Discussion\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h6\">Conclusion\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h7\">Data Availability Statement\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h8\">Ethics Statement\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h9\">Author Contributions\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h10\">Funding\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h11\">Conflict of Interest\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h12\">Publisher&#x2019;s Note\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h13\">Acknowledgments\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h14\">Supplementary Material\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h15\">Abbreviations\u003C/a>\u003C/li>\u003Cli>\u003Ca href=\"#h16\">References\u003C/a>\u003C/li>\u003C/ul>",[790,795,800,803,808],{"name":791,"fileServerPackageEntryId":19,"fileServerId":792,"fileServerVersionNumber":391,"type":793},"EPUB.epub","674965/epub",{"code":794,"name":794},"EPUB",{"name":796,"fileServerPackageEntryId":796,"fileServerId":797,"fileServerVersionNumber":391,"type":798},"fonc-11-674965.pdf","674965/pubmed-zip",{"code":799,"name":799},"PDF",{"name":796,"fileServerPackageEntryId":19,"fileServerId":801,"fileServerVersionNumber":391,"type":802},"674965/publishers-proof/pdf",{"code":799,"name":799},{"name":804,"fileServerPackageEntryId":804,"fileServerId":797,"fileServerVersionNumber":391,"type":805},"fonc-11-674965.xml",{"code":806,"name":807},"NLM_XML","XML",{"name":809,"fileServerPackageEntryId":19,"fileServerId":810,"fileServerVersionNumber":391,"type":811},"Provisional PDF.pdf","674965/provisional-pdf",{"code":799,"name":799},"v3",{"title":814,"link":815,"meta":819,"script":1028},"Frontiers | Identification of Eleven Novel BRCA Mutations in Tunisia: Impact on the Clinical Management of BRCA Related Cancers",[816],{"rel":817,"href":818},"canonical","https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/full",[820,823,826,828,831,835,838,842,845,848,851,853,855,857,859,861,864,867,869,872,874,876,879,882,885,888,891,895,899,902,904,907,909,912,914,917,919,922,924,927,929,932,934,937,940,943,945,948,951,954,956,959,962,965,967,970,972,975,977,980,982,985,987,990,992,995,998,1001,1004,1007,1010,1013,1015,1018,1020,1023,1025],{"hid":821,"property":821,"name":821,"content":822},"description","Background Breast cancer is the world's most common cancer among women. It is becoming an increasingly urgent problem in low- and middle-income countries (LM...",{"hid":824,"property":824,"name":825,"content":814},"og:title","title",{"hid":827,"property":827,"name":821,"content":822},"og:description",{"hid":829,"name":829,"content":830},"keywords","BRCA cancers,Genetic Testing,novel BRCA mutations,Clinicopathological signatures,precision medicine",{"hid":832,"property":832,"name":833,"content":834},"og:site_name","site_name","Frontiers",{"hid":836,"property":836,"name":384,"content":837},"og:image","https://images-provider.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/674965/fonc-11-674965-HTML/image_m/fonc-11-674965-g001.jpg",{"hid":839,"property":839,"name":840,"content":841},"og:type","type","article",{"hid":843,"property":843,"name":844,"content":818},"og:url","url",{"hid":846,"name":846,"content":847},"twitter:card","summary_large_image",{"hid":849,"name":849,"content":850},"citation_volume","11",{"hid":852,"name":852,"content":116},"citation_journal_title",{"hid":854,"name":854,"content":834},"citation_publisher",{"hid":856,"name":856,"content":771},"citation_journal_abbrev",{"hid":858,"name":858,"content":772},"citation_issn",{"hid":860,"name":860,"content":536},"citation_doi",{"hid":862,"name":862,"content":863},"citation_firstpage","674965",{"hid":865,"name":865,"content":866},"citation_language","English",{"hid":868,"name":868,"content":537},"citation_title",{"hid":870,"name":870,"content":871},"citation_keywords","BRCA cancers; Genetic Testing; novel BRCA mutations; Clinicopathological signatures; precision medicine",{"hid":873,"name":873,"content":542},"citation_abstract",{"hid":875,"name":875,"content":551},"citation_article_type",{"hid":877,"name":877,"content":878},"citation_pdf_url","https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/pdf",{"hid":880,"name":880,"content":881},"citation_xml_url","https://public-pages-files-2025.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.674965/xml",{"hid":883,"name":883,"content":884},"citation_fulltext_world_readable","yes",{"hid":886,"name":886,"content":887},"citation_online_date","2021/07/27",{"hid":889,"name":889,"content":890},"citation_publication_date","2021/08/20",{"hid":892,"name":893,"content":894},"citation_author_0","citation_author","Hamdi, Yosr ",{"hid":896,"name":897,"content":898},"citation_author_institution_0","citation_author_institution","Laboratory of Biomedical Genomics and Oncogenetics, LR20IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunisia",{"hid":900,"name":893,"content":901},"citation_author_1","Mighri, Najah ",{"hid":903,"name":897,"content":898},"citation_author_institution_1",{"hid":905,"name":893,"content":906},"citation_author_2","Boujemaa, Maroua ",{"hid":908,"name":897,"content":898},"citation_author_institution_2",{"hid":910,"name":893,"content":911},"citation_author_3","Mejri, Nesrine ",{"hid":913,"name":897,"content":898},"citation_author_institution_3",{"hid":915,"name":893,"content":916},"citation_author_4","Ben Nasr, Sonia ",{"hid":918,"name":897,"content":898},"citation_author_institution_4",{"hid":920,"name":893,"content":921},"citation_author_5","Ben Rekaya, Mariem ",{"hid":923,"name":897,"content":898},"citation_author_institution_5",{"hid":925,"name":893,"content":926},"citation_author_6","Messaoud, Olfa ",{"hid":928,"name":897,"content":898},"citation_author_institution_6",{"hid":930,"name":893,"content":931},"citation_author_7","Bouaziz, Hanen ",{"hid":933,"name":897,"content":898},"citation_author_institution_7",{"hid":935,"name":893,"content":936},"citation_author_8","Berrazega, Yosra ",{"hid":938,"name":897,"content":939},"citation_author_institution_8","Medical Oncology Department, Abderrahman Mami Hospital, Faculty of Medicine Tunis, University Tunis El Manar, Tunisia",{"hid":941,"name":893,"content":942},"citation_author_9","Rachdi, Haifa ",{"hid":944,"name":897,"content":939},"citation_author_institution_9",{"hid":946,"name":893,"content":947},"citation_author_10","Jaidane, Olfa ",{"hid":949,"name":897,"content":950},"citation_author_institution_10","Surgical Oncology Department, Salah Azaiez Institute of Cancer, Tunisia",{"hid":952,"name":893,"content":953},"citation_author_11","Daoud, Nouha ",{"hid":955,"name":897,"content":939},"citation_author_institution_11",{"hid":957,"name":893,"content":958},"citation_author_12","Zribi, Aref ",{"hid":960,"name":897,"content":961},"citation_author_institution_12","Department of Medical Oncology, Military Hospital of Tunis, Tunisia",{"hid":963,"name":893,"content":964},"citation_author_13","Ayari, Jihene ",{"hid":966,"name":897,"content":961},"citation_author_institution_13",{"hid":968,"name":893,"content":969},"citation_author_14","El Benna, Houda ",{"hid":971,"name":897,"content":898},"citation_author_institution_14",{"hid":973,"name":893,"content":974},"citation_author_15","Labidi, Soumaya ",{"hid":976,"name":897,"content":898},"citation_author_institution_15",{"hid":978,"name":893,"content":979},"citation_author_16","Ben Hassouna, Jamel ",{"hid":981,"name":897,"content":950},"citation_author_institution_16",{"hid":983,"name":893,"content":984},"citation_author_17","Haddaoui, Abderazzek ",{"hid":986,"name":897,"content":961},"citation_author_institution_17",{"hid":988,"name":893,"content":989},"citation_author_18","Rahal, Khaled ",{"hid":991,"name":897,"content":950},"citation_author_institution_18",{"hid":993,"name":893,"content":994},"citation_author_19","Benna, Farouk ",{"hid":996,"name":897,"content":997},"citation_author_institution_19","Department of Radiation Oncology, University of Tunis, Tunisia",{"hid":999,"name":893,"content":1000},"citation_author_20","Mrad, Ridha ",{"hid":1002,"name":897,"content":1003},"citation_author_institution_20","Department of Human Genetics, Charles Nicolle Hospital, Tunisia",{"hid":1005,"name":893,"content":1006},"citation_author_21","Ben Ahmed, Slim ",{"hid":1008,"name":897,"content":1009},"citation_author_institution_21","Faculty of Medicine of Sousse Department of Medical Oncology Farhat Hached University Hospital University of Sousse, Tunisia",{"hid":1011,"name":893,"content":1012},"citation_author_22","Boussen, Hamouda ",{"hid":1014,"name":897,"content":898},"citation_author_institution_22",{"hid":1016,"name":893,"content":1017},"citation_author_23","Boubaker, Samir ",{"hid":1019,"name":897,"content":898},"citation_author_institution_23",{"hid":1021,"name":893,"content":1022},"citation_author_24","Abdelhak, Sonia ",{"hid":1024,"name":897,"content":898},"citation_author_institution_24",{"hid":1026,"name":1026,"content":1027},"dc.identifier","doi:10.3389/fonc.2021.674965",[1029,1032,1034,1036,1038],{"src":1030,"body":13,"type":1031,"async":13},"https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6","text/javascript",{"src":1033,"body":13,"type":1031,"async":13},"https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML",{"src":1035,"body":13,"type":1031,"async":13},"https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js",{"src":1037,"body":13,"type":1031,"async":13},"https://api.altmetric.com/v1/doi/10.3389/fonc.2021.674965?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15",{"src":1039,"body":13,"type":1031,"async":13},"https://crossmark-cdn.crossref.org/widget/v2.0/widget.js",{"articleHubSlug":19,"articleHubPage":1041,"articleHubArticlesList":1042,"canJournalHasArticleHub":367,"articleDoiList":1043},{},[],[],{"title":19,"image":-1,"breadcrumbs":1045,"linksCollection":1046,"metricsCollection":1048},[],{"total":388,"items":1047},[],{"total":388,"items":1049},[]]</script>
<script>window.__NUXT__={};window.__NUXT__.config={public:{isDevMode:false,appName:"article-pages-2024",baseUrl:"https://www.frontiersin.org",domain:"frontiersin.org",loopUrl:"https://loop.frontiersin.org",ssMainDomain:"frontiersin.org",contentfulUrl:"https://graphql.contentful.com/content/v1/spaces",spaceId:1,spaceName:"Frontiers",liveSpaceId:1,tenantLogoUrl:"",frontiersGraphUrl:"https://apollo-federation-gateway.frontiersin.org",registrationApiUrl:"https://onboarding-ui.frontiersin.org",emailDigestApiUrl:"https://api-email-digest.frontiersin.org",journalFilesApiUrl:"https://files-journal-api.frontiersin.org",publicPagesFilesUrl:"https://public-pages-files-2025.frontiersin.org",searchApiUrl:"https://search-api.frontiersin.org",productionForumApiUrl:"https://production-forum-api-v2.frontiersin.org",gtmServerUrl:"https://tag-manager.frontiersin.org",gtmId:"GTM-M322FV2",gtmAuth:"owVbWxfaJr21yQv1fe1cAQ",gtmPreview:"env-1",figsharePluginUrl:"https://widgets.figshare.com/static/figshare.js",figshareApiUrl:"https://api.figshare.com/v2/collections/search",figshareTimeout:3000,crossmarkPublishedDate:"2015/08/24",googleRecaptchaSiteKey:"6LdG3i0UAAAAAOC4qUh35ubHgJotEHp_STXHgr_v",googleRecaptchaKeyName:"FrontiersRecaptchaV2",faviconSize16:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_16-tenantFavicon-Frontiers.png",faviconSize32:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_32-tenantFavicon-Frontiers.png",faviconSize180:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_180-tenantFavicon-Frontiers.png",faviconSize192:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_192-tenantFavicon-Frontiers.png",faviconSize512:"https://static2.frontiersin.org/static-resources/tenants/frontiers/favicon_512-tenantFavicon-Frontiers.png",socialMediaImg:"https://brand.frontiersin.org/m/1c8bcb536c789e11/Guidelines-Frontiers_Logo_1200x628_1-91to1.png",linkedArticleCopyText:"'{\"articleTypeCopyText\":[{\"articleTypeId\":0,\"originalArticleCopyText\":\"Part of this article's content has been mentioned in:\",\"linkedArticleCopyText\":\"This article mentions parts of:\"},{\"articleTypeId\":122,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an erratum on:\"},{\"articleTypeId\":129,\"originalArticleCopyText\":\"Parts of this article's content have been modified or rectified in:\",\"linkedArticleCopyText\":\"This article is an addendum to:\"},{\"articleTypeId\":128,\"originalArticleCopyText\":\"A correction has been applied to this article in:\",\"linkedArticleCopyText\":\"This article is a correction to:\"},{\"articleTypeId\":134,\"originalArticleCopyText\":\"A retraction of this article was approved in:\",\"linkedArticleCopyText\":\"This article is a retraction of:\"},{\"articleTypeId\":29,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"},{\"articleTypeId\":30,\"originalArticleCopyText\":\"A commentary has been posted on this article:\",\"linkedArticleCopyText\":\"This article is a commentary on:\"}],\"articleIdCopyText\":[]}'\n",acceptedArticleExcludedJournalIds:"'[2766,979]'\n",articleTypeConfigurableLabel:"\u003C\u003Carticle-type:uppercase>> article",settingsFeaturesSwitchers:"'{\"displayTitlePillLabels\":true,\"displayRelatedArticlesBox\":true,\"showEditors\":true,\"showReviewers\":true,\"showLoopImpactLink\":true,\"enableFigshare\":false}'\n",journalsWithArticleHub:"'{\"strings\":[\"science\"]}'\n",terminologySettings:"'{\"terms\":[{\"sequenceNumber\":1,\"key\":\"frontiers\",\"tenantTerm\":\"Frontiers\",\"frontiersDefaultTerm\":\"Frontiers\",\"category\":\"Customer\"},{\"sequenceNumber\":2,\"key\":\"submission_system\",\"tenantTerm\":\"submission system\",\"frontiersDefaultTerm\":\"submission system\",\"category\":\"Product\"},{\"sequenceNumber\":3,\"key\":\"public_pages\",\"tenantTerm\":\"public pages\",\"frontiersDefaultTerm\":\"public pages\",\"category\":\"Product\"},{\"sequenceNumber\":4,\"key\":\"my_frontiers\",\"tenantTerm\":\"my frontiers\",\"frontiersDefaultTerm\":\"my frontiers\",\"category\":\"Product\"},{\"sequenceNumber\":5,\"key\":\"digital_editorial_office\",\"tenantTerm\":\"digital editorial office\",\"frontiersDefaultTerm\":\"digital editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":6,\"key\":\"deo\",\"tenantTerm\":\"DEO\",\"frontiersDefaultTerm\":\"DEO\",\"category\":\"Product\"},{\"sequenceNumber\":7,\"key\":\"digital_editorial_office_for_chiefs\",\"tenantTerm\":\"digital editorial office for chiefs\",\"frontiersDefaultTerm\":\"digital editorial office for chiefs\",\"category\":\"Product\"},{\"sequenceNumber\":8,\"key\":\"digital_editorial_office_for_eof\",\"tenantTerm\":\"digital editorial office for eof\",\"frontiersDefaultTerm\":\"digital editorial office for eof\",\"category\":\"Product\"},{\"sequenceNumber\":9,\"key\":\"editorial_office\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"Product\"},{\"sequenceNumber\":10,\"key\":\"eof\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"Product\"},{\"sequenceNumber\":11,\"key\":\"research_topic_management\",\"tenantTerm\":\"research topic management\",\"frontiersDefaultTerm\":\"research topic management\",\"category\":\"Product\"},{\"sequenceNumber\":12,\"key\":\"review_forum\",\"tenantTerm\":\"review forum\",\"frontiersDefaultTerm\":\"review forum\",\"category\":\"Product\"},{\"sequenceNumber\":13,\"key\":\"accounting_office\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"Product\"},{\"sequenceNumber\":14,\"key\":\"aof\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"Product\"},{\"sequenceNumber\":15,\"key\":\"publishing_office\",\"tenantTerm\":\"publishing office\",\"frontiersDefaultTerm\":\"publishing office\",\"category\":\"Product\"},{\"sequenceNumber\":16,\"key\":\"production_office\",\"tenantTerm\":\"production office forum\",\"frontiersDefaultTerm\":\"production office forum\",\"category\":\"Product\"},{\"sequenceNumber\":17,\"key\":\"pof\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"Product\"},{\"sequenceNumber\":18,\"key\":\"book_office_forum\",\"tenantTerm\":\"book office forum\",\"frontiersDefaultTerm\":\"book office forum\",\"category\":\"Product\"},{\"sequenceNumber\":19,\"key\":\"bof\",\"tenantTerm\":\"BOF\",\"frontiersDefaultTerm\":\"BOF\",\"category\":\"Product\"},{\"sequenceNumber\":20,\"key\":\"aira\",\"tenantTerm\":\"AIRA\",\"frontiersDefaultTerm\":\"AIRA\",\"category\":\"Product\"},{\"sequenceNumber\":21,\"key\":\"editorial_board_management\",\"tenantTerm\":\"editorial board management\",\"frontiersDefaultTerm\":\"editorial board management\",\"category\":\"Product\"},{\"sequenceNumber\":22,\"key\":\"ebm\",\"tenantTerm\":\"EBM\",\"frontiersDefaultTerm\":\"EBM\",\"category\":\"Product\"},{\"sequenceNumber\":23,\"key\":\"domain\",\"tenantTerm\":\"domain\",\"frontiersDefaultTerm\":\"domain\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":24,\"key\":\"journal\",\"tenantTerm\":\"journal\",\"frontiersDefaultTerm\":\"journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":25,\"key\":\"section\",\"tenantTerm\":\"section\",\"frontiersDefaultTerm\":\"section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":26,\"key\":\"domains\",\"tenantTerm\":\"domains\",\"frontiersDefaultTerm\":\"domains\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":27,\"key\":\"specialty_section\",\"tenantTerm\":\"specialty section\",\"frontiersDefaultTerm\":\"specialty section\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":28,\"key\":\"specialty_journal\",\"tenantTerm\":\"specialty journal\",\"frontiersDefaultTerm\":\"specialty journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":29,\"key\":\"journals\",\"tenantTerm\":\"journals\",\"frontiersDefaultTerm\":\"journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":30,\"key\":\"sections\",\"tenantTerm\":\"sections\",\"frontiersDefaultTerm\":\"sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":31,\"key\":\"specialty_sections\",\"tenantTerm\":\"specialty sections\",\"frontiersDefaultTerm\":\"specialty sections\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":32,\"key\":\"specialty_journals\",\"tenantTerm\":\"specialty journals\",\"frontiersDefaultTerm\":\"specialty journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":33,\"key\":\"manuscript\",\"tenantTerm\":\"manuscript\",\"frontiersDefaultTerm\":\"manuscript\",\"category\":\"Core\"},{\"sequenceNumber\":34,\"key\":\"manuscripts\",\"tenantTerm\":\"manuscripts\",\"frontiersDefaultTerm\":\"manuscripts\",\"category\":\"Core\"},{\"sequenceNumber\":35,\"key\":\"article\",\"tenantTerm\":\"article\",\"frontiersDefaultTerm\":\"article\",\"category\":\"Core\"},{\"sequenceNumber\":36,\"key\":\"articles\",\"tenantTerm\":\"articles\",\"frontiersDefaultTerm\":\"articles\",\"category\":\"Core\"},{\"sequenceNumber\":37,\"key\":\"article_type\",\"tenantTerm\":\"article type\",\"frontiersDefaultTerm\":\"article type\",\"category\":\"Core\"},{\"sequenceNumber\":38,\"key\":\"article_types\",\"tenantTerm\":\"article types\",\"frontiersDefaultTerm\":\"article types\",\"category\":\"Core\"},{\"sequenceNumber\":39,\"key\":\"author\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":40,\"key\":\"authors\",\"tenantTerm\":\"authors\",\"frontiersDefaultTerm\":\"authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":41,\"key\":\"authoring\",\"tenantTerm\":\"authoring\",\"frontiersDefaultTerm\":\"authoring\",\"category\":\"Core\"},{\"sequenceNumber\":42,\"key\":\"authored\",\"tenantTerm\":\"authored\",\"frontiersDefaultTerm\":\"authored\",\"category\":\"Core\"},{\"sequenceNumber\":43,\"key\":\"accept\",\"tenantTerm\":\"accept\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":44,\"key\":\"accepted\",\"tenantTerm\":\"accepted\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":45,\"key\":\"assistant_field_chief_editor\",\"tenantTerm\":\"Assistant Field Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editor\",\"description\":\"An editorial role on a Field Journal that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":46,\"key\":\"assistant_specialty_chief_editor\",\"tenantTerm\":\"Assistant Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":47,\"key\":\"assistant_specialty_chief_editors\",\"tenantTerm\":\"Assistant Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":48,\"key\":\"associate_editor\",\"tenantTerm\":\"Associate Editor\",\"frontiersDefaultTerm\":\"Associate Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":49,\"key\":\"specialty_chief_editor\",\"tenantTerm\":\"Specialty Chief Editor\",\"frontiersDefaultTerm\":\"Specialty Chief Editor\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":50,\"key\":\"specialty_chief_editors\",\"tenantTerm\":\"Specialty Chief Editors\",\"frontiersDefaultTerm\":\"Specialty Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":51,\"key\":\"chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":52,\"key\":\"chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":53,\"key\":\"call_for_participation\",\"tenantTerm\":\"call for participation\",\"frontiersDefaultTerm\":\"call for participation\",\"category\":\"Process\"},{\"sequenceNumber\":54,\"key\":\"citation\",\"tenantTerm\":\"citation\",\"frontiersDefaultTerm\":\"citation\",\"category\":\"Misc.\"},{\"sequenceNumber\":55,\"key\":\"citations\",\"tenantTerm\":\"citations\",\"frontiersDefaultTerm\":\"citations\",\"category\":\"Misc.\"},{\"sequenceNumber\":56,\"key\":\"contributor\",\"tenantTerm\":\"contributor\",\"frontiersDefaultTerm\":\"contributor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":57,\"key\":\"contributors\",\"tenantTerm\":\"contributors\",\"frontiersDefaultTerm\":\"contributors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":58,\"key\":\"corresponding_author\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":59,\"key\":\"corresponding_authors\",\"tenantTerm\":\"corresponding authors\",\"frontiersDefaultTerm\":\"corresponding authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":60,\"key\":\"decline\",\"tenantTerm\":\"decline\",\"frontiersDefaultTerm\":\"decline\",\"category\":\"Process\"},{\"sequenceNumber\":61,\"key\":\"declined\",\"tenantTerm\":\"declined\",\"frontiersDefaultTerm\":\"declined\",\"category\":\"Process\"},{\"sequenceNumber\":62,\"key\":\"reject\",\"tenantTerm\":\"reject\",\"frontiersDefaultTerm\":\"reject\",\"category\":\"Process\"},{\"sequenceNumber\":63,\"key\":\"rejected\",\"tenantTerm\":\"rejected\",\"frontiersDefaultTerm\":\"rejected\",\"category\":\"Process\"},{\"sequenceNumber\":64,\"key\":\"publish\",\"tenantTerm\":\"publish\",\"frontiersDefaultTerm\":\"publish\",\"category\":\"Core\"},{\"sequenceNumber\":65,\"key\":\"published\",\"tenantTerm\":\"published\",\"frontiersDefaultTerm\":\"published\",\"category\":\"Core\"},{\"sequenceNumber\":66,\"key\":\"publication\",\"tenantTerm\":\"publication\",\"frontiersDefaultTerm\":\"publication\",\"category\":\"Core\"},{\"sequenceNumber\":67,\"key\":\"peer_review\",\"tenantTerm\":\"peer review\",\"frontiersDefaultTerm\":\"peer review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":68,\"key\":\"peer_reviewed\",\"tenantTerm\":\"peer reviewed\",\"frontiersDefaultTerm\":\"peer reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":69,\"key\":\"initial_validation\",\"tenantTerm\":\"initial validation\",\"frontiersDefaultTerm\":\"initial validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":70,\"key\":\"editorial_assignment\",\"tenantTerm\":\"editorial assignment\",\"frontiersDefaultTerm\":\"editorial assignment\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":71,\"key\":\"independent_review\",\"tenantTerm\":\"independent review\",\"frontiersDefaultTerm\":\"independent review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":72,\"key\":\"interactive_review\",\"tenantTerm\":\"interactive review\",\"frontiersDefaultTerm\":\"interactive review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":73,\"key\":\"review\",\"tenantTerm\":\"review\",\"frontiersDefaultTerm\":\"review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":74,\"key\":\"reviewing\",\"tenantTerm\":\"reviewing\",\"frontiersDefaultTerm\":\"reviewing\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":75,\"key\":\"reviewer\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":76,\"key\":\"reviewers\",\"tenantTerm\":\"reviewers\",\"frontiersDefaultTerm\":\"reviewers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":77,\"key\":\"review_finalized\",\"tenantTerm\":\"review finalized\",\"frontiersDefaultTerm\":\"review finalized\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":78,\"key\":\"final_decision\",\"tenantTerm\":\"final decision\",\"frontiersDefaultTerm\":\"final decision\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":79,\"key\":\"final_validation\",\"tenantTerm\":\"final validation\",\"frontiersDefaultTerm\":\"final validation\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":80,\"key\":\"ae_accept_manuscript\",\"tenantTerm\":\"recommend to accept manuscript\",\"frontiersDefaultTerm\":\"accept manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":81,\"key\":\"fee\",\"tenantTerm\":\"fee\",\"frontiersDefaultTerm\":\"fee\",\"category\":\"Accounting\"},{\"sequenceNumber\":82,\"key\":\"fees\",\"tenantTerm\":\"fees\",\"frontiersDefaultTerm\":\"fees\",\"category\":\"Accounting\"},{\"sequenceNumber\":83,\"key\":\"guest_associate_editor\",\"tenantTerm\":\"Guest Associate Editor\",\"frontiersDefaultTerm\":\"Guest Associate Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":84,\"key\":\"guest_associate_editors\",\"tenantTerm\":\"Guest Associate Editors\",\"frontiersDefaultTerm\":\"Guest Associate Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":85,\"key\":\"in_review\",\"tenantTerm\":\"in review\",\"frontiersDefaultTerm\":\"in review\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":86,\"key\":\"institutional_member\",\"tenantTerm\":\"institutional partner\",\"frontiersDefaultTerm\":\"institutional partner\",\"category\":\"Accounting\"},{\"sequenceNumber\":87,\"key\":\"institutional_membership\",\"tenantTerm\":\"institutional partnership\",\"frontiersDefaultTerm\":\"institutional partnership\",\"category\":\"Accounting\"},{\"sequenceNumber\":88,\"key\":\"article_processing_charge\",\"tenantTerm\":\"article processing charge\",\"frontiersDefaultTerm\":\"article processing charge\",\"category\":\"Accounting\"},{\"sequenceNumber\":89,\"key\":\"article_processing_charges\",\"tenantTerm\":\"article processing charges\",\"frontiersDefaultTerm\":\"article processing charges\",\"category\":\"Accounting\"},{\"sequenceNumber\":90,\"key\":\"apcs\",\"tenantTerm\":\"APCs\",\"frontiersDefaultTerm\":\"APCs\",\"category\":\"Accounting\"},{\"sequenceNumber\":91,\"key\":\"apc\",\"tenantTerm\":\"APC\",\"frontiersDefaultTerm\":\"APC\",\"category\":\"Accounting\"},{\"sequenceNumber\":92,\"key\":\"received\",\"tenantTerm\":\"received\",\"frontiersDefaultTerm\":\"received\",\"description\":\"Date manuscript was received on.\",\"category\":\"Core\"},{\"sequenceNumber\":93,\"key\":\"transferred\",\"tenantTerm\":\"transferred\",\"frontiersDefaultTerm\":\"transferred\",\"category\":\"Core\"},{\"sequenceNumber\":94,\"key\":\"transfer\",\"tenantTerm\":\"transfer\",\"frontiersDefaultTerm\":\"transfer\",\"category\":\"Core\"},{\"sequenceNumber\":95,\"key\":\"research_topic\",\"tenantTerm\":\"research topic\",\"frontiersDefaultTerm\":\"research topic\",\"category\":\"Core\"},{\"sequenceNumber\":96,\"key\":\"research_topics\",\"tenantTerm\":\"research topics\",\"frontiersDefaultTerm\":\"research topics\",\"category\":\"Core\"},{\"sequenceNumber\":97,\"key\":\"topic_editor\",\"tenantTerm\":\"Topic Editor\",\"frontiersDefaultTerm\":\"Topic Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":98,\"key\":\"review_editor\",\"tenantTerm\":\"Community Reviewer\",\"frontiersDefaultTerm\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":99,\"key\":\"title\",\"tenantTerm\":\"title\",\"frontiersDefaultTerm\":\"title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":100,\"key\":\"running_title\",\"tenantTerm\":\"running title\",\"frontiersDefaultTerm\":\"running title\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":101,\"key\":\"submit\",\"tenantTerm\":\"submit\",\"frontiersDefaultTerm\":\"submit\",\"category\":\"Process\"},{\"sequenceNumber\":102,\"key\":\"submitted\",\"tenantTerm\":\"submitted\",\"frontiersDefaultTerm\":\"submitted\",\"category\":\"Process\"},{\"sequenceNumber\":103,\"key\":\"submitting\",\"tenantTerm\":\"submitting\",\"frontiersDefaultTerm\":\"submitting\",\"category\":\"Process\"},{\"sequenceNumber\":104,\"key\":\"t_e\",\"tenantTerm\":\"TE\",\"frontiersDefaultTerm\":\"TE\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":105,\"key\":\"topic\",\"tenantTerm\":\"topic\",\"frontiersDefaultTerm\":\"topic\",\"category\":\"Process\"},{\"sequenceNumber\":106,\"key\":\"topic_summary\",\"tenantTerm\":\"topic summary\",\"frontiersDefaultTerm\":\"topic summary\",\"category\":\"Process\"},{\"sequenceNumber\":107,\"key\":\"figure\",\"tenantTerm\":\"figure\",\"frontiersDefaultTerm\":\"figure\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":108,\"key\":\"figures\",\"tenantTerm\":\"figures\",\"frontiersDefaultTerm\":\"figures\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":109,\"key\":\"editorial_file\",\"tenantTerm\":\"editorial file\",\"frontiersDefaultTerm\":\"editorial file\",\"category\":\"Core\"},{\"sequenceNumber\":110,\"key\":\"editorial_files\",\"tenantTerm\":\"editorial files\",\"frontiersDefaultTerm\":\"editorial files\",\"category\":\"Core\"},{\"sequenceNumber\":111,\"key\":\"e_book\",\"tenantTerm\":\"e-book\",\"frontiersDefaultTerm\":\"e-book\",\"category\":\"Core\"},{\"sequenceNumber\":112,\"key\":\"organization\",\"tenantTerm\":\"organization\",\"frontiersDefaultTerm\":\"organization\",\"category\":\"Core\"},{\"sequenceNumber\":113,\"key\":\"institution\",\"tenantTerm\":\"institution\",\"frontiersDefaultTerm\":\"institution\",\"category\":\"Core\"},{\"sequenceNumber\":114,\"key\":\"reference\",\"tenantTerm\":\"reference\",\"frontiersDefaultTerm\":\"reference\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":115,\"key\":\"references\",\"tenantTerm\":\"references\",\"frontiersDefaultTerm\":\"references\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":116,\"key\":\"sce\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"description\":\"Abbreviation for Specialty Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":117,\"key\":\"submission\",\"tenantTerm\":\"submission\",\"frontiersDefaultTerm\":\"submission\",\"category\":\"Process\"},{\"sequenceNumber\":118,\"key\":\"submissions\",\"tenantTerm\":\"submissions\",\"frontiersDefaultTerm\":\"submissions\",\"category\":\"Process\"},{\"sequenceNumber\":119,\"key\":\"editing\",\"tenantTerm\":\"editing\",\"frontiersDefaultTerm\":\"editing\",\"category\":\"Process\"},{\"sequenceNumber\":120,\"key\":\"in_preparation\",\"tenantTerm\":\"in preparation\",\"frontiersDefaultTerm\":\"in preparation\",\"category\":\"Process\"},{\"sequenceNumber\":121,\"key\":\"country_region\",\"tenantTerm\":\"country/region\",\"frontiersDefaultTerm\":\"country/region\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":122,\"key\":\"countries_regions\",\"tenantTerm\":\"countries/regions\",\"frontiersDefaultTerm\":\"countries/regions\",\"description\":\"Because of political issues, some of the country listings are actually classified as `regions` and we need to include this. However other clients may not want to do this.\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":123,\"key\":\"specialty\",\"tenantTerm\":\"specialty\",\"frontiersDefaultTerm\":\"specialty\",\"category\":\"Core\"},{\"sequenceNumber\":124,\"key\":\"specialties\",\"tenantTerm\":\"specialties\",\"frontiersDefaultTerm\":\"specialties\",\"category\":\"Core\"},{\"sequenceNumber\":125,\"key\":\"associate_editors\",\"tenantTerm\":\"Associate Editors\",\"frontiersDefaultTerm\":\"Associate Editors\",\"description\":\"An editorial role on a specialty that a Registered User may hold. This gives them rights to different functionality and parts of the platform\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":126,\"key\":\"reviewed\",\"tenantTerm\":\"reviewed\",\"frontiersDefaultTerm\":\"reviewed\",\"category\":\"Peer Review Process\"},{\"sequenceNumber\":127,\"key\":\"institutional_members\",\"tenantTerm\":\"institutional partners\",\"frontiersDefaultTerm\":\"institutional partners\",\"category\":\"Accounting\"},{\"sequenceNumber\":128,\"key\":\"institutional_memberships\",\"tenantTerm\":\"institutional partnerships\",\"frontiersDefaultTerm\":\"institutional partnerships\",\"category\":\"Accounting\"},{\"sequenceNumber\":129,\"key\":\"assistant_field_chief_editors\",\"tenantTerm\":\"Assistant Field Chief Editors\",\"frontiersDefaultTerm\":\"Assistant Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":130,\"key\":\"publications\",\"tenantTerm\":\"publications\",\"frontiersDefaultTerm\":\"publications\",\"category\":\"Process\"},{\"sequenceNumber\":131,\"key\":\"ae_accepted\",\"tenantTerm\":\"recommended acceptance\",\"frontiersDefaultTerm\":\"accepted\",\"category\":\"Process\"},{\"sequenceNumber\":132,\"key\":\"field_journal\",\"tenantTerm\":\"field journal\",\"frontiersDefaultTerm\":\"field journal\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":133,\"key\":\"field_journals\",\"tenantTerm\":\"field journals\",\"frontiersDefaultTerm\":\"field journals\",\"category\":\"Taxonomy\"},{\"sequenceNumber\":134,\"key\":\"program_manager\",\"tenantTerm\":\"program manager\",\"frontiersDefaultTerm\":\"program manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":135,\"key\":\"journal_manager\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":136,\"key\":\"journal_specialist\",\"tenantTerm\":\"journal specialist\",\"frontiersDefaultTerm\":\"journal specialist\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":137,\"key\":\"program_managers\",\"tenantTerm\":\"program managers\",\"frontiersDefaultTerm\":\"program managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":138,\"key\":\"journal_managers\",\"tenantTerm\":\"journal managers\",\"frontiersDefaultTerm\":\"journal managers\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":139,\"key\":\"journal_specialists\",\"tenantTerm\":\"journal specialists\",\"frontiersDefaultTerm\":\"journal specialists\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":140,\"key\":\"cover_letter\",\"tenantTerm\":\"manuscript contribution to the field\",\"frontiersDefaultTerm\":\"manuscript contribution to the field\",\"category\":\"Process\"},{\"sequenceNumber\":141,\"key\":\"ae_accepted_manuscript\",\"tenantTerm\":\"recommended to accept manuscript\",\"frontiersDefaultTerm\":\"accepted manuscript\",\"category\":\"Process\"},{\"sequenceNumber\":142,\"key\":\"recommend_for_rejection\",\"tenantTerm\":\"recommend for rejection\",\"frontiersDefaultTerm\":\"recommend for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":143,\"key\":\"recommended_for_rejection\",\"tenantTerm\":\"recommended for rejection\",\"frontiersDefaultTerm\":\"recommended for rejection\",\"category\":\"Process\"},{\"sequenceNumber\":144,\"key\":\"ae\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"description\":\"Associate Editor - board member\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":145,\"key\":\"re\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"description\":\"Review Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":146,\"key\":\"rev\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"description\":\"Reviewer\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":147,\"key\":\"aut\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"description\":\"Author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":148,\"key\":\"coraut\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"description\":\"Corresponding author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":149,\"key\":\"saut\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"description\":\"Submitting author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":150,\"key\":\"coaut\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"description\":\"co-author\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":151,\"key\":\"tsof\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"description\":\"Typesetter\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":152,\"key\":\"typesetting_office\",\"tenantTerm\":\"typesetting office\",\"frontiersDefaultTerm\":\"typesetting office\",\"category\":\"Product\"},{\"sequenceNumber\":153,\"key\":\"config\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"description\":\"Configuration office role\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":154,\"key\":\"jm\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"description\":\"Journal Manager\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":155,\"key\":\"rte\",\"tenantTerm\":\"RTE\",\"frontiersDefaultTerm\":\"RTE\",\"description\":\"Research topic editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":156,\"key\":\"organizations\",\"tenantTerm\":\"organizations\",\"frontiersDefaultTerm\":\"organizations\",\"category\":\"Core\"},{\"sequenceNumber\":157,\"key\":\"publishing\",\"tenantTerm\":\"publishing\",\"frontiersDefaultTerm\":\"publishing\",\"category\":\"Core\"},{\"sequenceNumber\":158,\"key\":\"acceptance\",\"tenantTerm\":\"acceptance\",\"frontiersDefaultTerm\":\"acceptance\",\"category\":\"Process\"},{\"sequenceNumber\":159,\"key\":\"preferred_associate_editor\",\"tenantTerm\":\"preferred associate editor\",\"frontiersDefaultTerm\":\"preferred associate editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":160,\"key\":\"topic_editors\",\"tenantTerm\":\"Topic Editors\",\"frontiersDefaultTerm\":\"Topic Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":161,\"key\":\"institutions\",\"tenantTerm\":\"institutions\",\"frontiersDefaultTerm\":\"institutions\",\"category\":\"Core\"},{\"sequenceNumber\":162,\"key\":\"author(s)\",\"tenantTerm\":\"author(s)\",\"frontiersDefaultTerm\":\"author(s)\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":163,\"key\":\"figure(s)\",\"tenantTerm\":\"figure(s)\",\"frontiersDefaultTerm\":\"figure(s)\",\"category\":\"Manuscript Metadata\"},{\"sequenceNumber\":164,\"key\":\"co-authors\",\"tenantTerm\":\"co-authors\",\"frontiersDefaultTerm\":\"co-authors\",\"description\":\"co-authors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":165,\"key\":\"editorial_board_members\",\"tenantTerm\":\"editorial board members\",\"frontiersDefaultTerm\":\"editorial board members\",\"description\":\"editorial board members\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":166,\"key\":\"editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"editorial board\",\"category\":\"Product\"},{\"sequenceNumber\":167,\"key\":\"co-authorship\",\"tenantTerm\":\"co-authorship\",\"frontiersDefaultTerm\":\"co-authorship\",\"description\":\"co-authorship\",\"category\":\"Misc.\"},{\"sequenceNumber\":168,\"key\":\"role_id_1\",\"tenantTerm\":\"registration office\",\"frontiersDefaultTerm\":\"registration office\",\"category\":\"User Role\"},{\"sequenceNumber\":169,\"key\":\"role_id_2\",\"tenantTerm\":\"editorial office\",\"frontiersDefaultTerm\":\"editorial office\",\"category\":\"User Role\"},{\"sequenceNumber\":170,\"key\":\"role_id_7\",\"tenantTerm\":\"field chief editor\",\"frontiersDefaultTerm\":\"field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":171,\"key\":\"role_id_8\",\"tenantTerm\":\"assistant field chief editor\",\"frontiersDefaultTerm\":\"assistant field chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":172,\"key\":\"role_id_9\",\"tenantTerm\":\"specialty chief editor\",\"frontiersDefaultTerm\":\"specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":173,\"key\":\"role_id_10\",\"tenantTerm\":\"assistant specialty chief editor\",\"frontiersDefaultTerm\":\"assistant specialty chief editor\",\"category\":\"User Role\"},{\"sequenceNumber\":174,\"key\":\"role_id_11\",\"tenantTerm\":\"associate editor\",\"frontiersDefaultTerm\":\"associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":175,\"key\":\"role_id_12\",\"tenantTerm\":\"guest associate editor\",\"frontiersDefaultTerm\":\"guest associate editor\",\"category\":\"User Role\"},{\"sequenceNumber\":176,\"key\":\"role_id_13\",\"tenantTerm\":\"review editor\",\"frontiersDefaultTerm\":\"review editor\",\"category\":\"User Role\"},{\"sequenceNumber\":177,\"key\":\"role_id_14\",\"tenantTerm\":\"reviewer\",\"frontiersDefaultTerm\":\"reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":178,\"key\":\"role_id_15\",\"tenantTerm\":\"author\",\"frontiersDefaultTerm\":\"author\",\"category\":\"User Role\"},{\"sequenceNumber\":179,\"key\":\"role_id_16\",\"tenantTerm\":\"corresponding author\",\"frontiersDefaultTerm\":\"corresponding author\",\"category\":\"User Role\"},{\"sequenceNumber\":180,\"key\":\"role_id_17\",\"tenantTerm\":\"submitting author\",\"frontiersDefaultTerm\":\"submitting author\",\"category\":\"User Role\"},{\"sequenceNumber\":181,\"key\":\"role_id_18\",\"tenantTerm\":\"co-author\",\"frontiersDefaultTerm\":\"co-author\",\"category\":\"User Role\"},{\"sequenceNumber\":182,\"key\":\"role_id_20\",\"tenantTerm\":\"production office\",\"frontiersDefaultTerm\":\"production office\",\"category\":\"User Role\"},{\"sequenceNumber\":183,\"key\":\"role_id_22\",\"tenantTerm\":\"typesetting office (typesetter)\",\"frontiersDefaultTerm\":\"typesetting office (typesetter)\",\"category\":\"User Role\"},{\"sequenceNumber\":184,\"key\":\"role_id_24\",\"tenantTerm\":\"registered user\",\"frontiersDefaultTerm\":\"registered user\",\"category\":\"User Role\"},{\"sequenceNumber\":185,\"key\":\"role_id_35\",\"tenantTerm\":\"job office\",\"frontiersDefaultTerm\":\"job office\",\"category\":\"User Role\"},{\"sequenceNumber\":186,\"key\":\"role_id_41\",\"tenantTerm\":\"special event administrator\",\"frontiersDefaultTerm\":\"special event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":187,\"key\":\"role_id_42\",\"tenantTerm\":\"special event reviewer\",\"frontiersDefaultTerm\":\"special event reviewer\",\"category\":\"User Role\"},{\"sequenceNumber\":188,\"key\":\"role_id_43\",\"tenantTerm\":\"submit abstract\",\"frontiersDefaultTerm\":\"submit abstract\",\"category\":\"User Role\"},{\"sequenceNumber\":189,\"key\":\"role_id_52\",\"tenantTerm\":\"events office\",\"frontiersDefaultTerm\":\"events office\",\"category\":\"User Role\"},{\"sequenceNumber\":190,\"key\":\"role_id_53\",\"tenantTerm\":\"event administrator\",\"frontiersDefaultTerm\":\"event administrator\",\"category\":\"User Role\"},{\"sequenceNumber\":191,\"key\":\"role_id_89\",\"tenantTerm\":\"content management office\",\"frontiersDefaultTerm\":\"content management office\",\"category\":\"User Role\"},{\"sequenceNumber\":192,\"key\":\"role_id_98\",\"tenantTerm\":\"accounting office\",\"frontiersDefaultTerm\":\"accounting office\",\"category\":\"User Role\"},{\"sequenceNumber\":193,\"key\":\"role_id_99\",\"tenantTerm\":\"projects\",\"frontiersDefaultTerm\":\"projects\",\"category\":\"User Role\"},{\"sequenceNumber\":194,\"key\":\"role_id_103\",\"tenantTerm\":\"configuration office\",\"frontiersDefaultTerm\":\"configuration office\",\"category\":\"User Role\"},{\"sequenceNumber\":195,\"key\":\"role_id_104\",\"tenantTerm\":\"beta user\",\"frontiersDefaultTerm\":\"beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":196,\"key\":\"role_id_106\",\"tenantTerm\":\"wfconf\",\"frontiersDefaultTerm\":\"wfconf\",\"category\":\"User Role\"},{\"sequenceNumber\":197,\"key\":\"role_id_107\",\"tenantTerm\":\"rt management beta user\",\"frontiersDefaultTerm\":\"rt management beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":198,\"key\":\"role_id_108\",\"tenantTerm\":\"deo beta user\",\"frontiersDefaultTerm\":\"deo beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":199,\"key\":\"role_id_109\",\"tenantTerm\":\"search beta user\",\"frontiersDefaultTerm\":\"search beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":200,\"key\":\"role_id_110\",\"tenantTerm\":\"journal manager\",\"frontiersDefaultTerm\":\"journal manager\",\"category\":\"User Role\"},{\"sequenceNumber\":201,\"key\":\"role_id_111\",\"tenantTerm\":\"myfrontiers beta user\",\"frontiersDefaultTerm\":\"myfrontiers beta user\",\"category\":\"User Role\"},{\"sequenceNumber\":202,\"key\":\"role_id_21\",\"tenantTerm\":\"copy editor\",\"frontiersDefaultTerm\":\"copy editor\",\"category\":\"User Role\"},{\"sequenceNumber\":203,\"key\":\"role_id_1_abr\",\"tenantTerm\":\"ROF\",\"frontiersDefaultTerm\":\"ROF\",\"category\":\"User Role\"},{\"sequenceNumber\":204,\"key\":\"role_id_2_abr\",\"tenantTerm\":\"EOF\",\"frontiersDefaultTerm\":\"EOF\",\"category\":\"User Role\"},{\"sequenceNumber\":205,\"key\":\"role_id_7_abr\",\"tenantTerm\":\"FCE\",\"frontiersDefaultTerm\":\"FCE\",\"category\":\"User Role\"},{\"sequenceNumber\":206,\"key\":\"role_id_8_abr\",\"tenantTerm\":\"AFCE\",\"frontiersDefaultTerm\":\"AFCE\",\"category\":\"User Role\"},{\"sequenceNumber\":207,\"key\":\"role_id_9_abr\",\"tenantTerm\":\"SCE\",\"frontiersDefaultTerm\":\"SCE\",\"category\":\"User Role\"},{\"sequenceNumber\":208,\"key\":\"role_id_10_abr\",\"tenantTerm\":\"ASCE\",\"frontiersDefaultTerm\":\"ASCE\",\"category\":\"User Role\"},{\"sequenceNumber\":209,\"key\":\"role_id_11_abr\",\"tenantTerm\":\"AE\",\"frontiersDefaultTerm\":\"AE\",\"category\":\"User Role\"},{\"sequenceNumber\":210,\"key\":\"role_id_12_abr\",\"tenantTerm\":\"GAE\",\"frontiersDefaultTerm\":\"GAE\",\"category\":\"User Role\"},{\"sequenceNumber\":211,\"key\":\"role_id_13_abr\",\"tenantTerm\":\"RE\",\"frontiersDefaultTerm\":\"RE\",\"category\":\"User Role\"},{\"sequenceNumber\":212,\"key\":\"role_id_14_abr\",\"tenantTerm\":\"REV\",\"frontiersDefaultTerm\":\"REV\",\"category\":\"User Role\"},{\"sequenceNumber\":213,\"key\":\"role_id_15_abr\",\"tenantTerm\":\"AUT\",\"frontiersDefaultTerm\":\"AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":214,\"key\":\"role_id_16_abr\",\"tenantTerm\":\"CORAUT\",\"frontiersDefaultTerm\":\"CORAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":215,\"key\":\"role_id_17_abr\",\"tenantTerm\":\"SAUT\",\"frontiersDefaultTerm\":\"SAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":216,\"key\":\"role_id_18_abr\",\"tenantTerm\":\"COAUT\",\"frontiersDefaultTerm\":\"COAUT\",\"category\":\"User Role\"},{\"sequenceNumber\":217,\"key\":\"role_id_20_abr\",\"tenantTerm\":\"POF\",\"frontiersDefaultTerm\":\"POF\",\"category\":\"User Role\"},{\"sequenceNumber\":218,\"key\":\"role_id_22_abr\",\"tenantTerm\":\"TSOF\",\"frontiersDefaultTerm\":\"TSOF\",\"category\":\"User Role\"},{\"sequenceNumber\":219,\"key\":\"role_id_24_abr\",\"tenantTerm\":\"RU\",\"frontiersDefaultTerm\":\"RU\",\"category\":\"User Role\"},{\"sequenceNumber\":220,\"key\":\"role_id_35_abr\",\"tenantTerm\":\"JOF\",\"frontiersDefaultTerm\":\"JOF\",\"category\":\"User Role\"},{\"sequenceNumber\":221,\"key\":\"role_id_41_abr\",\"tenantTerm\":\"SE-ADM\",\"frontiersDefaultTerm\":\"SE-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":222,\"key\":\"role_id_42_abr\",\"tenantTerm\":\"SE-REV\",\"frontiersDefaultTerm\":\"SE-REV\",\"category\":\"User Role\"},{\"sequenceNumber\":223,\"key\":\"role_id_43_abr\",\"tenantTerm\":\"SE-AUT\",\"frontiersDefaultTerm\":\"SE-AUT\",\"category\":\"User Role\"},{\"sequenceNumber\":224,\"key\":\"role_id_52_abr\",\"tenantTerm\":\"EVOF\",\"frontiersDefaultTerm\":\"EVOF\",\"category\":\"User Role\"},{\"sequenceNumber\":225,\"key\":\"role_id_53_abr\",\"tenantTerm\":\"EV-ADM\",\"frontiersDefaultTerm\":\"EV-ADM\",\"category\":\"User Role\"},{\"sequenceNumber\":226,\"key\":\"role_id_89_abr\",\"tenantTerm\":\"COMOF\",\"frontiersDefaultTerm\":\"COMOF\",\"category\":\"User Role\"},{\"sequenceNumber\":227,\"key\":\"role_id_98_abr\",\"tenantTerm\":\"AOF\",\"frontiersDefaultTerm\":\"AOF\",\"category\":\"User Role\"},{\"sequenceNumber\":228,\"key\":\"role_id_99_abr\",\"tenantTerm\":\"Projects\",\"frontiersDefaultTerm\":\"Projects\",\"category\":\"User Role\"},{\"sequenceNumber\":229,\"key\":\"role_id_103_abr\",\"tenantTerm\":\"CONFIG\",\"frontiersDefaultTerm\":\"CONFIG\",\"category\":\"User Role\"},{\"sequenceNumber\":230,\"key\":\"role_id_104_abr\",\"tenantTerm\":\"BETA\",\"frontiersDefaultTerm\":\"BETA\",\"category\":\"User Role\"},{\"sequenceNumber\":231,\"key\":\"role_id_106_abr\",\"tenantTerm\":\"WFCONF\",\"frontiersDefaultTerm\":\"WFCONF\",\"category\":\"User Role\"},{\"sequenceNumber\":232,\"key\":\"role_id_107_abr\",\"tenantTerm\":\"RTBETA\",\"frontiersDefaultTerm\":\"RTBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":233,\"key\":\"role_id_108_abr\",\"tenantTerm\":\"DEOBETA\",\"frontiersDefaultTerm\":\"DEOBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":234,\"key\":\"role_id_109_abr\",\"tenantTerm\":\"SEARCHBETA\",\"frontiersDefaultTerm\":\"SEARCHBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":235,\"key\":\"role_id_110_abr\",\"tenantTerm\":\"JM\",\"frontiersDefaultTerm\":\"JM\",\"category\":\"User Role\"},{\"sequenceNumber\":236,\"key\":\"role_id_111_abr\",\"tenantTerm\":\"MFBETA\",\"frontiersDefaultTerm\":\"MFBETA\",\"category\":\"User Role\"},{\"sequenceNumber\":237,\"key\":\"role_id_21_abr\",\"tenantTerm\":\"COPED\",\"frontiersDefaultTerm\":\"COPED\",\"category\":\"User Role\"},{\"sequenceNumber\":238,\"key\":\"reviewer_editorial_board\",\"tenantTerm\":\"editorial board\",\"frontiersDefaultTerm\":\"editorial board\",\"description\":\"This is the label for the review editorial board\",\"category\":\"Label\"},{\"sequenceNumber\":239,\"key\":\"field_chief_editor\",\"tenantTerm\":\"Field Chief Editor\",\"frontiersDefaultTerm\":\"Field Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":240,\"key\":\"field_chief_editors\",\"tenantTerm\":\"Field Chief Editors\",\"frontiersDefaultTerm\":\"Field Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":241,\"key\":\"editor\",\"tenantTerm\":\"editor\",\"frontiersDefaultTerm\":\"editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":242,\"key\":\"editors\",\"tenantTerm\":\"editors\",\"frontiersDefaultTerm\":\"editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":243,\"key\":\"board\",\"tenantTerm\":\"board\",\"frontiersDefaultTerm\":\"board\",\"category\":\"Label\"},{\"sequenceNumber\":244,\"key\":\"boards\",\"tenantTerm\":\"boards\",\"frontiersDefaultTerm\":\"boards\",\"category\":\"Label\"},{\"sequenceNumber\":245,\"key\":\"article_collection\",\"tenantTerm\":\"article collection\",\"frontiersDefaultTerm\":\"article collection\",\"category\":\"Label\"},{\"sequenceNumber\":246,\"key\":\"article_collections\",\"tenantTerm\":\"article collections\",\"frontiersDefaultTerm\":\"article collections\",\"category\":\"Label\"},{\"sequenceNumber\":247,\"key\":\"handling_editor\",\"tenantTerm\":\"handling editor\",\"frontiersDefaultTerm\":\"associate editor\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":248,\"key\":\"handling_editors\",\"tenantTerm\":\"handling editors\",\"frontiersDefaultTerm\":\"associate editors\",\"description\":\"This terminology key is for the person assigned to edit a manuscript. It is a label for the temporary handling editor assignment.\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":249,\"key\":\"ae_accept\",\"tenantTerm\":\"recommend acceptance\",\"frontiersDefaultTerm\":\"accept\",\"category\":\"Process\"},{\"sequenceNumber\":250,\"key\":\"rtm\",\"tenantTerm\":\"RTM\",\"frontiersDefaultTerm\":\"RTM\",\"category\":\"Product\"},{\"sequenceNumber\":251,\"key\":\"frontiers_media_sa\",\"tenantTerm\":\"Frontiers Media S.A\",\"frontiersDefaultTerm\":\"Frontiers Media S.A\",\"category\":\"Customer\"},{\"sequenceNumber\":252,\"key\":\"review_editors\",\"tenantTerm\":\"Community Reviewers\",\"frontiersDefaultTerm\":\"Review Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":253,\"key\":\"journal_card_chief_editor\",\"tenantTerm\":\"Chief Editor\",\"frontiersDefaultTerm\":\"Chief Editor\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":254,\"key\":\"journal_card_chief_editors\",\"tenantTerm\":\"Chief Editors\",\"frontiersDefaultTerm\":\"Chief Editors\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":255,\"key\":\"call_for_papers\",\"tenantTerm\":\"Call for papers\",\"frontiersDefaultTerm\":\"Call for papers\",\"category\":\"Label\"},{\"sequenceNumber\":256,\"key\":\"calls_for_papers\",\"tenantTerm\":\"Calls for papers\",\"frontiersDefaultTerm\":\"Calls for papers\",\"category\":\"Label\"},{\"sequenceNumber\":257,\"key\":\"supervising_editor\",\"tenantTerm\":\"Supervising Editor\",\"frontiersDefaultTerm\":\"Supervising Editor\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editor\"},{\"sequenceNumber\":258,\"key\":\"supervising_editors\",\"tenantTerm\":\"Supervising Editors\",\"frontiersDefaultTerm\":\"Supervising Editors\",\"description\":\"A Chief or Assistant Chief editor who is assigned to a manuscript to supervise.\",\"category\":\"Role\",\"externalKey\":\"supervising_editors\"},{\"sequenceNumber\":259,\"key\":\"reviewer_endorse\",\"tenantTerm\":\"endorse\",\"frontiersDefaultTerm\":\"endorse\",\"category\":\"Label\"},{\"sequenceNumber\":260,\"key\":\"reviewer_endorsed\",\"tenantTerm\":\"endorsed\",\"frontiersDefaultTerm\":\"endorsed\",\"category\":\"Label\"},{\"sequenceNumber\":261,\"key\":\"reviewer_endorse_publication\",\"tenantTerm\":\"endorse publication\",\"frontiersDefaultTerm\":\"endorse publication\",\"category\":\"Label\"},{\"sequenceNumber\":262,\"key\":\"reviewer_endorsed_publication\",\"tenantTerm\":\"endorsed publication\",\"frontiersDefaultTerm\":\"endorsed publication\",\"category\":\"Label\"},{\"sequenceNumber\":263,\"key\":\"editor_role\",\"tenantTerm\":\"editor role\",\"frontiersDefaultTerm\":\"Editor Role\",\"category\":\"Label\"},{\"sequenceNumber\":264,\"key\":\"editor_roles\",\"tenantTerm\":\"editor roles\",\"frontiersDefaultTerm\":\"Editor Roles\",\"category\":\"Label\"},{\"sequenceNumber\":265,\"key\":\"editorial_role\",\"tenantTerm\":\"editorial role\",\"frontiersDefaultTerm\":\"Editorial Role\",\"category\":\"Label\"},{\"sequenceNumber\":266,\"key\":\"editorial_roles\",\"tenantTerm\":\"editorial roles\",\"frontiersDefaultTerm\":\"Editorial Roles\",\"category\":\"Label\"},{\"sequenceNumber\":267,\"key\":\"call_for_paper\",\"tenantTerm\":\"Call for paper\",\"frontiersDefaultTerm\":\"Call for paper\",\"category\":\"Label\"},{\"sequenceNumber\":268,\"key\":\"research_topic_abstract\",\"tenantTerm\":\"manuscript summary\",\"frontiersDefaultTerm\":\"manuscript summary\",\"category\":\"Process\"},{\"sequenceNumber\":269,\"key\":\"research_topic_abstracts\",\"tenantTerm\":\"manuscript summaries\",\"frontiersDefaultTerm\":\"manuscript summaries\",\"category\":\"Process\"},{\"sequenceNumber\":270,\"key\":\"submissions_team_manager\",\"tenantTerm\":\"Journal Manager\",\"frontiersDefaultTerm\":\"Content Manager\",\"category\":\"Process\"},{\"sequenceNumber\":271,\"key\":\"submissions_team\",\"tenantTerm\":\"Journal Team\",\"frontiersDefaultTerm\":\"Content Team\",\"category\":\"Process\"},{\"sequenceNumber\":272,\"key\":\"topic_coordinator\",\"tenantTerm\":\"topic coordinator\",\"frontiersDefaultTerm\":\"topic coordinator\",\"category\":\"Process\"},{\"sequenceNumber\":273,\"key\":\"topic_coordinators\",\"tenantTerm\":\"topic coordinators\",\"frontiersDefaultTerm\":\"topic coordinators\",\"category\":\"Process\"},{\"sequenceNumber\":274,\"key\":\"frontiers_journal_team\",\"tenantTerm\":\"frontiers journal team\",\"frontiersDefaultTerm\":\"frontiers journal team\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":275,\"key\":\"research_topic_ic_submission\",\"tenantTerm\":\"RT:IC Submission\",\"frontiersDefaultTerm\":\"RT:IC Submission\",\"category\":\"Label (Role)\"},{\"sequenceNumber\":276,\"key\":\"research_topic_ic_submission_participant\",\"tenantTerm\":\"RT:IC Submission participant\",\"frontiersDefaultTerm\":\"RT:IC Submission participant\",\"category\":\"Label (Role)\"}]}'\n",impactGtmId:"GTM-NJF2ML9B",impactGtmAuth:"fYo-7NoDm9w37QgFMs03SA",impactGtmPreview:"env-1",impactGoogleMapsApiKey:"AIzaSyCTEhX2EU8PWfi86GW9FI00FTcyKk6Ifr8",qualtricsV4ToV3:"'{\"enabled\":true,\"interceptId\":\"SI_er0E2ze69Oz8Yn4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsUmux:"'{\"enabled\":false,\"interceptId\":\"SI_89fPHY3eTxQBwtU\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",qualtricsContinuousBrand:"'{\"enabled\":true,\"interceptId\":\"SI_9ZuT94UT81FcRh4\",\"projectId\":\"ZN_cLOy77JHkpc8Gai\",\"brandId\":\"frontiersin\"}'\n",defaultArticleTemplate:"v3"},app:{baseURL:"/",buildId:"ed555f16-85f7-4f41-8f2f-451827c59120",buildAssetsDir:"ap-2024/_nuxt",cdnURL:""}}</script>
<script src="https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6" type="text/javascript" async></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML" type="text/javascript" async></script>
<script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-f0bc9b243ff5677d05460c1eb71834ca998946d764eb3bc244ab4b18ba50d21e.js" type="text/javascript" async></script>
<script src="https://api.altmetric.com/v1/doi/10.3389/fonc.2021.674965?callback=_altmetric.embed_callback&domain=www.frontiersin.org&key=3c130976ca2b8f2e88f8377633751ba1&cache_until=14-15" type="text/javascript" async></script>
<script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript" async></script></body></html>